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Abstract !
T-cells appear to have multiple conflicting roles in CLL. On the one hand tumour-specific 
T-cells could be used to deliver effective immunotherapy; on the other hand, certain T-cell 
populations may enhance CLL survival and disease progression. The aim of this thesis was 
to address these contradictory aspects and to provide a deeper understanding of the role of 
T-cells in CLL. 
Firstly, candidate peptides from the pro-apoptotic protein Bax were used to 
activate potential CLL specific T-cells from HLA-A2+ patients. A CD8+ T-cell clone (6C5) 
was isolated and it’s specificity was initially mapped to (Bax161-170; LLSYFGTPT) and 
(Bax160–170; GLLSYFGTPT). However, 6C5 failed to recognise HLA-A2
+ CLL cells in vitro, 
and failed to recognise highly purified forms of the peptides. Further characterisation, 
involving mass spectrometry and HPLC, mapped T-cell specificity to a modified peptide 
(LLSY(3-tBu)FGTPT).  
A second strand of this project involved detailed phenotypic analysis of T-cells 
from CLL patients (n=97) in order to investigate the basis for immune dysfunction. This 
analysis indicated that patients with an inverted CD4:CD8 ratio (CLLIR), displayed a 
skewing towards a highly differentiated T-cell phenotype, as well as expression of markers 
associated with replicative senescence (CD57+, CD27-) within CD4+ and CD8+ T-cell 
compartments. In addition, CD4+ T-cells expressing markers associated with 
immunosuppression (PD-1+, TIM-3+) were also increased in CLLIR. Importantly, the 
inversion of the CD4:CD8 ratio was associated with shorter progression-free survival. 
Furthermore, the frequencies of distinct T-cell populations were also shown to have 
prognostic impact in both univariate analysis (CD4+PD-1+, CD4+CD57+, CD8+CD57+ and 
CD8+CD27-) and multivariate analysis (CD4+CD27-PD-1+LAG-3+ and CD8+CD27-
CD57+PD-1+). 
To further evaluate the differences between CLLIR and CLLNR patients, preliminary 
transcriptional analysis was performed, focusing on genes associated with T-cell function. 
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By contrast, transcriptional analysis suggested that genes associated with activation rather 
than suppression were enriched in CLLIR.  
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Chapter 1  
Introduction 
1.1 Immune system 
The immune system represents a highly developed and integrated system designed to 
protect the body against pathogens. The cellular components of this remarkable system 
originate from haematopoietic stem cells (HSC), which through the process of 
differentiation become committed to specific cellular lineages. The immune system can be 
divided into the innate immune system, which acts as the front line of defense and protects 
the host in a non-specific manner, and the adaptive immune system which is specific and 
develops in response to specific pathogens (Janeway 2012). 
1.1.1 Innate immunity 
The detection of pathogens occurs through the recognition of pathogen-associated 
molecular patterns (PAMPs), by pattern recognition receptors (PRRs), such as the toll like 
receptors (TLR). This process of recognition results in the activation of anti-microbial 
processes and enhancement of antigen presentation. This in turn allows for the 
presentation of antigens to the adaptive immune system (Medzhitov and Janeway 2002). 
The specific cells that contribute to the innate immune system include phagocytes 
(macrophages, neutrophils and dendritic cells (DCs)), mast cells, basophils, eosinophils and 
natural killer cells (NK cells) (Janeway and Medzhitov 2002). 
Phagocytic cells are principally characterised by their ability to phagocytose and 
demolish infected and diseased cells. Within the innate immune system neutrophils, 
macrophages and DCs undertake this task (Savina and Amigorena 2007). Neutrophils 
detect pathogens and damaged tissue through a range of PRRs, including members of the 
TLR family. Ligation of these receptors mediates neutrophil activation, phagocytosis, the 
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release of lytic enzymes and the production of reactive oxygen species (Mantovani et al. 
2011).  
Macrophages and DCs are derived from precursor monocytes. Their divergent 
development occurs in response to differing environmental stimuli and they are often 
distinguished by the expression of distinct surface markers. Macrophages can be divided 
into numerous subsets that are localised to specific anatomical locations and have distinct 
functions. “Classically” activated macrophages mediate anti-microbial and anti-tumour 
responses through the secretion of pro-inflammatory factors such as tumour necrosis 
factor alpha (TNF-α), nitric oxide (NO) and Interlukin-1 (IL-1). However, “alternatively” 
activated macrophages have been shown to mediate anti-inflammatory immune responses 
and regulate wound healing (Murray and Wynn 2011). 
DCs are specialised antigen presenting cells (APCs) that facilitate antigen specific 
activation within the adaptive immune system. DCs present peptides derived from both 
intracellular and extracellular proteins on major histocompatibility complexes; class I 
(MHC-I) and class II (MHC-II), respectively. Additionally, lipid antigens are presented on 
complexes formed through the heterodimerisation of the cluster of differentiation 1 (CD1) 
and β2-microglobulin (β2m). Furthermore, DCs also express essential co-stimulatory and 
adhesion molecules required for the formation of the immunological synapse (IS) and 
subsequent T-cell activation (Adams et al. 2005; Banchereau and Steinman 1998). 
Mast cells and basophils are functionally similar cells that contain histamine and 
heparin stored within intracellular granules. Cross-linking of the high affinity 
immunoglobulin E (IgE) fragment crystallisable (Fc) receptors initiates the process of 
cellular activation and degranulation. The in vivo functions of these cells are not yet fully 
understood, nevertheless reports have suggested that mast cells contribute to protecting the 
host against parasitic and bacterial infections, as well as supporting tumour rejection. While 
basophils have been indicated to mediate protection against helminths and ticks, moreover 
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both cell types have been suggested to have a modulatory effect on the adaptive immune 
system (Voehringer 2013). 
Eosinophils are granulocytes implicated in the pathology of allergies and protection 
against helminths. They express a wide array of receptors that modulate cell survival, 
proliferation, migration in response to chemoattractants and the release of intracellular 
granules. This is a process that can occur through three distinct routes, compound 
exocytosis, piecemeal degranulation and degranulation associated with cytolysis (Rosenberg 
et al. 2012; Muniz et al. 2012). 
NK cells are cytotoxic lymphocytes that possess the capacity to generate cytolytic 
responses against infected and diseased cells, similar to those observed with CD8+ T-cells. 
The activation of NK cells occurs through the synergy of multiple activating and inhibitory 
receptors. The effects of these receptors are mediated through the phosphorylation of 
immunoreceptor tyrosine-based activation motifs (ITAM) and immunoreceptor tyrosine-
based inhibitor motifs (ITIM), respectively (Long et al. 2013). 
1.1.2 Adaptive immunity 
The adaptive immune system represents a highly specific and specialised branch of 
the immune system that is characterised by lymphocytes that express antigen specific 
receptors, T-cell receptors (TCR) and B-cell receptors (BCR). The recognition of a 
seemingly countless number of antigens occurs through the expression of an array of 
receptors produced through the somatic rearrangement of the variable (V), diversity (D) 
and joining (J) gene segments (Boehm 2011). Furthermore, the antigen specific nature of 
cellular activation allows for the formation of immunological memory which functions to 
orchestrate rapid immune responses upon re-exposure to pathogens (Gourley et al. 2004). 
1.1.2.1 B-cells and humoral immunity  
The development of B-cells occurs within the bone marrow, through the 
commitment of the common leukocyte progenitor (CLP) to the B-cell linage. The process 
 Chapter 1: Introduction 
 
 Page 4  
of differentiation occurs in multiple stages firstly with the emergence of the pro-B-cell, 
followed by pre-B-cell and finally the immature B-cell. At this stage the B-cell expresses a 
mature BCR, which allows for the process of negative selection, to eliminate self reactive 
B-cells. The immature B-cells can then emerge from the bone marrow, as transitional B-
cells and migrate to secondary lymphoid organs such as the spleen and lymph nodes to 
undergo maturation (Cambier et al. 2007).  
Upon antigenic challenge, the interaction between the BCR (or surface Ig) (Fig 1.1) 
and antigen initiates an intracellular signaling cascade which results in antigen 
internalisation, processing and presentation on MHC-II (as described in section 1.1.2.2.3.2) 
(Janeway 2012). The resulting MHC-peptide complex can then be recognized by specific 
helper T-cells, which in turn expression B-cell co-stimulatory ligands such as CD40L 
(Noelle et al. 1992) and produce IL-4 (Zamorano et al. 2001), which supports B-cell 
proliferation and survival. Moreover, synergistic IL-4 and CD40L signaling has been shown 
to induce the expression of activation-induced cytidine deaminase (AID) (Dedeoglu et al. 
2004), which plays an integral role in the processes of class switch recombination (CSR) 
and somatic hyper mutation (SHM) (Stavnezer et al. 2008). 
CSR involves the rearrangement of the constant domain genes of the Ig heavy 
chain locus, which results in the switching of ones isotype to another. The process has no 
effect upon the antigen specificity of the antibody, but can alter its overall properties and 
interactions with effector molecules and cells. After several rounds of cell division the B-
cells undergo SHM, which induces the diversification of the BCR and the producetion of 
variants with enhanced binding affinity. The process involves the mutation (commonly 
single base pair substitutions) of V domain of the BCR at a rate of 10-5 to 10-3 mutations 
per base pair per generation, through this phenomenon can occur throughout the entire V 
domain, it has been shown to be more prevalent within certain motifs (Li 2004).  
Following activation within the germinal centres B-cells can differentiate into 
plasma cells and memory B-cells. Plasma cells produce high levels of soluble Ig and play an 
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integral role in the humeral immune response. The Ig is then able to bind to specific 
pathogens through interactions between the Ig fragment antigen-binding region (Fab) and 
antigens on the pathogen surface. This process can either inhibit the pathogen’s ability to 
enter the host’s cell or “tag” the pathogen of destruction by phagocytic cells (Janeway 
2012).  
Memory B-cells serve to provide protection against secondary pathogen exposure. 
The mechanism by which B-cells differentiate in memory B-cells is still not fully 
understood. While it has been suggested that the induction of a master transcription factor 
may mediate commitment to the memory B-cell linage, none have yet to be defined. An 
alternative hypothesis is that within the germinal centres, it is the B-cells that exhibit a 
survival advantage, which have the capacity to go on to form memory B-cells (Kurosaki et 
al. 2015). 
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Figure 1.1 Struture of Immunoglobulin. Immunoglobulins consist of two heavy chains (H) and two light 
chains (L), however it should be noted that the light chain could either a  or a  chain. Both chains 
consist of variable (V) and constant (C) domains, however the heavy chain is made up of three C domains 
CH1, CH2 and CH3. The structure is maintained through multiple disulfide bonds, located between each heavy 
and light chain, as well as the two heavy chains. Immunoglobulins can be divided into functionally distinct 
fragments. The Fab fragments contain the antigen binding sites and are responsible for the specificity 
associated with the antibody. While the Fc fragment consists of the paired CH2 and CH3 domains and is able to 
interact which effector molecules and cells to induce antibody-dependent cell-mediated cytotoxicity (ADCC) 
and complement-dependent cytotoxicity (CDC) (Schroeder and Cavacini 2010; Janeway 2012). 
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1.1.2.2 Cell mediated immunity 
T-cells are lymphocytes also derived from the bone marrow but which undergo 
maturation within the thymus. They can be divided into CD4+ T-cells and CD8+ T-cells 
and then further subdivided into specific subsets with differing functions. Broadly 
speaking, CD4+ T-cells are involved in assisting and regulating immune responses while 
CD8+ T-cells are responsible for inducing targeted killing of infected and malignant cells 
(Janeway 2012). 
1.1.2.2.1 CD4+ T-cells 
CD4+ T-cells represent a heterogeneous population of lymphocytes that possess 
effector and regulatory functions (Fig 1.2) (Zhu and Paul 2008). Type 1 helper T-cells 
(Th1) preferentially express the transcription factor T-bet and produce interferon gamma 
(IFN-γ), while Type 2 helper T-cells (Th2) express GATA-3 and produce IL-4 (Szabo et al. 
2000). Th1 cells provide protection against viruses and intracellular pathogens and support 
cell mediated immune responses while Th2 cells provide protection against extracellular 
parasites and support humoral responses (Janeway 2012). 
Th9 cells are closely related to Th2 cells, as their development requires many of the 
same factors, such as IL-4. However, Th9 cells express the master transcription factor 
PU.1, which induces the expression of IL-9 and inhibit the expression of cytokines 
associated with a Th2 phenotype such as IL-4, IL-5, IL-10, and IL-13 (Chang et al. 2005; 
Chang et al. 2010). 
Th17 cells produce IL-17 along with other inflammatory cytokines and contribute 
towards autoimmune diseases. The differentiation of Th17 cells is governed by the 
expression of the transcription factor RAR-related orphan receptor gamma (RORγt), 
which is up-regulated in response to TCR ligation in the presence of IL-6 and transforming 
growth factor beta (TGF-β) (Ivanov et al. 2006).  
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Th22 cells are a T-cell helper cell subset that is closely related to Th17 cells. Th22 
cells are characterised by the expression of chemokine (C-C motif) receptor 4 (CCR4), 
CCR6, CCR10 and production of IL-22, but not IFN-γ, IL-4 or IL-17 (Trifari et al. 2009). 
IL-22 producing T-cells have been shown to contribute to the population of localised T-
cells in inflammatory human skin disorders such as psoriasis (Boniface et al. 2007). It has 
been suggested that aryl hydrocarbon receptor (AHR), in combination with other 
molecules such as RORγt influences the differentiation and development of Th22 cells 
(Trifari et al. 2009).  
Follicular helper cells (Tfh) provide critical support for B-cells, specifically in 
germinal centres where B-cells undergo activation, proliferation and antibody affinity 
maturation. The development of Tfh is dependent upon the expression of the transcription 
factor B-cell lymphoma 6 protein (Bcl6), which is induced by IL-21 and IL-6. Bcl6 
orchestrates Tfh differentiation and induces the expression of IL-21R, IL-6R, and CXCR5. 
Moreover, Bcl6 inhibits the expression and function of transcription factors responsible for 
the development of other T helper cell lineages (Nurieva et al. 2009).  
Regulatory T-cells (Tregs) form a T-cell subset characterised by the expression of 
CD25 and the transcription factor forkhead box P3 (Foxp3) (Hori et al. 2003), and play an 
important role in the prevention of autoimmune responses and immunopathology 
(Sakaguchi et al. 2008).  
Tregs can be sub-divided into natural regulatory T-cells (nTregs) and induced 
regulatory T-cells (iTregs). nTregs are produced in the thymus via signalling through high 
affinity TCR and the induction of Foxp3 (Relland et al. 2009). iTregs on the other hand are 
produced in the periphery through the activation of naïve CD4+ T-cells in the presence of 
anti-inflammatory cytokines such as TGF-β (Chen et al. 2003). Both types exhibit the 
capacity to suppress immune responses and inhibit T-cell proliferation (Qiao et al. 2007),  
but the requirement for both cell types in maintaining peripheral tolerance is not yet fully 
understood. Haribhai et al observed there was a vast difference in the TCR repertoires of 
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nTreg and iTreg, suggesting that the need for both cell types stems from differing antigen 
specificity (Haribhai et al. 2011). 
The exact mechanism by which Tregs act to suppress immune function is not yet 
fully understood, however research from in vitro and in vivo systems has provided several 
concepts for their mode of action (Toda and Piccirillo 2006). Activated Tregs have been 
shown to produce the immunosuppressive cytokines TGF-β, IL-10, and IL-35, which may 
play a role in the contact-independent immune regulation by Tregs (Zhu and Paul 2008). 
Additionally, Tregs have been shown to inhibit the antigen presentation capacity of DCs in 
a contact-dependent manner, through the down-regulation of the co-stimulatory ligands 
CD80 and CD86, in a lymphocyte function-associated antigen 1 (LFA-1) and cytotoxic T-
lymphocyte antigen 4 (CTLA-4) dependent manner (Onishi et al. 2008). Interestingly, it has 
been suggested that CTLA-4 has the capacity to sequester CD80 and CD86 from the cell 
surface (Qureshi et al. 2011). Therefore it could be hypothesised that CTLA-4 present on 
Tregs acts to physically remove CD80 and CD86 from the cell surface of DCs, rather than 
inducing their down-regulation. 
Whether or not the T-cell subsets described above represent discrete T-cell lineages 
or are part of a ever changing network on CD4+ T-cells is still the subject of much debate 
(Nakayamada et al. 2012). For example the down-regulation of Foxp3 and subsequent 
expression of IL-17 can be induced in vitro via treatment with IL-6 and IL-1, indicating 
plasticity between Tregs and Th17 cells (Yang et al. 2008). This phenomenon has also been 
reported between Th1 and Th2 (Hegazy et al. 2010) and other CD4+ T-cells (Nakayamada 
et al. 2012).   
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Figure 1.2 Development of CD4+ T-cells subsets. CD4+ T-cells represent a heterogeneous population of 
lymphocytes that function to modulate immune responses (Zhu and Paul 2008). CD4+ T-cells recognise 
antigens derived from extracellular proteins presented on MHC-II (Neefjes et al. 2011) and were originally 
classified as two major subsets (Szabo et al. 2000), Th1 and Th2. However, extensive research has alluded to 
the potential for CD4+ T-cells to differentiate into a wide array of cell types, including, but not limited to, 
Th9, Th17, Th22, Tfh and Tregs (Jiang and Dong 2013). The differentiation of these subsets is governed by 
the ligation of the TCR under polarising cytokine conditions and the induction of specific transcription 
factors (Liu et al. 2013). 
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1.1.2.2.2 CD8+ T-cells 
CD8+ T-cells represent a population of cytotoxic lymphocytes (CTLs) that 
demonstrate the capacity to induce targeted killing of infected (Koelle et al. 2001) and 
malignant cells (Nunes et al. 2011; Wang et al. 2006; Kawakami et al. 1995). Activation of 
CD8+ T-cells is orchestrated through interactions between the TCR and MHC-I peptide 
complexes expressed on the surface of APCs (Janeway 2012). Furthermore, the strength 
and stability of this interaction is augmented through the interaction between CD8 and the 
MHC-I peptide complex (Artyomov et al. 2010). 
CD8+ T-cells employ multiple methods of inducing cell death. The principal 
mechanism utilised involves the delivery of cytotoxic granules into the cytoplasm of the 
target cell. This process is mediated through the secretion of perforin, granzymes (Gzms) 
and granulysin (Lieberman 2010).  
Perforin is a pore forming molecule that has been shown to be essential for granule 
mediated cell death (Voskoboinik et al. 2010). It was originally hypothesised that perforin 
generated pores within the target cell membrane providing a gateway to the cytosol for the 
Gzms. However, Thiery et al showed that perforin first acts to create small unstable pores 
within the plasma membrane, which result in a Ca2+ influx and the activation of membrane 
repair mechanisms. Gzms and perforin are then endocytosed and held within intracellular 
vesicles. The Gzms can then “escape” from these vesicles and form larger stable pores 
through the polymerisation of perforin within the vesicle membranes (Thiery et al. 2011). 
Gzms are serine proteases that are characterised by the catalytic triad His-Asp-Ser. 
Humans possess five separate Gzms (A, B, H, K, and M). With the exception of GzmB, 
the mechanism of action of the Gzms is yet to be elucidated (Ewen et al. 2012).  
GzmB has been shown to trigger the activation of the caspase cascade, primarily 
through the cleavage and activation of caspase-3, which initiates a second tier of caspase 
activation through processing of caspase-2, caspase-6 and caspase-9 (Adrain et al. 2005). 
However GzmB can also indirectly activate the caspase cascade by regulating the release of 
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cytochrome C from the mitochondria (Heibein et al. 2000), which can complex with 
apoptotic protease activating factor 1 (Apaf1) and other factors, to produce the 
apoptosome (Riedl and Salvesen 2007). 
Granulysin is a cytolytic molecule present in two forms, a 15-kDa form and a 
truncated 9-kDa form. It is the truncated form that has been shown to be responsible for 
the cytolytic activity associated with granulysin (Hanson et al. 1999). Granulysin directly 
interacts with lipids in the plasma membrane and triggers an influx of Ca2+ ions, thus alters 
the balance between intracellular Ca2+ and K+. This results in damage to the mitochondrial 
membrane and the release of cytochrome C (Kaspar et al. 2001) the formation of the 
apoptosome and activation of the caspase cascade (Riedl and Salvesen 2007).  
Another mechanism utilised by CD8+ T-cells to induce apoptosis involves the 
ligation of the Fas receptor (FasR). Activation of T-cells triggers an up-regulation in 
expression of the Fas ligand (FasL), which enhances the capacity for Fas-mediated cell 
death (Ju et al. 1995; Dhein et al. 1995). Upon ligation FasRs undergo conformational 
changes that allow for the recruitment of the adaptor protein Fas-Associated protein with 
Death Domain (FADD) (Chinnaiyan et al. 1995). This mediates the recruitment of 
caspase-8 and the formation of the Death-inducing signalling complex (DISC) (Scott et al. 
2009). Caspase-8 then undergoes conformational changes that initiate its activation and 
autoproteolytic cleavage. Consequently the activated caspase-8 is released and is able to 
target its intracellular substrates (Boatright et al. 2003).  
1.1.2.2.3 Antigen presenting cells 
The processing and presentation of antigens is essential in enabling the immune 
system to distinguish between self and non-self. The presentation of antigen occurs 
through MHC molecules, which can be divided into two classes (Fig 1.3) (Neefjes et al. 
2011). 
The presentation of antigens can occur by a range of cell types, including but not 
limited to myeloid and plasmacytoid DCs (Steinman and Idoyaga 2010), macrophages 
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(Ziegler and Unanue 1981) and B-cells (Rodríguez-Pinto 2005). These cells are commonly 
referred to as professional APCs because they constitutively express MHC-II and are 
highly efficient at capturing, processing and presenting antigens (Vyas et al. 2008). Non-
professional antigen presenting cells, which include fibroblasts and epithelial cells do not 
express MHC-II under normal conditions, but it’s expression can be induced under 
inflammatory conditions and exposure to IFN-γ (Steimle et al. 1994). 
1.1.2.2.3.1 MHC-I and the presentation of endogenous peptides 
MHC-I molecules present antigens of cytosolic origin, produced through the 
proteolytic processing of intracellular proteins by the proteasome (Fig 1.4a) (Raghavan et 
al. 2008). The delivery of substrates to the proteasome is mediated through the process of 
ubiquitination (Hershko et al. 1980). This multi-step reaction is orchestrated by ubiquitin-
activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s) and ubiquitin-ligating 
enzymes (E3s). The E1s bind to ubiquitin molecules in an ATP-dependent manner and 
induce their activation. The activated ubiquitin is then transferred to E2s and attached to 
the target protein through the activity of E3s (Glickman and Ciechanover 2002). 
Five receptors have been indicated to facilitate ubiquitin recognition. Rpn10 and 
Rpn13 are proteasomal subunits that mediate the direct recognition at the proteasome. 
While Rad23, Dsk2, and Ddi1 are shuttle proteins that apprehend substrates within the 
cytosol and escort them to the proteasome (Finley 2009).  
The process of proteolysis is initiated through the activity of ATPases belonging to 
AAA+ superfamily. Members of this family interact with the 20S core particle (CP) of the 
proteasome and induce gate opening along with protein unfolding and translocation (Smith 
et al. 2006). The CP of the proteasome is a cylindrical structure with narrow openings at 
each end and is comprised of 4 heptameric rings. The inner rings are made up of beta 
subunits while the outer rings are made up of alpha subunits (Baumeister et al. 1998). 
Within the beta rings, only 3 out of the 7 subunits are functionally active (β1, β2 and β5) 
and display differing enzymatic activities (Maupin-Furlow 2011).  
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The immunoproteasome represents a modified version of constitutionally 
expressed proteasome and it’s specific role is to improve the quality and quantity of MHC-I 
binding peptides (Schwarz et al. 2000; de Verteuil et al. 2010). Upon exposure to IFN-γ 
and TNF-α the 3 beta catalytic proteasome subunits are replaced with LMP2 (β1i), MECL-
1 (β2i), and LMP7 (β5i) (Nandi et al. 1996). In a study by Basler et al, it was suggested that 
the differential production of peptides by immunoproteasomes vs. standard proteasomes 
was due to differences in proteolytic cleavage specificity, rather than enhanced production 
of MHC-I binding peptides (Basler et al. 2012).  
The loading of the newly formed peptides onto MHC-I then occurs within the 
endoplasmic reticulum (ER). Transportation of peptide into the ER lumen occurs in an 
ATP-dependent manner via the assistance of the Transporter associated with Antigen 
Processing (TAP) (Neefjes et al. 1993; Androlewicz et al. 1993). Within the ER immature 
MHC-I molecules interact with the TAP complex through the bridging action of tapasin, a 
molecule that enhances peptide loading and stabilises the TAP1/2 heterodimer (Garbi et al. 
2003).  
Along with tapasin several other chaperone molecules are required for peptide 
loading. Calnexin and calreticulin promote the folding of proteins bearing 
monoglucosylated N-linked glycans (Wearsch and Cresswell 2008), while ERp57 mediates 
the quality control of newly synthesised protein. Furthermore, when complexed with 
calnexin, ERp57 facilities the formation of disulphide bonds within the MHC-I heavy 
chain, thus allowing for an association with β2m (Coe and Michalak 2010). 
Collectively these proteins form the peptide-loading complex (PLC) and 
orchestrate the incorporation of antigenic peptides within MHC-I. The MHC-I/peptide 
complexes then dissociate from the PLC, exit the ER and are presented on the cell surface 
for immune surveillance by CD8+ T-cells (Raghavan et al. 2008). 
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1.1.2.2.3.2 MHC-II and the presentation of exogenous peptides 
MHC-II mediates the presentation of peptides of extracellular origin to CD4+ T-
cells (Fig 1.4b) (Neefjes et al. 2011). The process of MHC-II formation occurs within the 
ER and is facilitated by the invariant chain (Ii); which acts as a core allowing the assembly 
of the α and β subset units of MHC-II (Roche et al. 1991), prevents the inappropriate 
loading of antigenic peptides (Roche and Cresswell 1990) and mediates the trafficking of 
MHC-II through the endosomal pathway (Warmerdam et al. 1996).  
The proteolytic processing of the Ii chain within the acidic environment of the 
endosome leaves behind an 20 amino acid (aa) peptide known as the class II–associated 
invariant chain peptide (CLIP) within the peptide binding groove (Chaturvedi et al. 2000). 
Human leukocyte antigen DM (HLA-DM) then mediates the translocation of the MHC-II-
CLIP complex to the late endosome by virtue of a tyrosine signalling motif located in the 
cytoplasmic tail of the HLA-DM β chain (Marks et al. 1995). Furthermore, HLA-DM 
induces conformational changes within the CLIP, which initiates its dissociation from 
MHC-II and enables the recruitment of antigenic peptides (Denzin and Cresswell 1995; 
Sloan et al. 1995).  
Before the loading of antigenic peptides can occur, proteins from the extracellular 
space must be sampled and processed. Potential antigens can enter the endocytic pathway 
through several mechanisms including clathrin and caveolae receptor mediated 
endocytosis, phagocytosis and macropinocytosis (Landsverk et al. 2009). Upon entry of the 
endosome/lysosome pathway, proteins encounter environments of increasing acidity and a 
diverse range of proteolytic enzymes, most notably members of the cathepsin family (Watts 
2001). The precise role that each cathepsin plays in the generation of antigenic peptides has 
yet to be elucidated, however some progress has been made to characterise their activity 
(Chapman 2006). Cathepsin S is the major proteolytic enzyme involved in Ii chain 
degradation (Riese et al. 1996). Furthermore, it has been shown to be essential for the in 
vitro generation of antigenic peptides and the maintenance of antigen specific T-cells in vivo 
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in mice (Shen et al. 2004). Additionally, the involvement of cathepsins B, C, H and X in 
editing the amino- and carboxy-terminal ends of peptides has been suggested (Chapman 
2006). 
Loading of antigenic peptides occurs within MHC-II containing compartments 
(MIICs), which are specialised endosomal organelles that contain all the molecules essential 
for peptide processing, editing and loading (Stern et al. 2006). After antigenic peptides have 
been successfully loaded on to MHC-II molecules, they are ready to be expressed on the 
cell surface. This occurs through the shuttling of MIIC vesicles to the plasma membrane. 
The vesicles then fuse with the plasma membrane, allowing for presentation of MHC-II-
peptide complexes to CD4+ T-cells (Chow et al. 2002; Turley et al. 2000). 
1.1.2.2.3.3 Cross presentation  
Cross presentation is an important yet poorly understood mechanism essential for 
immunosurveillance by CD8+ T-cells. The process involves the presentation of antigen of 
extracellular origin on MHC-I and predominantly occurs in professional APCs via two 
distinct pathways (Rock and Shen 2005). Proteins can be taken up into the cell and are held 
in early endosomes, before being exported into the cytoplasm for proteasomal processing 
and subsequently reimported to the endosomal compartment by TAP for loading on 
MHC-I (Burgdorf et al. 2008). Alternatively proteins can undergo proteolytic processing 
within endosomal compartments before loading on to pre-formed MHC-I (Di Pucchio et 
al. 2008). Examples of this phenomenon have been reported in vitro and in vivo in human 
and murine systems (Bozzacco et al. 2007; Pham et al. 2012). 
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Figure 1.3 Structure of MHC-I and MHC-II molecules. (A) MHC-I molecules are transmembrane 
glycoproteins formed through the non-covalent association of the α chain and β2m. The α chain is arranged 
into 3 extracellular domains α1, α2 and α3 as well as a transmembrane domain and short intracellular region. 
The α1 and α2 are the most distal domains and form the peptide binding groove, which allows for the 
incorporation of antigenic peptides of 8-10 aa residues (Hewitt 2003). However, through alternation in the 
peptide confirmation, longer or shorter peptides can be accommodated (Meydan et al. 2013). (B) MHC-II 
molecules are transmembrane glycoproteins that are formed by the association of single α and β chains, 
which are both arranged into two extracellular domains. The α1 and β1 are the most distal domains and form 
the peptide binding groove. Unlike MHC-I molecules, MHC-II molecules are open ended which allows for 
peptide over hang and the incorporation of larger peptides (Janeway 2012). 
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(A) (B) 
 
Figure 1.4 MHC-I and MHC-II peptide processing and presentation (Adapted from (Kobayashi and 
van den Elsen 2012)). (A) The MHC-I presentation route involves the processing of endogenous proteins 
by the proteasome to generate short antigen peptides to be loaded onto MHC-I molecules. The mature 
MHC-I-peptide complexes can then be shuttled through the ER/golgi apparatus to be expressed on the cell 
surface to CD8+ T-cells. (B) The MHC-II presentation route involves the “capture” of exogenous proteins 
which can be passed through multiple endosomal compartments that contain an array of proteolytic enzymes. 
Before presentation, the peptides must be loaded on the MHC-II, which are first assembled within the ER. 
Peptide loading can then occur within the MIIC and the mature MHC-II-peptide complexes can then be 
expressed on the cell surface to CD4+ T-cells (Neefjes et al. 2011). 
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1.1.2.2.4 T-cell activation  
The recognition of antigenic peptides occurs through the presentation of MHC-
peptide complexes to TCR-CD3 complexes. For complete cellular activation, this 
interaction must occur in concert with ligation of the co-stimulatory receptor CD28 by 
either CD80 or CD86. Furthermore, the process of T-cell activation is modulated through 
the interaction between CD4 and CD8 with their respective MHC molecules (Sharpe and 
Freeman 2002). 
The interface between the APC and T-cell where TCR signalling occurs is known 
as the IS. The IS is characterised by three concentric rings of membrane bound receptors 
and intracellular signalling molecules. The central supramolecular activation cluster 
(cSMAC) is composed of the TCR-CD3 complex and CD28 as well as intracellular 
signalling molecules such as protein kinase C (PKC) and lymphocyte-specific protein 
tyrosine kinase (Lck) (Alarcón et al. 2011). Initially it was thought that the cSMAC served 
as the site of TCR signalling due to the accumulation of TCR:CD3 complexes and 
accessory molecules essential for T-cell activation. However, recent evidence has indicated 
that the cSMAC functions as a site of receptor degradation and thus signal termination. 
Nevertheless, signalling through the cSMAC has been observed and current models suggest 
that the cSMAC can be divided into numerous functional domains, one of which being 
responsible of TCR signalling (Dustin et al. 2010). The cSMAC is surrounded by the 
peripheral SMAC (pSMAC), which is composed of molecules involved in cell adhesion 
such as talin and lymphocyte function-associated antigen 1 (LFA-1). Finally, the most 
external ring is the distal SMAC (dSMAC), which contains molecules such as CD45 
(Alarcón et al. 2011), which have been suggested to lower the threshold of T-cell activation 
(Saunders and Johnson 2010). 
Ligation of the TCR-CD3 complex induces the exposure of the ITAM of the CD3 
γε, δε and ξξ subunits and allows the recruitment of members of the SRC family of kinases 
such as Lck. Lck phosphorylates the ITAM allowing for the recruitment and activation of 
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zeta associated protein 70 (ZAP70), which results in the recruitment and activation of key 
adaptor molecules such as Linker for Activation of T cells (LAT). In turn LAT recruits 
numerous adaptors and downstream signalling molecules to orchestrate the activation of 
multiple signalling pathways responsible for cellular activation, proliferation and survival 
(Brownlie and Zamoyska 2013). 
In conjunction with TCR signalling, signals from the co-stimulatory receptor CD28 
are essential for complete activation and the absence of this second stimulatory signal has 
been shown to induce an unresponsive state known as T-cell anergy (Linsley and Ledbetter 
1993). Ligation of CD28 leads to the recruitment of phosphatidylinositol 3-kinase (PI3K). 
PI3K stimulates the production of the lipids phosphatidylinositol 4,5-bisphosphate (PIP2) 
and phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which associate with 
phosphoinositide-dependent protein kinase 1 (PDK1), resulting in the activation protein 
kinase B (PKB). PDK1 and PKB are then able to phosphorylate downstream signalling 
molecules and mediate the regulation of multiple signalling pathways necessary for protein 
synthesis and cell survival (Rudd et al. 2009). 
1.1.2.2.5 Formation of the immunological memory 
Primary T-cell interactions that occur within the lymph node induce T-cell 
activation in three phases. Naïve T-cells scan the lymph node forming multiple brief 
interactions with APCs; stimulatory interactions then induce the expression of activation 
markers and reduce cell motility. The T-cells then engage in prolonged interactions with 
APCs and secrete IL-2 and IFN-γ. Finally the cells undergo rapid clonal expansion to 
generating a population of highly motile effector T-cells (EFFs). The majority of these T-
cells undergo apoptosis after antigen clearance, but a small subset remain to give rise to 
long lived memory T-cells (Fig 1.5) (Mempel et al. 2004; Henrickson et al. 2008; Allam et 
al. 2009). 
Memory T-cells can be broadly divided into two subsets, central memory T-cells 
(CM) and effector memory T-cells (EM). CM T-cells represent a population of antigen 
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experienced T-cells that reside within secondary lymphoid organs and have the capacity to 
generation multiple waves of effector T-cells in response to secondary antigenic challenge. 
EM T-cells represent a population of antigen experienced T-cells localised to the periphery 
that allow for rapid responses to be generated upon antigen re-exposure (Sallusto et al. 
1999).  
CM T-cells are characterised by the expression of CCR7 and CD62L, which are 
required for migration to secondary lymphoid organs and extravasation via the high 
endothelial venules (HEV). EM T-cells on the other hand down-regulate CCR7 and exhibit 
heterogeneous expression of CD62L. Additionally EM T-cells express an assortment of 
receptors and adhesion molecules that enable them to migrate to sites of inflammation. 
When compared with CM T-cells, EM T-cells exhibit rapid effector functions and cytokine 
production. However, they have reduced replicative potential, shorter telomeres and 
increased sensitivity to apoptosis (Sallusto et al. 2004; Klebanoff et al. 2006).  Interestingly 
EM T-cells can be divided to form 4 distinct subsets based on the expression of the co-
stimulatory molecules CD27 and CD28. The progressive loss of CD28 and then CD27 is 
associated with increased cytotoxicity and cytokine production, but a decrease in replicative 
potential (Romero et al. 2007; Takata and Takiguchi 2006; Okada et al. 2008). 
The specific differentiation pathway taken by naïve T-cells has yet to be fully 
defined and a single model has yet to be agreed upon (Kaech and Cui 2012). Numerous 
studies support the theory that antigen experienced naïve T-cells differentiate into EFF T-
cells which can then mature into memory T-cells (EM and CM) (Wherry et al. 2003; 
Champagne et al. 2001). However, the existence of a long live memory T-cell with stem 
cell-like properties has been hypothesised within the field of immunology for many years. 
This elusive cell type would theoretically have the capacity to repopulate the pool of fully 
differentiated effector and memory T-cells following antigenic stimuli.  
Polychromatic flow cytometry has identified the existence of a discrete memory 
stem T-cell population (SCM) that represent ~2–3% of circulating CD8+ and CD4+ T-cells 
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in humans and non-human primates. These T-cells are characterised by the expression of 
multiple markers associated with a naïve T-cell phenotype but also express high levels of 
CD95, IL7Rβ and other differentiation markers (Gattinoni et al. 2011; Lugli et al. 2013). 
The specific mechanisms that underline the generation of this subset have not yet been 
defined but in vitro activation of naïve T-cells in the presence of IL-2 and IL-7 has been 
shown to play a critical role (Cieri et al. 2013). 
Transcriptional analysis has shown that SCM T-cells exhibit a distinct gene 
expression profile, which is more closely related to memory T-cells then naïve T-cells. 
Furthermore, SCM T-cells have been shown to rapidly acquire effector functions following 
in vitro stimulation, exhibit proliferative and survival advantages and have superior anti-
tumour activity in vivo in mice when compared to other memory subsets (Gattinoni et al. 
2011; Cieri et al. 2013). 
In chronic viral infection and tumour bearing states, constant antigen exposure 
drives T-cells further along the differentiation pathway to generate highly differentiated 
effector memory RA+ T-cells (EMRA) (Champagne et al. 2001; Valmori et al. 2002) and 
then “functionally exhausted” T-cells (Klebanoff et al. 2006). 
EMRA T-cells are described as “highly” differentiated T-cells that are defined by 
the re-expression of CD45RA by EM T-cells. The expansion of this population is normally 
associated with aging, chronic viral infection or tumour burden (Ibegbu et al. 2005; Wills et 
al. 1999; Nunes et al. 2012). EMRA T-cells also exhibit a reduction in replicative potential 
which is associated with the expression of CD57 and Killer cell lectin-like receptor 
subfamily G member 1 (KLRG1) (Ibegbu et al. 2005). Furthermore, EMRA T-cells can be 
divided into three distinct subsets based on the expression of CD28 and CD27 (Romero et 
al. 2007).  
Functionally exhausted T-cells represent a population that displays significant 
reductions in cytokine production, effector function, survival and proliferative potential. 
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Additionally this population is characterised by the expression of immunosuppressive 
receptors, which upon ligation deliver inhibitory signals to the T-cells (Wherry 2011). 
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Figure 1.5 Antigen experienced T-cell development. Exposure to cognate antigen induces the clonal expansion of naïve T-cells which undergo the process of functional and 
phenotypic differentiation to give rise to EFF T-cells. After antigen clearance has occurred remaining EFF T-cells can undergo further differentiation to produce a heterogeneous 
population of memory T-cells, which includes SCM, CM and EM T-cells. Whether or not these cells types represent discrete subsets or if plasticity occurs between them is still under much 
debate. However, it is thought that the SCM T-cells may act to maintain and replenish the CM and EM T-cell populations. Under normal conditions, the memory T-cells contribute to host 
protection from future pathogenic challenge. During chronic viral infections and tumour bearing states, repeated antigen challenge causes T-cells to undergo further differentiation to 
become EMRA T-cells. Over time the T-cell can become functional exhausted, a state which is characterised by a reduction in proliferative potential and effector function, increased 
sensitivity to apoptosis and the expression of immunosuppressive receptors (Klebanoff et al. 2006; Gattinoni et al. 2011). 
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1.2 Cancer immunology 
The immune system has the capacity to recognise and eliminate tumours but many 
of these mechanisms become compromised during the process of neoplastic development 
and progression. Tumours evade the immune system through the activation of inhibitory 
signalling pathways and creating a hostile microenvironment. Furthermore, given the ‘self’ 
nature of tumours, they often exhibit low immunogenicity, which impedes the immune 
system’s ability to “see” the malignant cells (Alderton and Bordon 2012).  
Research into the tumour microenvironment and immune systems of cancer 
patients has provided insights into the evasion mechanisms utilised to prevent the 
elimination of tumours, many of which are described below. An increasing appreciation of 
these mechanisms has led to the development of numerous immunotherapeutic strategies 
(Alderton and Bordon 2012). 
1.2.1 Immunosurveillance and immunoediting 
The concept of immunosurveillance was hypothesised by Burnet and Thomas 
(Burnet 1957). Studies involving immunocompromised individuals/animals have shown a 
greater tendency for the development of malignancies, thus supporting an active role of the 
immune system in preventing tumour development (Dighe et al. 1994; van den Broek et al. 
1996). However, as well as inducing tumour clearance this process can also lead to the 
selection of “lowly” immunogenic tumour variants. Thus it has been suggested that the 
immune system can promote tumour growth as well as rejection. Subsequently the concept 
of immunosurveillance has been revised to include the broad concept of immunoediting 
(Dunn et al. 2004; DuPage et al. 2012). 
Cancer immunoediting can be divided into three processes. The elimination phase 
represents the process of immunosurveillance. Successful completion of this phase should 
result in the clearance of the malignant cell population. An alternative process is a period of 
equilibrium between the host immune system and any remaining malignant cells. While this 
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process keeps the tumour at bay, it also exerts selective pressure on the remaining 
heterogeneous population of tumour cells. The final option is tumour escape and is 
characterised by the rapid proliferation of tumour clones with reduced immunogenicity 
(Dunn et al. 2002; Kim et al. 2007). 
1.2.2 Immune response to cancer 
Cellular and humoral responses to cancer are mediated through the recognition of 
tumour-associated antigens (TAAs), which differentiate malignant cells from their normal 
counterparts. These TAAs can be divided into numerous categories (Jäger et al. 2001).  
Cancer testis antigens are expressed on various malignant tissues, but are absent 
from all normal tissues except the testis (Jäger et al. 2001). The first example of an cancer 
testis antigen was reported by Bruggen et al who demonstrated the expression of MAGE1 
by malignant cells from a single melanoma patient (van der Bruggen et al. 1991). Further 
analysis of melanoma cancer cell lines led to the identification of the closely related genes 
MAGE2 (De Smet et al. 1994) and MAGE3 (Gaugler et al. 1994); both also serve as cancer 
testis antigens. 
Melanocyte differentiation antigens are expressed during the process of melanocyte 
differentiation from epidermal skin cells, and have been associated with CTLs responses to 
melanoma (Jäger et al. 2001). gp100 is a transmembrane glycoprotein that has been 
identified as a highly immunogenic TAA for melanoma. Numerous groups have reported 
the capacity of gp100 specific CTLs to induce killing of gp100+ melanoma cells and induce 
tumour regression (Bakker et al. 1994; Kawakami et al. 1995). Moreover, vaccination with 
gp100 in combination with IL-2 has been shown to increase clinical responses in a small 
number of melanoma patients; inducing tumour regression and prolonged progression-free 
survival (PFS) (Schwartzentruber et al. 2011; Rosenberg et al. 1998). 
TAAs can also be generated from normal cellular components that have undergone 
mutations (Jäger et al. 2001). p53 is an essential tumour suppressor gene that is referred to 
as the “guardian of the genome” (Menendez et al. 2009). Unsurprisingly mutations of this 
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gene have been reported in many cancers (Olivier et al. 2010). For example, tumours from 
squamous cell carcinomas of the head and neck (SCCHN) have been shown to exhibit 
numerous mutations within p53. Several of these mutations have been shown to yield 
immunogenic peptides that are recognised by CD8+ CTLs, which can induce the lysis of 
SCCHN cell lines that possess the specific Y220C mutation (Ito et al. 2007). This 
phenomenon has also been reported in lung cancer (Ciernik et al. 1996) and in other 
malignances with mutations of cellular control genes, such as BRAF (V599E) (Andersen et 
al. 2004). 
The overexpression of unmodified self proteins can also serve as a potential source 
of TAAs (Jäger et al. 2001). The epidermal growth factor receptor HER2 is well-defined 
example of this. HER2 is normally expressed at low levels on epithelial cells and plays an 
important role in tissue development. However, its overexpression in breast cancer induces 
inappropriate cell proliferation and serves as a target for immunotherapy (Vu and Claret 
2012). HER2 specific CTLs have been shown to induce the targeted lysis of HER2+ breast, 
renal and colon cancer cell lines (Brossart et al. 1998). Vaccination with HER2-derived 
peptides has been shown to induce peptide specific T-cell responses in HER2+ breast 
cancer patients (Brossart et al. 2000) and has been associated with prolonged PFS 
(Mittendorf et al. 2011). Furthermore, treatment with monoclonal antibodies against HER2 
have been shown to inhibit tumour growth and prevent metastasis in mice (Scheuer et al. 
2009) and increase the overall survival (OS) of breast cancer patients (Hudis 2007). 
However, as only 15-20% of invasive breast cancers are HER2+ there are limitations to the 
number of patients suitable for HER targeting treatments (Burstein 2005).  
The enhanced proteasomal degradation of self-proteins can serve as an additional 
source of TAAs. The pro-apoptotic protein Bcl-2-associated X (Bax) has been shown to 
undergo enhanced proteasomal processing in cancer cells (Agrawal et al. 2008; Oh et al. 
2010), and subsequently generate peptides that can be presented on MHC-I and allow for 
T-cell recognition and lysis of tumour cells (Nunes et al. 2011). 
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Infection with oncogenic viruses has been associated with cell transformation and 
the development of multiple malignances. Examples include the connection between 
Epstein Barr virus (EBV) infection and B-cell malignances (Rezk and Weiss 2007), Human 
T-cell lymphotropic virus-I (HTLV-I) and T-cell malignancies (Taylor 2006) and human 
papillomavirus (HPV) and cervical cancer. One of the hallmarks of HPV induced cervical 
cancer is the constitutive expression of the viral proteins E6 and E7, which serve as 
potential targets for immunotherapy. CTLs specific for peptides derived from HPV E6 and 
E7 have been shown to induce the targeted lysis of HPV transformed cervical cancer cell 
lines (Liu et al. 2007; Evans et al. 2001). Therapeutic vaccines against HPV have been 
tested in patients and have demonstrated that T-cell responses can be induced (Borysiewicz 
et al. 1996). However the association of a viral infection with the development of cancer, 
provides an opportunity for cancer prevention through the use of prophylactic vaccine. 
Encouragingly, in 2006 and 2007 the Food and Drug Administration (FDA) approved the 
use of prophylactic HPV vaccines Gardasil® and Cervarix®, respectively. Both vaccines have 
proven to be highly effective in preventing a range of HPV infections and the development 
of cervical cancerous lesions (Shi et al. 2007; Paavonen et al. 2009). This prophylactic 
approach can only be applied to cancers caused by infectious agents, and will not work on 
patients with established disease. For other cancers, targeted immunotherapeutic 
approaches will be needed.  
1.2.3 Mechanism of immune evasion  
Tumour evasion of immune responses is one of the confounding factors for the 
development of effective immunotherapies. Along with reducing tumour immunogenicity 
there are various other factors involved in the complex process of immune evasion. 
Immune cells within the tumour microenvironment are usually highly dysfunctional and 
exhibit an increased expression of immunosuppressive receptors. Furthermore, the tumour 
microenvironment is characterised by an increased abundance of immunosuppressive cells 
such as Tregs and myeloid-derived suppressor cells (MDSC) (Kerkar and Restifo 2012; 
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Wherry 2011). The specific details of the relationship between immunosuppression and 
tumour progression is still the subject of much research and debate and hence no unified 
theory on the role of immunosuppression has emerged. 
1.2.3.1 T-cell suppression through immunosuppressive receptors  
The process of T-cell activation is carefully orchestrated through balancing positive 
and negative signals received from the environment. While ligation of molecules such as 
CD28 and CD27 induce an effect that supports T-cell activation, effector function and 
proliferation, there is a wide array of molecules that have opposing effects. These are 
generally termed immunosuppressive receptors. Various immunosuppressive receptors 
have been characterised for human T-cells, however for the purposes of this study three 
will be discussed in detail: PD-1, TIM-3 and LAG-3. 
1.2.3.1.1 Programmed cell death 1 receptor (PD-1) 
PD-1 is a transmembrane immunosuppressive receptor belonging to the Ig 
superfamily. It has two known ligands, programmed cell death ligand 1 and 2 (PDL-1 and 
PDL-2 respectively), which exhibit differing patterns of distribution. PDL-1 is expressed 
on a multitude of haematopoietic cells (T-cells, B-cells, DCs, mesenchymal stem cells and 
mast cells) and non-haematopoietic cells. Furthermore, its expression can be induced in 
response to type I and II IFNs. PDL-2 however has a much more restricted pattern of 
expression but it can induced on DCs, macrophages and mast cells (Keir et al. 2008).  
The expression of PD-1, like many immunosuppressive receptors is governed by 
T-cell activation. The intricate link between T-cell activation and the expression of 
immunosuppressive receptors is thought to act as a “safe guard” to prevent exacerbated T-
cell activation and autoimmune responses (Yokosuka et al. 2012). However, in cases of 
excessive T-cell stimulation, such as chronic viral infections and tumour burden, the 
increased expression of PD-1 has a detrimental effect upon antigen specific T-cells 
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essential for viral (Golden-Mason et al. 2007) and tumour clearance (Ahmadzadeh et al. 
2009).  
Upon expression on the cell surface PD-1 is translocated into the cSMAC and co-
localises with the TCR and CD28. Subsequent activation of PD-1 induces the 
phosphorylation of ITIM and ITSM, and the transient recruitment of the protein-tyrosine 
phosphatase SHP-2. SHP-2 is then able to dephosphorylate the CD3ζ chain and essential 
signalling molecules occurring downstream of the TCR (Chemnitz et al. 2004; Yokosuka et 
al. 2012). It is interesting to note that mutagenesis studies have shown only ITSM is 
essential for PD-1 functionality (Okazaki et al. 2001; Yokosuka et al. 2012). PD-1 signalling 
has been shown to inhibit the production pro-inflammatory cytokines and suppress 
cytotoxic functions, as well as increasing the number of TCR/MHC-peptide interactions 
required to induce cellular activation (Wei et al. 2013). Engagement of PD-1 also inhibits 
the phosphorylation and activation signalling molecules downstream of CD28, such as 
PI3K/AKT (Parry et al. 2005). 
Modulating the effects of PD-1 to restore T-cell function and to reverse immune 
exhaustion has been a focal point of immunotherapeutic research for many years. The use 
of antagonist PD-1 antibodies both in vitro and in vivo in murine systems has been shown to 
increase T-cell survival, proliferative capacity and restore effector functions. This 
restoration of T-cell function has been shown to have a positive effect on viral and tumour 
clearance (Blackburn et al. 2008). In light of this encouraging evidence the efficacy of PD-1 
antagonistic antibodies has been investigated in numerous early phase clinical trials. One of 
the key concerns with using antagonistic antibodies against immunosuppressive receptors 
is the potential loss of immunological control and the generation of autoimmune 
responses. However, recent reports have indicated that antagonism of PD-1 is well 
tolerated and has positive clinical outcome in multiple malignances (Brahmer et al. 2012; 
Topalian et al. 2012; Hamid et al. 2013). 
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1.2.3.1.2 T-cell Immunoglobulin and Mucin Domain 3 (TIM-3) 
TIM-3 is an immunosuppressive receptor expressed upon the surface of IFN-γ 
producing CD4+ and CD8+ T-cells (Rangachari et al. 2012). Members of the Tim family are 
characterised by the expression of an extracellular immunoglobulin variable domain (IgV) 
that possess four non-canonical cysteines, which results in the formation of a unique 
binding groove not observed in any other members of the Ig superfamily. TIM-3 also 
possesses a mucin domain, a transmembrane domain and an intracellular domain 
containing tyrosine based signalling motifs (Sakuishi et al. 2011; Cao et al. 2007). Galectin-9 
(GAL-9) has been historically defined as the ligand for TIM-3 and their interactions has 
been shown to cause cellular aggregation and induce cell death (Zhu et al. 2005). 
Interactions with other galectin molecules at lower affinities have also been observed (Zhu 
et al. 2005) as well as galectin-independent interactions (Cao et al. 2007). However, these 
interactions do not appear to induce the inhibitory effects associated with TIM-3.  
The specific molecular events and downstream signalling molecules that mediate 
TIM-3 activity have not yet been fully defined. However, the ligation of TIM-3 by GAL-9 
has been shown to induce the phosphorylation of multi tyrosine residues present within 
the TIM-3 cytoplasmic tail (van de Weyer et al. 2006; Lee et al. 2011). Rangachari et al 
showed that under “resting” conditions HLA-B-associated transcript 3 (BAT-3) associates 
with the cytoplasmic tail of TIM-3 through interactions with aa residues 252–270. 
However, the ligation of TIM-3 induces the phosphorylation of Y256 and Y263 and results 
in BAT-3 dissociation. This loss of BAT-3 from the cSMAC is of importance due to its 
association with the catalytically active form of Lck, which plays a key role in T-cell 
activation. Therefore it has been suggested that the immunosuppressive effects associated 
with TIM-3 may be mediated by the removal of active Lck from the cSMAC (Rangachari et 
al. 2012). 
The increased expression of TIM-3 on T-cells has been observed in multiple 
chronic viral infections and tumour bearing states. These T-cells exhibit reductions in their 
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proliferative potential, effector functions and have been associated with viral persistence 
and tumour progression. Moreover, the use of antagonist TIM-3 monoclonal antibodies 
has been shown to rescue exhausted T-cells, restore effector function, promote tumour 
regression and viral clearance (Zhou et al. 2011; Ngiow et al. 2011; Sakuishi et al. 2011; 
McMahan et al. 2010). Thus the manipulation of the TIM-3 pathway may represent an 
attractive avenue for immunotherapy. 
1.2.3.1.3 Lymphocyte-activation gene 3 (LAG-3) 
LAG-3 is an immunosuppressive receptor closely related to CD4, which associates 
with MHC-II with greater affinity than CD4 (Huard et al. 1995). The ligation of LAG-3 has 
been shown to inhibit cytokine production, reduce proliferative potential and cause down-
regulation of CD3-TCR complexes in both CD4+ and CD8+ T-cells (Hannier et al. 1998).  
The expression of LAG-3 like many immunosuppressive receptors is intrinsically 
linked to cellular activation. Following antigen recognition and T-cell activation, LAG-3 
redistributes and associates with CD3-TCR complexes (Hannier and Triebel 1999). This 
subsequent recruitment of LAG-3 into the immunological synapse and into close proximity 
with the TCR may play a role in LAG-3 mediated T-cell suppression.  
The exact mechanisms usilised by LAG-3 to inhibit T-cell function are still 
unknown. Nevertheless it has been shown that the LAG-3 cytoplasmic tail, which contains 
multiple signalling domains, is essential for function. Specifically the introduction of a 
mutation within the KIEELE motif has been shown to completely abrogate LAG-3 
function (Workman et al. 2002; Workman and Vignali 2003). Thus these findings suggest 
that the inhibitory effects observed following LAG-3 ligation are due to specific interaction 
between the KIEELE motif and the recruitment of downstream signalling molecules. 
The over expression of LAG-3 has been associated with reduced proliferative 
potential, effector functions and the exhaustion of antigen specific T-cells in multiple viral 
infection and malignances. In addition to an inability to induce viral and tumour clearance. 
However, this can be overcome with the use of antagonistic LAG-3 (Woo et al. 2012; Li et 
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al. 2013; Matsuzaki et al. 2010), suggesting that manipulation of the LAG-3 pathway has 
the potential to augment immunotherapy. 
1.2.3.2 Regulatory cells  
Tregs are a specific subset of CD4+ T-cells that exhibit immunoregulatory 
properties that has been described in detail in section 1.1.2.2.1.  
MDSCs represent a heterogeneous population of partially differentiated myeloid 
progenitor cells and immature myeloid cells that have been shown to inhibit T-cell function 
and proliferation. The increased frequency of MDSCs has been reported in numerous 
human malignances and has been associated with poor prognosis, tumour evasion of host 
immune system and immune dysfunction. The precise mechanisms responsible for MDSC 
specific immune dysfunction have not yet been fully defined. However, the high expression 
of arginase and iNOS by MDSC has been shown to result in the enhanced catabolism of L-
arginine, which inhibits T-cell proliferation. Moreover MDSC have also been shown to 
suppress T-cells through the production of reactive oxygen species (ROS) (Gabrilovich and 
Nagaraj 2009; Talmadge and Gabrilovich 2013; Khaled et al. 2013).  
1.2.3.3 Soluble factors  
Various tumour-derived factors have been shown to contribute to the local and 
systemic immunosuppressive network utilised by cancer cells to evade the immune system. 
This process has been shown to involve the secretion of immunosuppressive cytokines 
such as IL-10 and TGF-β, as well as soluble FasL (Kim et al. 2006). 
Increased blood serum levels of IL-10 and its production following in vitro 
stimulation have been observed in chronic lymphocytic leukaemia (CLL) patients, when 
compared with healthy individuals. Moreover high blood serum levels of IL-10 (≥10 
pg/mL) has been associated with poor prognosis (Fayad et al. 2001; DiLillo et al. 2012). 
Similar findings have been observed with regards to soluble FasL; patients classified as 
ligand “high” (≥6 ng/ml) having shorter median survival (Osorio et al. 2001).  
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1.2.3.4 Reduction in antigen presentation capacity 
Reduced expression of TAAs is a common mechanism utilised by malignant cells 
to evade immune surveillance. This process can involve various mechanisms, such as gene 
deletion, point mutations and chromosomal rearrangements to cause the down-regulation 
or loss of the MHC and/or accessory molecules required for antigen processing and 
subsequent presentation (Rivoltini et al. 2002). 
Loss of TAP (TAP1 and TAP2 subunits) or tapasin expression has been shown to 
result in a down-regulation of MHC-I molecules, most likely due to the expression of 
empty and unstable MHC-I molecules, which would be rapidly endocytosed. Furthermore, 
proteasome defects can lead to impaired peptide processing and reductions in the 
repertoire of TAAs, thus potentially aiding immune evasion (Hicklin et al. 1999). 
Additionally, decreased expression of the co-stimulatory molecules essential for T-
cell activation have been observed in numerous malignancies and in some cases have been 
associated with poor prognosis (Chang et al. 2007). 
1.3 Cancer immunotherapy 
The principle of cancer immunotherapy is to harness and utilise an individual’s 
immune system to treat their disease and promote tumour clearance. Decades of research 
have led to the development of numerous strategies and treatments to achieve this goal. 
Promisingly, cancer immunotherapy was named as the “breakthrough of the year” by the 
journal Science in 2013, which highlights the immense potential that this field possesses 
(Couzin-Frankel 2013).  
1.3.1 Monoclonal Antibodies 
1.3.1.1 Mono-specific  
Monoclonal antibodies can exert their effects directly on malignant cells via 
mechanisms such as ADCC, CDC, blockade of growth factor receptors and the delivery of 
cytotoxic agents (Scott et al. 2012; King et al. 2008). The use of monoclonal antibodies to 
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target preferentially expressed antigens has proven to be successful in the treatment of 
multiple haematological malignancies e.g. CD30 (Brentuximab) in Hodgkin lymphoma 
(Younes et al. 2012). CD20 (Rituximab) in non-Hodgkin lymphoma (Maloney et al. 1997), 
Follicular lymphoma (van Oers et al. 2006), Diffuse Large-B-Cell Lymphoma (Feugier et al. 
2005) and CLL (Badoux et al. 2011). CD33 (Gemtuzumab ozogamicin) in Acute myeloid 
leukemia (Larson et al. 2005) and CLL (Robak et al. 2010). CD52 (Alemtuzumab) in CLL 
(Lundin et al. 2002). 
They have also been shown to be useful for the treatment of solid tumours, which 
includes, ERBB2 (Trastuzumab) in breast cancer (Slamon et al. 2001), VEGF 
(Bevacizumab) in non–small-cell lung cancer (Sandler et al. 2006), EGFR (Cetuximab)  in 
metastatic colorectal cancer (Jonker et al. 2007). 
Additionally monoclonal antibodies can be utilised to modulate T-cell inhibitory 
co-receptors to enhance anti-tumour immunity. Antagonism of immunosuppressive 
receptors, including but not limited to, CTLA-4, PD-1, TIM-3 and LAG-3, separately or in 
combination has been shown to induce anti-tumour immunity and have a significant effect 
on patient survival in multiple malignances (Sakuishi et al. 2010; Woo et al. 2012; Brahmer 
et al. 2012; Hodi et al. 2010; Hamid et al. 2013; Wolchok et al. 2013). However, it should 
be noted that the therapeutic effects observed with single or combined antibody treatment 
have been shown to be highly variable between patients and between malignancies, 
therefore strategies will be needed to identify patients that are most likely to respond to 
treatment. 
Alternatively the use of super-agonistic antibodies against stimulatory T-cell co-
receptors such CD28 and CD27 could provide an alternative option for the use of 
monoclonal antibodies in cancer immunotherapy. The use of agonistic anti-CD28 has been 
shown to induce the proliferation and expansion of T-cells in vitro, in a TCR-independent 
manner (Luhder et al. 2003). However, injection of TGN1412 (an agonistic anti-CD28 
antibody) into healthy volunteers caused the massive release of pro-inflammatory cytokines 
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and induced severe systemic inflammatory reactions. This resulted in the immediate 
hospitalisation of the volunteers, the termination of the trial and highlighted the potential 
dangers involved with the modulation of immune checkpoint regulators (Suntharalingam et 
al. 2006).  
The use of agonistic CD27 antibodies has been shown to enhance T-cell 
proliferation and effector function under sub-optimal TCR activation conditions in murine 
ex vivo experiments. In the absence of TCR signalling no response to CD27 agonistic 
antibodies was observed. Moreover treatment has been shown to induce tumour regression 
and increased survival in mice (He et al. 2013). Due to the dependence on TCR signalling 
to mediate their effects, agonistic anti-CD27 antibodies may be better tolerated clinically, 
than CD28 agonistic antibodies. The anti-CD27 agnostic antibody CDX-1127 is currently 
under investigation for safety and efficacy in humans (He et al. 2013). 
1.3.1.2 Bi-specific T-cell engaging antibodies (BiTEs) 
BiTEs simultaneously engage the TCR via the CD3ε chain and a selected surface 
antigen expressed on cancer cells. This process induces the formation of an 
“immunological synapse” between T-cells and cancer cells, thus allowing for targeted cell 
lysis. The main advantage of BiTEs is their ability to induce the lysis of target cells 
irrespective of TCR specificity and in a MHC-independent manner. A multitude of BiTEs 
have been developed, some of which have been shown to be efficacious for the treatment 
of multiple malignancies (Frankel and Baeuerle 2013).  
Blinatumomab is a BiTE that has been developed for the treatment of multiple B-
cell malignancies and thus possesses dual specificity for CD3 and CD19. Treatment of 
patients with non-Hodgkin lymphoma has been shown to induce the activation and 
expansion of CD4+ and CD8+ T-cells, specifically those of an effector memory phenotype. 
This coincides with the targeted killing of B-cells and in some patients complete and partial 
remissions were observed. Interestingly the treatment not only led to the depletion of 
peripheral tumour cells, but those located within lymph node lesions, the spleen and bone 
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marrow (Bargou et al. 2008). Blinatumomab has also shown efficacy in patients with acute 
lymphoblastic leukemia (ALL) (Topp et al. 2011). 
This technology has also been applied to the treatment of solid tumours with 
multiple BiTEs currently in clinical development. AMG 211 (Micromet) is a BiTE that 
possesses dual specificity for CD3 and CEA. The latter is a cell adhesion molecule that is 
over expressed on multiple cancers such as breast and lung. AMG 212 (Bayer) possesses 
dual specificity for CD3 and PSMA which is over expressed on prostate cancer cells 
(Frankel and Baeuerle 2013). 
1.3.2 Therapeutic vaccines 
The use of therapeutic vaccines to induce a successful immune response against 
pre-existing disease has been investigated within a multitude of cancers, but has failed to 
yield many positive outcomes. Disappointingly it has been reported that >96% of patients 
who received vaccine therapy failed to exhibit evidence of cancer regression, using the 
standard oncological reporting criteria. However, it has been suggested that this may be not 
only due to lack of treatment efficacy, but in part, due to the limitations of the response 
criteria applied when evaluating of immunotherapies (Klebanoff et al. 2010). 
1.3.2.1 Peptide vaccines 
Peptide vaccines are typically made up of a single or multiple aa sequences derived 
from TAA administered in combination with an adjuvant. The aim of this treatment is to 
induce the activation of T-cells specific for known tumour antigens in the hope these T-
cells will then be able to specifically target and kill tumour cells. Thus far they have failed to 
yield many positive results, which could be due to antigenic heterogeneity observed within 
patients and/or tumour-associated immune dysfunction. Additionally in vivo these peptides 
are susceptible to the rapid degradation by serum factors and can be tolerogenic when 
presented by non-professional APCs (Slingluff 2011). 
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Despite the mounting negative data, some successes has been achieved with the use 
of peptide vaccines, for example the treatment of melanoma patients with gp100 peptide 
vaccine in combination with IL-2 had an increased median survival of over six months 
when compared to patients who received IL-2 only (Schwartzentruber et al. 2011). 
1.3.2.2 Dendritic cell vaccines 
DCs are specialised APCs that have the capacity to capture, process, and present 
antigens to T-cells. Furthermore, they express essential co-stimulatory and adhesion 
molecules required for the formation of the immunological synapse and subsequent 
antigen specific T-cell activation (Adams et al. 2005; Banchereau and Steinman 1998). 
DC vaccines can be divided into three categories, each with the goal of providing 
retrospective anti-tumour immunity to patients (Palucka and Banchereau 2013).  
(1) Non-targeted peptide vaccines that are captured by DCs in vivo, as described 
above in section 1.3.2.1. 
(2) Antigenic peptides coupled to antibodies specific for DC markers, such as the 
endocytic receptor DEC-205, administered in combination with a selected adjuvant to 
enhance DC maturation. Treatment of DCs derived from healthy individuals and cancer 
patients in vitro with DEC-205 targeting vaccines have been shown to induce enhanced 
antigen processing and presentation. This resulted in activation and proliferation of antigen 
specific T-cells and the induction of effector functions (Birkholz et al. 2010). The capacity 
of this strategy has been evaluated in vivo in murine systems. The treatment of mice with 
DEC-205 targeting vaccines in combination with agonistic anti-CD40 has been shown to 
stimulation T-cell mediated immunity, induced effector functions and prevented the 
development of antigen-specific tumours (Bonifaz et al. 2004). Treatment with DEC-205 
targeting vaccines, in combination with adjuvants, in humans has been shown to induce 
humoral and cellular immunity against the tumour antigen NY-ESO-1. Furthermore, 
stabilisation of disease was observed in 13 patients and two patients experienced significant 
tumour shrinkage (Dhodapkar et al. 2014). While the clinically reported results are modest, 
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they highlight that DEC-205 targeting vaccines were well tolerated in vivo, induced both 
humoral and cellular immunity and exhibited some clinical effects. This supports their 
further development.  
(3) Ex vivo loading of DCs with antigen peptides. This process involved in the ex 
vivo culture of monocytes/ peripheral blood mononuclear cells (PBMCs) in cytokine 
conditioned media to induce their differentiation and development into DCs, which can 
then be loaded with selected tumour antigens and re-infused in patients. Thus far DC 
vaccines of this nature have been shown to be well tolerated and induced the activation 
and expansion of antigen specific T-cells (Palucka and Banchereau 2012). 
The greatest achievement thus far achieved with DC-based vaccines was the 
development of Sipuleucel-T, which in 2010 become the first cancer vaccine and cell based 
therapy approved by the FDA. Sipuleucel-T is an immunotherapy produced by the ex vivo 
treatment of autologous patients DCs with the recombinant fusion protein PA2024, which 
is made up of prostatic acid phosphatase fused to granulocyte–macrophage colony-
stimulating factor. In a double-blind, placebo-controlled, multi-centre trial it was shown 
that Sipuleucel-T induced humoral and cellular immune responses and increased the 
median survival by 4.1 months, over the placebo controls (Kantoff et al. 2010). Collectively 
these findings highlight the efficacy of in vivo targeting or ex vivo manipulation of DCs to 
induce anti-tumour immune responses and highlight the importance of effective antigen 
presentation to mediate this effect. 
1.3.3 Adoptive T-cell transfer (ACT) 
ACT is an active immunotherapeutic approach that involves the identification, ex 
vivo expansion and re-infusion of autologous or allogeneic T-cells with anti-tumour activity. 
Various approaches have been shown to increase the efficacy of ACT, such as lympho-
depletion before infusion, specifically targeting immunosuppressive cell types such as Tregs 
and complementing the transfusion with homeostatic cytokines. Furthermore, the 
differentiation state of the T-cells selected for reinfusion has been shown to be highly 
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important. While highly differentiated CD8+ T-cells exhibit increased effector functions in 
vitro they have been shown to be up to 100-fold less effective in vivo than T-cells at an early 
stage of differentiation, such as CM T-cells, due to defects in proliferative potential and 
increased sensitivity to apoptosis (Rosenberg et al. 2008; June 2007; Gattinoni et al. 2006). 
ACT has been shown to be successful in the treatment of patients with melanoma. 
In a clinical trial by Rosenberg et al, 20 out 93 patients (22%) showed complete tumour 
regression with ongoing regression beyond three years being observed in 19 patients 
(Rosenberg et al. 2011). Furthermore, melanoma specific ACT as been successful for the 
treatment of metastatic melanoma (Hong et al. 2010). In addition, ACT has shown varying 
degrees of efficacy in the treatment of other malignancies (June 2007) such as gastric 
cancer; patients that received ACT plus chemotherapy exhibited significantly longer 
survival (>3 months) when compared with chemotherapy alone (Kono et al. 2002). 
1.3.3.1 Genetic modification of T-cells 
Achieving successful T-cell engraftment, survival, proliferation and ultimately T-cell 
function can be hindered by the limitations associated with the cellular “starting material” 
and the hostile tumour microenvironment of the patients. Thus the genetic manipulation 
of T-cells to increase their efficacy and resistance to immunosuppressive strategies is an 
attractive option for cancer immunotherapy.  
To enhance survival and in vivo longevity, CTLs can be transduced with chimeric 
GM-CSF-IL-2 receptors. These T-cells deliver IL-2 signalling as a consequence of GM-
CSF binding, which results in an autocrine loop of proliferative signals (Evans et al. 1999). 
Other strategies include engineering T-cells to ubiquitously express the co-stimulatory 
receptor CD28 (Topp et al. 2003) and the catalytic subunit of telomerase reverse 
transcriptase (hTERT) to enhance replicative potential (Rufer et al. 2001). Additionally, the 
introduction of a chimeric protein expressing the extracellular PD-1 domain and the 
intracellular CD28 domain could redirect PD-1 signalling and overcome 
immunosuppression (Prosser et al. 2012). However, as many of these mechanisms redirect 
 Chapter 1: Introduction 
 
 Page 41  
“normal” T-cell processes to enhance activation, survival and proliferation, great care must 
to taken to not induce inappropriate T-cell responses, which could lead to the development 
of T-cell leukaemias. Furthermore, the specificity of T-cells can be redirected through TCR 
gene transfer and the use of chimeric antigen receptors. 
1.3.3.1.1 TCR gene transfer 
Under normal circumstances the antigen specificity of T-cells is dictated by the re-
arrangement of specific TCR α and β chains. The genetic transfer of new TCR α and β 
chains, utilising retroviral or lentiviral constructs, allows for the redirection of T-cell 
specificity towards a selected TTAs. This process has the potential to be a promising 
immunotherapy strategy for the treatment of various malignances as well as viral infectious 
diseases (Thomas et al. 2010). It has been shown that TCR transduced cells can be 
activated by antigen in vivo, undergo significant expansion, home to effector sites and 
contribute to tumour clearance in murine models (Schumacher 2002). 
For stable TCR expression the α and β chains must form a heterodimer and 
associate with the CD3 complex. However, the undesired pairing of introduced TCR 
chains with endogenous TCR chains could occur and result in the generation of TCRs of 
unknown specificity, which could potentially be auto-reactive (Kershaw et al. 2014). This 
highlights one of the main limitations of this approach. 
1.3.3.1.2 Chimeric Antigen Receptors Therapy (CAR-T) 
CAR-T is an immunotherapeutic strategy that involves manipulating and re-
directing the specificity of autologous T-cells towards a selected cell-surface antigen. 
Chimeric antigen receptors (CARs) combine the antigen-recognition domain of a specific 
monoclonal antibody with an intracellular domain of the CD3-ζ chain or FcγRI, which 
allows the receptor to trigger T-cell activation. Furthermore, the lack of HLA specificity 
and MHC recognition required for recognition makes the process an attractive personalised 
‘off the shelf’ immunotherapy (Maus et al. 2014).  
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The first generation of CAR-T trials involved the introduction of only a chimeric 
antigen receptor into prospective T-cells but had limited success as a treatment option as 
the absence of co-stimulatory signalling led to anergy and failure to expand in vivo (Heslop 
2010). However, the addition of co-stimulatory signalling domains from molecules such as 
CD137 (4-1BB) and CD28 have been shown to enhance CAR-mediated T-cell responses 
and has led to the emergence of second and third generation CARs (Maus et al. 2014). 
This approach has been applied to both solid tumours (Zhao et al. 2009) and 
haematological malignancies, in various in vitro and in vivo models and clinical trials 
including CLL (Porter et al. 2011; Kalos et al. 2011) and ALL (Grupp et al. 2013). 
Encouragingly it has been recently shown that CAR T-cells can be detected in patients 11 
years post infusion at frequencies higher than expected for most vaccine approaches 
(Scholler et al. 2012). 
1.4 Chronic lymphocytic leukaemia 
CLL is a B-cell leukaemia that is characterised by the accumulation of mature B-
cells in the blood, bone marrow, lymph nodes and lymphoid tissue. These cells can be 
phenotypically identified by their expression of CD19, CD5 and CD23, and the low 
expression of other markers such as CD22 (Zenz et al. 2010b). 
1.4.1 Aetiology and epidemiology 
CLL is most common type of leukaemia in the western world, representing 22-30% 
of all leukaemia cases with a worldwide incidence of between 1 and 5.5/100,000 people. 
The incidence of CLL increases with age, with the median age at diagnosis being 64-70 
years of age. Furthermore, CLL has been shown to be more prevalent in males than 
females (approximately 2:1) and the highest incidence in Caucasians (Redaelli et al. 2004).  
The specific cellular origin and the exact mechanisms that result in development of 
CLL are still unknown. However, it is widely accepted that CLL is derived from the 
development of a CD19+CD5+ pre-malignant B-cell (Seifert et al. 2012). Familial history 
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has been shown to be a risk factor associated with the development of CLL (Goldin et al. 
2009), suggesting the role of inherited traits in the manifestation of the disease. Multiple 
genome-wide association studies have identified numerous single nucleotide 
polymorphisms (SNP) that are associated with an increased incidence of disease in CLL 
patients such as hTERT and protection of telomeres protein 1 (POT1) which are both 
important in telomere maintenance (Di Bernardo et al. 2008; Speedy et al. 2013). 
1.4.2 Symptoms and diagnosis 
Diagnosis is made based on the detection of a clonal population of B-cells within 
the bone marrow, lymphoid organs or the peripheral blood, that bears the phenotypic and 
morphological hallmarks associated with CLL. Furthermore, the presence of at least 5000 
CD19+CD5+ B-cells/L is required for a diagnosis (Gribben 2010). At the time of diagnosis 
many patients present with few symptoms but this changes with disease progression. 
Common symptoms include hepatomegaly, splenomegaly, lymphadenopathy and a increase 
in lymphocyte doubling time, leading to the accumulation of malignant CLL cells (Hallek 
2005). Furthermore, due to inherent abnormalities in humoral and cell mediated immunity, 
CLL patients are subject to numerous opportunistic infections (Morrison 2010). 
1.4.3 Staging 
Rai (Rai et al. 1975) and Binet (Binet et al. 1981) developed the current systems 
utilised for the clinical staging of CLL patients. The Rai staging system is based on the 
progressive accumulation of malignant CLL cells due to lymphocytosis, lymphadenopathy, 
splenomegaly and hepatomegaly. While the Binet staging systems is based upon the 
involvement of five specific lymphoid sites (cervical, axillary and inguinal lymph nodes, 
spleen and liver) with the disease. Collectively these two systems allow patients be divided 
into those that have early (Binet A, Rai 0), intermediate (Binet stage B, Rai I and II) or 
advanced (Binet stage C, Rai III and IV) disease. However, to obtain a comprehensive 
evaluation of an individual patient’s disease, likelihood of progression, time to first 
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treatment (TTFT) and overall predicted survival, numerous molecular prognosis markers 
must be considered (Gribben 2010). 
1.4.4 Prognostic markers 
CLL is highly heterogeneous disease with some patients presenting with stable non-
progressive disease, while other rapidly progress to develop an aggressive disease. These 
two forms of CLL can be stratified based on the presence of a combination of prognostic 
markers (Gribben 2010). 
1.4.4.1 ZAP-70 
ZAP-70 is a member of the protein-tyrosine kinase family that is typically expressed 
by T-cells and natural killer cells (Wang et al. 2010). Multiple independent studies have 
shown that the high expression of ZAP-70 (>20% ZAP-70+ CLL cells) is associated with 
shorter PFS and OS (Del Principe et al. 2006; Dürig et al. 2003) as well as shorter TTFT 
(Rassenti et al. 2008).  
The specific molecular mechanisms behind this have not yet been fully elucidated 
but the increased expression of ZAP-70 has been associated with enhanced signalling via 
the BCR in CLL cells (Chen et al. 2005). Furthermore, the expression of ZAP-70 has been 
shown to enhance nuclear factor-κB (NF-κB) signalling downstream of the BCR. Pede et al 
demonstrated that the induction of ZAP-70 in previously ZAP-70- CLL cells induced the 
expression of NF-κB target genes (IL-1β, IL-6 and IL-8) at the mRNA and protein level, 
following BCR signalling. Furthermore, blockade of the NF-κB resulted in a complete 
knockdown of the expression of the NF-κB target genes described above (Pede et al. 
2013). In addition, the increased expression of ZAP-70 has been shown to enhance cell 
survival and increase the expression of chemokine receptors, adhesion molecules and cell 
migration (Calpe et al. 2011; Richardson et al. 2006). 
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1.4.4.2 CD38 
CD38 is a single chain type II transmembrane molecule involved in regulating the 
activation and proliferation of T-cells. However, it’s expression on CLL cells can be utilised 
to differentiate patients into two sub-groups with different clinical outcomes (Damle et al. 
1999; Del Poeta et al. 2001). Patients that have >30% CD38+ CLL cells have been shown 
to have shorter OS, TTFT and higher absolute lymphocyte counts (Malavasi et al. 2011).  
The exact cause of the poor prognosis associated with increased CD38 expression 
is still not fully known. However, CD38+ CLL cells have been shown to more resistant to 
apoptosis in in vitro culture, suggesting they may have a survival advantage, over their CD38- 
counterparts. Furthermore, CD38+ CLL cells exhibit a differential gene expression profile 
when compared to CD38- CLL isolated from the same monoclonal source. For example, 
CD38+ CLL cells have relative over expression of genes associated with cytoprotection and 
resistance to apoptosis, such as MCL-1 and VEGF (Pepper et al. 2007).  
CD38 has one known ligand, CD31 (Deaglio et al. 2010). The interaction between 
these molecules has been shown to induced the proliferation of CLL cells and induce a 
gene transcript signature associated with cell migration and lymph node homing (Deaglio et 
al. 2010). Furthermore, the expression and activation of CD38 has been shown to increase 
the migration of cells in response to the chemo-attractant CXCL12 (Vaisitti et al. 2010). 
Additionally, when compared to CD38- CLL cells, CD38+ CLL cells have been shown to 
have higher levels of cGDPR and cADPR, both of which are associated with Ca2+ 
mobilisation. This indicates that CD38 is enzymatically active in CLL cells. Furthermore, 
transfection of the CLL-like cell line, Mec-1, with CD38 was shown to significantly 
increase the production of cADPR and induce proliferation and cell migration, when 
compared with CD38- Mec-1 cells and Mec-1 cells transfected with a enzymatically 
defective mutant CD38 (Vaisitti et al. 2015). 
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1.4.4.3 CD49d 
The process of leukocyte migration from the periphery to second lymphoid organs 
is a 4 stage process that involves tethering and rolling across the endothelial surface, 
leukocyte stimulation, cell arrest, spreading and finally migration. At each stage α4 integrins 
play a critical role (Rose et al. 2002).  
CD49d is an α subunit of the α4β1 lymphocyte homing receptor, which interacts 
with vascular cell adhesion molecule-1 (VCAM-1) and is key in the lymphocyte migration 
(Zucchetto et al. 2012). Furthermore, it has been shown that interaction between CD49d 
and its ligand can inhibit the process of apoptosis through the up-regulation of the anti-
apoptotic molecule BCL-xL (Koopman et al. 1994; Hayashida et al. 2000). 
The expression of CD49d has been shown to be highly variable in CLL patients, 
however high expression has been shown to significant correlate with other CLL related 
prognostic markers, and is associated with shorter TTFT and OS (Nückel et al. 2009; Majid 
et al. 2011; Gattei et al. 2008). Additionally it has been shown the CD49d is the most 
powerful flow-based marker for the evaluation of CLL prognosis (Bulian et al. 2014).  
Although the specific mechanism for these clinical correlations is unknown, it 
could be hypothesised that CLL cells with high CD49d expression are able to more readily 
undergo migration re-enter lymphoid tissue tumour microenvironments that are 
cytoprotective and drive proliferation. Interestingly the blockage of CD49d in a 
physiologically relevant model of the peripheral vasculature was shown to inhibit CLL cell 
migration (Walsby et al. 2014) This suggests that CD49d could be a useful therapeutic 
target for the treatment of CLL. 
1.4.4.4 Immunoglobulin heavy chain variable (IGHV) mutation 
The formation of Ig through the selection and recombination of the V, D and J 
domain gene segments occurs within the bone marrow. These genes can then be subject to 
somatic hypermutation within the germinal centres of secondary lymphoid organs, to 
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produce high affinity Ig. This process of somatic hypermutation, specifically within the 
IGHV region, has been shown to stratify CLL patients into two discrete subsets which 
exhibit significantly different clinical outcomes (Damle et al. 1999). Patients with 
unmutated IGHV regions (>98% homology to germline) have been shown to have a 
median survival time that is over three times shorter than patients with mutated IGHV 
status (Hamblin et al. 1999). 
The specific cellular origin of unmutated and mutated CLL is still an area 
surrounded by a great deal of debate. Some suggest that both mutated and unmutated CLL 
is derived from same subset of marginal zone B-cells (Chiorazzi and Ferrarini 2011). While 
others support the concept that unmutated IGHV CLL is derived from naive “pre-
germinal centre” B-cells and mutated IGHV CLL from antigen experienced B-cells 
presented within the germinal centres (Gribben 2010). Interestingly, transcriptome analyses 
of CLL cells and normal B-cells from healthy PBMCs has shown that mutated IGHV CLL 
cells were transcriptionally more similar to CD5+CD27+ memory B-cells while unmutated 
IGHV CLL cells were transcriptional more similar to CD5+CD27- B-cells (Seifert et al. 
2012). This suggests potential differences in the cellular origin of unmutated and mutated 
CLL. 
1.4.4.5 Genetic aberrations 
Analysis of CLL cells by fluorescent in situ hybridisation (FISH) has led to the 
identification of multiple genetic aberrations that can be associated with prognosis and 
patient outcome. Deletion of the short arm of chromosome 17 (del 17p) occurs in 
approximately 7% of CLL patients and has been associated with highly aggressive disease 
and is typically accompanied by loss of p53 function. p53 plays an intrinsic role in 
regulating the cell cycle, repairing DNA damage and initiating apoptosis when DNA repair 
fails, thereby preventing the introduction of mutations that may lead to cell transformation 
and cancer (Menendez et al. 2009). Unsurprisingly mutations of p53 have been widely 
associated with significantly shorter PFS and OS in CLL. Furthermore, patients with p53 
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mutations or deletions exhibit greater resistance to treatment and increased incidence of 
relapse (Zenz et al. 2010a; Rossi et al. 2014). 
Deletion of the long arm on chromosome 11 (del 11q) occurs in approximately 
15% of CLL patients and is associated with aggressive disease, shorter survival and 
unmutated IGHV status (Döhner et al. 2000). The presence of three copies of 
chromosome 12 (trisomy 12) occurs in approximately 15% of CLL patients and has also 
been associated with shorter survival (Döhner et al. 2000). Conversely deletion of the long 
arm of chromosome 13 (del 13q), which is the most common genetic aberration observed 
in CLL (approximately 50%), is associated with a favourable clinical outcome and mutated 
IGHV status (Döhner et al. 2000; Chiorazzi 2012). 
1.4.4.6 CD4:CD8 ratio 
Healthy middle-aged individuals have a CD4:CD8 T-cell ratio between 2-11, 
however with age it has been observed that there is a steady decrease in this ratio, which 
can sometimes result in an inversion (CD4:CD8 ≤1). The inversion in the CD4:CD8 ratio 
in “healthy” individuals has been associated with CD4+ and CD8+ T-cells of a highly 
differentiated or activated phenotype, and decreased survival in follow-up studies (Wikby et 
al. 2002; Strindhall et al. 2007; Olsson et al. 2000). 
Within CLL patients this inversion has been associated with a highly differentiated 
memory phenotype in both the CD4+ and CD8+ T-cells, increased PD-1 expression as well 
as significantly shorter TTFT and PFS (Nunes et al. 2012). The specific mechanism behind 
this observation is unknown, however it could be related to phenotypic and potentially 
functional differences within the T-cell compartment of normal ratio (CLLNR) and inverted 
ratio (CLLIR) CLL patients.  
1.4.5 The lymph node microenvironment 
CLL cells derived from the peripheral blood are predominantly in G0/G1 “resting” 
phase of the cell cycle. This is in stark contrast to the cells located within the specialised 
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niche known as the lymph node microenvironment, where CLL cell survival and 
proliferation is supported by a host of accessory cells (Fig 1.6) (Messmer et al. 2005; Burger 
and Gribben 2014). Because of the reliance on external signals from the 
microenvironment, CLL cells express an array of adhesion molecules to facilitate migration 
and infiltration into the lymph nodes (Behr et al. 1998). In keeping with this statement, the 
recent development of a model in vitro circulating system has shown that CLL cells under 
sheer force up-regulate the expression of L-selectin (CD62L), CXCR4 and CD49d (Walsby 
et al. 2014), all of which are involved in cell migration and chemotaxis (Venturi et al. 2003; 
Burger et al. 1999).  
Once within the lymph node mircroenvironment CLL cells are able to interact with 
bone marrow-derived stromal cells, nurse-like cells and T-cells, which collectively provide 
proliferative and cytoprotective support (Burger and Gribben 2014). However, it is T-cells, 
specifically CD4+ helper cells that have been shown to be essential for the engraftment, 
survival and proliferation of CLL cells in in vivo murine systems (Bagnara et al. 2011). 
Furthermore, it has been shown that proliferating CLL cells co-localise with activated 
CD4+ within lymph nodes of patients (Patten et al. 2008). 
1.4.6 Immunological defects within CLL 
T-cells from CLL patients have been shown to exhibit numerous defects in their 
ability to form IS with CLL cells. Co-culture of healthy allogeneic T-cells with CLL cells 
has been shown to significantly decrease the recruitment of key molecules involved in the 
formation of the IS and impair recruitment of Lck (Ramsay et al. 2008). Collectively, the 
data from this study indicates that direct interaction between CLL cells and T-cells 
interferes with recruitment of molecules essential for the formation of the IS and thus 
antigen-dependent activation. Therefore it could be suggested that CLL cells are able to 
evade the immune system by preventing the recognition of potential TAAs by inhibiting 
the successful formation of the IS and induction of T-cell activation. Additionally, it has 
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shown CLL cells have been shown to decrease the differentiation of Th1 cells and cause a 
skewing towards a Th2 response (Görgün et al. 2005).  
Additionally, the increased expression of PD-1 has been observed within the CD8+ 
T-cell populations, specifically within the effector population. This increased expression 
has been associated with the inversion of CD4:CD8, a known marker for poor prognosis 
(Nunes et al. 2012), suggesting a role of immunosuppressive receptors in disease 
progression. However, the increased expression of PD-1 has also been associated with the 
increased production of the effector cytokines IFN-γ and TNF-α (Riches et al. 2013) 
suggesting that PD-1+ T-cells in CLL patients may represent an activated rather than an 
exhausted phenotype. Therefore investigations into the expression of multiple 
immunosuppressive receptors may be required to distinguish between activated and 
exhausted T-cells within CLL. 
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Figure 1.6 The CLL tumour microenvironment (Adapted from Fecteau and Kipps 2012). Accessory 
cells within the lymph node microenviroment provide proliferative and supportive signals to CLL cells in a 
contact dependent (receptor-ligand interactions) and independent manner (cytokines and chemokines).  
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1.4.7 Treatments 
The treatment approaches used for CLL are extremely wide and varied, which is to 
be expected in such a heterogeneous disease. Over the past decades the treatment options 
for patients have dramatically improved and expanded to include chemotherapy, utilising 
established and novel compounds, immunotherapy and combinations of the two 
approaches, known as chemoimmunotherapy. 
1.4.7.1 Chemotherapy 
1.4.7.1.1 Alkylating agents 
Generally cancer cells undergo more rapid proliferation and have defects within 
multiple DNA repair mechanisms, when compared to healthy cells. Thus making them 
more susceptible to DNA damage. Alkylating agents act though the transfer of alkyl carbon 
groups onto the DNA bases, resulting in covalent adducts and the formation of DNA 
lesions. Due to defects in the DNA repair processes in cancer cells, double-strand DNA 
breaks can accumulate and result in cell death (Fu et al. 2012). 
The most widely used alkylating agents in the treatment of CLL are chlorambucil 
and cyclophosphamide. However, the exact mechanisms of action through which these 
drugs work still remains unclear. Chlorambucil has been shown to intercalate into 
numerous cellular components such as proteins, RNA and DNA; the intercalation with 
DNA, and the induction of cross-linking and subsequent DNA damage is thought to 
mediate the major anti-tumour effects (Begleiter et al. 1996). Cyclophosphamide is pro-
drug that requires in vivo metabolism to produce active derivatives, such as 4-hydroxy-CTX. 
It has been suggested that cyclophosphamide derivatives can induce cytoskeleton 
alterations and the expression of anti-angiogenic and pro-apoptotic factors. Furthermore, 
cyclophosphamide has been suggested to have immunomodulatory effects (Penel et al. 
2012).  
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Despite its use as a front line therapy, chlorambucil has been shown to have a low 
level of efficacy and no effect on OS (Dighiero et al. 1998). Therefore there remains a need 
for new and improved treatments. Bendamustine is a novel alkylating agent that received 
FDA approval for use in CLL in 2008. When compared to chlorambucil as first line 
treatment, bendamustine induced significantly higher response rates and longer PFS 
(Knauf et al. 2009). 
1.4.7.1.2 Purine analogues 
Purine analogues are a class of drugs that mimic the structure of metabolic purines, 
inhibit the function of multiple enzymes involved in DNA synthesis and repair, and 
ultimately induce cell death via apoptosis. There are currently several purine analogues used 
in the treatment of CLL, including fludarabine, cladribine and pentostatin (Pettitt 2003). 
Fludarabine is the most extensively used purine analogue in the treatment of CLL. 
Fludarabine is a pro-drug that requires metabolism and dephosphorylation for successful 
entry into CLL cells. The metabolite must then undergo rephosphorylation in order to 
produce the active substance F-ara-ATP. F-ara-ATP inhibits enzymes involved in DNA 
synthesis, such as DNA polymerase, primase and ligase (Ricci et al. 2009). The clinical 
efficacy of fludarabine has been investigated in numerous studies and has been shown to 
have an overall response rate of 53-74% in patients and is more effective than cladribine 
and pentostatin. However, fludarabine is still not a curative option and numerous side 
effects have been associated with its use such as myelosuppression and the development of 
secondary malignancies (Lukenbill and Kalaycio 2013). Thus more research towards the 
development of specific and targeted therapy options is required. 
1.4.7.2 Emerging pharmaceutical agents 
Bruton tyrosine kinase (BTK) has been shown to play a key role in signalling 
downstream of the BCR and is expressed in multiple B-cell malignancies (Hendriks et al. 
2014), including CLL, however the level of expression has been shown to be highly 
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variable among patients (Herman et al. 2011). Ibrutinib is a specific BTK inhibitor that 
inhibits the kinase activity through irreversibly binding to the cysteine at position 481 
(Hendriks et al. 2014). In vitro treatment with ibrutinib has been shown to induce apoptosis 
and inhibit replication of CLL cells, even in the presence of pro-survival signals designed to 
mimic the in vivo microenvironment (Herman et al. 2011; Ponader et al. 2012). Ibrutinib 
treatment has been shown to inhibit disease progression in vivo in murine systems (Ponader 
et al. 2012) and inhibit in vivo proliferation in CLL patients (Cheng et al. 2014). Recently, a 
phase 3 multi-centre clinical trial showed that treatment with Ibrutinib increased PFS and 
OS in comparison to treatment with the anti-CD20 monoclonal antibody, Ofatumumab 
(Byrd et al. 2014). 
PI3Ks are another family of molecules essential for transmitting signals from the 
BCR (Srinivasan et al. 2009). PI3Ks can be divided into 3 classes with class I containing 
four different isoforms. Of interest, PI3Kδ has been shown to be critical for B-cell survival 
and function (Fruman and Rommel 2014). Idelalisib is a PI3Kδ isoform-specific kinase 
inhibitor, in vitro treatment has been shown to inhibit cell migration in response to 
chemokine gradients and decrease cell viability even in the context of BCR activation. 
Additionally, treatment has been shown to inhibit the phosphorylation and activation of 
AKT and ERK (Hoellenriegel et al. 2011).  
Idelalisib has been shown to be well tolerated and when used as a single agent has 
shown a 72% response rate in CLL patients. Additionally, it was shown that patients 
treated with ≥150mg had signifcantly longer PFS then those treated with a lower dose (32 
months vs 7 months) (Brown et al. 2014). Futhermore, Idelalisib when used in 
combination with Rituximab resulted in signifcant improvements in PFS and OS, 
compared to Rituximab alone (Furman et al. 2014).  
1.4.7.3 Haematopoietic stem cell transplantation (HSCT) 
 Allogeneic HSCT involves the transfer of HSCs from a HLA tissue-matched 
donor to a recipient. The aim is to use the donor immune system to induce a graft versus 
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leukaemia (GVL) effect and thereby promote the killing of the recipient’s CLL cells. 
However, there is also the potential for the development of graft versus host disease 
(GVHD) (Dreger and Montserrat 2002). Generally HSCTs is not a suitable treatment 
strategy for many CLL patients due to the indolent nature of the disease and the age-
related risks associated with transplantation. Furthermore, the efficacy of HSCT in 
comparison to other more suitable treatments is still unclear (Gribben 2009). A recent 
study has shown that HSCT can result in prolonged event-free survival for some patients, 
when compared to those who received no treatment. However, when compared to 
chemotherapy as a first-line therapy it offered no survival advantage (Dreger et al. 2010). 
Therefore further research is required to determine the efficacy and value of HSCT as a 
treatment option over immunotherapy, chemotherapy or combination of them both.  
1.4.7.4 Immunotherapy 
1.4.7.4.1 CLL specific monoclonal antibody therapy 
CD20 is a phosphoprotein ubiquitously expressed by CLL cells making it an 
attractive target for mAb therapy. Rituximab is a chimeric CD20 antibody that when used 
as a single agent to treat CLL is able to induce the clearance of circulating malignant cells, 
but this effect can only be sustained with further treatment (Winkler et al. 1999). 
Furthermore, the rate of complete remission observed with rituximab treatment is 
extremely low (9%) (Hainsworth et al. 2003). However, when used in combination with 
standard chemotherapy, rituximab has proven to have greater clinical efficacy (Robak et al. 
2010; Badoux et al. 2011). Since the development of rituximab, second and third 
generation CD20 antibodies have been developed which interact with different CD20 
epitopes and contain different Fc fragments to enhance binding to Fc gamma receptors. 
Ofatumumab is a third generation type I, fully humanised CD20 antibody, which 
recognises a different region of the CD20 protein than rituximab, and has been shown to 
be effective in CLL patients that are refractory to fludarabine and alemtuzumab (Wierda et 
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al. 2011; Wierda et al. 2010). Obinutazumab is a third generation type II fully humanised 
CD20 antibody that has been shown to significantly prolong PFS and OS compared to 
chlorambucil alone or rituximab plus chlorambucil (Goede et al. 2014).  
CD52 is a glycoprotein that is highly expressed on a variety of haematopoietic cells 
including normal and malignant B and T-cells, but not HSCs (Rodig et al. 2006). 
Alemtuzumab is a humanised CD52 antibody, which has been shown to be effective in the 
treatment of CLL patients, specifically fludarabine refractory patients (Keating et al. 2002; 
Montillo et al. 2008). 
BiTE represent a novel antibody therapy, described in section 1.3.1.2, that involves 
the conjugation of Ab fragments that simultaneously engage the TCR and antigen on target 
cells. Blinatumomab is a BiTE that has dual specificity for the CD3 and CD19 and proven 
to be successful in the treatment of numerous hematological malignancies. To date 
blinatumomab has not been tested in vivo in the context of CLL. However, in vitro treatment 
of PBMCs from CLL patients was shown to induce the activation and expansion of T-cells, 
specifically of an effector memory phenotype. Furthermore, these T-cells released cytotoxic 
granules, expressed high levels of effector cytokines and induced apoptosis of CLL cells 
(Wong et al. 2013).  
While antibody therapy has been shown to be beneficial in the treatment of CLL, 
this therapeutic option does have limitations such as high cost of production, limited 
access to tumour microenvironments and discrepancies between the in vitro and in vivo 
results have been observed (Chames et al. 2009). 
1.4.7.4.2 T-cell based therapies  
1.4.7.4.2.1 CLL associated tumor antigens 
One of the key factors of any successful T-cell based therapy is the identification of 
TAAs expressed exclusively by malignant cells but absent on healthy tissue, to prevent off-
target effects. One of the common sources of TAAs are proteins that are overexpressed 
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specifically by the malignant cells. Survivin (Schmidt et al. 2003), MDM2 (Mayr et al. 2006), 
CD23 (Bund et al. 2007), RHAMM (Giannopoulos et al. 2006) and CD229 (Bund et al. 
2006) have all been shown to be relatively overexpressed by CLL cells. Moreover, peptide-
specific CTL lines generated from healthy donors and CLL patients have been shown to be 
activated in response to CLL cells and induce their targeted lysis. However, in each of the 
reported cases T-cell clones specific to a defined peptide epitope were never generated. 
Vaccination with peptides derived from RHAMM has been investigated in a limited 
number of CLL patients. RHAMM vaccination appeared to increase the frequency of 
RHAMM-specific T-cell in vivo in CLL patients, which exhibited effector function ex vivo 
and could induce the lysis of autologous CLL cells. However, the data presented in the 
study was highly variable and the association with clinical efficacy was weak (Giannopoulos 
et al. 2010). Therefore further research on the identification of more immunogenic targets 
is clearly required. 
Proteins that exhibit other irregularities in their expression can also be potential 
TAAs in CLL. For example the pro-apoptotic protein Bax has been shown to undergo 
enhanced proteasomal degradation in CLL (Agrawal et al. 2008). As the proteasome is 
instrumental in the generation of MHC-I/peptide complexes it could be hypothesised that 
peptides derived from the degradation of Bax could be presented to CD8+ T-cells. This 
concept was confirmed in a proof-of-principle study by Nunes et al, in which Bax-specific 
CD8+ T-cell clones, isolated from healthy individuals, were able to induce the targeted lysis 
of CLL cells (Nunes et al. 2011). However, the existence of these T-cells in CLL patients 
was not explored. 
1.4.7.4.3 CLL specific CAR-T 
CART-19 is lentiviral vector that expresses the chimeric antigen receptors specific 
for the B-cell antigen CD19, as well as the CD3-zeta chain and the signalling domain for 
CD137. Recognition of CD19 by CART-19 transduced T-cells has been shown to induce 
the temporal release of various cytokines and the lysis of leukaemia cells, as well as healthy 
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B-cells, in vivo. Furthermore, these modified T-cells have been shown to expand >1000-
fold in vivo and persist in the peripheral blood and bone marrow of patients for up to six 
months. It has been hypothesised that after the elimination of the tumour cells, CART-19 
T-cells may be stimulated by healthy B-cells within the bone marrow to generate “CAR 
memory”, thus allowing for the maintenance of CART-19 T-cells in vivo and hence 
immunosurveillance (Kalos et al. 2011; Porter et al. 2011). While CART-19 has proven to 
be an extremely effective treatment, it has the major drawback of targeting normal healthy 
B-cells.  
The receptor tyrosine kinase-like orphan receptor 1 (ROR1) was identified as a 
highly expressed gene in malignant CD19+ CD5+ CLL cells, but not normal B-cells (CD19+ 
CD5-), T-cells (CD19- CD5+) or other components of PBMCs (CD19- CD5-), isolated from 
CLL patients and healthy individuals. Furthermore, the expression of the protein in normal 
B-cells does not appear to be affected by activation status. This tight regulation and 
association with CD19+ CD5+ malignant CLL cells makes ROR1 a highly attractive target. 
Promisingly, ROR1-CAR T-cells from healthy donor and CLL patients have been shown 
to induce target lysis of CLL cells in vitro, while having no effect on resting, activated, and 
EBV-transformed B-cells (Hudecek et al. 2010). 
Further refinement of this approach has shown that the addition of a shorter 
“hinge” section and a higher affinity mAb region can significantly improve ROR1-CAR T-
cells effector function, their ability to lyse target cells and their in vitro proliferation. 
Additionally, in in vivo mice experiments ROR1-CAR T-cells were shown to have 
comparable efficacy to CD19-CAR transduced T-cells (Hudecek et al. 2013). Therefore the 
use of CAR T-cells targeting ROR1 appears to be a promising immunuotherapeutic 
strategy for the treatment of CLL. However, while CAR transduced T-cells appear to be 
highly promising option for the treatment of CLL, serious adverse effects, and in extreme 
cases patient deaths, associated with the release of pro-inflammatory cytokines, have been 
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reported in some clinical trials (Brentjens et al. 2009; Kochenderfer et al. 2012; Morgan et 
al. 2010). 
1.4.7.5 Combination therapy  
Due to the numerous varieties of treatment options available for CLL patients, the 
combination of different therapeutic strategies has been employed. The addition of 
monoclonal antibodies to “traditional” chemotherapy has been actively investigated. For 
example, the combination of fludarabine, cyclophosphamide and rituximab (FCR), is now 
generally regarded as the gold standard of treatment for CLL. This is because treatment 
with FCR resulted in improvement in overall response rates, PFS and OS when compared 
to FC or single agent therapy (Tam et al. 2008; Hallek et al. 2010; Badoux et al. 2011).  
1.5 Hypothesis and Aim 
1) The enhanced proteasomal degradation of Bax will render CLL cells susceptible to 
immune surveillance by CD8+ T-cells 
a) Determine the existence of Bax-specfic T-cells in HLA-A2+ patients 
b) Isolate and clone Bax-specfic T-cells  
c) Characterisation of Bax-specfic T-cells 
d) Determine the ability of Bax-specfic T-cells to recognise and kill HLA-A2+ CLL 
cells. 
2) The inversion in the CD4:CD8 ratio will be associated with phenotypic and 
transcriptional hallmarks of immune exhaustion. 
a) Investigation the expression of marker associated with immunological 
differentiation (CD57 / CD27) and immune suppression (PD-1 / TIM-3/ LAG-3) 
within the CD4+ and CD8+ T-cell compartments. 
b) Investigate the expression of the immunosuppressive ligands with the B-cell 
compartment  
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c) Investigation transcription differences in genes related to T-cell activation and 
anergy within the CD4+ and CD8+ T-cell compartments of CLL patients. 
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Chapter 2  
Materials and Methods 
2.1 Tissue culture basics 
2.1.1 Media and buffers 
FCS-RPMI 
Roswell Park Memorial Institute (RPMI) 1640 (Sigma) was supplemented with L-
Glutamine (2mM, Invitrogen), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) buffer (25mM, Sigma), penicillin (100U/ml, Invitrogen), streptomycin 
(100µg/ml, Invitrogen) and foetal calf serum (FCS) (10%, Invitrogen). 
 
Serum-free RPMI 
RPMI 1640 was supplemented as above but without the addition of FCS. 
 
AB-RPMI  
RPMI 1640 was supplemented as above but without FCS. Instead 5% human AB serum 
was added (Welsh blood service). 
 
FCS-DMEM 
Dulbecco’s Modified Eagle’s Media (DMEM) (Sigma) was supplemented with L-
Glutamine (2mM), HEPES buffer (25mM), penicillin (100U/ml), streptomycin (100µg/ml) 
and FCS (10%). 
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Cryopreservation solution 
FCS (50%), RPMI 1640 (40%) and 10% dimethyl sulfoxide (DMSO) (Sigma). 
Cyropreservation solution was stored at -20oC or 4oC. 
 
Magnetic-activated cell sorting (MACS) separation buffer 
Sterile phosphate buffered saline (PBS) (Invitrogen) was supplemented with bovine serum 
albumin (BSA) (0.5%, Sigma) and ethylenediaminetetraacetic acid (EDTA) (2mM, Sigma). 
The buffer was then sterile filtered using a 0.2µm bottle top filter (Millipore). 
 
Fluorescence-activated cell sorting (FACS) buffer 
PBS was supplemented with FCS (1%). 
2.1.2 Tissue culture plastics 
All tissue culture flasks (T25 and T75) and plates (6, 48 and 96 wells) were obtained from 
Greiner Bio-one or Fisher. 
2.1.3 Cell counts and viability 
Cell counts and cell viability were assessed using a Vi-Cell XR (Beckman Coulter) or 
manually using trypan blue solution (Sigma) and a haemocytometer (Hycor). For the Vi-
Cell XR, cells were diluted 1 in 10 in PBS and added to a cell counting cup (Beckman 
Coulter). The cups were loaded into the Vi-Cell XR, the cell suspension was taken up, 
mixed with trypan blue and the viable cells were counted. For manual counting the cell 
suspension was diluted 1 in 10 with trypan blue solution (Sigma) and loaded (10µl) into a 
haemocytometer slide. Viable cells were then counted using a high-resolution microscope 
and non-viable (stained dark blue) cells were excluded from the count. The number of 
cells/ml, was calculated by taking the average count as follows: (mean of 2-3 grids × 10) × 
10000. 
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2.1.4 Routine maintenance of cell lines 
Culturing established cell lines 
Adherent and non-adherent cell lines were cultured in T25 or T75 flasks in FCS-RPMI or 
FCS-DMEM. Cells were routinely split 1:3 every 2-3 days using the following procedure.  
Adherent cells were first rinsed with sterile PBS (10ml) and then incubated at 37oC for 5-10 
minutes with EDTA-trypsin (1ml - T25 or 5ml - T75, Invitrogen). After the cells had 
detached, an appropriate volume of FCS-RPMI was added to deactivate the trypsin (5ml 
for a T25; 15ml for a T75). The cells were harvested, centrifuged at 470×g for 5 minutes, 
resuspended in the appropriate media and split between new flasks.  
 
Cryopreservation of cells  
Selected cells were pelleted by centrifugation, before being resuspended in cryopreservation 
solution (2-10×106 cells/ml) and divided between cryovials (Greiner Bio-one). The 
cryovials were then placed in a Nalgene 5100 cryofreezing container (Merck Laboratory 
Supplies) at -80oC for 24 hours. The cells were then transferred to liquid nitrogen for long-
term storage. 
 
Thawing cryopreserved cells 
Cells were rapidly thawed using a 37oC water bath and then aliquoted into a new sterile 
tube containing FCS-RPMI. The cells then centrifuged at 470×g for 5 minutes and 
resuspended in the appropriate media for further use. 
2.2 Peptide Libraries 
2.2.1 Bax peptide pool P601 – P623 
The Bax peptide pool P601-P623 consisted of 23 peptides (9-mer and 10-mer) that 
originated from the Bax-α protein. These peptides were identified as potential antigens 
through the use of computer algorithms (BIMAS, SYFPEITHI, SMM, MHCpep, NET 
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MHC, EpiJen) that predict HLA binding. Within the pool there were fourteen peptides 
predicted to bind HLA-A*0201, one to HLA-A3, one to HLA-B7, two to HLA-A1, two to 
HLA-B8 and three to HLA-B44 (Table 2.1). The peptides were synthesised to a purity of 
greater than 35% (Mimotope) and dissolved in DMSO to produce stock solutions 
(10mg/ml and 50mg/ml) and peptide pools (10mg/ml). The individual peptides and 
peptide pools were stored at -80oC. 
 
Table 2.1 Bax peptide pool P601-623 
 
2.2.2 Nonamer combinatorial peptide library (CPL) 
The Nonamer CPL (Pepscan) was acquired from Professor Linda Wooldridge (Faculty of 
Medical and Veterinary Sciences, Bristol University) and contained a total of 5×1011 
different nonamer peptides and was divided into 180 different peptide mixtures. In every 
peptide mixture, one position had a fixed L-amino acid residue and all other positions were 
degenerate, with the possibility of any one of 19 natural L-amino acids being incorporated 
at each position (cysteine was excluded, due to its high oxidative potential). Each library 
Number Sequence Position HLA 
Restriction 
Databases Purity (%) 
601 RMGGEAPEL 37 A2 6/6 73 
602 QIMKTGALL 18 A2 4/6 37 
603 LLSYFGTPT 161 A2 4/6 77 
604 LLQGFIQDRA 26 A2 3/6 83 
605 GLLSYFGTPT 160 A2 3/6 79 
606 FVAGVLTASL 176 A2 3/6 67 
607 ELQRMIAAV 75 A2 5/6 69 
608 ALDPVPQDA 46 A2 4/6 65 
609 LLLQFIQDR 25 A2 4/6 83 
610 TIMGWTLDFL 135 A2 3/6 51 
611 FLRERLLGWI 143 A2 3/6 76 
612 KLSECLKRI 58 A2 6/6 36 
613 IMGWTLDFL 136 A2 6/6 68 
614 ALCTKVPEL 124 A2 6/6 64 
615 DELDSNMEL 68 B44 3/3 51 
616 MELQRMIAA 74 B44 3/3 77 
617 SEQIMKTGAL 16 B44 3/3 68 
618 CLKRIGDEL 62 B8 2/3 49 
619 ASKLVLKAL 117 B8 3/3 37 
620 GGWDGLLSY 156 A1 2/5 59 
621 DTDSPREVF 84 A1 4/4 84 
622 VALFYFASK 111 A3 5/5 78 
623 SPREVFFRV 87 B7 3/5 84 
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mixture consisted of 1.7×1010 different nonamer peptides in approximately equimolar 
concentrations. 
2.2.3 Peptides identified from the CPL screen 
Three degenerate peptide sequences were utilised to probe the UniProt Knowledgebase 
peptide database, to identify potential antigenic peptides originating from multiple 
biological sources (self, viral, bacterial and fungal). Degenerate peptides searches were 
performed on 13/5/2013 using the ScanProsite (de Castro et al. 2006). Ten peptides (Table 
2.2) were synthesised to purities of greater than 95% (Peptide synthetics) and dissolved in 
DMSO to produce stock solutions (10mg/ml and 100mg/ml). The peptides and were 
stored at -80oC. 
 
Table 2.2: Candidate peptides identified from nonamer CPL 
Type Source Sequence Purity 
Optimal  N/A IIGWMWIPV >95% 
Self Protein LYRIC LLGYGWAAA  >95% 
Parathyroid hormone 2 receptor.    LIGWGFPAA >95% 
Serine palmitoyltransferase small subunit B YTAYVFIP >95% 
Viral Influenza A virus VVWYGGRPV >95% 
Varicella-zoster virus STGYGLARI >95% 
FSPYGWSST >95% 
Hepatitis C virus subtype 1a KAAYGFTGI >95% 
Bacterial Staphylococcus    FIAWGFIAA >95% 
Fungal Candida dubliniensis MIAWGFISV  >95% 
  
2.3 Peptide binding assay 
T2 cells (1×105) were cultured in serum-free media (100µl) supplemented with peptide 
(10µg/ml) overnight at 37oC in a 5% CO2 atmosphere. MART-1 peptide (ELAGIGILTV, 
ProImmune), which is an analogue of the natural MART-1 peptide (AAGIGILTV), was 
used as a positive control due to its superior HLA-A2 binding properties. Cells were also 
treated with DMSO alone as a negative control. After the incubation period, the cells were 
washed and stained with anti-human HLA*A201-Fluorescein isothiocyanate (FITC) 
(Biolegend, Clone BB7.2). The cells were washed once and resuspended in FACS buffer 
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(200µl). The cells were analysed using an Accuri C6 flow cytometer (BD) and data analysis 
was performed using CFlow software (BD). HLA-A2 expression was quantified as the 
percentage increase according to the formula:  
% change in MFI = [(mean fluorescence with peptide - mean fluorescence without 
peptide) / mean fluorescence without ×100]. 
2.4 Blood origin and preparation 
2.4.1 Blood donors 
Whole blood samples from CLL patients were obtained from outpatient clinics held at the 
University Hospital Wales and Llandough Hospital by Professor Chris Fegan. Dr Guy 
Pratt also provided additional CLL samples from Birmingham Heartlands Hospital. 
Professor Chris Fegan also provided age-matched control samples derived from healthy 
volunteers. In all cases informed consent and ethical approval was obtained in compliance 
with the ethical approval granted for this study [South East Wales Research Ethics 
Committee (02/4806)]. 
2.4.2 Isolation of PBMCs 
Fresh blood samples from healthy donors were collected in falcon tubes containing heparin 
(10U/ml; LEO Pharma) and CLL blood samples were collected in EDTA tubes (BD). In 
both cases PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation. The 
blood was carefully layered on top of the Histopaque (Sigma) at a 1:1 ratio and centrifuged 
at 840×g for 20 minutes with the centrifuge brake off. The PBMC monolayer formed at 
the interface between the plasma and Histopaque was carefully aspirated using a sterile 
pasteur pipette (Fisher Scientific). The cells were washed in PBS (at least three times the 
volume of the aspirated PBMC) and centrifuged at 470×g for 5 minutes with the brake on. 
The supernatant was aspirated; the cell pellet was resuspended in 1x red blood cell lysis 
buffer (Miltenyi, 1ml) and incubated at room temperature for 10 minutes. The cells were 
washed with PBS and centrifuged at 470×g for 5 minutes. The supernatant was aspirated; 
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the cells were resuspended in an appropriate volume of media and counted using the Vi-
Cell XR. 
2.5 Primary cell cultures 
2.5.1 CLL cell co-culture 
Irradiated (6000 rads) murine fibroblast expressing CD40L was cultured in 6-well (1×106 
cells/well) or 24-well (1×105 cells/well) tissue culture plates in FCS-DMEM overnight at 
37oC in a 5% CO2 atmosphere to allow for cell adhesion. The media was aspirated the 
following day and the wells were washed with PBS (1ml). CLL cells was then placed on top 
of the fibroblast layer in FCS-RPMI supplemented with IL-4 (5µg/ml; Miltenyi), at a ratio 
of 10:1 CLL cells:fibroblast. CLL cells were harvested after two days for further use. 
2.5.2 In vi tro culture of T-cells and CLL cells 
Enriched CD8+ T-cells, as described in section 2.6.1, were cultured in a 48-well tissue 
culture plates in of AB-RPMI (1ml) supplemented with IL-7 (10ng/ml, Peprotech) for two 
days, to allow for the activation of CLL cells to serve as APC. CD8+ T-cells (≥2×106) were 
cultured in the presence of irradiated (3000 rads) activated CLL cells at a ratio of 1:4 in AB-
RPMI (1ml) supplemented with IL-2 (40U/ml, Proleukin) and Bax peptides (10µg/ml). 
The initial T-cell stimulation was performed with fresh CLL cells and all subsequent 
stimulations were done with cryopreserved cells. On day three, AB-RPMI (500µl) 
supplemented with IL-2 (120U/ml) and IL-7 (30ng/ml) was added to each well. The 
cultures were harvested on day seven, counted and re-stimulated. The cells were re-
stimulated for five weeks and the immunogenicity of the Bax peptides was determined via 
IFN-γ ELISpot assays as described in section 2.8.1. 
2.5.3 Nonamer CPL screen 
C1R-A2 cells (6×105) were pre-incubated with each peptide mixture (1mM) in 
serum-free media (50µl) for two hours at 37°C in a 5% CO2 atmosphere. After the peptide 
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pulsing phase, CD8+ T-cells (3×105) in AB-RPMI (50µl) were added to each well. 
Phytohaemagglutinin (PHA) (10µg/ml, Sigma) was used as a positive control to determine 
the presence of viable responsive cells. The cells were incubated at 37°C in a 5% CO2 
atmosphere for 16-18 hours. Cell-free supernatants (75µl) were then harvested and stored 
at -20oC for further processing. C1R-A2 cells were acquired from Professor Linda 
Wooldridge and used as APC for experiments using macrophage inflammatory protein 1 
beta (MIP-1β) as a functional readout, due to the low background production of M1β 
observed with C1R-A2 cells. 
2.5.4 Expansion of T-cells using allogeneic feeder cells 
T-cells (1×106) were placed in a T25 tissue culture flask with AB-RPMI media (25ml) 
supplemented with IL-2 (20U/ml), PHA (10µg/ml) and irradiated PBMC (4×105/ml, 
isolated from 2-3 allogeneic donors). The flasks were then incubated at a 45o angle to 
enhance the cell-to-cell contact for five days at 37°C in a 5% CO2 atmosphere. 
After five days AB-RPMI (1ml) supplemented with IL-2 (520U/ml) was added to 
each flask. The flasks were the returned to the original position for an additional 2-3 days. 
The cells were then harvested, counted and cultured (2×106 cells/ml) in 24-well tissue 
culture plates in AB-RPMI (1ml) supplemented with IL-2 (100U/ml) and IL-15 (50ng/ml). 
After 3-4 days the cells were split 1:2 and AB-RPMI (500µl) supplemented with IL-2 
(100U/ml) and IL-15 (50ng/ml) as was added to each well. T-cells were then harvested and 
cryopreserved for future use. 
2.6 Cell enrichment 
2.6.1 Enrichment of T-cells and CLL cells using magnetic microbeads 
CD8+ and CD4+ T-cells were enriched through positive selection using anti-human CD8 or 
CD4 microbeads (Miltenyi). Furthermore, CD19+ CLL cells were enriched through 
positive selection using anti-human CD19 microbeads (Miltenyi).  
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PBMC were washed once in PBS and centrifuged at 470×g for 5 minutes. The 
supernatant was removed and the cells were resuspended in cold MACS buffer (80µl/107 
cells) and CD8 or CD4 microbeads (20µl/107 cells). The cells were mixed thoroughly and 
incubated at 4oC for 15 minutes under rotation using a MACSmix (Miltenyi). The cells were 
then washed in cold MACS buffer (2ml/107 cells) and centrifuged at 470×g for 5 minutes. 
The supernatant was then poured off and the cells were resuspended in cold MACS buffer 
(500µl) for magnetic enrichment using the autoMACS Pro Separator or manually using MS 
columns (Miltenyi). 
MS columns were washed with cold MACS buffer (500µl) and then the samples 
were then loaded on to the column. The unlabelled cells passed through the column, which 
was then washed three times with cold MACS buffer (500µl). The positively selected cells 
were then eluted from the column. The column was removed from the magnetic field and 
washed with cold MACS buffer (1ml). Rather than allowing the cells to pass through, the 
positively selected cells were forced through using a syringe plunger. The enriched fraction 
was then passed through a second column to maximise purity. The cells were counted and 
an aliquot was then assessed for purity by flow cytometry.  
2.6.2 Enrichment of IFN-γ secreting T-cells 
Peptide-specific IFN-γ production was induced by culturing the polyclonal CD8+ T-cells 
with the Bax peptide pool (10µg/ml) presented on irradiated (3000 rad), autologous 
activated, CLL cells at a 1:1 ratio. The cells were cultured in AB-RPMI (500µl) in a 24-well 
tissue culture plate for five hours at 37°C in a 5% CO2 atmosphere. The cells were then 
harvested, transferred to a 15ml falcon tube and washed with cold MACS buffer (10ml). 
The cells were centrifuged at 470×g for 5 minutes and the supernatant was carefully 
aspirated. The cells were resuspended in cold MACS buffer (80µl/107 cells), IFN-γ 
microbeads added (20µl/107 cells) and the mixture incubated on ice for 5 minutes.  
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To reinitiate the process of IFN-γ secretion the cells were resuspended in warm 
AB-RPMI and incubated under gentle rotation for 45 minutes. The volume of media was 
selected according to the expected number of IFN-γ positive cells (<5% 1-2×106 cells/ml 
or 5-20% 1-2×105 cells/ml). To terminate IFN-γ secretion the cells were then incubated at 
4oC under gentle rotation for 10 minutes using a MACSmix (Miltenyi). The cells were 
subsequently centrifuged at 470×g for 5 minutes and the supernatant was carefully 
aspirated. The cells were then resuspended in cold MACS buffer (80µl/107 cells) containing 
detection antibody (20µl/107 cells) and incubated on ice in the dark for 10 minutes.  
The cells were then washed in cold MACS buffer (10ml), centrifuged and the cell 
pellet was resuspended in cold MACS buffer (80µl/107 cells) and anti-Phycoerythrin (PE) 
microbeads (20µl/107 cells) and incubated at 4oC for 15 minutes. The cells were washed in 
cold MACS buffer (10ml), the cell pellet was resuspended in cold MACS buffer (500µl) and 
separated using the MS magnetic columns as described in section 2.6.1.  
IFN-γ+ CD8+ T-cells were then “rested” overnight in AB-RPMI (200µl) 
supplemented with IL-2 (40U/ml) and IL-7 (10ng/ml) at 37°C in a 5% CO2 atmosphere. 
The cells were then cloned using limiting dilution as described in section 2.7.1. 
2.7 Generating peptide-specific T-cell clones 
2.7.1 Generation of T-cell lines from peptide-specific T-cells under limited 
dilution 
After IFN-γ enrichment and “resting”, T-cells were counted using a haemocytometer and 
approximately 800 cells were recovered. The T-cells were diluted in varying volumes of 
cloning mixture to achieve either 0.5 cells/50µl or 10 cells/50µl. The cloning mixture 
consisted of AB-RPMI supplemented with IL-2 (20U/ml), PHA (10µg/ml) and irradiated 
PBMC (4×106/ml, isolated from 2-3 allogeneic donors). The combined T-cell/cloning 
mixture was then added to 96-well U bottom tissue culture plates (50µl/well) and the plates 
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were then incubated for 7 days at 37°C in a 5% CO2 atmosphere. 6 plates of 0.5 cells/well 
were produced and 2/3 of a plate of 10 cells/well was produced. 
On day seven the cells were “fed” with AB-RPMI (100µl) supplemented with IL-2 
(100U/ml) and IL-15 (50ng/ml). On day 14 supernatant (100µl) was removed from each 
well and replaced with fresh cloning mixture (100µl). For the duration of this procedure 
the cells were checked regularly and cultures that showed a high level of growth (large 
pellet size and yellow media) were split 1:2 into new wells.  
The process of alternating “feeding” with high dose IL-2 + IL-15 and replacement 
of cloning mixture was repeated for five weeks, after which the T-cell lines were tested for 
peptide specificity by IFN-γ ELISpot assay as described in section 2.8.1.  
2.7.2 Screening of peptide-specific lines  
T-cell lines were produced as described in section 2.7.1 and were tested for Bax peptide 
reactivity by IFN-γ ELISpot assays as described in section 2.8.1. To determine the average 
number of cells/culture, four wells were randomly selected and counted using a 
haemocytometer. The values ranged from 0.6×105 – 5.7×105 cells, with an average count 
of 2.47×105 cells/well.  
Each T-cell line (~3×104 cells) was then cultured individually with T2 cells at a 1:1 
ratio ± Bax peptide pool (10µg/ml) in AB-RPMI (150µl) at 37oC in a 5% CO2 atmosphere 
for 16-18 hours. The ELISpot plates were then developed as described in section 2.8.1. 
2.8 Detection of peptide-specific responses  
2.8.1 IFN-γ ELISpot 
The wells of MultiScreenHTS IP Filter Plates (Millipore) were coated with anti-human IFN-γ 
antibody (10µg/ml, Mabtech) for 24 hours at 4oC and then washed five times with PBS 
(150µl/well). FCS-RPMI (100µl) was then added to each well and the plates were incubated 
at room temperature for 1 hour. The washing process was then repeated.  
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T-cells (1×105 polyclonal T-cells or 1-3×104 T-cell clones) were cultured in AB-
RPMI (150µl) in triplicate at 1:1 ratio with APC ± peptides (10µg/ml) for 16-18 hours at 
37oC in a 5% CO2 atmosphere. T-cells were also incubated in the absence of APC (negative 
control) or with mitogen (positive control).  
The plates were washed three times with PBS (150µl/well) and were incubated with 
sterile water (100µl/well) at room temperature to lyse any remaining cells. The plates were 
washed a further two times with PBS and incubated with a secondary biotinylated antibody 
(50µl/well, 10µg/ml, Mabtech) at room temperature for two hours. The plates were 
protected from direct light by covering in metal foil for the duration of the incubation 
process. The plate was then washed five times with PBS and incubated with streptavidin 
(50µl/well, 10µg/ml, Mabtech) at room temperature for two hours. 
Development solution was made by combining 25xAP colour development buffer 
(40µl, Bio-Rad) and AP conjugate substrate A (10µl, Bio-Rad) and B solution (10µl, Bio-
Rad) with sterile water (1ml). Subsequently, 50µl of this solution was added to each well 
and incubated at room temperature for 10-50 minutes. Again, the plates were protected 
from direct light by covering in metal foil for the duration of the incubation process.  
Plates were then washed four times with tap water and air dried in the dark. The 
numbers of spots/well were counted with an ELISpot reader (Oxford Biosystems 
Cadama). Wells were also checked by eye to correct for any machine counting errors e.g. 
false positive or false negative spot counts. Peptide-specific responses were calculated by 
subtracting the spot counts for T-cells + T2 (background response) from the T-cells + T2 
+ peptide wells. 
2.8.2 IFN-γ Intracellular staining 
T-cells (1×105) were cultured in AB-RPMI (180µl) at 1:1 ratio with T2 cells ± peptide or 
PHA (10µg/ml). GolgiStop™ (0.7µl, BD) and GolgiPlug™ (1.0µl, BD) were diluted in 
PBS (198.3µl) and the solution (20µl) was then added to each sample. The samples were 
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then spun down to increase the cell-to-cell contact and incubated for 5-6 hours at 37°C in a 
5% CO2 atmosphere. The cells were then washed once with FACS buffer and co-stained 
with anti-human CD3-FITC (Biolegend - clone UCHT1) and CD8-Peridinin chlorophyll 
protein (PerCP) (Biolegend – clone HIT8a) for 15 minutes at 4oC. The cells were then 
fixed with solution A (50µl) for 15 minutes at room temperature and permeabilised with 
solution B (50µl) for 15 minutes at room temperature using a Leucoperm™ kit (AbD 
Serotec). Intracellular IFN-γ was identified through the addition of anti-human IFN-γ-PE 
(eBioscience - clone 4S.B3) during the permeabilisation step. The cells were washed once, 
resuspended in FACS buffer (200µl) and then analysed using an Accuri C6 flow cytometer 
(BD). Data analysis was performed using CFlow software (BD). 
2.8.3 IFN-γ enzyme-linked immunosorbent assay (ELISA) 
T-cells (1×105) were cultured in AB-RPMI (200µl) at a 1:1 ratio with peptide pulsed T2 
cells for 18 hours in U-bottomed tissue culture plates. T-cells were also cultured with 
unpulsed T2 cells (negative control) or PHA (10µg/ml). Cell-free supernatants (75µl) were 
harvested and analysed for human IFN-γ (Human IFN-γ ELISAPRO kit, Mabtech) 
The plates were pre-coated with IFN-γ capture antibody were equilibrated to room 
temperature and washed six times with ELISA wash solution (200µl/well). ELISA diluent 
(50µl) and either the standard or sample supernatant (50µl) were then added to each well. 
Plates were covered with an adhesive strip and incubated at room temperature for two 
hours followed by a further wash step. 1× IFN-γ detection antibody (100µl) was added to 
each well, the plates were covered and incubated at room temperature for one hour. The 
washing process was then repeated. 1x Streptavidin-horseradish peroxidase (SA-HRP) 
(100µl) was added to each well, the plates were covered and incubated at room temperature 
for one hour. The washing process was then repeated. 3,3′,5,5′-tetramethylbenzidine 
(TMB) substrate (100µl) was added to each well and the plates were incubated in the dark 
for 15 minutes. Stop solution (100µl) was then added to terminate the reaction. Plates were 
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then analysed using the iMark Microplate Absorbance Reader (Bio-Rad) and IFN-γ 
concentrations were calculated using a standard curve generated from the purified 
recombinant IFN-γ supplied in the kit. 
2.8.4 MIP-1β ELISA 
For the nonamer CPL screen, cell stimulation was performed as described in section 2.5.3. 
T-cells (1×105) were cultured in AB-RPMI (200µl) at a 1:1 ratio with peptide pulsed T2 
cells for 18 hours in U-bottomed tissue culture plates. T-cells were also cultured with 
unpulsed T2 cells (negative control) or 10µg/ml PHA (positive control). Cell-free 
supernatants (75µl) were harvested and analysed by ELISA for human MIP-1β (R&D 
Systems). 
MIP-1β capture antibody was diluted 1 in 200 in PBS and added to each plate 
(50µl/well), the plates were then incubated at room temperature overnight. The plates were 
then washed three times with ELISA wash solution (400µl/well) and blocked for one hour 
at room temperature with 1x ELISA diluent (50µl/well). The washing process was then 
repeated. MIP-1β standard or supernatant (50µl/well) was then added to each plate, which 
were then incubated at room temperature for one hour and 15 minutes. The washing 
process was then repeated. The detection antibody was diluted 1 in 200 in the reagent 
diluent and added to each plate (50µl/well), which were then incubated at room 
temperature for one hour and 15 minutes. The washing process was then repeated. SA-
HRP was diluted 1 in 200 in reagent diluent and added to each plate (50µl/well), followed 
by incubation at room temperature in the dark for 20 minutes. Equal volumes of colour 
reagent A and B were combined together and the resulting solution was added to each 
plate (50µl/well). The plates were incubated for up to 20 minutes in the dark and the 
reaction was terminated by the addition of the stop solution (25µl/well). Plates were then 
analysed using the iMark Microplate Absorbance Reader (Bio-Rad) and MIP1-β 
concentrations were calculated using the standard curve. 
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2.8.5 CD107α surface staining 
T-cells (1×105) were cultured in AB-RPMI (180µl) at 1:1 ratio with T2 cells ± peptide or 
PHA (10µg/ml) as a positive control. GolgiStop™ (0.7µl) and GolgiPlug™ (1.0µl) were 
diluted in PBS (198.3µl) and the solution (20µl) was then added to each sample. Changes in 
the surface expression of CD107α were determined after the addition of anti-human 
CD107α-PE (Biolegend – clone H4A3) to each culture. The samples were then spun down 
to increase the cell-to-cell contact and incubated for five hours at 37°C in a 5% CO2 
atmosphere. After five hours the cells were washed and co-stained with anti-human CD3-
FITC (Biolegend – clone UCHT1) and CD8-PerCP (Biolegend – clone HIT8a). The cells 
were washed once and resuspended in FACS buffer (200µl). The cells were analysed using 
the Accuri C6 flow cytometer (BD) and data analysis was performed using CFlow software 
(BD). 
2.9 Flow cytometry and Monoclonal Antibodies  
2.9.1 Single and multi-colour immunophenotyping 
To ensure optimal staining, the antibodies used in this study were tested at 100% and 50% 
of the manufactuers’ recommendations prior to use. The antibodies were then incubated 
with the cells (0.2 – 2×106 ) for 15-30 minutes at 4oC. The cells were then washed with 
FACS buffer and resuspended in FACS buffer or 1% PFA (100 - 400µl). The cells were 
analysed using the Accuri C6 flow cytometer or ARIA III FACS sorter (BD) and data 
analysis was performed using CFlow software (BD) or FlowJo (Tree star), respectively. 
2.9.2 Antibody panels 
Table 2.3 TCR Vβ chain antibodies 
Antigen Fluorochrome Supplier Description 
TCR Vβ 1 FITC Beckman Coulter Rat IgG1, Clone BL37.2 
TCR Vβ 2 FITC Serotec Mouse IgG1, Clone MPB2D5 
TCR Vβ 3 FITC Serotec Mouse IgG1, Clone CH92 
TCR Vβ 4 PE Serotec Rat IgM, Clone WJF24 
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TCR Vβ 5.1 FITC Serotec Mouse IgG2a, Clone IMMU157 
TCR Vβ 5.2 PE Beckman Coulter Mouse IgG1, Clone 36213 
TCR Vβ 5.3 PE Beckman Coulter Mouse IgG1, Clone 3D11 
TCR Vβ 7.1 FITC Serotec Mouse IgG1, Clone ZOE 
TCR Vβ 7.2 FITC Beckman Coulter Mouse IgG2a, Clone ZIZOU4 
TCR Vβ 8 FITC Serotec Mouse IgG2a, Clone 56C5 
TCR Vβ 9 FITC Serotec Mouse IgG2a, Clone FIN9 
TCR Vβ 11 FITC Serotec Mouse IgG2a, Clone C21 
TCR Vβ 12 FITC Serotec Mouse IgG2a, Clone VER2.3.2 
TCR Vβ 13.1 FITC Serotec Mouse IgG2b, Clone IMMU222 
TCR Vβ 13.2 PE Beckman Coulter Mouse IgG1, Clone H132 
TCR Vβ 13.6 FITC Serotec Mouse IgG1, Clone JU-74 
TCR Vβ 14 FITC Serotec Mouse IgG1, Clone CAS1.1.3 
TCR Vβ 16 FITC Serotec Mouse IgG1, Clone TAMAYA1.2 
TCR Vβ 17 FITC Serotec Mouse IgG1, Clone E17.5F3 
TCR Vβ 18 FITC Serotec Mouse IgG1, Clone BA62 
TCR Vβ 20 FITC Serotec Mouse IgG1, Clone ELL1.4 
TCR Vβ 21.3 FITC Serotec Mouse IgG1, Clone IG125 
TCR Vβ 22 FITC Serotec Mouse IgG1, Clone IMMU546 
TCR Vβ 23 FITC Serotec Mouse IgG1, Clone AF-23 
TCR Vα 24 FITC Beckman Coulter Mouse IgG1, Clone C15 
 
Table 2.4 T-cell subsets and immunosuppressive receptors panel 
Antigen Fluorochrome Supplier Description 
CD3 APC-H7 BD Biosciences Mouse IgG1, Clone SK7 
CD4 V500 BD Biosciences Mouse IgG1, Clone RPA-T4 
CD8 Alexa Fluor 700 BD Biosciences Mouse IgG1, Clone RPA-T8 
CCR7 PE-CY7 BD Biosciences Rat IgG2a, Clone 3D12 
CD45R0 ECD Beckman Coulter Mouse IgG2a, Clone UCHL1 
CD57 FITC BD Biosciences Mouse IgM, Clone NK-1 
CD27 QDOT605 Life Technologies Mouse IgG2a, CloneCLB-27/1 
PD-1 Brilliant Violet 421 Biolegend  Mouse IgG1, Clone EH12.2H7 
LAG3 APC R&D Systems Goat IgG,  
TIM3 PE R&D Systems Rat IgG2a, Clone 215008 
 
Table 2.5 CLL and immunosuppressive ligands panel 
Antigen Fluorochrome Supplier Description 
CD19 PE-CY7 Biolegend Mouse IgG1, Clone HIB19 
CD5 PerCP-Cy5.5 BD Biosciences Mouse IgG2a, Clone L17F12 
CD38 PE-CY7 eBiosciences Mouse IgG1, Clone HIT2 
PDL-1 APC Biolegend Mouse IgG2b, Clone 29E.2A3 
HLA-DR FITC BD Biosciences Mouse IgG2a, Clone G46-6 
GAL-9 PE Biolegend Mouse IgG1, Clone 9M1-3 
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Table 2.6 General antibodies 
Antigen Fluorochrome Supplier Description 
CD3 FITC Biolegend Mouse IgG1, Clone UCHT1 
CD3 PerCP Biolegend Mouse IgG2a, Clone OKT3 
CD4 PE Biolegend Mouse IgG1, Clone RPA-T4 
CD8 APC Biolegend Mouse IgG1, Clone HIT8a 
CD8 PerCp Biolegend Mouse IgG1, Clone HIT8a 
CD107α PE Biolegend Mouse IgG1, Clone H4A3 
IFN-γ PE eBioscience Mouse IgG1, Clone 4S.B3 
HLA*A201 FITC Biolegend Mouse IgG2b, Clone BB7.2 
HLA-DR PE R&D Mouse IgG1, Clone L203 
CD86 FITC R&D Mouse IgG1, Clone 37301 
 
2.10 RT2 polymerase chain reaction array  
2.10.1 RNA extraction 
RNA extraction was performed using the RNeasy kit (Qiagen). CD4+ and CD8+ T-cells 
were purified from PBMC as described in section 2.6.1. The cell pellets were resuspended 
in RLT lysis buffer (350µl) supplemented with β-mercaptoethanol (10µl/1ml) and stored at 
-80oC until further processing.  
Samples were then thawed at room temperature, transferred to a QIAshedder spin 
column and centrifuged for 2 minutes at 11700×g. 70% ethanol (350µl) was added to the 
homogenised sample, which was then transferred to an RNeasy mini column. The sample 
was centrifuged for 15 seconds at 6900×g and the flow-through was discarded. RW1 buffer 
(350µl) was added to the RNeasy mini column, centrifuged for 15 seconds at 6900×g and 
the flow-through was then discarded.  
 The DNase mixture was formulated by combining DNase I stock (10µl) with 
RDD buffer (70µl). This was then transferred directly onto the RNeasy silica-gel 
membrane and incubated at room temperature for 15 minutes. RW1 buffer (350µl) was 
added to the RNeasy mini column, centrifuged for 15 seconds at 6900×g and the flow-
through discarded. The RNeasy column was then transferred to a new 2ml collection tube. 
RPE buffer (500µl) was added to the column, centrifuged for 15 seconds at 6900×g and 
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the flow-through was discarded. This wash step was then repeated, however the column 
was centrifuged for 2 minutes at 6900×g. The RNeasy column was transferred to a new 
1.5ml collection tube. RNase-free water (20µl) was added to the RNeasy mini column and 
centrifuged for 1 minute at 6900×g. To increase RNA yield the elution step was repeated 
by passing the flow-through through the column for a second time. The RNA was stored 
at -80oC until further processing. 
2.10.2  RNA quantification and quality control 
The RNA concentration was determined using a NanoDrop UV-Vis 
Spectrophotometer (Thermo scientific). The integrity of the RNA was determined using 
the RNA Analysis Kit (Agilent Technologies) by Central Biotechnology Services (Cardiff 
University). Before use, all the reagents were equilibrated to room temperature. The RNA 
6000 pico dye concentrate was vortexed for 10 seconds and then centrifuged briefly at 
300×g. The dye (1µl) was added to filtered gel (65µl), the mixture was vortexed thoroughly 
and centrifuged for 10 minutes at 13000×g. The gel-dye mix (9µl) was added to the well 
marked (G) on the RNA Pico chip. The chip was locked into the chip priming station; the 
plunger of the syringe was pushed down and held for 30 seconds to distribute the gel-dye 
mixture. The plunger was then released and the chip removed from the station. Additional 
gel-dye (9µl) was then added to the wells marked (G). 
The RNA ladder and samples were thawed at room temperature, heat denatured at 
70oC for 2 minutes and placed on ice until use. The RNA ladder and RNA samples (1µl) 
were added to their designated wells and the chip was then vortexed for 60 seconds using 
an IKA vortex mixer. The chip was then analysed using the Agilent 2100 bioanalyser and 
the ratio between the 18S and 28S ribosomal RNA were used to determine the RNA 
Integrity Number (RIN).  
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2.10.3 Reverse transcription 
RNA samples and all the reagents from the RT2 first strand kit (Qiagen) were thawed at 
room temperature. RNA (60ng) was combined with 5× genomic DNA Elimination Buffer 
(4µl) and the solution was adjusted to a final volume (20µl) with RNase-free water. The 
samples were then incubated at 42oC for 5 minutes and then placed on ice for 1 minute. 
The reverse transcription mix (Table 2.7) was combined with the RNA and the sample was 
incubated at 42oC for 15 minutes. The reaction was terminated by incubating the sample at 
95oC for 5 minutes. RNase-free water (182µl) was added to the sample, which was stored at 
-20oC until further processing. 
 
Table 2.7 Reverse transcription mixture 
Component Volume 
5x Buffer BC3 8µl 
Control P2 2µl 
RE3 Reverse Transcriptase Mix 4µl 
RNase-free water 6µl 
 
2.10.4 Real-time PCR 
The real-time PCR mixture was formulated in accordance with Table 2.8 and was 
dispensed across the RT2 Profiler PCR Array (25µl/well). The array was then sealed tightly 
with the Optical Thin-Wall 8-Cap Strips and centrifuged for 1 minute at 200×g. The arrays 
were then inspected for bubbles and then the PCR was performed using the Applied 
Biosystems 7900HT (Life technologies) in accordance with Table 2.9 by the Core Genomic 
Facility (University of Sheffield). The cycle threshold (CT) values were calculated for each 
gene (Table 2.10 and 2.11) and data analysis was performed using RT2 Profiler PCR Array 
Data Analysis (SA Biosciences). 
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Table 2.8 Real-time PCR mixture 
Component Volume 
2x RT2 SYBR Green Mastermix 2700µl 
cDNA synthesis reaction 204µl 
RNase-free water 2496µl 
 
Table 2.9 Real-time PCR programme 
Cycles Duration Temperature 
1 10 minutes 95oC 
40 15 seconds 95oC 
1 minute 60oC 
 
Table 2.10 T-cell & B-cell activation PCR array gene list 
Symbol Description 
ADA Adenosine deaminase 
AICDA Activation-induced cytidine deaminase 
APC Adenomatous polyposis coli 
BCL2 B-cell CLL/lymphoma 2 
BLM Bloom syndrome, RecQ helicase-like 
BLNK B-cell linker 
CCL3 Chemokine (C-C motif) ligand 3 
CCR1 Chemokine (C-C motif) receptor 1 
CCR2 Chemokine (C-C motif) receptor 2 
CCR3 Chemokine (C-C motif) receptor 3 
CCR4 Chemokine (C-C motif) receptor 4 
CCR5 Chemokine (C-C motif) receptor 5 
CD1D CD1d molecule 
CD2 CD2 molecule 
CD27 CD27 molecule 
CD274 CD274 molecule 
CD276 CD276 molecule 
CD28 CD28 molecule 
CD3D CD3d molecule, delta (CD3-TCR complex) 
CD3E CD3e molecule, epsilon (CD3-TCR complex) 
CD3G CD3g molecule, gamma (CD3-TCR complex) 
CD4 CD4 molecule 
CD40 CD40 molecule, TNF receptor superfamily member 5 
CD40LG CD40 ligand 
CD47 CD47 molecule 
CD5 CD5 molecule 
CD7 CD7 molecule 
CD80 CD80 molecule 
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CD81 CD81 molecule 
CD86 CD86 molecule 
CD8A CD8a molecule 
CD8B CD8b molecule 
CSF2 Colony stimulating factor 2  
CX3CL1 Chemokine (C-X3-C motif) ligand 1 
CXCR3 Chemokine (C-X-C motif) receptor 3 
CXCR4 Chemokine (C-X-C motif) receptor 4 
CXCR5 Chemokine (C-X-C motif) receptor 5 
DPP4 Dipeptidyl-peptidase 4 
EGR1 Early growth response 1 
FAS Fas  
FASLG Fas ligand  
FOXP3 Forkhead box P3 
ICOSLG Inducible T-cell co-stimulator ligand 
IFNG Interferon, gamma 
IL10 Interleukin 10 
IL11 Interleukin 11 
IL12A Interleukin 12A  
IL12B Interleukin 12B  
IL12RB1 Interleukin 12 receptor, beta 1 
IL12RB2 Interleukin 12 receptor, beta 2 
IL13 Interleukin 13 
IL15 Interleukin 15 
IL18 Interleukin 18  
IL18R1 Interleukin 18 receptor 1 
IL1B Interleukin 1, beta 
IL2 Interleukin 2 
IL2RA Interleukin 2 receptor, alpha 
IL3 Interleukin 3  
IL4 Interleukin 4 
IL4R Interleukin 4 receptor 
IL5 Interleukin 5  
IL6 Interleukin 6  
IL7 Interleukin 7 
IL8 Interleukin 8 
IRF4 Interferon regulatory factor 4 
LAG3 Lymphocyte-activation gene 3 
LCK Lymphocyte-specific protein tyrosine kinase 
MAP3K7 Mitogen-activated protein kinase 7 
MICB MHC class I polypeptide-related sequence B 
MS4A1 Membrane-spanning 4-domains, subfamily A, member 1 
NCK1 NCK adaptor protein 1 
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NOS2 Nitric oxide synthase 2, inducible 
PTPRC Protein tyrosine phosphatase, receptor type, C 
RAG1 Recombination activating gene 1 
RIPK2 Receptor-interacting serine-threonine kinase 2 
SOCS1 Suppressor of cytokine signalling 1 
TGFB1 Transforming growth factor, beta 1 
TLR1 Toll-like receptor 1 
TLR2 Toll-like receptor 2 
TLR4 Toll-like receptor 4 
TLR6 Toll-like receptor 6 
TLR9 Toll-like receptor 9 
TNFSF14 Tumour necrosis factor (ligand) superfamily, member 14 
VAV1 Vav 1 guanine nucleotide exchange factor 
ACTB Actin, beta 
B2M Beta-2-microglobulin 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 
RPLP0 Ribosomal protein, large, P0 
 
Table 2.11 Human T-cell Anergy and Immune Tolerance PCR Array gene list 
Symbol Description 
BTLA B and T lymphocyte associated 
CBLB Cas-Br-M (murine) ecotropic retroviral transforming sequence b 
CCL3L1 Chemokine (C-C motif) ligand 3-like 1 
CCR4 Chemokine (C-C motif) receptor 4 
CD27 CD27 molecule 
CD28 CD28 molecule 
CD40 CD40 molecule, TNF receptor superfamily member 5 
CD40LG CD40 ligand 
CD70 CD70 molecule 
CDK2 Cyclin-dependent kinase 2 
CDK4 Cyclin-dependent kinase 4 
CMA1 Chymase 1, mast cell 
CSF1 Colony stimulating factor 1 (macrophage) 
CSF2 Colony stimulating factor 2 (granulocyte-macrophage) 
CTLA4 Cytotoxic T-lymphocyte-associated protein 4 
DGKA Diacylglycerol kinase, alpha 80kDa 
DGKZ Diacylglycerol kinase, zeta 
EGR2 Early growth response 2 
EGR3 Early growth response 3 
EOMES Eomesodermin 
FAS Fas  
FASLG Fas ligand  
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FOS FBJ murine osteosarcoma viral oncogene homolog 
FOXP1 Forkhead box P1 
FOXP2 Forkhead box P2 
FOXP3 Forkhead box P3 
GATA3 GATA binding protein 3 
GZMB Granzyme B  
HDAC9 Histone deacetylase 9 
ICAM1 Intercellular adhesion molecule 1 
ICOS Inducible T-cell co-stimulator 
IFNG Interferon, gamma 
IL10 Interleukin 10 
IL10RA Interleukin 10 receptor, alpha 
IL13 Interleukin 13 
IL15 Interleukin 15 
IL17A Interleukin 17A 
IL1A Interleukin 1, alpha 
IL2 Interleukin 2 
IL2RA Interleukin 2 receptor, alpha 
IL2RB Interleukin 2 receptor, beta 
IL31 Interleukin 31 
IL4 Interleukin 4 
IL5 Interleukin 5  
IL6 Interleukin 6  
IL7R Interleukin 7 receptor 
ING4 Inhibitor of growth family, member 4 
IRF4 Interferon regulatory factor 4 
ITCH Itchy E3 ubiquitin protein ligase homolog  
ITGA1 Integrin, alpha 1 
JAK1 Janus kinase 1 
JAK3 Janus kinase 3 
JUN Jun proto-oncogene 
LAT Linker for activation of T cells 
LEP Leptin 
LGALS3 Lectin, galactoside-binding, soluble, 3 
LTA Lymphotoxin alpha  
MEF2A Myocyte enhancer factor 2A 
NFATC1 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 
NFATC2 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 
NFATC3 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 
NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
NHLH2 Nescient helix loop helix 2 
NOTCH1 Notch 1 
PDCD1 Programmed cell death 1 
PRF1 Perforin 1 (pore forming protein) 
PRKCG Protein kinase C, gamma 
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PTGER2 Prostaglandin E receptor 2 (subtype EP2), 53kDa 
PTGS2 Prostaglandin-endoperoxide synthase 2 
RNF128 Ring finger protein 128 
SELL Selectin L 
STAT3 Signal transducer and activator of transcription 3 (acute-phase response factor) 
STAT6 Signal transducer and activator of transcription 6, interleukin-4 induced 
TBX21 T-box 21 
TGFB1 Transforming growth factor, beta 1 
TNFRSF10A Tumour necrosis factor receptor superfamily, member 10a 
TNFRSF14 Tumour necrosis factor receptor superfamily, member 14  
TNFRSF18 Tumour necrosis factor receptor superfamily, member 18 
TNFRSF4 Tumour necrosis factor receptor superfamily, member 4 
TNFRSF8 Tumour necrosis factor receptor superfamily, member 8 
TNFRSF9 Tumour necrosis factor receptor superfamily, member 9 
TNFSF10 Tumour necrosis factor (ligand) superfamily, member 10 
TNFSF14 Tumour necrosis factor (ligand) superfamily, member 14 
TNFSF8 Tumour necrosis factor (ligand) superfamily, member 8 
ACTB Actin, beta 
B2M Beta-2-microglobulin 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 
RPLP0 Ribosomal protein, large, P0 
 
2.11 Statistical analysis 
Non-parametric Mann-Whitney U test or parametric student’s t-test was used for 
comparison of two independent groups. Non-parametric Kruskal-Wallis ANOVA with the 
Dunn's multiple comparisons test or the parametric ANOVA with Tukey Post-hoc analysis 
was used for the comparison of three or more independent groups. The prognostic 
relevance of individual parameters was performed using the method of Kaplan and Meier 
and statistical significance was determined using a log-rank (Mantel Cox) test. Statistical 
analysis was carried out using Prism 6.0 (GraphPad Software) or SPICE (SPICE 5.35). 
2.12 Pathway enrichment analysis 
MetaCore Analytical Suite (https://portal.genego.com) was used to perform Gene 
Ontology (GO) term enrichment in order to interpret the results generated from the PCR 
array. This process involved comparing the input gene list with a database of manually 
curated pathways. To determine enrichment, a randomly generated list of genes of the 
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same size was simultaneously compared to the MetaCore pathways. Significance was 
evaluated based upon the size of the intersection between the input gene list and the 
corresponding pathway. This was determined through a variation of Fisher’s exact test and 
that was adjusted for multiple testing using Benjamini-Hochberg false discovery rate (FDR) 
analysis, which was an inbuilt function within the MetaCore Analytical Suite. 
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Chapter 3  
Generation and Characterisation of Bax-Specific CD8+  
T-cell Clones from CLL patients 
The enhanced proteasomal degradation of the pro-apoptotic protein Bax is one mechanism 
utilised by CLL cells to resist apoptosis (Liu et al. 2008). However, usage of this pathway 
has the potential to result in the generation of Bax-derived peptides for presentation on the 
surface of CLL cells. These peptides could potentially serve as TAA, triggering the 
activation of CD8+ cytotoxic T-cells and the subsequent killing of CLL cells. This concept 
has been confirmed in a proof of principle study utilising T-cells from healthy donors 
(Nunes et al. 2011), but the existence and function of Bax-specific T-cells from CLL 
patients is currently unknown. Therefore the main aim of this study was to establish 
whether it was possible to isolate and then characterise Bax-specific CD8+ T-cells from 
CLL patients. A schematic diagram showing the experimental workflow for these assays is 
given in Figure 3.1. 
 
 Chapter 3: Results 
 
  Page 86 
 
Experimental design 
 
Figure 3.1 Experimental design for the cloning and characterisation of Bax-specific T-cells from CLL patients. 
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3.1 Activation of CLL cells 
It is well established that resting CLL cells have extremely poor antigen presentation 
potential due to low expression of co-stimulatory and adhesion molecules. However, 
activation of the CD40 signalling pathway has been shown to enhance antigen presentation 
potential (Van den Hove et al. 1997; Os et al. 2013). Therefore it was investigated whether 
co-culture with CD40L-expressing fibroblasts would result in the activation of CLL cells 
and enhance antigen presentation potential.  
The expression of the activation marker HLA-DR and co-stimulatory ligand CD86 
were determined by flow cytometry. In the resting state HLA-DR was constitiutively 
expressed on the surface of all CLL cells (Fig 3.2a), therefore changes in the mean 
fluorescence intensity (MFI) of HLA-DR were investigated. A significant increase in the 
level of expression of HLA-DR was observed in response to CD40L stimulation (Fig 3.2b) 
when compared to baseline (Time 0) and cultures with non-transfected murine fibroblasts 
(NTL) (P ≤ 0.01) as well as liquid culture (LC) conditions (P ≤ 0.001). 
Co-culture of the CLL cells with CD40L-expressing fibroblasts resulted in a 
significant increase in the precentage of cells expressing CD86 (P<0.0001) (Fig 3.2c) and 
the level of expression as determined by the increase in MFI (P ≤ 0.001) (Fig 3.2d). These 
changes were observed in comparsion with Time 0, LC and NTL and confirmed that 
CD40L activation of CLL cells up-regulated HLA-DR and CD86. 
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(A) (B) 
HLA-DR (% Expression) HLA-DR (MFI) 
 
 
(C) (D) 
CD86 (% Expression) CD86 (MFI) 
 
 
Figure 3.2 Analysis of the expression of the activation maker HLA-DR and co-stimulatory ligand 
CD86. PBMC (1×106) from CLL patients were cultured alone (LC) or co-cultured with either non-
transfected murine fibroblasts (NTL) or CD40 ligand (CD40L) expressing fibroblasts. For each condition the 
cells were cultured in FCS-RPMI (1ml) supplemented with IL-4 (5ng/ml) for 48 hours. (A) and (B) show the 
analysis of HLA-DR expression as a percentage of CD19+ B-cells and MFI, respectively. (C) and (D) show 
the analysis of CD86 expression as percentage of CD19+ B-cells and MFI, respectively. Mean ± SD of 6 
individual patient samples. Statistical analysis (Repeat measure ANOVA with Tukey Post-hoc analysis) was 
carried out using GraphPad Prism 5.0. 
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3.2 Donor response 
PBMC were isolated from whole blood by ficoll density centrifugation of a CLL 
patient (R6A8R89). CD8+ T-cells were isolated by immunomagnetic separation and the 
remaining PBMC were co-cultured with CD40L-expressing murine fibroblasts. CD19+ B-
cells were then isolated by immunomagnetic separation to exclude other cell types for the 
in vitro stimulation process. The activated CLL cells were then utilised to present the full 
Bax peptide pool (P601- P623) to the autologous CD8+ T-cells, which were then subjected 
to five rounds of stimulation over five weeks. T-cell reactivity against Bax peptides was 
then tested by IFN-γ ELISpot and a highly significant Bax peptide-specific response was 
observed (P=0.0008) (Fig 3.3), indicating the presence of Bax-specific T-cells. 
3.3 Cloning by limiting dilution 
Immunomagnetic enrichment of Bax-specific T-cells was carried out utilising the 
process of IFN-γ secretion, in response to peptide-specific T-cell activation. After the 
enrichment process the T-cells were “rested” overnight in AB-RPMI supplemented with 
IL-2 (40U/ml) and IL-7 (10ng/ml). The cells were counted the following day and 
approximately 800 cells were recovered and used to establish T-cell lines by limiting 
dilution. Six plates of 0.5 cells/well, 2/3 of a plate of 10 cells/well and half a plate of 
“cloning mix”(containing irradiated stimulator cells) alone were established. After 4 weeks 
of antigen independent expansion, the cultures that showed a high level of growth were 
assessed for Bax peptide immunogenicity by IFN- γ ELISpot.  
From the 0.5 cells/well plate, 19/576 cultures showed significant growth and were 
selected for testing. Six cultures (6C2, 6E2, 6C5, 8C9, 7F7 and 9D7) showed potential Bax-
specific responses (>20 SFC/ 3×104) varying from 42 to 770 SFC/3×104 cells and were 
selected for antigen independent expansion and further characterisation (Fig 3.4).  
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(A) 
T-cell alone T-cells + CLL cells T-cells + CLL cells + Bax  
   
(B) 
 
Figure 3.3 Bax T-cell response in CLL Patient samples after five weeks of stimulation. CD8+ T-cells 
were repeatedly stimulated with irradiated activated autologous CLL cells at a ratio of 4 T-cells : 1 CLL cell, 
in AB-RPMI (1ml) supplemented with the Bax peptide pool (10µg/ml) and IL-2 (40U/ml). On day 3 the 
cells were “fed” with AB-RPMI (500µl) supplemented with IL-2 (120U/ml) and IL-7 (30ng/ml). On day 7 
the cells were harvested, counted and re-stimulated. After 5 weeks of in vitro stimulation a significant Bax 
specific response was observed by IFN-γ ELISpot (P=0.0008). T-cells (1×105 cells/well) were plated in 
triplicate in ELISpot plates with CLL cells ± Bax peptide pool (10µg/ml) at a ratio of 1:1. The spots were 
counted and the background response (T-cells + CLL cells) was subtracted from the data. Mitogen control 
wells were also set up which resulted in a completely dark well, which could not be accurately counted but 
indicated the presence of viable T-cells. (A) A representative example of the response observed in a single 
set of wells. (B) Mean ± SD of triplicate wells for each condition. Statistical analysis (unpaired two-tailed t-
test) was carried out using GraphPad Prism 5.0. 
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3.4 Epitope mapping of Bax-specific T-cells 
For the process of in vitro stimulation the full Bax peptide pool was utilised, therefore 
the putative T-cell clones had the potential to be reactive to any of the 23 candidate 
peptides. These T-cell clones were first tested against the full peptide pool to reaffirm Bax 
specificity; then against four smaller peptide pools (Bax P601-606, Bax P607-612, Bax 
P613-618 and Bax P619-623) to narrow down the response, followed by individual 
peptides for epitope identification. The putative T-cell clones 6C5 and 8C9 both exhibited 
positive responses against the full Bax peptide pool and the sub pool Bax P601-606. Of the 
peptides within the Bax P601-606 pool, only P603 and P605 induced an ELISpot response 
(Fig. 3.5). Interestingly, these two peptides shared an overlapping nine amino acid 
sequence: Bax P603 was a 9mer (Bax161-170; LLSYFGTPT) and Bax P605 was a 10mer 
(Bax160–170; GLLSYFGTPT). Furthermore, as HLA-A2 is the only functional MHC 
molecule expressed by T2 cells, and as the T-cell clones were isolated from an HLA-A2+ 
patient, it would suggest that the peptide and its activity was restricted to this specific MHC 
molecule. It should be noted that for this experiment and all subsequent peptide 
stimulation experiments T2 cells were used as source of APC, due the lack of available 
autologous CLL cells. 
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Figure 3.4 T-cell cultures generated under limiting dilution conditions were tested for Bax 
immunogenicity by IFN-γ ELISpot. To determine the average number of cells per culture, four cultures 
were selected at random, counted and averaged. T-cells (~3×104) were cultured at an approximate 1:1 ratio 
with T2 cells ± Bax peptide pool (10µg/ml) in ELISpot plates. For each culture tested, only one well was 
set up per culture condition. The spots were counted and the background response (T-cells + APC) was 
subtracted from the experimental data (T-cells+APC+peptide). Mitogen control wells were also set up 
which resulted in a completely dark well, which could not be accurately counted but indicated the presence 
of viable T-cells. Six cultures showed positive responses against the Bax peptide pool (>20 SFC/ 3×104). 
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(A) 
8C9 
 
(B) 
6C5 
 
Figure 3.5 Epitope mapping of T-cell clones 6C5 and 8C9. The putative T-cell clones 8C9 and 6C5 
were tested by IFN-γ ELISpot against the full Bax peptide pool, four split pools and individual peptides, to 
determine the T-cells epitope specificity. T-cells (1×104 cells/well) were plated in duplicate in ELISpot 
plates with T2 cells ± Bax peptide pool (10µg/ml) at a ratio of 1:1. The spots were counted and the 
background response (T-cells + T2) was subtracted from the experimental data (T-cells+T2+peptide). 
Mitogen control wells were also set up which resulted in a completely dark well, which could not be 
accurately counted but indicated the presence of viable T-cells. Data are presented as the mean ± SD and 
are representative of two independent experiments.  
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3.5 Avidity of 6C5 and 8C9 for Bax P603 and P605 
Peptide dose-response experiments were performed to validate the activity of the 
peptides P603 and P605 and to determine the functional avidity between peptides and the 
respective T-cell clones. Both 6C5 and 8C9 were able to recognise P603 at a higher 
functional avidity than P605. Furthermore, 6C5 appeared to have higher functional avidity 
then 8C9; the half maximal effective concentration (EC50) values in response to P603 were 
4.92µM for 6C5 and 8.56µM for 8C9. For P605 a suitable EC50 value could not be 
calculated due to the limitations of the range of the dose-response curve. However, this 
was estimated to be ~100µM (Fig 3.6). These results indicated that P603 was the optimum 
epitope for both 6C5 and 8C9. Furthermore, of the two clones identified, 6C5 was selected 
for further characterisation due to higher functional avidity and superior growth kinetics. 
3.6 Analysis of the TCR Vβ chain used by 6C5 
The TCR of αβ T-cells is formed by the association of a single alpha and a single 
beta chain on the cell surface. Historically, the expression of a single TCR Vβ chain, in 
combination with consistent antigen specificity, function and phenotype has been used to 
infer T-cell clonality (Evans et al. 2001; Nunes et al. 2011). 
The initial TCR analysis of 6C5 using TCR Vβ specific monoclonal antibodies 
indicted that 95.2% of the T-cells expressed TCR Vβ 13.1, 38.6% expressed TCR Vβ 18 
and 27.8% expressed TCR Vβ 5.3 (Fig 3.7a). In light of these puzzling results, 6C5 was re-
analysed using a different panel of TCR Vβ antibodies provided by Professor Linda 
Wooldridge (Faculty of Medical and Veterinary Sciences, Bristol University). The second 
analysis indicated that 6C5 comprised T-cells expressing mainly TCR Vβ 13.1 and TCR Vβ 
5.2 (46.9% and 31.1%, respectively) (Fig 3.7b). Although dominant Vβ 13.1 expression was 
common to both analyses, it was not clear whether 6C5 was truly monoclonal or 
comprised a mixture of T-cell clones.  
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To resolve this, 6C5 was flow-sorted based on the expression of either TCR Vβ5.2 
or Vβ 13.1, the T-cells were collected, subjected to antigen independent expansion and 
analysed for the expression of TCR Vβ 5.2 and Vβ 13.1. The analysis indicated that both 
expanded T-cell cultures expressed TCR Vβ 13.1 and not Vβ5.2, regardless of which TCR 
Vβ chain they were sorted on (Fig 3.7c). Based on pre and post flow sorting expression of 
Vβ 13.1, the consistent expression of TCR Vβ13.1 in two separate TCR Vβ panels, and the 
cloning protocol employed to establish 6C5, it seemed highly likely that 6C5 was a single 
CD8+ T-cell clone.  
3.7 Recongition of primary CLL cells by 6C5 
It has been reported that Bax undergoes abnormal and enhanced proteasomal 
degradation in CLL cells (Agrawal et al. 2008). It was therefore hypothesised that this 
enhanced proteasomal processing would result in the presentation of Bax-derived peptides 
on the surface of CLL cells but not healthy cells. This hypothesis was supported by a proof 
of principle study that demonstrated that CD8+ T-cells specific for Bax-derived peptides 
could recognise and kill CLL cells (Nunes et al. 2011). However, in that study the T-cells 
were sourced from healthy donors and restricted to a different epitope (IMGWTLDFL) to 
the one recognised by CD8+ T-cell clone 6C5 (LLSYFGTPT).  
The ability of the 6C5 to recognise primary CLL cells from HLA-A2+ and HLA-
A2- CLL patients was investigated by IFN-γ ELISpot. Initially recognition of “resting” 
CLL cells was investigated. However, no response above background was observed for any 
of the patient samples tested, regardless of HLA-A2 status. Therefore CLL cells were 
activated by co-culture on CD40L-expressing fibroblasts to induce the up-regulation of co-
stimulatory molecules to assist with T-cell activation. Variable responses were observed 
from both HLA-A2- patients (11-31 SFC/104) and HLA-A2+ (1-88 SFC/104) but no 
difference was observed between HLA-A2+ and HLA-A2- patients (Fig. 3.8). This suggests 
that either CLL cells do not present the Bax-derived peptide epitope LLSYFGTPT or that 
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the avidity of 6C5 for P603 was too low to induce T-cell activation in response to 
LLSYFGTPT expressed by CLL cells. 
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(A) 
8C9 
 
(B) 
6C5 
 
Figure 3.6 Peptide dose-response for 8C9 and 6C5 recognition for P603 and P605 pulsed target 
cells. T2 cells (5×105) pulsed with varying concentrations of P603 (77% Pure, 20µg/ml to 6.25 µg/ml) and 
P605 (79% Pure, 20µg/ml to 6.25µg/ml). T2 cells were incubated in the presence of DMSO alone were 
used as negative control to determine background production of IFN-γ. After one hour any unbound 
peptide was washed off and the T2 cells (1×105) were cultured overnight at a 1:1 ratio with 8C9 or 6C5 at 
37°C / 5% CO2.. Furthermore, PHA (10µg/ml) was used as a positive control. Cell-free supernatants were 
harvested and evaluated for the presence of IFN-γ by ELISA. Taking into consideration the molecular 
weight of P603 (885), the molar EC50 values were calculated from the curve of best fit; 6C5 was 4.92µM and 
8C9 was 8.56µM. For P605 a suitable EC50 value could not be calculated due to the limitations of the curve, 
however was ~100µM. Data are presented as the mean ± SD and are representative of three independent 
experiments.  
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(A) 
 
(B) 
 
(C) 
 
Figure 3.7 Analysis of the TCR Vβ chain used by Bax specific T-cell line. Initially (A and B) 6C5 
T-cells (1×105) were co-stained with anti-human CD8 and two different panels of TCR Vβ chain 
antibodies, to determine TCR Vβ chain usage. Due to the puzzling results, 6C5 was cell sorted based on 
the expression of either TCR Vβ 13.1 or TCR Vβ 5.2. After antigen independent expansion, the pre and 
post sorted T-cells (1×105) were then (C) co-stained with anti-human CD8 and either anti-human TCR 
Vβ 13.1 or TCR Vβ 5.2. 
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(A) 
 
(B) 
 
Figure 3.8 6C5 recognition of HLA-A2- and HLA-A2+ activated CLL cells. CLL PBMC (1×106) was co-
cultured with CD40L transfected murine fibroblasts at a ratio of 10:1 in FCS-RPMI (1ml) supplemented with 
IL-4 (5ng/ml) for 48 hours at 37°C / 5% CO2. The cells were the harvested, resuspended in fresh FCS-RPMI 
and counted. The activated CLL PBMC (1×104) was cultured in triplicate ± CD8+ T-cell clone 6C5 at 1:1 
ratio for 18 hours at 37°C / 5% CO2 in ELISpot plates. T2 cells pulsed with P603 was used as a positive 
control. Mitogen control wells were also set up which resulted in a completely dark well, which could not be 
accurately counted but indicated the presence of viable T-cells. Data are presented as the mean ± SD and are 
representative of 3 HLA-A2- and 11 HLA-A2+ patients. Statistical analysis (unpaired two-tailed t-test) was 
carried out using GraphPad Prism 5.0. 
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3.8 Recognition of crude P603 (77% pure) but not pure P603 (>95%) by 6C5 
Initial results using crude peptides (77% purity) suggested that the T-cell clone 6C5 
recognised the 9aa sequence (LLSYFGTPT) common to P603 and P605 (Fig. 3.5b). To 
confirm this observation and to obtain a more accurate estimate of functional avidity, 6C5 
was tested against higher purity P603 peptides (>95% purity) from two different 
commercial sources (Proimmune and Peptide Synthetics). 6C5 failed to respond to the 
purified forms of P603 (>95% purity), however the original P603 preparation (77% purity) 
induced a robust and highly significant IFN-γ response (P<0.0001) (Fig. 3.9). These results 
suggested that the immunogenicity associated with the original P603 (77% purity) was not 
due to the main peptide sequence (LLSYFGTPT). Furthermore, it was likely that the active 
component recognised by 6C5 was present in the remaining 23% of the peptide 
preparation. 
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(A) 
 
(B) 
 
Figure 3.9 6C5 recognition of crude P603 but not pure P603. 6C5 T-cells (1×105) were cultured with T2 
cells ± P603 (>95% Pure, 10µg/ml) or P603 (77% Pure, 10µg/ml) at 1:1 for 5 hours. T2 cells + DMSO was 
used as a negative control to determine background production of IFN-γ and PHA (10µg/ml) was used a 
positive control. IFN-γ production was assessed through intracellular staining of T-cells (CD3+CD8+) with 
anti-IFN-γ antibody (A) Raw data showing IFN-γ production in response to P603 (77% Pure) but not P603 
(>95% Pure). (B) Significant production of IFN-γ in response to P603 (P<0.0001); 77% Pure) when 
compared to P603 (>95% Pure). Data are presented as the mean ± SD and represent three independent 
experiments. Statistical analysis (unpaired two-tailed t-test) was carried out using GraphPad Prism 5.0. 
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3.9 Identification of active component within crude P603 (77% pure) 
Samples of crude and purified P603 peptide were analysed by ion trap Liquid 
chromatography-mass spectrometry (LCMS), by Dr James Redman (School of Chemistry, 
Cardiff University). The analysis of the both the 77% and >95% pure peptide preparations 
revealed the presence of minor/trace amounts of 8mer, 10mer and modified 9mer peptides 
(Table 3.1). 
The potential immunogenicity of 8mer and 10mer peptides was initially investigated 
by synthesising a small library of crude peptides (Dr James Redman). The library consisted 
of four peptide preparations: (1) full length 9mer, LLSYFGTPT, (2) enhanced deletions in 
the C-terminal residues (deletion of G/T/P/T), (3) enhanced deletions in the N-terminal 
residues (deletion of L/S/Y/F) and (4) 10mer LLLSYFGTPT (additional N-terminal 
leucine). Assessment of all four peptide preparations induced similar levels of IFN-γ 
secretion suggesting that neither a truncated nor an extended peptide were solely 
responsible for the activation of 6C5. Furthermore, 6C5 remained unresponsive to P603 
(>95% purity) while producing a robust IFN-γ response when challenged with P603 
(>77% purity). These results suggest that a peptide common to all four preparations and 
P603 (>77% purity) was responsible for the activation of 6C5 (Fig. 3.10).  
Peptide preparation 1 (crude full length 9mer, LLSYFGTPT) was fractionated by 
reverse phase HPLC, with fraction collection guided by UV absorbance (Dr James 
Redman) (Fig. 3.11a). Individual fractions (F1-F8) were collected, lyophilised and assayed 
to determine their capacity to induce T-cell activation (Fig 3.11b). Fraction 8 resulted in T-
cell activation, suggesting that this fraction contained the peptide responsible for the 
activation of 6C5. Fractions 6 and 7 induced significant but minor T-cell activation, which 
may have been due to contamination from fraction 8 that occurred during the fractionation 
process. Furthermore, 6C5 remained unresponsive to the purified P603 (>95% purity) 
while producing a robust IFN-γ response when challenged with P603 (>77% purity) and 
peptide preparation 1. 
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LCMS analysis of the active fraction 8 (Dr James Redman) revealed the presence of 
a peptide with a fragmentation pattern associated with tyrosine tertiary butyl (Tyr(3-tBu)) 
modification. Furthermore, a peptide with an identical fragmentation pattern was identified 
within the original crude P603 preparation (Fig 3.12).  
 
Table 3.1 Comparison of purified and crude P603 peptide samples by LCMS. 
Peptide r.t. (min) Transition Crude 
P603 
Purified 
P603 
LLSYGTPT 5.5 851.5 ! 617.3 (b6−H2O) " " 
LSYFGTPT 6.3 885.4 ! 651.3 (b6−H2O) " " 
LLSFGTPT 6.8 835.5 ! 601.3 (b6−H2O) " " 
LLSYFGTT 7.0 901.5 ! 764.4 (b7−H2O) " " 
LLSYFGTPT 7.1 998.5 ! 764.4 (b7−H2O) " " 
LLSYFTPT 7.1 941.5 ! 707.4 (b6−H2O) # " 
LLSYFGTP 7.2 897.5 ! 764.4 (b7−H2O) " # 
LLYFGTPT 7.4 911.5 ! 677.4 (b6−H2O) " " 
LLLSYFGTPT 8.0 1111.6 ! 877.5 (b8−H2O) " # 
LLSY(3-
tBu)FGTPT 
9.3 1054.6 ! 820.5 (b7−H2O) " # 
Chromatography was performed on an Ace Excel 2 C18 column (100×2.1mm), eluting with a linear gradient 
of 5-95 % acetonitrile (0.1 % formic acid) at 0.5 ml/min over 20 minutes.  MS/MS spectra were measured on 
a Bruker amaZon SL ion trap spectrometer. The sequence and retention times (r.t.) of each of the peptides 
identified are indicated. The presence (") or absence (#) of the peptides in each sample was assessed using 
extracted ion chromatograms for the indicated transition. 
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Figure 3.10 Mapping 6C5 response to peptide preparation representing potentially active 
contaminates identified from crude P603. 6C5 T-cells (1×105) were cultured with T2 cells ± P603 (>95% 
Pure, 10µg/ml), P603 (77% Pure, 10µg/ml) or 4 separate peptide presentation (P1-P4, 10µg/ml) at 1:1 ratio 
for 5 hours. T2 cells + DMSO was used as a negative control to determine background production of IFN-γ, 
and PHA (10µg/ml) was used as a positive control. IFN-γ production was assessed through intracellular 
staining of T-cells (CD3+CD8+) with anti-IFN-γ antibody. Data are presented as the mean ± SD and are 
representative of three independent experiments. Statistical analysis (unpaired two-tailed t-test, in comparison 
to P603 >95% Pure) was carried out using GraphPad Prism 5.0; significance was indicated by asterisks **** 
< 0.0001 and *** 0.0001 to 0.001.  
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(A) 
Fractionation of P1 
 
(B) 
 
Figure 3.11 Mapping 6C5 response to the fractions generated from peptide preparation 1. (A) P1 was 
the most abundant peptide preparation available and was selected for fractionation by reverse phase HPLC 
and eight fractions were obtained. (B) Each fraction was reconstituted in 30µl of 100% DMSO and tested 
for activity against 6C5. 6C5 T-cells (1×105) were cultured at 1:1 ratio with T2 cells in the presence of each 
fraction F1-F8 (unknown concentration), P603 (>95% Purity, 10µg/ml) or P603 (77% Purity, 10µg/ml). T2 
cells + DMSO were used as a negative control to determine background production of IFN-γ and PHA 
(10µg/ml) was used as a positive control. IFN-γ production was assessed through intracellular staining of T-
cells (CD3+CD8+) with anti-IFN-γ antibody. A significant production of IFN-γ in response to P603 (77% 
Purity), P1, F6, F7 and F8 in comparison to P603 (>95% Pure) was observed. Data are presented as the 
mean ± SD and are representative of three independent experiments. Statistical analysis (unpaired two-tailed 
t-test, in comparison to P603 >95% Purity) was carried out using GraphPad Prism 5.0; significance was 
indicated by asterisks **** < 0.0001, *** 0.0001 to 0.001, ** 0.001 to 0.01 and * 0.01 to 0.05.  
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(A) 
Crude P603 
 
(B) 
Fraction 8 
 
Figure 3.12 LCMS analysis of purified and crude P603 peptide samples. Chromatography was 
performed on an Ace Excel 2 C18 column (100×2.1mm), eluting with a linear gradient of 5-95% acetonitrile 
(0.1% formic acid) at 0.5 ml/min over 20 minutes. MS/MS spectra are shown with the m/z of the precursor 
ion indicated with a diamond, $. (A) Crude P603, retention time (r.t.) 9.5 min, precursor m/z 1054.6, (B) 
Fraction 8, r.t. 9.2 min, precursor m/z 1054.6. 
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3.10 Recognition of P603 tBu by 6C5 
The previous data (Fig 3.11 and 3.12) suggested that a peptide species containing 
Tyr(3-tBu) was responsible for the observed activation of 6C5. To investigate this further 
the inactive wt P603 peptide (95% purity) was subjected to conditions intended to generate 
tBu cations. It was predicted that this treatment would re-introduce the alkylated side 
products and confer activity to the previously inactive wt sequence. Peptide samples were 
treated under differing conditions, methylpropene with trifluoroacetic acid (TFA) or di-tert-
butyl dicarbonate (BoC20) with TFA (Dr James Redman) (Fig. 3.13a). Analysis of the 
reaction products by HPLC and LCMS indicated the presence of peptides carrying the 
Tyr(3-tBu) (Dr James Redman). Both of the Tyr(3-tBu) modified preparations were able to 
induce IFN-γ secretion; strongly suggesting that modification of Tyr by tBu was sufficient 
to mimic the activity associated with the crude P603 peptide preparation (Fig. 3.13b). 
To confirm that P603 Tyr(3-tBu) was responsible for the activation of 6C5, a highly 
purified (>98%) preparation of this modified peptide, was obtained from a commercial 
supplier (PolyPeptide Group). This peptide was able to stimulate robust and highly 
significant IFN-γ and CD107α responses from 6C5 (P<0.0001). However, the unmodified 
wt P603 (95% pure) failed to induce T-cell activation under the same conditions (Fig. 3.14 
and 3.15). Peptide dose-response experiments were performed to validate the activity of 
P603 Tyr(3-tBu) and to compare the activity of this peptide against the original crude (77% 
purity) P603 preparation. P603 Tyr(3-tBu) (>98% purity) was more potent than P603 (77% 
purity) as determined by comparison of the calculated EC50 values (Fig. 3.16a and b). Using 
IFN-γ production as a functional read-out, the EC50 values were 0.2 µM for P603 Tyr(3-
tBu) (>98% purity) and 1.4 µM for P603 (77% purity). By contrast, using CD107α 
expression as a read-out, the EC50 values were 0.52 nM for P603 Tyr(3-tBu) (>98% purity) 
and 610 nM for P603 (77% purity). For both assays the highly purified P603 Tyr(3-tBu) 
peptide induced 1-3 log greater activity than the crude P603 (77% purity). These results 
were consistent with the chemical analysis data, as HPLC analysis of the crude P603 (77% 
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pure) preparation indicated that the Tyr(3-tBu) modified form of the peptide comprised 
less than 1% of the crude P603 (77% pure) preparation (Dr James Redman). 
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(A) 
Reaction schematic 
 
 
(B) 
 
Figure 3.13 Recognition of butylated P603 by 6C5 T-cells. (A) P603 (>95% Purity), which exhibited no 
activity in respect to 6C5, was reacted with methylpropene and TFA, or Boc2O and TFA to induce butylation 
of P603. The modified peptides were collected and reconstituted in 100% DMSO. (B) 6C5 T-cells (1×105) 
were cultured at 1:1 ratio with T2 cells in the presence of P603 (>95% Purity, 10µg/ml), P603 (77% Purity, 
10µg/ml) or the two modified P603 peptides (di-tert-butyl dicardonate and methylpropene, 10µg/ml) for 5 
hours at 37°C / 5% CO2. T2 cells + DMSO were used as a negative control to determine background 
production of IFN-γ and PHA (10µg/ml) was used as a positive control. IFN-γ production was assessed 
through intracellular staining of T-cells (CD3+CD8+) with anti-IFN-γ antibody. Significantly increased 
production of IFN-γ was observed in response to P603 (77% Purity) and the two modified P603 peptides 
when comparison with P603 (>95% Purity). Data are presented as the mean ± SD and are representative of 
three independent experiments. Statistical analysis (unpaired two-tailed t-test, in comparison to P603 >95% 
Purity) was carried out using GraphPad Prism 5.0; significance was indicted by asterisks **** < 0.0001. 
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(A) 
 
(B) 
 
Figure 3.14 Production of IFN-γ by 6C5 T-cells in response to P603 tBu. 6C5 T-cells (1×105) were 
cultured at 1:1 ratio with T2 cells in the presence of P603 (>95% Purity, 10µg/ml), P603 (77% Purity, 
10µg/ml) or P603 tBu (>98% Purity, 10µg/ml) for 5 hours at 37°C / 5% CO2. T2 cells + DMSO were used 
as a negative control to determine background production of IFN-γ and PHA (10µg/ml) was used as a 
positive control. IFN-γ production was assessed through intracellular staining of T-cells (CD3+CD8+) with 
anti-IFN-γ antibody. A significant production of IFN-γ in responses to P603 (77% Purity) and P603 tBu 
(>98% Purity) in comparison to P603 (>95% Purity) was observed. (A) Representative example of the flow 
cytometry analysis. (B) Data are presented as the mean ± SD and are representative of three independent 
experiments. Statistical analysis (unpaired two-tailed t-test, in comparison to P603 >95% Purity) was carried 
out using GraphPad Prism 5.0. 
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(A) 
 
(B) 
 
Figure 3.15 Expression of CD107α in 6C5 T-cells in response to P603 tBu. 6C5 T-cells (1 × 105) were 
cultured at 1:1 ratio with T2 cells in the presence of P603 (>95% Purity, 10µg/ml), P603 (77% Purity, 
10µg/ml) or P603 tBu (>98% Purity, 10µg/ml) for 5 hours at 37°C / 5% CO2. T2 cells + DMSO was used 
as a negative control to determine background expression of CD107α and PHA (10µg/ml) was used as a 
positive control. Changes in the surface expression of CD107α on T cells (CD3+CD8+) were determined 
through culturing the cells in the presence of anti-CD107α. A significant increase in the expression of 
CD107α in responses to P603 (77% Purity) and P603 tBu (>98% Purity) in comparison to P603 (>95% 
Purity) was observed. (A) Representative sample of flow cytometry analysis. (B) Data are presented as the 
mean ± SD and are representative of three independent experiments. Statistical analysis (unpaired two-tailed 
t-test, in comparison to P603 >95% Purity) was carried out using GraphPad Prism 5.0. 
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(A) 
 
(B) 
 
Figure 3.16 Peptide dose-response for 6C5 recognition of crude P603 and P603 tBu pulsed target 
cells. (A) T2 cells (5×105) pulsed with varying concentrations of P603 (77% Purity, 10µg/ml to 1×10-6 
µg/ml) and P603 tBu (>98% Purity, 10µg/ml to 1×10-6µg/ml). T2 cells incubated in the presence of DMSO 
were used as a negative control to determine background production of IFN-γ. After 1 hour any unbound 
peptide was washed off and the pulsed T2 cells (1×105) were cultured overnight at 37°C / 5% CO2 with 6C5 
T-cells at a 1:1 ratio. Furthermore, PHA (10µg/ml) was used as a positive control. Cell-free supernatants 
were harvested and evaluated for the presence of IFN-γ by ELISA. (B) 6C5 T-cells (1×105) were cultured at 
1:1 ratio with T2 cells in the presence of varying concentrations of P603 (77% Pure, 10µg/ml to 1×10-6 
µg/ml) and P603 tBu (>98% Pure, 10µg/ml to 1×10-6 µg/ml) for 5 hours at 37°C / 5% CO2. T2 cells + 
DMSO was used as a negative control to determine background expression of CD107α and PHA (10µg/ml) 
was used as a positive control. Change in the surface expression of CD107α on T-cells (CD3+CD8+) was 
determined by culturing the cells in the presence of anti-CD107α. Data are presented as the mean ± SD and 
are representative of three independent experiments. Taking into consideration the molecular weight of P603 
(885) and P603 tBu (1053.6), the molar EC50 values were calculated from the curve of best fit. For IFN-γ 
production P603 (77% Purity) had an EC50 of 1.4µM and P603 tBu had an EC50 of 0.2µM For CD107α 
expression P603 (77% Purity) had a EC50 of 610 nM and P603 tBu had an EC50 of 0.52nM. 
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3.11 Peptide binding to HLA-A2 on the T2 cell line 
One potential explanation for the difference observed between P603 tBu (>98% 
Purity) and P603 (>95% Purity) could be related to a differential ability to bind to HLA-A2 
and thus be presented to the TCR. Typically nine amino acid peptides are anchored to 
MHC-I molecules using the amino acids at position 2 and 9 (Denkberg et al. 2002). Since 
the modified tyrosine is at position 4 it unlikely that the modification would directly affect 
peptide binding. However, the presence of the Tyr(3-tBu) residue could potentially alter the 
tertiary structure of the peptide and thus alter its interactions with HLA-A2. This 
hypothesis was tested by incubating each peptide in the presence of the TAP-deficient and 
HLA-A2+ T2 cell line. This cell line’s inherent inability to process and present endogenous 
peptide results in the expression of empty and unstable HLA-A2 molecules. These unstable 
HLA-A2 molecules are thus rapidly endocytosed, but the presence of an exogenous source 
of HLA-A2 binding peptide would result in the stability of the molecules and the 
maintance of their surface expression.  
The surface expression of HLA-A2 was assessed by flow cytometry and changes in 
the percentage expression were compared to the negative control (DMSO alone). MART-1 
peptide (ELAGIGILTV), which is an analogue of the natural MART-1 peptide 
(AAGIGILTV), was used as a positive control due to its superior HLA-A2 binding 
properties (Maeurer et al. 2002). Culturing T2 cells with ELAGIGILTV resulted in the 
successful up-regulation of HLA-A2. However, neither P603 tBu (>98% Purity) nor P603 
(>95% Purity) were able to induce an up-regulation in the expression of HLA-A2 (Fig 
3.17). This suggested that neither peptide was a strong binder, but did not rule out weak or 
transient binding. It should be noted that HLA-A2 binding is not always an indicator of 
peptide activity, as peptides that exhibit poor HLA binding can successfully activate and 
expand peptide-specific T-cells (Khanna 2004). Nevertheless, these results show that the 
tBu modification did not substantially improved the binding of P603 to HLA-A2, therefore 
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suggesting that the differences in the T-cell response induced by the two peptides may 
occur due to TCR recognition rather than HLA-A2 binding. 
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Figure 3.17 Binding of candidate peptides to HLA-A2. T2 cells (1×105) were incubated in the presence 
of P603 (>95% Purity, 10µg/ml), P603 tBu (>98% Purity, 10µg/ml) or MART-1 (70% Purity, 10µg/ml) 
overnight at 37°C / 5% CO2. Due to its known superior HLA-A2 binding, the MART-1 peptide was used as 
a positive control and T2 cells treated with DMSO-only were used as a negative control in order to determine 
background HLA-A2 expression. After culturing, the cells were then stained with anti-HLA-A2 and 
expression was determined by flow cytometry. As T2 cells ubiquitously express HLA-A2, changes in the 
mean fluorescence intensity (MFI) were investigated. The percentage change in HLA-A2 expression was 
determined according to the formula: % change = [(mean fluorescence with peptide – mean fluorescence 
without peptide) / mean fluorescence without peptide x 100]. Culturing with MART-1 resulted in an increase 
in the expression of HLA-A2, while P603 (>95% Purity) and P603 tBu (>98% purity) resulted in a decrease 
in the expression of HLA-A2. Data are presented as the mean ± SD and are representative of three 
independent experiments. 
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3.12 Peptide:MHC computer modelling 
Investigation of HLA-A2 binding suggested that the presence of the Tyr(3-tBu) 
residue did not alter the HLA-A2 binding potential of the P603 peptide (Fig 3.17). To 
investigate this further, MHC/peptide complex computer modelling was performed by Dr 
Pierre Rizkallah (School of Medicine, Cardiff University). The molecular modelling of the 
two peptides suggested that the presence of the Tyr(3-tBu) would not alter the interaction 
between the peptide and the MHC molecules. However, the modification was predicted to 
result in an extension of the tyrosine side chain out of the MHC towards the TCR and 
produce a peptide with the capacity to adopt two different conformations due to the 
rotation of the aryl ring (Fig 3.18). The predicted similarity between the peptide and MHC 
interactions supports the hypothesis that differential activity of the tBu modified vs 
unmodified peptides is due to differential recognition by the TCR, rather than differences 
in HLA-A2 binding capacity.  
3.13 Nonamer Combinatorial Peptide Library (CPL) screen 
In summary, the data presented indicates that the CD8+ T-cell clone 6C5 was unable 
to recognise HLA-A2+ CLL (Fig 3.8) or the predicted Bax sequence (LLSYFGTPT) but 
was able to recognise a chemically modified peptide (LLSY(3-tBu)FGTPT) (Fig 3.14-3.16). 
Since tBu modifications do not occur naturally, it is unlikely that this artificial epitope is the 
source of the TCR specificity of 6C5. CPL screens have been successfully used to map the 
specificity of expanded T-cell populations of unknown specificity in leukaemia (L, 
Wooldridge, personal communication). Therefore, a CPL screen was performed to probe 
the molecular landscape recognised by the 6C5 TCR, which allowed for the identification 
of potential “naturally occurring” antigenic targets. 6C5 exhibited varying degrees of 
degeneracy at each position, however the greatest degrees of degeneracy were observed 
outside of central region (position 4-6), suggesting that these residues were important for 
TCR recognition of 6C5. Additionally, the index peptide (LLSY(3-tBu)FGTPT) appeared 
to be suboptimal at every position, except position 8 (Fig 3.19 and Table 3.2). Collectively 
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these findings suggest that 6C5 could recognise a multitude of peptide sequences, with 
potentially greater affinity than its index peptide. This supports the notion that the 
modified peptide LLSY(3-tBu)FGTPT is not the natural peptide epitope recognised by 
6C5. 
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(A) 
P603:MHC complex 
 
 
(B) 
P603 tBu:MHC complex 
 
Figure 3.18 Peptide/MHC modelling of unmodified and Tyr(3-tBu) modified peptide bound to 
HLA-A*0201. Computer models of Peptide:/HLA*0201 complexes were generated using entry 4I4W from 
the Protein Data Bank (PDB). Crystallographic Object-Oriented Toolkit (COOT) was used to modify the 
sequence of the peptide to be LLSYFGTPT. (A) and (B) show that for both peptides the anchor residues at 
either end of the peptide were buried in the MHC molecular groove. However, the presence of the Tyr(3-
tBu) resulted in the extension of the tyrosine side chain out of the MHC and towards the TCR.  
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Figure 3.19 Nonamer CPL screen. The nonamer library contained a total of 5×1011 different nonamer peptides and was divided into 180 different peptide mixtures. In every peptide 
mixture, one position has a fixed L-amino acid residue and all other positions were degenerate, thus allowing for any one of 19 natural L-amino acids to being incorporated at each position 
(cysteine is excluded). C1R-A2 cells (6×104) were pulsed in duplicate with each mixture from a nonamer CPL (100 µg/ml). After 2 hours, 6C5 T-cells were added at a ratio of 2:1 and 
incubated overnight at 37°C / 5% CO2. Cell free supernatants were harvested and evaluated for MIP-1β by ELISA. Data presented as the mean ± SD and is representative of 2 
independent experiments. 
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Table 3.2 Summary of data from the nonamer CPL screen performed on 6C5. 
1L 2L 3S 4Y* 5F 6G 7T 8P 9T 
I H R A V M Q  G  W F W Y  H M F Y W W  G S I K M G P N H F V I  L 
F K T W I L   A  S L    C G H  S F  L  T A Q  S G  Q A T  S 
M V S N T A     P      V   A     V R   T R  V     
C     S              
N      L   A        
L                   
C      S           
                         P           
MIP-1β(pg/ml) - RED (2000 - 3600) BLUE (1000 - 2000) GREEN (500 - 1000) BLACK (250 - 500) 
The amino acid residues at each position were grouped based the quantity of the MIP-1β produced. For ease of interpretation the amino acids were coloured, sized and 
arranged in descending order based on the amount of MIP-1β produced. 
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3.14 Identification and screening of cross-reactive peptides  
Three degenerate peptide sequences were identified based on MIP-1β production 
(Table 3.3) and were utilised to probe the UniProt Knowledgebase peptide database on 
13/5/2013 using the ScanProsite (de Castro et al. 2006). This was an attempt to identify 
antigenic peptides originating from multiple biological sources (self, viral, bacterial and 
fungal) that could be recognised by 6C5. Twenty five peptide sequences of interest were 
identified and subsequently 10 were selected for synthesis and further testing (Table 3.4). 
The selection criteria were based on the likelihood of the peptides to induce T-cell 
activation (as determined by the MIP-1β production profile of the sequence), and to 
provide candidates from the four biological sources sampled (self, viral, bacterial and 
fungal). All of these were synthesised together with the “optimal peptide” identified from 
the CPL screen. This peptide comprised the amino acid sequence that resulted in the 
greatest MIP-1β production for each given position. 
Of the 10 peptides selected for testing only four produced T-cell responses above 
background (Fig 3.20). Of these peptides only two, IIGWMWIPV (optimal peptide) and 
YTAYVFIPI (originated from serine palmitoyltransferase, SPT), resulted in responses 
greater than the index peptide (Fig 3.20 and Table 3.5). Analysis of the EC50 values 
indicated that the IIGWMWIPV peptide (5.45×10-9M) out-performed the index peptide 
(LLSY(3-tBu)FGTPT) by approximately two logs and the YTAYVFIPI (7.16×10-8M) out-
performed the index peptide by approximately one log. The two peptides that produced 
responses below the index peptide were MIAWGFISV (4.20×10-5M) and FIAWGFIAA 
(1.23×10-5M), which originated from Candida dubliniensis and multiple strains of 
Staphylococcus, respectively.  
The CPL screen indicated that the index peptide for 6C5 was suboptimal at each 
position except position 8, which provided the potential for multiple peptide sequences to 
be generated that could be recognised by 6C5 and out-perform the index peptide. This 
concept was validated through the superior T-cell activation observed with the “optimal 
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peptide”. Additionally, the CPL screen indicated that the 6C5 was capable of recognising 
peptides in which the modified tyrosine was substituted for a naturally occurring amino 
acid in combination with other changes to the peptide sequence.  
 
Table 3.3 Degenerate peptide seqeunces produced from the nonamer CPL 
MIP-1β 
production 
Sequence 
≥500µg/ml [IFMCYLHKVRTS]-[VITMLAS]-[AGWSP]-[WY]-[FGHMVY]-[FGLW]-
[IVTKARLSPMQ]-[PSTANGRH]-[AITV] 
≥1000µg/ml [IFMCYLHKV]-[VITMLAS]-[GA]-[WY]-[MGVFH]-[WF]-
[IVTKARLSP]-[PSTANGR]-[VAIT] 
≥2000µg/ml [IFMCYL]-[VIT]-[GA]-W-[MGV]-[WF]-[IVT]-[PSTA]-[VA] 
 
 
Table 3.4 Candidate peptides identified from the nonamer CPL 
Type Source Sequence 
Optimal  N/A IIGWMWIPV 
Self Protein LYRIC LLGYGWAAA  
Parathyroid hormone 2 receptor.    LIGWGFPAA 
Serine palmitoyltransferase small 
subunit B 
YTAYVFIP 
Viral Influenza A virus VVWYGGRPV 
Varicella-zoster virus STGYGLARI 
FSPYGWSST 
Hepatitis C virus subtype 1a KAAYGFTGI 
Bacterial Staphylococcus    FIAWGFIAA 
Fungal Candida dubliniensis MIAWGFISV  
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Figure 3.20 Peptide dose-response for 6C5 recognition of candidate peptide identified from CPL. 
C1R-A2 cells (1×105) were pulsed with varying concentrations (10µg/ml to 1×10-6 µg/ml) of the selected 
peptides. After 1 hour 6C5 T-cells were added at a 1:1 ratio and cultured overnight at 37°C / 5% CO2. Cell-
free supernatants were harvested and evaluated for the presence of MIP-1β by ELISA. C1R-A2 and 6C5 T-
cells incubated in the presence of DMSO alone were used as a negative control to determine background 
production of MIP-1β. Furthermore, PHA (10 µg/ml) was used as a positive control. Taking into 
consideration the differing molecular weights of each peptide the molar EC50 values were calculated from the 
curve of best fit. Data are presented as the mean ± SD and are representative of three independent 
experiments. 
 
Table 3.5 Candidate peptides that produced MIP-1β responses above background. 
Sequence Source EC50 M 
IIGWMWIPV  Optimal peptide 5.45×10-9 
YTAYVFIPI  Serine palmitoyltransferase 7.16×10-8 
LLSY*FGTPT Index 6.44×10-7 
MIAWGFISV  Candida dubliniensis 4.20×10-5 
 FIAWGFIAA  Staphylococcus  1.23×10-5 
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3.15 Discussion 
The initial phase of this study centred on generating CD8+ T-cell clones from CLL 
patients that were specific for peptides derived from the pro-apoptotic protein Bax. Based 
on previous work, this had been proposed as a TAA for CLL (Agrawal et al. 2008; Nunes 
et al. 2011). However, the existence of Bax-specific CD8+ T-cells had not been previously 
investigated in primary CLL patient samples. 
To investigate this 23 candidate peptides were identified from the Bax-α protein 
using a computer algorithm to predict HLA binding. A pool of these peptides was used to 
stimulate CD8+ T-cells from a CLL patient (R6A8R89) in vitro using CD40L-activated 
autologous CLL cells as APC (Rodríguez-Pinto 2005; Van den Hove et al. 1997). CD40L 
activation was shown to induce CLL expression of molecules important for T-cell 
activation such as CD86 and HLA-DR (Fig 3.1).  
Repeated Bax peptide stimulation of CD8+ T-cells from CLL patient R6A8R89 
allowed detection of Bax-specific T-cells. This showed that it was possible to generate an 
apparent T-cell response against a “self” protein from a CLL patient using a similar 
procedure as previously described for healthy donors (Nunes et al. 2011). Limiting dilution 
cloning generated a T-cell clone 6C5 that recognised two peptides from the peptide pool: 
P603 (Bax161-170; LLSYFGTPT) and P605 (Bax160-170; GLLSYFGTPT), which shared an 
overlapping 9 amino acid sequence. The superior IFN-γ response observed with P603 
indicated that 6C5 had a preference of nonamer peptides. The concept of a TCR having a 
preference for a specific length peptide, while demonstrating recognition of shorter or 
longer peptides, is not uncommon and has been observe with numerous T-cell clones 
(Ekeruche-Makinde et al. 2013). Furthermore, it has been suggested that the variation in 
the quality of response to similar peptides of different lengths is not due to effects on 
MHC binding but presentation at the level of the TCR (Ekeruche-Makinde et al. 2013).  
While the process of generating T-cell clones utilised in this study (peptide pool 
stimulation and limiting dilution) is common practice (Mariotti and Nisini 2009; Gallagher 
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and Man 2007; Yee et al. 2002; Nunes et al. 2011), alternative approaches to the generation 
of clonal populations of T-cells have been used by others. For example, the ex vivo 
culturing and expansion of tetramer sorted T-cells (Dunbar et al. 1999). However, this 
approach was not utilised in this study for the following reasons:  
1. Several Cardiff laboratories, including ours, had failed to generate long-
lived T-cell clones using tetramer sorting (S Man, C Pepper, personal 
communication).  
2. The proof of principle study (Nunes et al. 2011) indicated that a CD8+ 
T-cell restricted to the Bax epitope P613 (IMGWTLDFL) was capable 
of recognising and killing CLL cells. However, it was unknown whether 
T-cells with the same specificity actually existed in CLL patients or 
whether this was indeed the optimal epitope in patients.  
3. The high production costs associated with manufacturing multiple 
tetramers made this approach financially unfeasible.  
4. Activation-induced cell death is a common side-effect of tetramer 
sorting thereby decreasing the efficacy of isolating and growing specific 
clones (Cebecauer et al. 2005).  
The use of IFN-γ ELISpot to determine T-cell recognition of target cells has been 
successfully used to validate CD8+ T-cells specific for epitopes associated with CLL 
(Nunes et al. 2011; Foster et al. 2010). Furthermore, as chromium release CTL assays are 
not suitable with CLL targets due to inherent instability associated with CLL cell 
membranes (S Man, C Pepper, personal communication), IFN-γ ELISpot was used to 
investigate the recognition of primary CLL cells by 6C5. It was observed that the 6C5 was 
unable to specifically recognise resting or activated HLA-A2+ CLL cells. This suggested 
that the Bax-derived epitope P603 was not expressed on either resting or activated CLL 
cells. Alternatively, the affinity of 6C5 may be too weak to induce cellular activation in 
response to the quantity peptide expressed on the CLL cells. 
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An unexpected finding from the epitope mapping indicated the 6C5 was not 
actually specific for P603. By utilising an immunological and chemical approach it was 
determined that 6C5 was actually specific for a modified version of P603, which contained 
a tertiary butyl on the tyrosine residue (LLSY(3-tBu)FGTPT). It is likely that the modified 
P603 peptide identified in this study was generated during the peptide synthesis process 
due to the alkylation of tyrosine by tBu cations under peptide deprotection conditions. This 
reaction has been reported during model deprotection conditions (Lundt et al. 1979) and 
for preparative scale synthesis (Taka et al. 2009) of Tyr(3-tBu). Therefore the observation 
of a peptide containing Tyr(3-tBu) as a minor constituent of the crude P603 preparation 
was perhaps not surprising. 
Peptide modifications can alter MHC binding kinetics (Parkhurst et al. 1996), the 
TCR contact residues of the peptides (de Haan et al. 2005a; de Haan et al. 2005b) and 
ultimately peptide immunogenicity. While it is clear that the presence of the Tyr(3-tBu) 
dictated the peptide recognition of 6C5, the precise mechanism by which this modification 
modulates peptide immunogenicity was unknown e.g. altered MHC binding or differential 
TCR contact. 
 HLA-A2 binding assays were performed to determine if the presence of Tyr(3-
tBu) allowed for enhanced MHC binding and thus superior peptide presentation. This was 
determined by investigating changes in the stability of HLA-A2 on T2 cells, in presence of 
peptides by flow cytometry. The results suggested that the presence of Tyr(3-tBu) had little 
or no influence on peptide binding. However, these results were inconclusive as no clear 
difference could be determined between the two peptides. Additionally only a single 
peptide concentration was tested, to provide an extensive evaluation of the interaction 
between the peptides of interest and MHC, it would be desirable to test multiple peptide 
concentrations. To fully assess the differences in MHC binding between the two peptides a 
more sensitive and efficient assay would be required e.g. a chemiluminescence HLA 
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binding assay such as the one used by the human MHC project (Harndahl et al. 2009) or a 
Biacore-based assay (Fayad et al. 2001). 
However, as these techniques were not available at the time of this study, 
peptide/MHC models (Dr Pierre Rizkallah) were computer generated based on known 
peptide/MHC structures 4I4W (Ekeruche-Makinde et al. 2013). These models predicted 
that the presence of the Tyr(3-tBu) would not change the peptide/MHC interactions 
involved in binding, but would result in an extension of the tyrosine side chain out of the 
MHC towards the TCR. This would potentially alter the peptide structure “observed” by 
the TCR. However, as this is only a computer model, based on previously described 
“natural” sequences, it remains uncertain whether the presence of the Tyr(3-tBu) would 
actually alter the tertiary structure of the P603 thereby influencing MHC binding and/or 
the TCR contact residues. This could be investigated further by crystallisation of HLA-A2 
complexed with the wild type and modified P603 peptides, but this was beyond the scope 
of this project. 
Encouragingly it has been shown the chemical modification of amino acid side 
chains involved in TCR contact can result in the loss of peptide immunogenicity, whilst 
have no significant influence on MHC binding (de Haan et al. 2005a; de Haan et al. 2005b). 
Furthermore, it has been observed that a minor change in tyrosine, the conversion of 
tyrosine to nitrotyrosine, can abrogate peptide recognition in both CD4+ (Birnboim et al. 
2003) and CD8+ T-cells (Hardy et al. 2008), whilst not affecting MHC binding. Conversely, 
it has been shown that alterations of MHC binding residues, which have positive effects on 
MHC binding, can have a negative effect on peptide recognition and T-cell responses (Cole 
et al. 2010). Thus highlighting the complexity involved in the relationships between peptide 
binding, TCR recognition and subsequent T-cell responses. 
Since peptides containing Tyr(3-tBu) are synthetic entities and do not occur in 
nature, it is unclear how a CD8+ T-cell with specificity for LLSY(3-tBu)FGTPT could have 
arisen. There are two possibilities for the origin of CD8+ T-cell clone 6C5. Firstly, it could 
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be a memory T-cell generated in vivo against a naturally occurring epitope that is able to 
cross-react with LLSY(3-tBu)FGTPT. Theoretically, a different, naturally occurring residue 
that possessed an extended side chain with similar properties to the (3-tBu) group could 
result in a suitable peptide confirmation allowing for TCR contact and activation. Secondly, 
6C5 could have been generated from naïve T-cells primed against P603 tBu in vitro, which 
expanded to functionally detectable levels during the 5-week culturing period. This 
possibility could be tested by culturing flow sorted naïve T-cells in the presence of LLSY(3-
tBu)FGTPT (van der Burg et al. 2001). 
Thus far it has been shown that the specificity of 6C5 is restricted to a modified 
version of P603 (LLSY(3-tBu)FGTPT) rather then the original wild type Bax-derived 
peptide, P603 (LLSYFGTPT). This difference in specificity could therefore explain the 
inability of 6C5 to recognise primary HLA-A2+ CLL cells. However, in the absence of T-
cell clones specific for the wild type P603 it is still unknown whether this epitope could be 
generated and presented on the CLL cells.  
To investigate the potential for 6C5 to cross-react with naturally occurring peptides 
a CPL screen was performed. This revealed that the 6C5 showed varying degrees of 
degeneracy across all 9 amino acids, but the greatest degeneracy were observed outside of 
central region (positions 4-6), suggesting that conservation of these residues is important 
for T-cell activation. Position 4 showed the least degeneracy with only four different amino 
acids being successfully recognised (W > Y > H > C). Interestingly the CPL screen 
suggested that the unmodified form of tyrosine would be successful recognised by 6C5. It 
is possible that the unmodified tyrosine may need to be “paired” with specific residues 
within the central region to allow for successful T-cell activation. This hypothesis could be 
tested through synthesis and assaying of a series of analogues of the P603 peptide that are 
fixed at all positions apart from 5 and 6. 
Four out of the 10 peptides generated from the data produced by the CPL screen 
exhibited activity above the background, but only two showed activity above the index 
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peptide; the optimal peptide (IIGWMWIPV) and a peptide sequence originating from the 
enzyme SPT (YTAYVFIPI). SPT is the initial and rate-limiting enzyme in the sphingolipid 
synthesis process and is made up of two subunits SPT1 and SPT2. Immunocytochemistry 
analysis showed enhanced expression of both subunits in colon, ovarian, pancreas and 
thyroid carcinomas as well as Leiomyosarcoma (Carton et al. 2003). Therefore, it could be 
hypothesised that the enhanced expression of SPT in these malignancies could lead to the 
expression of SPT-derived peptides, which could serve as targets for T-cells that express 
TCRs specific for SPT-derived peptides, such as 6C5. However, investigation of this 
hypothesis was beyond the scope of this project. 
In summary, this study highlights how the chemical modification of a single amino 
acid, Tyr ! Tyr(3-tBu), could affect the activation of the CD8+ T-cell clone 6C5. This 
modified P603 tBu peptide arose as a byproduct of the peptide synthesis process and 
formed <1% of the original P603 crude (77% Purity) peptide preparation and <0.05% of 
the original 23 peptide mixture used during in vitro T-cell stimulation. These statistics 
emphasise the acute specificity and sensitivity of TCR and their ability to discriminate 
between peptides with identical primary amino sequence but which differ by a single 
chemical modification (de Haan et al. 2005a; de Haan et al. 2005b; Birnboim et al. 2003; 
Hardy et al. 2008). Additionally, this study highlights how minor peptide contaminants can 
potentially cause misleading results within immunological research (Mannering et al. 2003; 
Brezar et al. 2011). Given the standard methodology that is currently employed for peptide 
synthesis, this data could have wider implications in relation to the interpretation of results 
derived from the in vivo use of synthetic peptides for vaccination. The use of a CPL screen 
provided insight in which naturally occurring amino acids could function in place of the 
modified tyrosine and indicated that 6C5 could potentially cross-react with several 
“natural” peptides.  
While this chapter ultimately failed to address the original aim of generating Bax-
specific CD8+ T-cells from CLL patients, it showed that activated CLL cells can serve as 
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effective source of APCs to expand low frequency peptide-specific T-cells. Furthermore, 
the study demonstrated that long-lived and functionally competent CD8+ T-cell clones 
could be isolated from CLL patients. Therefore, although the investigation into the 
existence and function of Bax-specific T-cells within CLL patients was not further 
investigated within this thesis, the techniques and the knowledge acquired have proved 
invaluable for further work. 
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Chapter 4  
Immunophenotyping of CLL patients  
CLL has been widely characterised as a disease that exhibits multiple T-cell defects 
(Ramsay et al. 2008; Nunes et al. 2012; Riches et al. 2013), which could limit the 
immunological control of the tumour and increase susceptibility to opportunistic 
infections. Additionally, these immunological defects could limit the efficacy of T-cell 
based immunotherapies for the treatment of CLL such as adoptive T-cell therapy and bi-
specific antibodies. Moreover it has become increasing apparent that T-cells may play a role 
in the survival of CLL cells in vivo (Bagnara et al. 2011) and may even influence the 
pathology of the disease (Nunes et al. 2012). Therefore the acquisition of knowledge 
regarding T-cell immunophenotype from CLL patients might identify patients who are 
most suitable for T-cell therapies and provide evidence for the involvement of specific T-
cell populations in the pathology of the disease. 
The objective of this study was to use polychromatic flow cytometry to perform a 
phenotypic analysis of T-cells and B-cells from the peripheral blood of 97 CLL patients 
(Appendix 1) and 21 healthy donor (HD) age-matched controls (Appendix 2) to identify 
potential immunological abnormalities. Patients were either analysed as whole cohort or 
divided into two groups based on their CD4:CD8 ratio: normal (<1) or inverted (>1). 
Additionally due to overwhelming dominance of CLL cells in peripheral blood samples, 
partial enrichment of the T-cell compartment was performed by the removal of CD19+ 
leukaemic B-cells to allow for a more detailed analysis of T-cell populations expressing 
multiple markers in combination. 
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Immunophenotyping strategy 
 
Figure 4.1 Immunophenotyping strategy. Schematic showing the markers investigated in this study and 
the potential interactions that could occur between the T-cells and B-cells. 
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Gating strategy 
(A)  
T-cells and subset gating 
 
(B) 
Gating for CD57/CD27 
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(C) 
Gating for Immunosuppressive receptors 
 
Figure 4.2 Representative results of T-cell phenotypic analysis. The percentage of positive cells was 
determined by flow cytometry (FACSAria) and analysis was carried out using FlowJo software. (A) The 
gating strategy used to identify the CD4+ and CD8+ T-cells as well as T-cell memory subsets, which were 
defined using CCR7 and CD45RO labelling: CCR7+ CD45RO- (Naïve), CCR7+ CD45RO+ (CM), CCR7- 
CD45RO+ (EM) and CCR7- CD45RO- (EMRA). (B) Gating strategy used to characterise the expression of 
CD27 and CD57 within the CD4+ and CD8+ T-cell compartments. (C) Gating strategy used to characterise 
the expression of PD-1, TIM-3 and LAG-3 within the CD4+ and CD8+ T-cell compartments. To assist with 
the gating of positive cell populations fluorescence minus one (FMO) controls were applied where necessary. 
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4.1 CD4+ T-cells 
4.1.1 Memory subsets 
T-cells can be sub-divided into 4 main subsets (Naïve, CM, EM and EMRA) based 
on the expression of CCR7 and CD45RO (Fig 4.1 and 4.2a). As well as displaying 
phenotypic differences these subsets have been shown to exhibit functional distinctions 
both in vitro and in vivo (Sallusto et al. 2004; Klebanoff et al. 2006; Geginat et al. 2003). 
When the 97 CLL patients were analysed as a group, no significant differences in 
the frequencies of CD4+ T-cell subsets were observed when compared with age-matched 
healthy donors (HD) (Fig 4.3). However, when CLL patients were stratified into two 
groups based on CD4:CD8 ratios (normal ratio, CLLNR and inverted ratio, CLLIR) it was 
observed that there was a significant decrease in the percentage of naïve CD4+ T-cells 
within the CLLIR patient group when compared to the CLLNR (P ≤ 0.001) and the HD 
controls (P ≤ 0.01). Furthermore, there was a significant increase in the percentage of EM 
CD4+ T-cells within the CLLIR patient group when compared to the CLLNR (P ≤ 0.001) and 
HD controls (P ≤ 0.01). In contrast, no significant difference in the frequency of naïve or 
EM CD4+ T-cells was observed between CLLNR and HD controls (Fig 4.4). These results 
highlight that the distribution of the CD4+ T-cell subsets within CLL patients is 
heterogeneous, with the CLLIR patient group displaying a reduced naïve T-cell pool and an 
increased EM compartment.  
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Total CLL cohort 
 
 
Figure 4.3 CD4+ T-cell memory subsets in the total CLL cohort (n=97) and age-matched healthy 
donor (HD) controls (n=21). The percentages of positive cells were quantified using 10-colour flow 
cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile and T-cell 
memory subsets were defined using CCR7 and CD45RO, Naïve (CCR7+ CD45RO-), CM (CCR7+ 
CD45RO+), EM (CCR7- CD45RO+) and EMRA (CCR7- CD45RO-). Data are represented as dot plots with 
the median (red bar) shown for each distribution. Statistical analysis (Mann-Whitney U test) was performed 
using GraphPad Prism 5.0. 
 
Stratified CLL cohort 
 
 
Figure 4.4 CD4+ T-cell memory subsets in the stratified CLL cohort (CLLIR, n=32 and CLLNR, n=65) 
and age-matched healthy donor (HD) controls (n=21) The percentages of positive cells were quantified 
using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter 
profile and T-cell memory subsets were defined using CCR7 and CD45RO, Naïve (CCR7+ CD45RO-), CM 
(CCR7+ CD45RO+), EM (CCR7- CD45RO+) and EMRA (CCR7- CD45RO-). Data are represented as dot 
plots with the median (red bar). Statistical analysis (Kruskal-Wallis ANOVA with the Dunn's Multiple 
Comparison Test) was performed using GraphPad Prism 5.0. The level of statistical significance is denoted 
by asterisks (** P ≤ 0.01, *** P ≤ 0.001). 
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4.1.2 Expression of CD57 and CD27 
The expression of CD57 has been historically associated with a “highly 
differentiated” T-cell phenotype, as CD57+ T-cells have been shown to be more 
susceptible to apoptosis, and exhibit reduced proliferative potential and diminished effector 
function (Dolfi et al. 2008; Brenchley et al. 2003; Focosi et al. 2010). However, the specific 
fate bestowed upon a T-cell due to the expression of CD57 is still under debate (Chong et 
al. 2008). Additionally, the loss of expression and/or effective signalling via the co-
stimulatory T-cell receptor CD27 has been associated with immune dysfunction and 
differentiation (Dolfi et al. 2008; Plunkett et al. 2007; Hendriks et al. 2000). The 
development of the described phenotypes typically coincide with a stepwise transition from 
the acquisition of CD57 and the loss of co-stimulatory receptors such as CD27 and CD28 
(Klebanoff et al. 2006). Therefore because of their association with T-cell differentiation 
and function, the expression of CD57 and CD27 on T-cells was investigated.  
When considering the total CLL cohort, no significant differences regarding the 
frequency of CD57+ (Fig 4.5) or CD27- T-cells were observed (Fig 4.7) when compared 
with the HD controls. However, when CLL patients were stratified into two groups (CLLIR 
and CLLNR) there was a significant increase in the frequency of CD57+ T-cells within the 
CLLIR patient group when compared to the CLLNR (P ≤ 0.001) and the HD controls (P ≤ 
0.001). In contrast, no significant differences were observed between CLLNR and the HD 
controls (Fig 4.6). Additionally, there was a significant increase in the frequency of CD27- 
T-cells within the CLLIR patient group when compared to the CLLNR (P ≤ 0.001) with a 
trend towards an increase in the frequency of a CD27- phenotype within the CLLIR patient 
group when compared to the HD controls (Fig 4.8).  
These results indicated that CLL patients exhibit a diverse range of expression of 
CD57 and CD27 within the CD4+ T-cell compartments. However, distinct differences were 
observed between subsets of patients with increased frequencies of CD57+ and CD27- 
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expression being associated with the CLLIR patient group. This suggests that individuals 
within this group exhibit features associated with augmented immunological differentiation.  
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Stratified CLL cohort 
 
 
Figure 4.6 CD57 expression within CD4+ T-cells of the stratified CLL cohort (CLLIR, n=32 and 
CLLNR, n=65) and age-matched healthy donor (HD) controls (n=21). The percentages of positive cells 
were quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward 
and side scatter profile. CD57 expression was measured in the total CD4+ T-cell population. Data are 
represented as dot plots with the median (red bar) shown for each distribution. Statistical analysis (Kruskal-
Wallis ANOVA with the Dunn's Multiple Comparison Test) was performed using GraphPad Prism 5.0. 
Statistical significance is denoted by asterisks (*** P ≤ 0.001). 
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Figure 4.5 CD57 expression within CD4+ T-cells of the total CLL cohort (n=97) and age-matched 
healthy donor (HD) controls (n=21). The percentages of positive cells were quantified using 10-colour 
flow cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile. CD57 
expression was measured in the total CD4+ T-cell population. Data are represented as dot plots with the 
median (red bar) shown for each distribution. Statistical analysis (Mann-Whitney U test) was performed using 
GraphPad Prism 5.0.  
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Total CLL cohort 
 
  
Figure 4.7 CD27 expression within CD4+ T-cells of the total CLL cohort (n=97) and age-matched 
healthy donor (HD) controls (n=21). The percentages of positive cells were quantified using 10-colour 
flow cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile. CD27 
expression was measured in the total CD4+ T-cell population and was presented as CD27- CD4+ T-cells. 
Data represented as dot plots with the median (red bar) shown for each distribution. Statistical analysis 
(Mann-Whitney U test) was performed using GraphPad Prism 5.0.  
 
 
Stratified CLL cohort 
 
  
Figure 4.8 CD27 expression within CD4+ T-cells of the stratified CLL patients (CLLIR, n=32 and 
CLLNR, n=65) and age-matched healthy donor (HD) controls (n=21). The percentages of positive cells 
were quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward 
and side scatter profile. CD27 expression was measured in the total CD4+ T-cell population and was 
presented as CD27- CD4+ T-cells. Statistical analysis (Kruskal-Wallis ANOVA with the Dunn's Multiple 
Comparison Test) was performed using GraphPad Prism 5.0. Statistical significance is denoted by asterisks 
(*** P ≤ 0.001). 
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4.1.3 Immunosuppressive receptors 
The expression of immunosuppressive receptors has been observed in numerous 
haematological (Nunes et al. 2012; Riches et al. 2013) and solid malignancies (Matsuzaki et 
al. 2010; Fourcade et al. 2009) as well as viral infections (McMahan et al. 2010; Day et al. 
2006). The expression and activation of these receptors has been associated with reduced 
T-cell effector functions, diminished proliferative potential and increased sensitivity to 
apoptosis. Ultimately this can result in the development of an “exhausted” T-cell 
phenotype, loss of immunological control and the inability to induce tumour and viral 
clearance (Keir et al. 2008; Woo et al. 2012; Wei et al. 2013; McMahan et al. 2010). This 
investigation focused on PD-1 (Chemnitz et al. 2004; Yokosuka et al. 2012; Okazaki et al. 
2001; Parry et al. 2005), TIM-3 (Rangachari et al. 2012) and LAG-3 (Workman et al. 2002; 
Workman and Vignali 2003) due to each receptor mediating immunosuppression and T-
cell dysfunction through the activation of divergent signalling pathways, thus allowing for 
the potential evaluation of multiple immunosuppressive mechanisms. 
4.1.3.1 PD-1 
The expression of PD-1 was investigated due to its association with 
immunosuppression and T-cell exhaustion (Wei et al. 2013; Parry et al. 2005; Keir et al. 
2008). When CLL patients were grouped as a whole no significant difference in the 
frequency of CD4+PD-1+ T-cells were observed in comparison with HD controls (Fig 4.9). 
However, the data were heterogeneous and a proportion of CLL patients appeared to 
exhibit higher percentages of CD4+PD-1+ T-cells than the HD controls. When the CLL 
patients were stratified into two groups (CLLIR and CLLNR) it was observed that there was a 
significant increase in the percentage of CD4+PD-1+ T-cells within the CLLIR patient group 
when compared to the CLLNR (P ≤ 0.001) and the HD controls (P ≤ 0.001) (Fig 4.10). 
These data indicate that although PD-1 expression was heterogeneous in CLL patients, a 
high proportion of the patients with high frequencies of CD4+PD-1+ T-cells were in the 
CLLIR group.  
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4.1.3.2 TIM-3 
The expression of TIM-3 was investigated due to its association with 
immunosuppression and T-cell exhaustion (Zhu et al. 2005; Wherry 2011). When 
considering the total CLL cohort there was a small but significant (P ≤ 0.05) increase in the 
frequency of CD4+TIM-3+ T-cells when compared to the HD controls (Fig 4.11). As with 
PD-1, when CLL patients were stratified into two groups (CLLIR and CLLNR), there was a 
more obvious, significant increase in the frequency of CD4+TIM-3+ T-cells within the 
CLLIR patient group when compared to the CLLNR (P ≤ 0.01) and the HD controls (P ≤ 
0.001) (Fig 4.12). These results indicated that the expression of TIM-3 within the CD4+ T-
cell compartment of CLL patients was significantly increased when compared with HD 
controls. Additionally, the elevated expression of TIM-3 appeared to be more pronounced 
within the CLLIR patient group.  
4.1.3.3 LAG-3 
The expression of LAG-3 was investigated due to its association with 
immunosuppression and T-cell exhaustion (Hannier et al. 1998; Wherry 2011). The data 
obtained was highly heterogeneous (as observed with the other markers under 
investigation). However, no statistically significant differences in the frequencies 
CD4+LAG3+ T-cells were observed between CLL patients and the HD controls, either 
when patients were analysed as a total cohort (Fig 4.13) or stratified into CLLIR and CLLNR 
patient groups (Fig 4.14).  
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Total CLL cohort 
 
  
Figure 4.9 PD-1 expression within CD4+ T-cells of the total CLL cohort (n=97) and age-matched 
healthy donor (HD) controls (n=21). The percentages of positive cells were quantified using 10-colour 
flow cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile. PD-1 
expression was measured in the total CD4+ T-cell population. Statistical analysis (Mann-Whitney U test) was 
performed using GraphPad Prism 5.0.  
 
 
Stratified CLL cohort 
 
  
Figure 4.10 PD-1 expression within CD4+ T-cells of the stratified CLL cohort (CLLIR, n=32 and 
CLLNR, n=65) and age-matched healthy donor (HD) controls (n=21). The percentages of positive cells 
were quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward 
and side scatter profile. PD-1 expression was measured in the total CD4+ T-cell population. Statistical 
analysis (Kruskal-Wallis ANOVA with the Dunn's Multiple Comparison Test) was performed using 
GraphPad Prism 5.0. Statistical significance is denoted by asterisks (*** P ≤ 0.001). 
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Total CLL cohort 
 
  
Figure 4.11 TIM-3 expression within CD4+ T-cells of the total CLL cohort (n=97) and age-matched 
healthy donor (HD) controls (n=21). The percentages of positive cells were quantified using 10-colour 
flow cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile. TIM-3 
expression was measured in the total CD4+ T-cell population. Statistical analysis (Mann-Whitney U test) was 
performed using GraphPad Prism 5.0. Statistical significance is denoted by asterisks (* P ≤ 0.05). 
 
 
Stratified CLL cohort 
 
  
Figure 4.12 TIM-3 expression within CD4+ T-cells of the stratified CLL cohort (CLLIR, n=32 and 
CLLNR, n=65) and age-matched healthy donor (HD) controls (n=21). The percentages of positive cells 
were quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward 
and side scatter profile. TIM-3 expression was measured in total CD4+ T-cell population. Statistical analysis 
(Kruskal-Wallis ANOVA with the Dunn's Multiple Comparison Test) was performed using GraphPad Prism 
5.0. Statistical significance is denoted by asterisks (** P ≤ 0.01, *** P ≤ 0.001). 
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Total CLL cohort 
 
 
Figure 4.13 LAG-3 expression within CD4 T-cells of the total CLL cohort (n=97) and age-matched 
healthy donor (HD) controls (n=21). The percentages of positive cells were quantified using 10-colour 
flow cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile. LAG-3 
expression was measured in total CD4+T-cell population. Data represented as dot plots with the median (red 
bar) shown for each distribution. Statistical analysis (Mann-Whitney U test) was performed using GraphPad 
Prism 5.0.  
 
 
Stratified CLL cohort 
 
 
Figure 4.14 LAG-3 expression within CD4+ T-cells of the stratified CLL patients (CLLIR, n=32 and 
CLLNR, n=65) and age-matched healthy donor (HD) controls (n=21). The percentages of positive cells 
were quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward 
and side scatter profile. (A) LAG-3 expression was measured in total CD4+ T-cell population. Data 
represented as dot plot with the median (red bar) shown for each distribution. Statistical analysis (Kruskal-
Wallis ANOVA with the Dunn's Multiple Comparison test) was performed using GraphPad Prism 5.0.  
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4.1.4 Combined expression of immunosuppressive receptors 
Numerous reports have suggested that T-cells expressing multiple 
immunosuppressive receptors may represent populations, which exhibit the most profound 
impairments in T-cell function (Sakuishi et al. 2010; McMahan et al. 2010; Fourcade et al. 
2010). Thus these T-cell populations may be more indicative of an “exhausted” T-cell 
phenotype and exhibit the greatest immune dysfunction. 
To determine the frequency of combined expression of PD-1, TIM-3 and LAG-3 
in the CD4+ T-cells, Boolean gating was performed and the subsequent data was analysed 
and presented using SPICE 5.35 software. When CLL patients were grouped as a whole 
and compared to the HD controls, significant differences (P = 0.047) in the frequencies of 
T-cells expressing multiple immunosuppressive receptors were observed between the two 
groups (Fig 4.15 and Table 4.1). Further analysis indicated that the main differences were 
due to a significant increase in the frequency of the PD-1+TIM-3+LAG-3+ (P=0.011) and 
PD-1+TIM-3+LAG-3- (P < 0.001) T-cells within the CD4+ T-cell compartment of CLL 
patients when compared to HD controls (Table 4.2). 
Stratification of CLL patients into two groups (CLLIR and CLLNR) revealed 
significant differences between CLLIR and CLLNR, and CLLIR and HD groups (Fig 4.16 and 
Table 4.3). Further analysis revealed that this was due to the differences in the frequency of 
multiple cell populations, each expressing different combinations of immunosuppressive 
receptors. In terms of combined expression, significant increases in the frequency of PD-
1+TIM-3+LAG-3+, PD-1+TIM-3+LAG-3- and PD-1+TIM-3-LAG-3+ T-cell were observed 
in the CLLIR patient group, when compared to either CLLNR or the HD controls (Table 
4.4). In addition there was a significant decrease in the frequency of PD-1-TIM-3-LAG-3- 
CD4+ T-cells in the CLLIR patient group when compared to either CLLNR or the HD 
controls (Table 4.4). These findings suggested that the increased frequency of CD4+ T-cells 
expressing multiple immunosuppressive receptors is particularly associated with the CLLIR 
patient group. 
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Total CLL cohort 
 
Figure 4.15 Combined expression of immunosuppressive receptors within CD4+ T-cells of the total CLL cohort (n=97) and age-matched healthy donor (HD) controls 
(n=21). The percentage of positive cells was quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile. Combined 
expression of PD-1, TIM-3 and LAG-3 were determined using Boolean gating. Colours of the pie arcs depict the expression of individual inhibitory receptors, while the colour in the pie 
depicts the number of co-expressed inhibitory receptors. Data representation and statistical analyses (Mann-Whitney U test) were performed using SPICE 5.35 software. 
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Stratified CLL cohort 
 
Figure 4.16 Combined expression of immunosuppressive receptors within CD4+ T-cells of the stratified CLL cohort (CLLIR, n=32 and CLLNR, n=65) and age-matched 
healthy donor (HD) controls (n=21). The percentage of positive cells was quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward and 
side scatter profile. Combined expression of PD-1, TIM-3 and LAG-3 were determined using Boolean gating. Colours of the pie arcs depict the expression of individual inhibitory 
receptors, while the colour in the pie depicts the number of co-expressed inhibitory receptors. Data representation and statistical analyses (Mann-Whitney U test) were performed using 
SPICE 5.35 software. 
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Table 4.1 Overall CD4+ T-cell pie chart analysis (CLL vs HD)1 
Pie Type CLL HD 
CLL  0.0466 
HD 0.0466  
 
Table 4.2 Detailed CD4+ T-cell pie chart analysis (CLL vs HD)1 
Category TYPE: HD 
PD-1+LAG-3+TIM-3+ 0.011 
PD-1+LAG-3+TIM-3- 0.350 
LAG-3+TIM-3+PD-1- 0.399 
PD-1+TIM-3+LAG-3- <0.0001 
PD-1-TIM-3-LAG-3- 0.103 
Compared to CLL 
 
Table 4.3 Overall CD4+ T-cell pie chart analysis (CLLNR vs CLLIR vs HD)1 
Pie Type CLLIR CLLNR HD 
CLLIR  <0.0001 <0.0001 
CLLNR <0.0001  0.7093 
HD <0.0001 0.7093  
 
Table 4.4 Detailed CD4+ T-cell pie chart analysis (CLLNR vs CLLIR vs HD)1 
Category CLLNR HD 
PD-1+LAG-3+TIM-3+ <0.0001 <0.0001 
PD-1+LAG-3+TIM-3- <0.0001 0.007 
LAG-3+TIM-3+PD-1- 0.945 0.469 
PD-1+TIM-3+LAG-3- <0.0001 <0.0001 
PD-1-TIM-3-LAG-3- <0.0001 <0.0001 
Compared to CLLIR  
  
                                                
1 Statistical analysis (Mann-Whitney U test) was performed using SPICE 5.35. Statistically significant 
differences were highlighted in red. 
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4.2 CD8+ T-cells 
Since CD8+ T-cells have a distinctly different functional role to CD4+ T-cells 
(Janeway 2012). Therefore, this T-cell subset was analysed separately to investigate 
potential phenotypic differences within our CLL and healthy donor populations using a 
similar gating strategy to that described in section 4.1. 
4.2.1 Memory subset 
In contrast to CD4+ T-cells, there were significant differences in the frequencies of 
CD8+ T-cell subsets when CLL patients were compared to age-matched HD controls (Fig 
4.17). Significant decreases in the naïve (P ≤ 0.05) and CM (P ≤ 0.01) CD8+ T-cells in CLL 
patients was observed when compared to the HD controls (Fig 4.17). These differences 
were more pronounced when the CLL patients were stratified. For example, naïve and CM 
CD8+ T-cell subsets were decreased in the CLLIR patient group when compared with either 
CLLNR or HD controls (Fig 4.18). However, there were no significant differences when 
CD8+ T-cell subsets were compared between CLLNR and the HD control.  
In contrast to CD4+ T-cells (Fig 4.2 and 4.3), there was a marked skewing towards 
EMRA in CD8+ T-cells in both CLL patients and HD controls (Fig 4.17 and 4.18). 
Comparisons between CLL patients and HD control showed no statistically significance 
differences, however stratification of the CLL patients indicated a significant increase in the 
percentage of EMRA CD8+ T-cells within the CLLIR patient group when compared to the 
CLLNR (P ≤ 0.05) and a trend towards an increase when compared to the HD controls (Fig 
4.18). These results demonstrated that the distribution of the T-cell memory subsets within 
CLL patients was heterogeneous, but the CLLIR patient group displayed a marked skewing 
in the naïve, CM and EMRA subsets. 
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Total CLL cohort 
 
 
Figure 4.17 CD8+ T-cell memory subsets in the total CLL cohort (n=97) and age-matched healthy 
donor (HD) controls (n=21). The percentages of positive cells were quantified using 10-colour flow 
cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile and T-cell 
memory subsets were defined using CCR7 and CD45RO, Naïve (CCR7+ CD45RO-), CM (CCR7+ 
CD45RO+), EM (CCR7- CD45RO+) and EMRA (CCR7- CD45RO-). Data represented as dot plots with the 
median (red bar) shown for each distribution. Statistical analysis (Mann-Whitney U test) was performed using 
GraphPad Prism 5.0. Statistical significance is denoted by asterisks (* P ≤ 0.05, ** P ≤ 0.01). 
 
Stratified CLL cohort 
 
 
Figure 4.18 CD8+ T-cell memory subsets in the stratified CLL cohort (CLLIR, n=32 and CLLNR, 
n=65) and age-matched healthy donor (HD) controls (n=21). The percentages of positive cells were 
quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward and 
side scatter profile and T-cell memory subsets were defined using CCR7 and CD45RO, Naïve (CCR7+ 
CD45RO-), CM (CCR7+ CD45RO+), EM (CCR7- CD45RO+) and EMRA (CCR7- CD45RO-). Data 
represented as dot plots with the median (red bar) shown for each distribution. Statistical analysis (Kruskal-
Wallis ANOVA with the Dunn's Multiple Comparison Test) was performed using GraphPad Prism 5.0. 
Statistical significance is denoted by asterisks (* P ≤ 0.05, *** P ≤ 0.001). 
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4.2.2 Expression of CD57 and CD27 
Due to the association between T-cell differentiation status and function (Dolfi et 
al. 2008; Brenchley et al. 2003; Focosi et al. 2010; Plunkett et al. 2007; Hendriks et al. 
2000), the expression of the late differentiation markers CD57 and CD27 were investigated 
within the CD8+ T-cell compartment. When the total CLL cohort was analysed for the 
frequencies of CD8+CD57+ (Fig 4.19) or CD8+CD27- (Fig 4.21) T-cells, there were no 
significant differences when compared to the HD control group. However, when CLL 
patients were stratified into two groups (CLLIR and CLLNR) there was a significant increase 
in the percentage of CD8+CD57+ T-cells within the CLLIR patient group when compared 
to CLLNR (P ≤ 0.001) and the HD controls (P ≤ 0.001) (Fig 4.20). When the loss of CD27 
was investigated in the CD8+ T-cell compartment, a significant increase in the CD8+CD27- 
phenotype was observed within the CLLIR patient group when compared to CLLNR (P ≤ 
0.001); no other significant differences were observed between the groups (Fig 4.22). These 
results suggested that the CLLIR patient group manifested higher frequencies of CD8+ T-
cells with a “highly” differentiated memory T-cell phenotype when compared to either 
CLLNR or HD controls.  
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Total CLL cohort 
 
 
Figure 4.19 CD57 expression within the CD8+ T-cells of the total CLL cohort (n=97) and age-
matched healthy donor (HD) controls (n=21). The numbers of positive cells were quantified using 10-
colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile. 
CD57 expression was measured in total CD8+ T-cell population. Data are represented as dot plots with the 
median (red bar). Statistical analysis (Mann-Whitney U test) was performed using GraphPad Prism 5.0.  
 
 
Stratified CLL cohort 
 
 
Figure 4.20 CD57 expression within the CD8+ T-cells of the stratified CLL cohort (CLLIR, n=32 and 
CLLNR, n=65) and age-matched healthy donor (HD) controls (n=21). The numbers of positive cells 
were quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward 
and side scatter profile. CD57 expression was measured in total CD8+ T-cell population. Data are 
represented as dot plots with the median (red bar). Statistical analysis (Kruskal-Wallis ANOVA with the 
Dunn's Multiple Comparison Test) was performed using GraphPad Prism 5.0. Statistical significance is 
denoted by asterisks (*** P ≤ 0.001). 
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Total CLL cohort 
 
 
Figure 4.21 CD27 expression within the CD8+ T-cells of the total CLL cohort (n=97) and age-
matched healthy donor (HD) controls (n=21). The percentages of positive cells were quantified using 10-
colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile. 
CD27 expression was measured in total CD8+ T-cell population and was presented at CD27- CD8+ T-cells. 
Data represented as dot plots with the median (red bar). Statistical analysis (Mann-Whitney U test) was 
performed using GraphPad Prism 5.0.  
 
 
Stratified CLL cohort 
 
 
Figure 4.22 CD27 expression within the CD8+ T-cells of the stratified CLL cohort (CLLIR, n=32 and 
CLLNR, n=65) and age-matched healthy donor (HD) controls (n=21). The percentage of positive cells 
were quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward 
and side scatter profile. CD27 expression was measured in total CD8+ T-cell population and was presented at 
CD27- CD8+ T-cells. Statistical analysis (Kruskal-Wallis ANOVA with the Dunn's Multiple Comparison test) 
was performed using GraphPad Prism 5.0. Statistical significance is denoted by asterisks (*** P ≤ 0.001). 
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4.2.3 Immunosuppressive receptors 
As previously described, the expression of immunosuppressive receptors such as 
PD-1, TIM-3 and LAG-3 has been associated with immune dysfunction and “exhausted” 
T-cells (Wherry 2011). The expression of PD-1, TIM-3 and LAG-3 were investigated 
within the CD8+ T-cell compartment of CLL patients and the HD control group.  
No differences in the frequency of CD8+PD-1+ (Fig 4.23) or CD8+TIM-3+ T-cells 
(Fig 4.25) were observed when the total CLL cohort was compared to the HD controls. 
This was also the case when CLL patients were stratified into two groups (CLLIR and 
CLLNR) (Fig 4.24 and Fig 4.26). Unexpectedly when the expression of LAG-3 was 
investigated within the CD8+ T-cell compartment, a significant increase in CD8+LAG-3+ 
T-cells (P ≤ 0.01) was observed within the HD controls when compared to CLL patients 
(Fig 4.27), as well as when compared to stratified CLLIR (P ≤ 0.05) and CLLNR (P ≤ 0.01) 
patients (Fig 4.28). Comparison between CLLIR and CLLNR indicated no difference with 
respect to the frequency of CD8+LAG-3+ T-cells. 
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Total CLL cohort 
 
 
Figure 4.23 PD-1 expression within CD8+ T-cells of the total CLL cohort (n=97) and age-matched 
healthy donor (HD) controls (n=21). The numbers of positive cells were quantified using 10-colour flow 
cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile. PD-1 
expression was measured in the total CD8+ T-cell population. Data are represented as dot plots with the 
median (red bar) shown for each distribution. Statistical analysis (Mann-Whitney U test) was performed using 
GraphPad Prism 5.0. 
 
 
Stratified CLL cohort 
 
 
Figure 4.24 PD-1 expression within CD8+ T-cells of the stratified CLL cohort (CLLIR, n=32 and 
CLLNR, n=65) and age-matched healthy donor (HD) controls (n=21). The numbers of positive cells 
were quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward 
and side scatter profile. PD-1 expression was measured in total CD8+ T-cell population. Data are represented 
as dot plots with the median (red bar) shown for each distribution. Statistical analysis (Kruskal-Wallis 
ANOVA with the Dunn's Multiple Comparison test) was performed using GraphPad Prism 5.0.  
  
CLL HD 0
20
40
60
80
100
%
 C
D8
+ P
D-
1+
 T
-c
el
ls
CLLIR CLLNR HD 0
20
40
60
80
100
%
 C
D8
+ P
D-
1+
 T
-c
el
ls
 Chapter 4: Results 
 
 Page 157 
 
Total CLL cohort 
 
 
Figure 4.25 TIM-3 expression within the CD8+ T-cells of the total CLL cohort (n=97) and age-
matched healthy donor (HD) controls (n=21). The numbers of positive cells were quantified using 10-
colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile. 
TIM-3 expression was measured in total CD8+ T-cell population. Data are represented as dot plots with the 
median (red bar) shown for each distribution. Statistical analysis (Mann-Whitney U test) was performed using 
GraphPad Prism 5.0.  
 
Stratified CLL cohort 
 
 
Figure 4.26 TIM-3 expression within the CD8+ T-cells of the stratified CLL cohort (CLLIR, n=32 and 
CLLNR, n=65) and age-matched healthy donor (HD) controls (n=21). The numbers of positive cells 
were quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward 
and side scatter profile. TIM-3 expression was measured in total CD8+ T-cell population. Data are 
represented as dot plots with the median (red bar) shown for each distribution. Statistical analysis (Kruskal-
Wallis ANOVA with the Dunn's Multiple Comparison Test) was performed using GraphPad Prism 5.0.  
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Total CLL cohort 
 
 
Figure 4.27 LAG-3 expression within CD8 T-cells of CLL patients (n=97) and age-matched healthy 
donor (HD) controls (n=21). The percentage of positive cells were quantified using 10-colour flow 
cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile. LAG-3 
expression was measured in total CD8+ T-cell population. Data are represented as dot plots with the median 
(red bar) shown for each distribution. Statistical analysis (Mann-Whitney U test) was performed using 
GraphPad Prism 5.0. Statistical significance is denoted by asterisks (** P ≤ 0.01) 
 
 
Stratified CLL cohort 
 
 
Figure 4.28 LAG-3 expression within CD8+ T-cells of stratified CLL patients (CLLIR, n=32 and 
CLLNR, n=65) and age-matched healthy donor (HD) controls (n=21). The percentage of positive cells 
were quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward 
and side scatter profile. LAG-3 expression was measured in total CD8+ T-cell population. Data are 
represented as dot plots with the median (red bar). Statistical analysis (Kruskal-Wallis ANOVA with the 
Dunn's Multiple Comparison Test) was performed using GraphPad Prism 5.0. Statistical significance is 
denoted by asterisks (* P ≤ 0.05, ** P ≤ 0.01). 
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4.2.4 Combined expression of immunosuppressive receptors 
Previously published observations have suggested that T-cells, which expressed 
multiple immunosuppressive receptors, represent populations that exhibit greater 
functional defects and thus may be more representative of an “exhausted” T-cell 
phenotype (Sakuishi et al. 2010; McMahan et al. 2010; Fourcade et al. 2010).  
To assess T-cell populations with expression of multiple immunosuppressive 
receptors, Boolean gating was performed and the subsequent data was presented and 
analysed using SPICE 5.35 software. When the CLL cohort was considered as a whole, a 
significant difference in the proportion of CD8+ T-cells expressing multiple 
immunosuppressive receptors was observed when compared to the HD controls (P = 
0.0384) (Fig 4.29 and Table 4.5). Further analysis indicated that the main differences 
concerning combined expression were due to a significant increase in the frequency of PD-
1+TIM-3+LAG-3- T-cells within the CLL patient group when compared to HD controls. In 
addition, a decrease in the frequency of PD-1+TIM-3-LAG-3+ CD8+ T-cells (P = 0.004) 
within the CLL group was seen in comparison to the HD group (Table 4.6). When patients 
were stratified, similar results were observed when CLLIR patients were compared to the 
HD controls (Table 4.8). 
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Total CLL patients 
 
Figure 4.29 Combined expression of immunosuppressive receptors within the CD8+ T-cells of the total CLL cohort (n=97) and age-matched healthy donor (HD) controls 
(n=21). The percentage of positive cells was quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward and side scatter profile. Combined 
expression of PD-1, TIM-3 and LAG-3 were determined using Boolean gating. Colours of the pie arcs depict the expression of individual inhibitory receptors, while the colour in the pie 
depicts the number of co-expressed inhibitory receptors. Data representation and statistical analysis (Mann-Whitney U test) were performed using SPICE 5.35. 
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Stratified CLL cohort 
 
Figure 4.30 Combined expression of immunosuppressive receptors within the CD8+ T-cells of the stratified CLL cohort (CLLIR, n=32 and CLLNR, n=65) and age-matched 
healthy donor (HD) controls (n=21). The percentage of positive cells was quantified using 10-colour flow cytometry (FACSAria). Live lymphocytes were gated based on forward and 
side scatter profile. Combined expression of PD-1, TIM-3 and LAG-3 were determined using Boolean gating. Colours of the pie arcs depict the expression of individual inhibitory 
receptors, while the colour in the pie depicts the number of co-expressed inhibitory receptors. Data representation and statistical analysis (Mann-Whitney U test) were performed using 
SPICE 5.35. 
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Table 4.5 Overall CD8+ T-cell pie chart analysis (CLL vs HD)2 
Pie Type CLL HD 
CLL  0.0384 
HD 0.0384  
 
Table 4.6 Detailed CD8+ T-cell pie chart analysis (CLL vs HD)2 
Category TYPE: HD 
PD-1+LAG-3+TIM-3+ 0.0574 
PD-1+LAG-3+TIM-3- 0.004 
LAG-3+TIM-3+PD-1- 0.836 
PD-1+TIM-3+LAG-3- <0.0001 
PD-1-TIM-3-LAG-3- 0.513 
Compared to CLL 
 
Table 4.7 Overall CD8+ T-cell pie chart analysis (CLLNR vs CLLIR vs HD)2 
Pie Type CLLIR CLLNR HD 
CLLIR  0.5686 0.0705 
CLLNR 0.5686  0.0814 
HD 0.0705 0.0814  
 
Table 4.8 Detailed CD8+ T-cell pie chart analysis (CLLIR vs CLLNR vs HD)2 
Category CLLNR HD 
PD-1+LAG-3+TIM-3+ 0.334 0.358 
PD-1+LAG-3+TIM-3- 0.311 0.039 
LAG-3+TIM-3+PD-1- 0.747 0.935 
PD-1+TIM-3+LAG-3- 0.143 <0.0001 
PD-1-TIM-3-LAG-3- 0.288 0.971 
Compared to CLLIR  
 
 
  
                                                
2 Statistical analysis (Mann-Whitney U test) was performed using SPICE 5.35. Statistically significant 
differences were highlighted in red. 
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4.3 Prognostic relevance of T-cells in CLL 
4.3.1 Univariate analysis 
To investigate the effects that T-cells may have on the progression of CLL, Cox 
proportional hazards regression analysis was conducted on 83 CLL patients with respect to 
progression-free survival (PFS). This tested whether the inversion in the CD4:CD8 ratio or 
the phenotypic markers studied (CD57, CD27, PD-1, TIM-3 and LAG-3) influenced PFS.  
Analysis of the CD4:CD8 ratio indicated that it had a significant influence on 
patient prognosis. In keeping with a previous study (Nunes et al. 2012), patients with a 
CD4:CD8 ratio <1 showed significantly more progressive disease (P = 0.0417; HR = 2.2) 
(Fig 4.31). 
Within the CD4+ T-cell compartment CD57 (Fig 4.32a) and PD-1 (Fig 4.32c) both 
significantly influenced PFS, (P = 0.026 and P = 0.008, respectively). Patients that were 
above the median frequency for CD4+CD57+ and CD4+PD-1+ T-cells exhibited more 
progressive disease, HR = 2.6 and HR = 2.2, respectively. 
Within the CD8+ T-cell compartment, CD57 (Fig 4.33a) and CD27 (Fig 4.33b) 
both appeared to significantly influence PFS (P = 0.020 and P = 0.004, respectively). 
Patients that were above the median frequency for CD8+CD57+ and CD8+CD27- T-cells 
exhibited more progressive disease (HR = 2.3 and HR = 2.9, respectively). 
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CD4:CD8 ratio 
 
Figure 4.31 Kaplan–Meier curves for progression-free survival for CLLNR and CLLIR patients. Kaplan-
Meier analysis was used to assess the effect of the CD4:CD8 ratio upon PFS. The patients were divided based 
upon a ratio of CD4:CD8 <1 (CLLIR) or a ratio of CD4:CD8 >1 (CLLNR). A log-rank test was used to test 
the difference between the two curves. (HR = Hazard ratio).  
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CD4+ T-cells 
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CD57+ CD27- 
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PD-1+ TIM-3+ 
  
  
(E)  
LAG-3+ Figure 4.32 Kaplan-Meier curves for the 
progression-free survival for CD57, CD27, PD-1, 
TIM-3 and LAG-3 expression in CD4+ T-cells. 
Kaplan-Meier analysis was used to assess the effects 
of the CD57, CD27, PD-1, TIM-3 and LAG-3 
within the CD4+ T-cell compartment on PFS. For 
each marker the patients were divided into two 
groups based on the median frequency of CD4+ T-
cells. A log-rank test was used to test the difference 
between the two curves. (HR = Hazard ratio). 
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CD8+ T-cells 
  
(A) (B) 
CD57+ CD27- 
  
  
(C) (D) 
PD-1+ TIM-3- 
  
  
(E)  
LAG-3+ Figure 4.33 Kaplan-Meier curves for the 
progression-free survival for CD57, CD27, PD-1, 
TIM-3 and LAG-3 expression in CD8+ T-cells. 
Kaplan-Meier analysis was used to assess the effects 
of the CD57, CD27, PD-1, TIM-3 and LAG-3 
within the CD8+ T-cell compartment on PFS. For 
each marker the patients were divided into two 
groups based on the median frequency of CD8+ T-
cells. A log-rank test was used to test the difference 
between the two curves. (HR = Hazard ratio). 
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4.3.2 Multivariate analysis 
Multivariate analysis was performed using Cox proportional hazards regression 
with forward selection by Dr Robert Hills (Dept. Haematology, Cardiff University, School 
of Medicine). A total of 459 T-cell subset variables were considered in the model. Two 
clusters of variables were shown to have the greatest influence on PFS: CD4+CD27-PD-
1+LAG-3+ and CD8+CD27-CD57+PD-1+, respectively (Table 4.8). 
Each of these clusters was then subjected to univariate analysis and Kaplan-Meier 
curves drawn. The patients were divided into two cohorts, again based on the median 
frequency of T-cells expressing the relevant markers. This analysis indicated that patients 
that were above the median for CD4+CD27-PD-1+LAG-3+ T-cells had significantly more 
progressive disease (P =0.0003; HR = 3.8) (Fig 4.34). The phenotype CD8+CD27-
CD57+PD-1+ also appeared to significantly influence patient progression, but to a lesser 
degree (P =0.041, HR = 2.1) (Fig 4.35). 
Overall this analysis showed that by using multivariate and univariate analysis, 
phenotypically distinct T-cell populations were potentially contributing to the clinical 
progression of CLL patients. Furthermore, it suggested that the T-cell populations that 
expressed multiple markers associated with T-cell dysfunction were having the most 
profound effect upon patient prognosis.  
 
Table 4.9 Multivariate analysis was performed using Cox proportional hazards regression with 
forward selection 
Summary of forward selection 
Phenotype DF Number in Chi-Square P-value 
CD4+CD27-PD-1+LAG+ 1 1 24.59 < 0.0001 
CD8+CD27-CD57+PD-1+ 1 2 12.66 0.0004 
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CD4+CD27-PD-1+LAG-3+ 
 
Figure 4.34 Kaplan-Meier curves for progression-free survival for the T-cell phenotype CD4+CD27-
PD-1+LAG-3+. Kaplan-Meier analysis was used to assess the effect of the expression of the T-cell 
phenotypes CD4+CD27-PD-1+LAG-3+ on PFS. The patients were divided into two groups based on the 
median frequency of CD4+ T-cells. A log-rank test was used to test the difference between the two curves. 
(HR = Hazard ratio). 
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Figure 4.35 Kaplan-Meier curves for progression-free survival for the T-cell phenotype CD8+CD27-
CD57+PD-1+. Kaplan-Meier analysis was used to assess the effect of the expression of the T-cell phenotype 
CD8+CD27-CD57+PD-1+ on PFS. The patients were divided into two groups based on the median 
frequency of CD8+ T-cells. A log-rank test was used to test the difference between the two curves. (HR = 
Hazard ratio). 
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4.4 Expression of complementary ligands by CLL cells 
The immunosuppressive effects associated with receptors such as PD-1, TIM-3 and 
LAG-3 are mediated through their interactions with complementary ligands (Keir et al. 
2008; Zhu et al. 2005; Workman et al. 2002). In light of this the expression of the ligands 
PDL-1 (PD-1), GAL-9 (TIM-3) and MHC-II (LAG-3) were investigated on the malignant 
CD19+CD5+ CLL cells. The expression of the ligands was also investigated on normal 
CD19+ B-cells from age-matched controls. This was due to the extremely low 
frequency/absence of CD19+CD5+ B-cells in non-CLL individuals.  
No statistical differences between CLL patients and HD controls were observed 
regarding the percentage of PDL-1+ and GAL-9+ B-cells (Fig 4.37a and b). This was also 
the case when CLL patients were stratified into the CLLIR and CLLNR patient groups (Fig 
4.38a and b). However, CLLIR patients exhibited a trend towards increased frequency of 
PDL-1+ and GAL-9+ compared the HD controls. 
Due to the constitutive expression of MHC-II molecules on professional APC, 
such as B-cells (Rodríguez-Pinto 2005; Vyas et al. 2008) it was unsurprising that greater 
than 97% of B-cell from both CLL patients and HD controls were positive for HLA-DR. 
However, comparisons between CLL patients and HD controls indicated that there was a 
small but significant (P ≤ 0.01) increase in the percentage of HLA-DR expressing cells 
within CLL patients (Fig 4.37c). This finding was also observed when the patients were 
stratified; significant differences were observed in comparison to HD for both CLLIR (P ≤ 
0.05) and CLLNR (P ≤ 0.05) (Fig 4.38c). These results show that while the complementary 
ligands investigated were commonly expressed on CLL cells, there were no striking 
differences in ligand expression between prognostic subsets.  
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Gating strategy 
 
 
 
Figure 4.36 Representative results of B-cell immunosuppressive ligand expression analysis. The 
percentage of positive cells was determined by flow cytometry (FACSAria) and flow cytometric analysis was 
carried out using FlowJo software. Gating strategy was used to characterise the expression of PDL-1, GAL-9 
and HLA-DR within the CD19+CD5+ B-cell compartment. To assist with the gating of positive cell 
populations FMO controls were applied where necessary. 
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Total CLL Cohort 
  
(A) (B) 
  
  
(C)  
  
 
Figure 4.37 PDL-1, GAL-9 and HLA-DR 
expression within B-cells of CLL patients (n=52) 
and healthy age-matched healthy donor (HD) 
controls (n=21). The numbers of positive cells were 
quantified using 5-colour flow cytometry (FACSAria). 
Live lymphocytes were gated based on forward and 
side scatter profile. Expression was measured in 
CD19+CD5+B-cells (CLL patient) and CD19+ B-cells 
(HD). (A) PDL-1 expression. (B) GAL-9 expression 
(C) HLA-DR. Data are represented as dot plots with 
the median (red bar) shown for each distribution. 
Statistical analysis (Mann-Whitney U test) was 
performed using GraphPad Prism 5.0. Statistical 
significance is denoted by asterisks (** P ≤ 0.01). 
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Stratified CLL Cohort 
  
(A) (B) 
  
(C)  
  
 
Figure 4.38 PDL-1, GAL-9 and HLA-DR 
expression within B-cells of stratified CLL patients 
(CLLIR, n=18 and CLLNR, n=34) and age-matched 
healthy donor (HD) controls (n=21). The numbers 
of positive cells were quantified using 5-colour flow 
cytometry (FACSAria). Live lymphocytes were gated 
based on forward and side scatter profile. Expression 
was measured in CD19+CD5+ B-cells (CLL patient) 
and CD19+ B-cells (HD). (A) PDL-1 expression. (B) 
GAL-9 expression (C) HLA-DR. Data are represented 
as dot plots with the median (red bar) shown for each 
distribution. Statistical analysis (Kruskal-Wallis 
ANOVA with the Dunn's Multiple Comparison Test) 
was performed using GraphPad Prism 5.0. Statistical 
significance is denoted by asterisks (* P ≤ 0.05) 
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4.5 Summary of phenotypic analysis 
Table 4.10 Summary of phenotypic analysis of CD4+ T-cells 
CD4+ T-cells 
Memory subset 
CLL vs HD No statistically significant differences 
CLLIR vs CLLNR ! % naïve T-cells, " % EM T-cells   
CLLIR vs HD ! % naïve T-cells, " % EM T-cells    
CLLNR vs HD No statistically significant differences 
Late differentiation marker 
CLL vs HD No statistically significant differences 
CLLIR vs CLLNR " % CD57+ T-cells, " % CD27- T-cells 
CLLIR vs HD " % CD57+ T-cells 
CLLNR vs HD No statistically significant differences 
Immunosuppressive receptors 
CLL vs HD " % TIM-3+ T-cells 
CLLIR vs CLLNR " % TIM-3+ T-cells, " % PD-1+ T-cells 
CLLIR vs HD " % TIM-3+ T-cells, " % PD-1+ T-cells 
CLLNR vs HD No statistically significant differences 
 
Table 4.11 Summary of phenotypic analysis of CD8+ T-cells 
CD8+ T-cells 
Memory subset 
CLL vs HD ! % naïve T-cells, ! % CM T-cells 
CLLIR vs CLLNR ! % naïve T-cells, ! % CM T-cells, " % EMRA T-cells 
CLLIR vs HD ! % naïve T-cells, ! % CM T-cells 
CLLNR vs HD No statistically significant differences 
Late differentiation marker 
CLL vs HD No statistically significant differences 
CLLIR vs CLLNR " % CD57+ T-cells, " % CD27- T-cells 
CLLIR vs HD " % CD57+ T-cells 
CLLNR vs HD No statistically significant differences 
Immunosuppressive receptors 
CLL vs HD ! % LAG-3+ T-cells 
CLLIR vs CLLNR No statistically significant differences 
CLLIR vs HD ! % LAG-3+ T-cells 
CLLNR vs HD ! % LAG-3+  T-cells 
 
Table 4.12 Summary of phenotypic analysis of CD19+ / CD19+CD5+ B-cells 
 
B-cells 
Immunosuppressive ligands 
CLL vs HD " % HLA-DR+  B-cells 
CLLIR vs CLLNR No statistically significant differences 
CLLIR vs HD " % HLA-DR+  B-cells 
CLLNR vs HD " % HLA-DR+  B-cells 
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4.6 Discussion 
This study set out to perform phenotypic analysis of T-cells and B-cells from CLL 
patients with the aim of acquiring a deeper understanding of the immunological 
environment of CLL. The analysis was performed on both the CD4+ and CD8+ T-cells 
within a cohort of 97 CLL patients and 21 age-matched controls. Furthermore, within the 
CLL cohort the analysis was either performed on the entire cohort or on patient subsets 
stratified based their CD4:CD8 ratio.  
Previous studies have shown that within CLL the absolute numbers of both CD4+ 
T-cells and CD8+ T-cells are elevated, however this elevation has been shown to be more 
pronounced within the CD8+ T-cells compartment (Porakishvili et al. 2001; Serrano et al. 
1997). The preferential expansion within the CD8+ T-cell compartment results in an 
inversion in the CD4:CD8 ratio in some patients, which has been associated with 
phenotypic abnormalities and poor patient prognosis (Nunes et al. 2012). 
Analysis of the T-cell memory subsets indicated no discernible difference between 
CLL patients as a whole and the HD controls. However, when the patients were stratified 
into two groups (CLLIR and CLLNR) it was revealed that there was substantial skewing 
within the distribution of memory T-cell subsets. A significant decrease in the proportion 
of naïve CD4+ and CD8+ T-cells within the CLLIR patient group when compared to the 
CLLNR and the HD controls was observed. Additionally, there was a significant increase in 
the proportion of EM CD4+ T-cells and EMRA CD8+ T-cells within the CLLIR patient 
group compared to the CLLNR. These findings indicate a skewing towards a more 
differentiated T-cell memory phenotype in the both the CD4+ and CD8+ T-cell 
compartments of the CLLIR patient group, particularly in the CD8+ compartment.  
The process of memory differentiation induces functionally as well as phenotypic 
changes in T-cells. While EM and EMRA populations exhibit rapid effector functions, 
when compared to “less differentiated” T-cell populations such as naïve or CM, they also 
exhibit reductions in replicative potential, shorter telomeres and increased sensitivity to 
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apoptosis (Sallusto et al. 2004; Klebanoff et al. 2006; Geginat et al. 2003). Additionally, 
adoptive transfer of “less differentiation” T-cell populations has been shown to 
demonstrate superior in vivo expansion, persistence and anti-tumour activity in murine 
systems (Klebanoff et al. 2012). Furthermore, in human studies naïve T-cells have been 
shown to exhibit superior in vitro expansion and resistance to apoptosis (Hinrichs et al. 
2011). Therefore it could be suggested that CLL patients who exhibit a shift in T-cell 
subset distribution from naïve to EM or EMRA may experience immune dysfunction and a 
reduced ability to respond to new antigens. 
To further investigate the differentiation status of CD4+ and CD8+ T-cells from 
CLL patients the expression of CD57 and CD27 on T-cells was measured. Overall 
comparison between CLL patients and the HD controls revealed no significant differences 
regarding the frequency of CD57+ or CD27- T-cells in either the CD4+ or CD8+ 
compartments. However, when the patients were stratified it was observed that increases in 
the frequency of CD57+ or CD27- T-cells appeared to be associated with the CLLIR group. 
These results, in combination with the observed skewing in the memory subsets suggest 
that T-cells from CLLIR patients may have been driven further along the T-cell 
differentiation pathway. 
The development of the CD57+CD27- phenotype has been observed in chronic 
viral infections (Palmer et al. 2005) as well as haematological malignancies (Serrano et al. 
1997; Nunes et al. 2012; Frassanito et al. 1998) and has historically been associated with T-
cell differentiation, replicative senescence and a greater susceptibility to apoptosis (Dolfi et 
al. 2008; Brenchley et al. 2003). However, the specific fate conferred upon T-cells in 
response to the expression of CD57 is still controversial as it has been shown that CD57+ 
T-cells can maintain functional competence (Chong et al. 2008).  
Additionally, the down-regulation of other T-cell co-receptors such CD28, as well 
as the development of an EMRA phenotype, has been suggested to represent a T-cell 
population with reduced proliferative potential. However, given the appropriate co-
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stimulatory signals, CD28-CD45RAhi T-cells have been shown to maintain proliferative 
drive (Waller et al. 2007). This suggests that T-cell populations, which exhibit phenotypic 
hallmarks associated with replicative senescence, can still maintain functional competency 
under the appropriate conditions.  
The development of CD57+ and CD27- phenotypes within the T-cell compartment 
of CLL patients has been previously observed (Serrano et al. 1997) and has been shown to 
be more pronounced in CLLIR patients (Nunes et al. 2012). Interestingly, the relationship 
between an inversion in the CD4:CD8 ratio and expression of CD57 does not appear to be 
a phenomenon specific to CLL as it has been observed in multiple myeloma (Frassanito et 
al. 1998) and also within aged healthy individuals (Olsson et al. 2000).  
The process of T-cell differentiation is closely associated with the expansion of 
antigen-specific T-cell populations (Klebanoff et al. 2006) and aging (Olsson et al. 2000). 
Comparison between the two patient groups indicated that patients, which exhibited an 
inversion in their CD4:CD8, appeared to be significantly older, CLLIR (median 79, range 53 
– 92) and CLLNR (median 70, range 43 – 94). Suggesting that age may be a factor in the 
inversion of the ratio and the phenotypic observations. However the age ranges overlap 
considerably suggesting that age may not be sole driving force behind the observations. 
Additionally, it could be suggested that the “highly” differentiated T-cell phenotype 
observed within CLL, specifically in CLLIR patients, may be due to an oligoclonal 
expansion of antigen-specific T-cells. The presence of clonal T-cell populations have been 
reported in CLL (Wen et al. 1990), within both the CD8+ (Wikby et al. 2002) and CD4+ T-
cell compartments and has been suggested to be more pronounced within the CD4+CD57+ 
population (Serrano et al. 1997). Although the specific cause of T-cell expansions within 
CLL has yet to be universally agreed upon, several studies have suggested chronic antigen 
stimulation in response to CMV may play a role (Pourgheysari et al. 2010; Mackus 2003). 
Within this study, analysis of the effects of CMV serostatus suggested it did not have a 
significance influence on the CD4:CD8 ratio of CLL patients (Appendix 3), which is in line 
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with our previously published data (Nunes et al. 2012). CMV serostatus did appear to 
significantly influence the percentage of CD57+ and CD27- cells within the CD4+ and 
CD8+ T-cell compartment, with these differences more pronounced within the CD4+ 
compartment (Appendix 4).  
This observation supports the concept that CMV infection can cause 
immunological changes within CLL patients, but suggests it may not be the sole driving 
force behind these observations. In support of this, T-cell expansions as well as functional 
and phenotypic changes have been observed within the T-cell compartment of CLL 
patients regardless of CMV serostatus (Pourgheysari et al. 2010; Riches et al. 2013). This 
suggests that other non-CMV antigen sources could potentially influence T-cell expansion 
and differentiation in CLL patients. 
Numerous potential TAAs have been suggested for CLL such as Bax (Nunes et al. 
2011), survivin (Schmidt et al. 2003), fibromodulin (Mayr et al. 2005) and MDM2 (Mayr et 
al. 2006). Furthermore, it has been shown that multiple mutations within CLL cells can 
result in the generation of immunogenic CLL-specific neoantigens (Rajasagi et al. 2014). 
Additionally, vaccinations with autologous CLL cells or CLL cell lysates have been shown 
to generate CLL-specific and personalised T-cell responses in some patients (Biagi et al. 
2005; Burkhardt et al. 2013). All of these studies support the concept that CLL cells can 
express immunogenic tumour antigens, which could result in the activation and expansion 
of T-cells within some CLL patients. However, to date no dominant tumour-specific T-cell 
response has been correlated with CD8+ or CD4+ T-cell expansion in CLL. It also cannot 
be ruled out that chronic viral infections, other than CMV, may play a role in driving T-cell 
expansion and differentiation. However, it was not possible to investigate this concept in 
this study.  
As the specificity of the T-cells investigated within this study were not determined, 
the extent of the role of CMV (or other antigen sources) on the development of a “highly” 
differentiated T-cell phenotype could not be directly assessed. This could be investigated 
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by the addition of specific tetramers (CMV, tumour antigens etc) to the previously utilised 
phenotyping strategy in order to determine if there is antigen specificity associated with the 
skewed T-cell phenotypes observed in this study. 
Additionally, T-cell proliferation and differentiation in response to homeostatic 
cytokines, such as IL-7 and IL-15 has been previously reported (Geginat et al. 2003; Alves 
et al. 2003). Interestingly, the expression of IL-7 gene transcript (Frishman et al. 1993) and 
protein (Long et al. 1995) has been reported within CLL cells but not in normal B-cells. 
Therefore if CLL cells are capable of producing IL-7 and/or other homeostatic cytokines 
this could represent an alternative mechanism for the T-cell differentiation in CLL, which 
certainly warrants further investigation. For example, it would be interesting to determine 
the affects of exogenous homeostatic cytokines upon T-cells from CLL patients in vitro. It 
would also be useful to measure endogenous serum levels of homeostatic cytokines within 
CLL patients to determine if they correlate with phenotypic changes.  
In addition to disrupting the normal formation of the immunological memory, 
chronic antigen stimulation can also result in the development of “exhausted” T-cell 
phenotypes, which can be characterised by the expression of immunosuppressive 
receptors. Signalling invoked by immunosuppressive ligand/receptor interactions have 
been shown to impair T-cell function through a variety of mechanisms (Wherry 2011).  
PD-1 is an immunosuppressive receptor, which upon ligation with its ligand PDL-1 
has been shown to negativity regulate T-cell function (Keir et al. 2008). The expression of 
PD-1 has previously been associated with the development of an T-cell “exhaustion” in 
chronic viral infection such as HIV and has been associated with increased viral load and 
disease progression (Day et al. 2006). Additionally, PD-1 expression has been observed 
within the T-cell populations of patients with solid tumours (Fourcade et al. 2009). 
In this study it was observed that there was significant increase in the expression of 
PD-1 within the CD4+ T-cell compartment of the CLLIR patient group. This, in 
combination with other phenotypic observations, may suggest the development of a 
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potential immunosuppressed or “exhausted” T-cell phenotype. The increased expression of 
PD-1 within the CD4+ T-cell compartment of CLL patients has been previously reported 
(Brusa et al. 2013), however they did not examine whether the high expression of PD-1 
was a feature specifically associated with the CLLIR  patients within that cohort.  
In contradiction to some previously published reports (Riches et al. 2013; Brusa et al. 2013; 
Nunes et al. 2012), this study showed no difference in PD-1 expression within the CD8+ T-
cell compartment when compared to HD controls or between the CLLIR and CLLNR 
patient groups. It should be noted that the cohort of patients in which the inversion of the 
CD4:CD8 ratio and PD-1 expression in the CD8+ T-cell compartment was first reported 
(Nunes et al. 2012), and the cohort in this study showed no discernible differences in age 
or disease staging. The discrepancies between this study and previously published findings 
could be due to technical differences e.g. the use of different antibody panels, different 
flow cytometer set up and tracking and variations in gating strategies. Alternatively, it could 
be due to patient-to-patient variations between the cohorts in these studies or differences 
in the control groups. The majority of patients in the current study were stage A, untreated 
patients, and these were compared to age-matched healthy donor controls. The 
discrepancies between this study and others published findings highlight a requirement for 
multi-centre studies utilising standardised methodologies and respectively similar patient 
cohorts, when evaluating disease-specific phenomenon. Additionally combining results 
from multiple studies could provide a greater insight into the overall effect of the inversion 
of CD4:CD8 ratio. However this was not possible within the timeframe of this thesis but 
collation and analysis of data across multiple studies is currently underway. TIM-3 is an 
immunosuppressive receptor, which upon ligation with its ligand GAL-9 has been shown 
to negatively regulate T-cell function (Rangachari et al. 2012). Similar to PD-1, the 
expression of TIM-3 on T-cells has previously been associated with T-cell dysfunction in 
chronic viral infections (Wu et al. 2012) and patients with solid tumours (Fourcade et al. 
2010). 
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In this study a significant increase in the expression of TIM-3 was observed within 
the CD4+ T-cell compartment of the CLL patients when compared to HD controls, which 
appeared to be a feature specifically associated with the CLLIR patient group. Potentially 
highlighting a population of T-cell that might be more susceptible to immunosuppression. 
However, analysis of the CD8+ T-cell compartment showed that no differences were 
observed, either when the patients were considered as a whole or when stratified. It has 
been suggested that CLL patients exhibit no difference in the expression of TIM-3 when 
compared to age-matched controls (Riches et al. 2013; Zenz 2013). However, these authors 
did not present any data regarding the expression of TIM-3 nor did they state which T-cell 
population (CD4+ or CD8+) was studied.  
LAG-3 is an immunosuppressive receptor, which upon ligation with its ligand 
MHC-II has been shown to negatively impact upon T-cell function (Hannier et al. 1998; 
Freeman and Sharpe 2012). When the expression of LAG-3 was investigated on CD4+ T-
cells in CLL, there were no differences in comparison to the age-matched controls. Biagi et 
al showed that there was an increase in the percentage of CD4+LAG-3+ cells within the 
CD25+ population when compared to the CD25- population. Thus suggesting that CLL 
patients exhibit increased expression of LAG-3 within their T-reg population (Biagi et al. 
2005). However, as Foxp3 staining was not included in this experiment it cannot be 
definitively stated that T-regs from CLL patients express more LAG-3, as CD25 is also a 
marker of activated T-cells (Caruso et al. 1997) and LAG-3 expression is linked to T-cell 
activation. Unexpectedly, when LAG-3 was investigated within the CD8+ T-cell 
compartment, it appeared to be significantly higher in the age-matched controls, but the 
cause of this observation remains unresolved. 
Analysis of the combined expression of PD-1, TIM-3 and LAG-3 was performed 
as T-cells multiple immunosuppressive receptors have been suggested represent 
populations that exhibit the most profound impairments in T-cell function (Sakuishi et al. 
2010; McMahan et al. 2010; Fourcade et al. 2010). 
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Analysis of the combined expression of PD-1, TIM-3 and LAG-3 within the CD4+ 
T-cell compartment indicated that CLL patients exhibited an increased frequency of T-cells 
expressing multiple immunosuppressive receptors. Additionally, this observation appeared 
to be a hallmark of the CLLIR patient group, which is in keeping with previous observations 
that this group has an abnormal distribution of T-cell subsets. Analysis of the CD8+ 
compartment revealed that there was a significant decrease in PD-1+TIM-3-LAG-3+ CD8+ 
T-cells within the CLL patient group when compared to the controls. However, an increase 
in the frequency of PD-1+TIM-3+LAG-3- T-cells was observed within the CLL patients.  
While differences in the frequency of T-cell populations expressing multiple 
immunosuppressive receptors has been observed, it is unknown if they represent 
populations that would exhibit the greater defects within CLL or if they represent activated 
T-cell phenotypes. Therefore functional analysis of the individual populations is essential to 
determine any potential differences between the groups. 
The increased expression of immunosuppressive receptors (individually or in 
combination), particularly within the CD4+ T-cell compartment of CLLIR patients, indicates 
the presence of cell populations that exhibit phenotypic profiles previously associated with 
immune dysfunction. Blockade of the PD-1/PDL-1 pathway in vitro has been shown to 
alleviate defects in immunological synapse formation, (Ramsay et al. 2012) enhance the 
production of IFN-γ (Brusa et al. 2013). Furthermore, in vivo blockade in the TCL murine 
model of CLL (Johnson 2006) indicated that inhibition of PD-1/PDL-1 limited tumour 
progression, enhance T-cell function and prevent the inversion of the CD4:CD8 ratio 
(Hanna et al. 2014). This indicates that early intervention could enhance T-cell mediated 
tumour control and suggests a role for PD-1 in the inversion of CD4:CD8 ratio observed 
in CLL. However, populations expressing immunosuppressive receptors have been shown 
to maintain component T-cell function and been termed “pseudo-exhausted” in CLL 
(Riches et al. 2013) and other haematological malignancies (Lichtenegger et al. 2013). 
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Therefore to determine if any of these phenotypic observations translate into functional 
effects, further analysis is clearly essential. 
The manifestation of these observations may be underpinned by responses to 
chronic antigen stimulation, due to the close association between elevated expression of 
immunosuppressive receptors and chronic viral infection (Day et al. 2006; Sakhdari et al. 
2012). Within the CD4+ T-cell compartment, CMV infection appeared to significantly 
influence the expression of TIM-3, it also appeared to increase the expression of PD-1 and 
LAG-3 however these observations did not reach significance (Appendix 5). Within the 
CD8+ T-cell compartment, less distinct differences were observed and none reached 
significance (Appendix 5). These observations support the concept that CMV infection is 
playing a role in the manifestation of “exhausted” T-cell phenotypes within CLL, but are 
not consistent with CMV being the sole or dominant driver for expansion of these T-cells 
(Riches et al. 2013). Additionally, it has been suggested that CMV+ T-cells from CLL 
patients may exhibit reduced expression of immunosuppressive markers in comparison to 
CMV+ T-cells from healthy individuals (Raa et al. 2014). This further suggests a role of 
other antigens in driving the expression of immunosuppressive markers in CLL. 
Prognostication has historically been a key feature of the clinical management of 
CLL, with numerous markers predicting good or bad patient outcome. However, the 
majority of these markers (CD38, ZAP70, IGHV mutational status etc) apply specifically 
to the malignant CLL cells (Gribben 2010), rather than other immune cells. In this chapter, 
I attempted to link the wide array of abnormalities observed in the neighbouring T-cell 
compartment of CLL patients with patient outcome. Several significant phenotypic 
differences were observed between the T-cells of CLLIR and CLLNR patient groups. The 
clinical importance of these observations was supported by the demonstration that patients 
displaying a CD4:CD8 <1, exhibited more progressive disease. This confirms previously 
reported data (Nunes et al. 2012), but the specific mechanism behind this relationship is 
unknown. Previous analysis indicated a significant relationship between the inversion in the 
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CD4:CD8 ratio and lymphocyte doubling time less than 12 months (Nunes et al. 2012). 
Therefore it could be suggested that the T-cell populations from CLLIR patients mediate 
enhanced CLL cell proliferation. However, it is unknown whether this is due to defects in 
tumour control or due to T-cell populations supporting CLL cell proliferation.  
Some clues to potential mechanisms were provided by further analysis of the 
relationship between individual markers and clinical prognosis. Univariate analysis 
demonstrated an increase frequency of CD4+PD-1+ T-cells was associated with shorter 
PFS and disease progression. This observation could be related to immune exhaustion and 
loss of immunological control, as PD-1+ T-cells have been shown to represent a 
functionally impaired T-cell population (Keir et al. 2008). Additionally, increases in 
CD4+PD-1+ T-cells have been associated with the recurrence of melanoma in murine 
systems, suggesting a possible association between CD4+PD-1+ T-cells and tumour control 
(Goding et al. 2013).  
However, the expression of PD-1 is tightly regulated by T-cell activation and thus 
there is a great deal of debate regarding the classification of PD-1 as a marker of T-cell 
exhaustion or activation (Keir et al. 2008). Interestingly, activated T-cells have been shown 
to be essential for the successful engraftment, survival, and proliferation of CLL cells in vivo 
in murine systems (Bagnara et al. 2011). Additionally, proliferating CLL have been shown 
to co-localise with activated CD4+ T-cells within the lymph nodes of CLL patents (Patten 
et al. 2008), specifically CD4+PD-1+ T-cells (Brusa et al. 2013). Therefore, the association 
between CD4+PD-1+ T-cells and disease progression observed in this study could be due 
to enhanced CLL cell survival mediated via support from CD4+PD-1+ “activated” T-cells. 
This hypothesis could be explored by investigating the in vitro proliferative potential and 
survival of the autologous CLL cells in the presence and absence of CD4+PD-1+ T-cells. 
Increased frequencies of CD57+ T-cell within the CD4+ and CD8+ compartments 
were associated with shorter PFS and disease progression within this cohort. The 
association between CD57+ T-cells and poor prognosis has been reported in patents with 
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solid malignancies (Akagi and Baba 2008) and increases in the frequency of CD4+CD57+ 
T-cells have been shown to be associated with advanced disease stage within CLL (Serrano 
et al. 1997). However, the mechanisms behind these observations remain unclear. The 
expression of CD57 within the CD4+ and CD8+ T-cell compartment has been associated 
with an increased sensitivity to apoptosis and reductions in proliferative potential 
(Brenchley et al. 2003; Focosi et al. 2010), both of which are characteristically associated 
with immune dysfunction. The classification of CD57 as true marker of replicative 
senescence is still contentious as Chong et al have shown, by several methods, that 
CD8+CD57+ T-cells are capable of maintaining proliferative competence (Chong et al. 
2008).  
Although the function of CD57+ T-cells was not studied in this chapter, future 
work could test the proliferative potential of T-cells from CLL patients in several ways. For 
example, measuring the expression of Ki-67 within the CD57+ and CD57- T-cell 
compartment of CLL patients in response to in vitro stimulation. Other assays for T-cell 
proliferations such as CFSE dilution and 7-amino-actinomycin D (7AAD) uptake 
experiments could also be performed.  
Alternatively the poor prognosis associated with expression of CD57 could be due 
to this T-cell population supporting survival of the CLL cells. CD8+CD57+ T-cells have 
been shown to produce high levels of IFN-γ upon activation, which has been shown to 
support CLL cell survival in vitro (Van den Hove et al. 1998; Chong et al. 2008; Buschle et 
al. 1993). Stimulated CD57+ and CD57- T-cells from CLL patients could be investigated in 
vitro through various assay systems (ICS, ELISA and cytometic bead array) to determine if 
these two cell subsets exhibit differential cytokine profiles, which could influence CLL cell 
survival. Additionally, the assessment of the viability (via annexin/PI staining) of 
autologous CLL cells cultured with the supernatant isolated from activated CD57+ and 
CD57- T-cells, could provide indications as to whether factors produced by the different 
subtypes could augment CLL cell survival in vitro. 
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CD27 is a marker that is down-regulated during T-cell differentiation (Klebanoff et 
al. 2006). The CD27- phenotype within the CD8+ T-cell compartment appeared to be 
associated with shorter PFS and disease progression. The expression and signalling through 
CD27 has been shown to play an essential role in supporting the T-cell survival, 
development and preventing apoptosis (Song et al. 2012; Dolfi et al. 2008; Ochsenbein et 
al. 2004). Therefore patients that exhibit reduced expression of CD27 may possess a 
population of CD8+ T-cells with reduced proliferative potential and increased sensitivity to 
apoptosis. This could thereby limit their general immunological capacity and restrict their 
ability to mediate tumour control. 
To further investigate the effects of specific T-cell populations on patient prognosis 
and the pathology of the disease, unbiased multivalent analysis was performed (Dr Robert 
Hills). This analysis indicated that two specific T-cell phenotypes CD4+CD27-PD-1+LAG-
3+ and CD8+CD27-CD57+PD-1+ had the greatest influence upon PFS. The mechanism 
behind this observation could be due to reduced T-cell function associated with the 
combined expression of these phenotypes markers, which in turn could impair immune 
function and limit immunological control of the tumour. Conversely it could be due to the 
relationship between cellular activation state and the described markers and thus the T-cell 
populations could be supporting the survival and proliferation of CLL cells.  
These hypotheses could be examined by investigating the functionality of these 
specific T-cell populations through cell sorting, then testing function through the various 
methods described above. The ability for the specific T-cell populations to support CLL 
cell survival and proliferation, either in a contact-dependent or independent manner, could 
be investigated, again utilising the experimental methodologies describe above.  
The findings from this chapter highlight the existence of several abnormalities 
within the T-cell compartment of CLL patients, many of which seem to be specific features 
of patients that exhibit an inversion in the CD4:CD8 ratio. The involvement of an array of 
molecules and multiple T-cell subsets, suggest that it would require a combination of 
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approaches to circumvent T-cell dysfunction and allow for successful T-cell based 
therapies in CLL. 
Additionally this analysis supports the concept that the frequency of specific T-cell 
populations can be used as markers of clinical progression. However, the precise role of T-
cells in the pathology of CLL remains unknown; it is not clear whether they play an active 
or passive role. It remains to be determined whether defects in various T-cell functions, 
could result in loss of tumour control. Alternatively, the augmented T-cells populations 
could be supporting CLL cell survival. This highlights the necessity for further 
characterisation and understanding of the role of T-cells within CLL. 
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Chapter 5  
Gene expression analysis of T-cells in CLL 
Numerous studies have described transcriptional differences between T-cells derived from 
CLL patients and those isolated from healthy individuals (Göthert et al. 2013; Kiaii et al. 
2013; Görgün et al. 2005; Görgün et al. 2009). However, differences between prognostic 
subsets of patients have not been evaluated to date. The inversion of the CD4:CD8 ratio 
has been shown to highlight a patient group with greater prognostic risk, which also 
exhibits numerous phenotypic differences within the CD4+ and CD8+ T-cell compartments 
(as described in Chapter 4). Therefore the aim of this study was to compare the expression 
of a subset of genes related to T-cell function and biological processes between CLLIR and 
CLLNR patients.  
Commercial kits, purchased from SABiosciences, were utilised to investigate 
pathway-specific genes across two separate arrays: T-cell and B-cell activation RT2 Profiler 
PCR array (PAMM-053Z) and T-cell anergy and tolerance RT2 Profiler PCR array (PAMM-
074Z). The analysis was performed on total mRNA isolated from purified CD4+ and CD8+ 
T-cells derived from CLLIR and CLLNR patients. The aim was to explore potential 
differences between the two patient groups in terms of T-cell related gene transcription 
and to highlight candidate genes and/or processes for further evaluation. A schematic 
diagram showing the experimental workflow for these assays is given in Figure 5.1. 
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Experimental design 
 
 
Figure 5.1 Schematic of experimental design. CD4+ and CD8+ T-cells (>90% purity) were isolated by immunomagnetic separation from CLLNR patents (CD4:CD8 range 1.17 – 2.21, 
mean 2.13), CLLIR patents (CD4:CD8 range 0.18 – 0.67, median 0.52). RNA extraction was performed using RNeasy Mini Kit (Qiagen) and was quantified using the Nanodrop (Thermo 
science). Investigation of the RNA integrity was performed using the RNA 6000 Nano Kit (Agilent). 60ng of RNA from each sample was then reverse transcribed using the RT² First 
Strand Kit (Qiagen) and qPCR performed using the 7500 Real-time PCR Systems (Life technologies) with the resulting cDNA. 
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5.1 CD4+ T-cell analysis 
Analysis of the differential expression of genes between the CLLIR and CLLNR 
patients was performed utilising two independent qPCR arrays. Due to the heterogeneity 
observed in the expression of the five housekeeping genes included on each array, 
ribosomal protein large P0 (RPLP0) was selected for data normalisation. This selection 
process was based upon relative abundance of the gene and as well the relatively low 
variation in expression across the samples (Appendix 4 and 5). 
 The transcriptional analysis indicated that a substantial number of genes were 
lower within CLLNR patients when compared to the CLLIR. Specifically, there was reduced 
transcription (>2 fold) in 61/84 genes in the T-cell activation array (Fig 5.2 and Appendix 
8). Similarly, analysis of the T-cell anergy array revealed lower transcription (>2 fold) in 
43/84 genes. In contrast, 7/84 genes showed increased transcription (>2 fold) within 
CLLNR patients relative to the CLLIR (Fig 5.3 and Appendix 9). Due to the limited number 
of samples analysed in these experiments, statistical analysis of the differentially expressed 
genes between the patient groups was not performed. However, to attempt to identify 
specific T-cell pathways/processes and to highlight genes of interest for validation, 
enrichment analysis was performed using the MetaCore Analytical Suite 
(https://portal.genego.com) with the assistance of Dr Robert Andrews (Bioinformatics 
support, Cardiff University). 
The differentially expressed genes identified from the T-cell activation array (Fig 
5.2 and Appendix 8) and T-cell anergy array (Fig 5.3 and Appendix 9) were utilised as the 
input gene list for analysis. The output from the analysis emphasised enrichment for 
processes involved in cellular activation, differentiation, cytokine production and survival.  
To highlight specific genes for potential further investigation and validation, the 
focus of the analysis was on selected genes within the pre-defined Metacore pathways 
“Naive CD4+ T cell differentiation” (IL-2, IL-1β, IL-5, CD28, IL-6, IL-12, CD40L, IL-13, 
IL-18, CD86, CD80, IRF4, IL-10, TGF-β1, CD40, CD4) and “Generation of memory 
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CD4” (IL-2, IL-2R α chain, CD28, IL4R α chain, Bcl-2, CD86, CD80, IL-7, CD4, STAT3, 
AP-1, IL-17, IRF4, IL-10). It is worthy of note that the transcription of all genes in these 
MetaCore pathways were reduced within the CLLNR patient samples relative to the CLLIR 
patient samples. Focus was placed upon these two pathways due to the importance of T-
cell differentiation and appropriate development of immunological memory in sustaining a 
competent immune system. 
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T-cell activation array (CD4+ T-cells) 
 
Figure 5.2 Differentially expressed genes (T-cell activation array) in CD4+ T-cells between CLLNR 
patients and CLLIR patients. qPCR was performed on the ABI Prism 7500HT Sequence Detector (Applied 
Biosystems) using primer sets embedded within T-cell and B-cell activation RT2 Profiler PCR array. For data 
analysis the ΔΔCt method was used and the fold change for each gene were calculated as the difference in 
gene expression between CLLIR patents (n = 4) and CLLNR (n =2). Data are represented as a scatter plot with 
a fold change of >2 selected as the cut off. Data analysis and representation was performed with the RT2 
Profiler PCR Array Data Analysis 3.5 (Qiagen). 
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T-cell anergy array (CD4+ T-cells) 
 
Figure 5.3 Differentially expressed genes (T-cell anergy array) in CD4+ T-cells between CLLNR 
patients and CLLIR patients. qPCR was performed on the ABI Prism 7500HT Sequence Detector (Applied 
Biosystems) using primer sets embedded within T-cell anergy and tolerance RT2 Profiler PCR array. For data 
analysis the ΔΔCt method was used and the fold change for each gene were calculated as the difference in 
gene expression between CLLIR patents (n = 4) and CLLNR (n =2). Data are represented as a scatter plot with 
a fold change of >2 selected as the cut off. Data analysis and representation was performed with the RT2 
Profiler PCR Array Data Analysis 3.5 (Qiagen). 
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5.2 CD8+ T-cell analysis 
Similar to the CD4+ analysis, two independent qPCR arrays were used and data 
normalisation was performed using RPLP0 as a housekeeping gene (Appendix 6 and 7).  
The analysis indicated that the transcription of a substantial number of genes were 
lower within CLLNR patients when compared to the CLLIR. Specifically the T-cell activation 
array showed lower transcription (>2 fold) in 49/84 genes (Fig 5.4 and Appendix 10) and 
the T-cell anergy array showed lower transcription (>2 fold) in 68/84 genes (Fig 5.5 and 
Appendix 11).  
The differentially expressed genes identified from the T-cell activation array (Fig 
5.4 and Appendix 10) and T-cell anergy array (Fig 5.5 and Appendix 11) were utilised as the 
input gene list for enrichment analysis. Prior to input, the gene list was filtered for 
abnormally high and potentially anomalous fold changes, which resulted in the removal of 
TLR4 (-349.22) and TLR6 (-78.14) (Appendix 10).  
To highlight specific genes for potential further investigation and validation, the 
focus of the analysis was placed upon selected genes within the pre-defined MetaCore 
pathways “Differentiation and clonal expansion of CD8+ T-cells” (CD137, CD28, IFN-γ, 
NF-kB, NF-AT2, STAT3, CD40L, NF-AT1, CD27, GzmB, ICAM1, CD70, CD40, FasL, 
T-bet, perforin, OX40). The transcription of all genes was reduced within CLLNR patients 
relative to CLLIR. This process was selected due to the importance of appropriate CD8+ T-
cell differentiation and the acquisition of effector functions.  
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T-cell activation array (CD8+ T-cells) 
 
Figure 5.4 Differentially expressed genes (T-cell activation array) in CD8+ T-cells between CLLIR 
patients and CLLIR patients. qPCR was performed on the ABI Prism 7500HT Sequence Detector (Applied 
Biosystems) using primer sets embedded within T-cell and B-cell activation RT2 Profiler PCR array. For data 
analysis the ΔΔCt method was used and the fold change for each gene were calculated as the difference in 
gene expression between CLLIR patents (n = 5) and CLLNR (n =2). Data are represented as a scatter plot with 
a fold change of >2 selected as the cut off. Data analysis and representation was performed with the RT2 
Profiler PCR Array Data Analysis 3.5 (Qiagen). 
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T-cell anergy array (CD8+ T-cells) 
 
Figure 5.5 Differentially expressed genes (T-cell anergy array) in CD8+ T-cells between CLLNR 
patients and CLLIR patients. qPCR was performed on the ABI Prism 7500HT Sequence Detector (Applied 
Biosystems) using primer sets embedded within T-cell anergy and tolerance RT2 Profiler PCR array. For data 
analysis the ΔΔCt method was used and the fold change for each gene were calculated as the difference in 
gene expression between CLLIR patents (n = 5) and CLLNR (n =2). Data are represented as a scatter plot with 
a fold change of >2 selected as the cut off. Data analysis and representation was performed with the RT2 
Profiler PCR Array Data Analysis 3.5 (Qiagen). 
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5.3 Discussion 
The underlying mechanisms that contribute to changes in T-cell number 
(Porakishvili et al. 2001; Frassanito et al. 1998), subset frequency (Nunes et al. 2012) and 
function (Sakuishi et al. 2010; Fourcade et al. 2010) in cancer patients have not yet been 
fully resolved within any specific malignancy. However, it seems likely that these 
perturbances could be due, in part, to factors secreted by tumour cells, cell-to-cell contact, 
repeated T-cell stimulation in response to tumour-specific antigen(s) or other antigen 
sources. Transcriptional analysis of the non-malignant T-cell compartment of cancer 
patients has been employed in an attempt to provide a further understanding of these 
observations, for example analysis of the CD8+ T-cell compartment in melanoma patients 
highlighted an increase in the expression of genes associated with apoptosis when 
compared to healthy donors (Xu et al. 2004). This suggested that melanoma patients might 
exhibit immune dysfunction due to enhanced death of CD8+ CTL. 
The aim of this study was to generate preliminary data to determine whether there 
were differences in gene expression between CLLIR and CLLNR patients. Each T-cell subset 
(CD4+ and CD8+) was analysed independently in order to identify candidate genes of 
interest for further evaluation and investigation. 
Previous transcriptional analysis of CLL patients using purified CD3+ T-cells 
revealed an increase in the expression of numerous genes encoding for stimulatory and 
inhibitory co-receptors from the killer cell lectin-like receptor and NK-cell receptor 
families, relative to healthy donors. Additionally, the transcription of genes involved with 
cytotoxic effector functions such as CRTAM and perforin were also increased (Göthert et 
al. 2013). Gene set enrichment analysis (GSEA) of the data suggested that CLL patients 
exhibited enrichment in genes associated with CD8+ effector T-cell function (Göthert et al. 
2013). The authors, like many others (Nunes et al. 2012; Riches et al. 2013), showed that 
CLL patents exhibit an increased frequency of CD8+ effector T-cells when compared to 
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controls (Göthert et al. 2013). However, they failed to perform transcriptional analysis on 
purified CD8+ T-cells.  
Other studies have also investigated the differential gene expression within the total 
T-cell population (CD3+) from CLL patients by microarray and subsequently confirmed 
observations of interest by qPCR within the separate CD4+ and CD8+ T-cell compartments 
(Kiaii et al. 2013). An increased expression in chemokines such as CCL4 and CCL5 were 
observed  Kiaii et al. 2013), which are both powerful chemoattractants for T-cells (Bystry 
et al. 2001; Schall et al. 1990). It has been suggested that the elevated expression of these 
chemokines could result in the recruitment of T-cells, which could in turn support CLL cell 
survival (Hacken and Burger 2014). 
In a study by Gorgun et al, microarray analysis of the transcriptional differences 
within the separate CD4+ and CD8+ T-cell compartments, suggested that CLL patients’ T-
cells exhibited altered expression of genes involved in differentiation, proliferation and 
survival. Specifically, numerous genes involved in signalling pathways such as the Ras-
dependent JNK and p38 MAPK pathways, together with PIK3CB, which plays a key role in 
the transduction of stimulatory signals from the TCR/CD28, were down-regulated. 
Interestingly NF-κB, which plays a fundamental role in cellular activation, was also down-
regulated at the level of transcription and protein expression. Overall these results 
suggested that the CD4+ T-cells from CLL patients have defects in cellular activation 
(Görgün et al. 2005). Additionally, transcriptional defects in cytoskeletal formation were 
observed (Görgün et al. 2005), which have subsequently been shown to affect 
immunological synapse formation (Ramsay et al. 2008;  Ramsay et al. 2012). 
Analysis of the CD8+ T-cell compartment indicated altered transcription of genes 
involved in the formation and trafficking of secretory vesicles and cytotoxicity. For 
example, decreased expression of VAMP2, which is involved in trafficking vesicles to the 
cell surface, was observed at the level of both mRNA and protein. This suggested that 
CD8+ T-cells from CLL patents might show defects in secretory pathways involved in the 
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release of cytotoxic factors such as GzmB (Görgün et al. 2005). Reports of transcriptional 
differences remain conflicted as Gorgun et al initially observed no difference in GzmB 
expression (Görgün et al. 2005). This contrasted with subsequent studies that observed an 
increase in both primary human samples and the Eµ-TCL1 CLL mouse model (Gorgun et 
al. 2009). However, in both reports a decrease in protein expression was evident when 
compared to controls. This suggests that reduced CTL function may be due to defects in 
packaging and trafficking processes within secretory pathways rather than altered 
transcription per se (Görgün et al. 2005; Gorgun et al. 2009). However, T-cells from CLL 
patients have been shown to be effective at inducing the lysis of target cells in a GzmB-
dependent manner, albeit in the context of forced immunological synapse following 
treatment with blinatumomab (Wong et al. 2013).  
To determine if the differential gene and protein expression observed in T-cell 
from CLL patients was induced in a contact dependent manner, Gorgun et al went on to 
culture T-cells from health donors with sera from CLL patients or CLL cells. Changes in 
the expression of genes decreased in CD4+ or CD8+ T-cells derived from CLL patients, 
were not observed in normal T-cells in response to sera from CLL patients. However, co-
culture with CLL cells induced similar changes to those observed in T-cells isolated from 
CLL patients. Furthermore, these changes were prevented by the blockade of adhesion 
molecules using anti-CD54 and anti-CD11a mAbs (Görgün et al. 2005). This indicates that 
cell-to-cell contact may be essential for the induction of CLL cell mediated changes within 
the T-cell compartment, a concept supported by others (Ramsay et al. 2008; Ramsay et al. 
2012). 
These examples highlight differences and potential defects within the T-cell 
compartment of CLL patients. However, CLL is a highly heterogeneous disease, wherein 
patients can be sub-divided based upon laboratory and prognostic markers (Gribben 2010). 
In all of the described studies to date CLL patients were analysed as a whole and compared 
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to healthy donors. In this study, patients were divided based upon their CD4:CD8 ratio 
and comparisons were made between these two patients groups.  
Transcriptional analysis of the CD4+ T-cells within this study highlighted the 
differential expression of numerous genes (T-cell activation array 61/84 genes, T-cell 
anergy array 50/84 genes), which were subsequently grouped and integrated utilising 
MetaCore Analysis Suite.  
Transcriptional analysis indicated that CLLNR patients exhibited a relative decrease 
in the expression of the transcripts of the stimulatory co-receptors CD28 and CD4. These 
co-receptors contribute to the amplification of TCR signalling, through the recruitment of 
components essential for the T-cell activation signalling cascade (Barber et al. 1989) and 
provide essential secondary T-cell activation, specifically through the P13K/AKT pathway 
(Rudd et al. 2009). Additionally, a relative decrease in the expression of the transcription 
factors such as AP-1 and IRF4, which facilitate T-cell activation, differentiation and inhibit 
apoptosis (Rincón and Flavell 1994; Brüstle et al. 2007; Honma et al. 2008; Lohoff et al. 
2004), were observed within CLLNR patients compared to CLLIR. 
Taken together, these data suggest that CLLNR patients may exhibit comparative 
defects in processes relating to T-cell activation when compared to CLLIR patients. 
Conversely this analysis could suggest that CD4+ T-cell from CLLIR patients represent a 
more activated T-cell populations. Thus evaluation of the expression and function of genes 
involved in T-cell activation and survival warrant further investigation. 
CLLNR patients further exhibited a relative decrease in the expression of cytokines 
and their associated receptors, which support T-cells, such as IL-2, IL-6 IL-2Rα and IL-
7Rα chains, in comparison to CLLIR patients. IL-2 plays an essential role in the 
proliferation and differentiation of activated T-cells, through interactions with the IL-2 
receptor, composed of the constitutively expressed β and γ chains. However, addition of 
the inducible IL-2Rα chain results in the formation of the high affinity IL-2 receptor, 
making T-cells more sensitive to IL-2 signalling (Gaffen and Liu 2004). Additionally, 
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responses to IL-7 and IL-6 have been shown to mediate T-cell proliferation and enhance 
survival (Schluns et al. 2000; Lotz et al. 1988). However, others have suggested that IL-6 
may inhibit T-cell proliferation and play a role in mediating the immune dysfunction 
associated within CLL (Buggins et al. 2007). It should be noted that in this study CLL cells 
were observed as the predominate source of IL-6. 
Furthermore, CLLNR patients further exhibited a relative decrease in the expression 
of cytokines such as IL-13 (Cocks et al. 1993; Chaouchi et al. 1996), IL-5 (Kouro and 
Takatsu 2009) and IL-6 (Tanner and Tosato 1992) as well as surface molecules such as 
CD40L (Schultze et al. 1997) which support B-cell proliferation, survival and 
differentiation. While these cytokines have been shown to support normal B-cells, 
published reports suggest that they have an opposing effect upon CLL cells (Aderka et al. 
1993; Mainou-Fowler et al. 1994). Moreover, clinical evaluations have shown that elevated 
levels of serum IL-6 are associated with poor patient prognosis (Fayad et al. 2001). Overall 
the specific roles of IL-5, IL-6 and similar cytokines within CLL remains unclear and thus 
the differential expression and effects of these cytokines warrants further investigation. 
Based on this gene expression data, CD4+ T-cells from CLLNR patients might 
exhibit defects in responsiveness and cytokine production, which could affect processes 
involved in supporting T-cell and B-cell proliferation and survival. However, due to the 
comparative nature of this analysis it could not be definitively determined if CLLNR patients 
exhibit defects within these processes and thus may represent a “defective” T-cell 
population or whether CLLIR patients exhibit relatively increased expression of these genes, 
suggesting that they represent a “more functional” or activated T-cell population. 
CD8+ T-cells represent a functionally distinct branch of the adaptive immune 
system and thus were analysed separately. Transcriptional analysis indicated a relative 
reduction in the transcription of genes encoding for the stimulatory co-receptors CD27, 
CD28, OX40 and CD137, which orchestrates divergent pathways that promote T-cells 
survival and proliferation (Rudd et al. 2009; Lee et al. 2002; Cannons et al. 2001; Croft et al. 
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2009; Denoeud and Moser 2011; Barber et al. 1989), within the CLLNR patients relative to 
CLLIR.  
However, phenotypic analysis in this thesis, and confirmed by previously published 
findings (Nunes et al. 2012), showed a decrease in the surface expression of stimulatory co-
receptors, such as CD27 and CD28, within CLLIR patients compared to CLLNR patients, in 
the total CD8+ population and specific memory subsets (Nunes et al. 2012). These 
differences could be due altered translation of the CD27 and CD28 transcripts within 
CD8+ T-cell from CLLIR and CLLNR patients, such as the differential expression of 
microRNA, which silences mRNA translation (Djuranovic et al. 2012). Therefore, further 
investigation into the relationship between mRNA expression, mRNA processing, protein 
production and protein expression could be informative. 
Consistent with the down-regulation of genes encoding co-stimulatory molecules, 
there was also decreased expression of the genes encoding for transcription factors related 
to T-cell activation such as NF-κB, NFAT, T-bet and STAT-3, within the CLLNR patients 
relative to CLLIR. These transcription factors have been shown to mediate processes 
involved in T-cell differentiation and function (Arch and Thompson 1998; Gerondakis et 
al. 2014; Feau et al. 2013; Rincón and Flavell 1994; Sullivan et al. 2011; Olson and Jameson 
2011).  
CLLNR patients further exhibited a relative decrease in the expression of GzmB, 
perforin and FasL, all of which are involved to cytotoxic T-cell processes, (Lieberman 
2010; Ju et al. 1995; Dhein et al. 1995) as well as effector cytokines such as IFN-γ (Teixeira 
et al. 2005), relative to CLLIR. The down-regulation of these genes suggests that CD8+ T-
cells from CLLNR patients may exhibit defects in cytotoxic function. The expression factors 
associated with CD8+ T-cell effector function, IFN-γ (Sica et al. 1997), GzmB (Huang et al. 
2006) and FasL (Hsu et al. 1999) have been shown to be mediated by transcription factors 
such as NF-κB and NFAT. Therefore it could be hypothesised that decreased expression 
of cytotoxic and effector factors could be a related to a reduction in transcription factor 
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expression, due to defects in T-cell signalling. Therefore further investigation of T-cell co-
receptor expression and signalling, transcription factor dynamics and the expression factors 
associated with CD8+ cytotoxicity between these two patient groups would be beneficial to 
further elaborate upon these preliminary observations. In this regard, it is worth noting that 
a high proportion of the genes observed in this study (Appendix 10 and 11) are regulated 
by NF-κB (Glimore et al. 2015). 
It should be noted that one of the limitations of this study, was the number of 
available samples that could be studied. Obtaining patient samples that exhibit a CD4:CD8 
ratio of 0.5 or 2.0 proved to be challenging and initially limited the number of patient 
samples suitable for this study. The ratios 0.5 or 2.0 were selected to provide consistency 
within the patient groups and afford a large separation between the groups. Additionally, 
due to the overwhelming dominance of CLL cells in patient-derived peripheral blood 
samples, purification of CD4+ and CD8+ T-cells to >90% by immunomagnetic separation 
proved to be challenging and further limited the number of suitable of samples. Even in 
those samples where this was achieved, the absolute numbers of purified T-cells obtained 
was relatively small resulting in low RNA yields. A total of 60ng of RNA was used for the 
downstream qPCR analysis. This amount was selected as it was within the suitable range of 
RNA quantities recommended by the manufacturer (http://www.sabiosciences.com/ 
pcrarrayperformance.php). However, it should be noted that the use of low concentrations 
of RNA might disproportionately affect the detection of low abundance transcripts.  
To obtain a greater number of T-cells with higher purity, alternative methods of T-
cell isolation could be employed in future, such as direct flow sorting. However, one of 
caveats associated with this process is the potential for FACS-induced activation of the T-
cells due physical shear force, which could potentially influence the subsequent 
transcriptional profile. 
Within this study transcriptional analysis was only performed on the total CD4+ 
and CD8+ T-cell populations. This approach was taken for pragmatic reasons associated 
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with the number of available T-cells and thus the subsequent amount of RNA. However, it 
is well established that both the CD4+ and CD8+ T-cell compartments are made up of a 
diverse range of subsets (Liu et al. 2013; Klebanoff et al. 2006), which exhibit differential 
gene expression profiles (Willinger et al. 2005). This appears to be particularly pronounced 
in CLL patients where there is a marked skewing towards memory subsets (Nunes et al. 
2012; Riches et al. 2013). Therefore, it would be interesting to investigate if any of the 
changes in gene expression observed in this study occurred within specific T-cell 
populations. For this concept to be explored, highly sensitive analysis platforms would be 
required, which would be more suitable for very low concentrations of RNA, such as 
RNAseq (Saliba et al. 2014).  
Additionally, while the target gene PCR array approach used in this study was an 
attractive option, to allow for the investigation of pathway-specific transcriptional 
differences, the approach could be seen as reductionist. By definition, the arrays pre-define 
the genes of interest and so prevented the evaluation of potentially novel and unexpected 
differences between the groups.  
Because of the limitation and caveats of this study many of the initial observations 
presented will require further investigation and validation. Initially it would be logical to 
validate the differential expression of the gene list as defined in this preliminary study. This 
should be done using the original cDNA, using optimally designed primer sets. These 
primer sets could be further utilised to investigate the expression of genes in a much larger 
patient cohort to determine if the findings observed here are representative of the different 
patient groups. Investigation of changes at the protein level would also be a desirable and 
valuable way of continuing this work in order to determine if changes at the transcriptional 
level impact upon protein expression (Western blot / ICS / flow cytometry). As the genes 
highlighted in this discussion focused on the process of T-cell activation and effector 
function, the evaluation of functionally differences between the two patient groups would 
be a valuable progression of this study. Finally, to provide a more comprehensive 
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evaluation of the transcriptional differences between the two patient groups, an unbiased 
global gene analysis approach, such as microarray or RNAseq, could also be beneficial.  
In conclusion, while several practical limitations have been highlighted in this study 
it still provides some preliminary data as a basis for further work (technical and biological) 
to evaluating transcriptional differences between CLLNR and CLLIR patients. Due to the 
large number of differentially expressed genes identified, a complete and comprehensive 
evaluation of all the genes and their related functions was not achievable within the 
timeframe of this thesis. However, pathway enrichment analysis, as well as hypothesis 
driven approaches (processes related to T-cell activation and function), were employed 
during data analysis in an effort to shortlist specific genes of interest for further 
investigation. 
Based on the phenotypic observations from Chapter 4, it was hypothesised that T-
cells from CLLIR patients were representative of exhausted/highly differentiated or 
activated T-cell populations. These contrasting hypotheses were based upon the 
mechanisms and processes involved with the expression of the phenotypic markers in 
Chapter 4, such as T-cell activation and the historical knowledge associated with the 
presence and signalling through the markers, such as immune dysfunction. Therefore the 
observations from this transcriptional analysis potentially support the concept that T-cells 
from CLLIR patients may be more representative of an activated T-cell population when 
compared to CLLNR, which exhibited a greater capacity to support B-cells survival and 
proliferation. However, the role of the described genes in modulating T-cell behaviour in 
CLL requires further investigation. 
5.4 Suggested further work  
• Selection of candidate gene of interest from preliminary analysis for further 
investigation. 
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• Confirm transcriptional observation in initial cDNA samples using single 
gene qPCR. 
• Validate transcriptional observation within a larger cohort of patients; 
CLLIR (n=10) and CLLNR (n=10), in addition to age-matched healthy 
controls. 
• Determine differential protein expression of selected genes. 
• Evaluate functional differences in processes involved in T-cell activation 
and effector functions between CLLIR and CLLNR patients. 
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Chapter 6   
Final Discussion 
The initial aim of Chapter 3 was to investigate the potential of peptides derived from the 
pro-apoptotic Bax protein to generate Bax-specific T-cells from CLL patients. Abnormally 
low levels of expression of the Bax protein have been observed within CLL cells, due to 
enhanced proteasomal degradation (Agrawal et al. 2008). Therefore, it was hypothesised 
that MHC-I molecules might preferentially present Bax-derived peptides to CD8+ T-cells 
as a byproduct of the degradation process, providing a CLL-specific TAA.  
The concept of a protein expressed at low levels serving as a TAA may seem 
counter-intuitive as many TAAs are derived from self proteins that exhibit over expression 
(Jäger et al. 2001). However, several studies have shown that endogenous proteins that are 
unstable and have increased susceptibility to protein degradation, can be recognised by 
CD8+ T-cells (Castilleja et al. 2001; Sirianni et al. 2004). Encouragingly, this phenomenon 
has previously been observed with a peptide derived from Bax, but in a study in which the 
T-cell clones were isolated from healthy individuals not CLL patients (Nunes et al. 2011). 
Therefore it was not known, whether Bax-specific T-cells could be detected within CLL 
patients.  
The use of T-cells in the treatment of CLL has gathered more attention with the 
recent development of CAR T-cell therapy. Polyclonal T-cell populations are genetically 
manipulated to redirect T-cell activity towards specific molecules expressed upon the 
malignant cells in a MHC-independent manner (Maus et al. 2014). Due to the lack of 
obvious TAAs, current experimental therapeutics have used the CART-19 construct to 
redirect T-cell activity towards the pan B-cell antigen CD19 (Kalos et al. 2011; Porter et al. 
2011). However, this process targets healthy as well as malignant B-cells and so the 
identification of novel tumour-specific antigens would have considerable therapeutic 
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advantages. Additionally, while this has proven to be an efficacious treatment option, it has 
been reported that 5-10% of acute lymphoblastic leukaemia (ALL) patients treated with 
CART-19 (or with the CD3-CD19 Bi-specific antibody, Blinatumomab) relapse with a 
CD19- clone (Ruella et al 2014). If this observation holds true for the treatment of other 
CD19+ malignancies, such as CLL, then this would further highlight the need for the 
discovery of novel CLL-specific TAAs.  
Initial results suggested that CD8+ T-cells from an HLA-A2+ CLL patient 
recognised the Bax-derived peptides (P603 and P605). Furthermore, peptide-specific T-
cells were capable of being isolated, cloned and expanded rapidly in vitro resulting in the 
maintenance of long-term peptide specificity. However, the subsequent T-cell clone 
identified in this study (6C5), failed to respond to HLA-A2+ CLL cells in vitro, suggesting 
that either the Bax-derived peptide P603 was not expressed on the surface of CLL cells or 
that the peptide was expressed but T-cell recognition was of low affinity. 
Further analysis of 6C5 demonstrated that it actually recognised a modified version 
of P603, P603 tBu (LLSY(3-tBu)FGTPT) rather than the Bax-derived wild type sequence 
(LLSYFGTPT). Since this modified peptide does not occur in nature, it was not surprising 
that T-cells recognising this peptide were unable to identify CLL cells. Thus the potential 
for the wild type P603 peptide to act as a TAA for CLL cannot be ruled out. However, 
without a T-cell specific for the wild type P603, the presentation of this peptide on CLL 
cells cannot be determined. An alternative approach to investigate the potential presence of 
P603 (or other Bax peptides) on the surface of CLL could be to elute the naturally 
occurring peptide complexes with MHC-I molecules from the CLL and interrogate their 
peptide sequences using mass spectrometry (Hunt et al. 1992; Cox et al. 1994).  
Because P603 tbu is not a natural peptide it is likely that the observed specificity is 
due to TCR cross reactivity. A nonamer combinatorial peptide library screen was utilised to 
probe the entire repertoire of possible 9aa peptides to identify potential naturally occurring 
antigens. These results revealed that the index peptide (P603 tBu) was suboptimal at 8/9 
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positions and suggested the potential for the TCR to cross-react with multiple naturally 
occurring peptide sequences.  
While this method has proven to be effective at investigating the cross reactivity of 
other T-cell clones (Wooldridge et al. 2012), one of the limitations of this approach is that 
poorly binding peptides may be underrepresented, due to competition for available MHC 
molecules. Therefore it is unknown if the entire 9mer repertoire is truly being sampled and 
presented to T-cells. Furthermore, it has been shown the peptide affinity for MHC does 
not always correlate with immunogenicity (Khanna 2004), thus potentially highly 
immunogenic peptides could be out-competed and therefore not effectively sampled. 
Reconfiguring the assay into a high throughput screen to test each peptide individually 
could address this concern.  
While this study failed to demonstrate the existence of Bax-specific T-cells within 
CLL patients, it did show that it was technically feasible to generate and expand large 
numbers of peptide-specific CD8+ T-cell clones from limited amounts of patient material 
(2-3ml of whole blood). However, the approach utilised in this study would not be feasible 
in a clinical setting due to the protracted (3-4 month) timescale associated with the 
procedure. Several improvements to this protocol might be envisaged in order to identify 
novel CLL-specific T-cell from patients. While in vitro stimulation with pools of candidate 
peptides is advantageous, in order to investigate the potential of multiple epitopes 
simultaneously, subsequent T-cell cultures would require extensive processing and 
characterisation (limiting dilution cloning, antigen independent expansion and epitope 
mapping). The direct sorting and expansion of tetramer-specific T-cells could reduce the 
timescale of this process. Additionally, the tetramer staining protocol could be combined 
with the staining for other markers to identify desirable T-cell subsets, such as naïve T-
cells, which have been suggested to resist terminal differentiation and maintain a high 
proliferative potential (Hinrichs et al. 2011). 
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 Both approaches described above, are dependent on the existence of peptide-
specific T-cells within an individual patient’s T-cell repertoire. This could be overcome 
through the isolation and genetic modification (TCR transfer or CAR) of polyclonal 
populations of T-cells to express receptors for specific peptide or protein sequences. The 
efficacy of T-cell based therapies for the treatment of CLL (Porter et al. 2011; Kalos et al. 
2011), other hematological malignancies (Grupp et al. 2013; Maude et al. 2014) and solid 
cancers (Rosenberg et al. 2011) has been shown in small scale clinical trials and patient case 
reports. However, this was cemented in 2014, with the FDA approval of the first T-cell 
therapy (CART-19 modified T-cells) for the treatment of relapsed or refractory ALL. 
Despite this breakthrough, several obstacles could limit the efficacy of T-cell based 
immunotherapies for the treatment of CLL (and other malignancies), such as immune 
dysfunction and immunosuppression induced by tumour burden and/or tumour cell-
mediated microenvironmental changes. Therefore a greater understanding of the processes 
and mechanisms, which could affect T-cell function to influence T-cell activation and 
suppression within CLL, is essential. This knowledge may identify immunological 
hallmarks of the disease and potential differences between patients, which would be 
beneficial in the development of novel immunotherapies and the stratification of the most 
suitable patients to receive them.  
In Chapter 4 an immunophenotyping approach was employed to characterise the 
T-cells from CLL patients in an attempt to identify common immunological abnormalities. 
Within this study, CLLIR patients exhibited a skewing in their T-cells towards “highly” 
differentiated effector memory phenotypes (EM and EMRA) and displayed an increased 
frequency of CD57+/CD27- T-cells, which has been associated with limited proliferative 
potential and increased sensitivity to apoptosis (Dolfi et al. 2008; Brenchley et al. 2003; 
Focosi et al. 2010; Plunkett et al. 2007; Hendriks et al. 2000). In addition, there was a 
significant increase in T-cells expressing the immunosuppressive receptors PD-1+ (Keir et 
al. 2008) and TIM-3+ (Rangachari et al. 2012) within the CD4+ T-cell compartment. 
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Therefore the altered phenotypes observed within the CLLIR patient group could denote a 
T-cell pool, which exhibits defects in proliferative potential, function and survival.  
Analysis of the prognostic impact of the increased frequencies of CD8+CD57+, 
CD8+CD27-, CD4+PD-1+ and CD4+CD57+ T-cells revealed that they were associated with 
shorter PFS. Thus suggesting a potential role for specific T-cell populations in the 
prognosis of CLL and implying that T-cell dysfunction may be a driver of disease 
progression or progressive disease could drive the accumulation of dysfunctional T-cells.  
Accounts of T-cell dysfunction in CLL have been well documented within the field. 
CLL cells have been shown to negatively impact T-cell activation (Görgün et al. 2009) and 
proliferation (Hock et al. 2014), transcriptional profile (Görgün et al. 2005; Görgün et al. 
2009), immunological synapse formation (Ramsay et al. 2008) and T-cell migration 
(Ramsay et al. 2013). 
Defects in immunological synapse formation, induced by CLL cells, have been 
shown to be mediated by the interactions between immunosuppressive ligands and their 
corresponding receptors on T-cells (Ramsay et al. 2012). This demonstrated a mechanism 
by which CLL cells can actively reduce immune recognition and immune surveillance. The 
in vitro treatment of CLL cells with the immunomodulatory drug lenalidomide (Cortelezzi 
et al. 2012) was shown to down-regulate immunosuppressive ligand expression, alleviate 
tumour-induced synapse dysfunction and enhance CTL killing (Ramsay et al. 2008; Ramsay 
et al. 2012). Ex vivo analysis of CLL samples from patients treated with lenalidomide 
showed similar results, highlighting the clinical efficacy of the drug (Ramsay et al. 2012).  
In addition to affecting the formation of the immunological synapse, the PD-
1/PDL-1 pathway has been shown to impair the production of IFN-γ, IL-2 and TNF-α by 
T-cells in CLL xenograft murine models (McClanhan et al. 2014) (McClanhan et al. 2013). 
Treatment with lenalidomide (McClanhan et al. 2014) and ibrutinib (McClanhan et al. 2014) 
appeared to reduce PD-1 expression and enhance IFN-γ production. In vitro blockade of 
the PD-1/PDL-1 in primary CLL samples has also been shown to enhance the production 
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of IFN-γ (Brusa et al. 2013). Furthermore, in vivo blockade in the CLL TCL1 murine model 
(Johnson 2006), induced a significant reduction in the frequency of CLL cells, increased T-
cell effector function and proliferative potential and prevented the loss of naïve CD8+ T-
cell and the inversion of the CD4:CD8 ratio (Hanna et al. 2014). Taken together, these data 
suggest that early blockade of the PD-1/PDL-1 could prevent the development of CLL 
associated immune dysfunction and facilitate tumour control.  
However, others have shown that whilst T-cells from CLL patients may exhibit 
increased expression of markers associated with immunosuppression and exhaustion, they 
can maintain their ability to produce effector cytokines and so may actually represent 
pseudo-exhausted populations (Riches et al. 2013). This pseudo-exhaustion phenomenon 
has been observed in other haematological malignancies (Lichtenegger et al. 2013). 
Therefore the specific role of the PD-1/PDL-1 pathway (and other immunosuppressive 
pathways) in CLL requires further investigation. In addition to immunosuppressive 
receptors, the expression of markers associated with replicative senescence (CD57+ / 
KLRG1+ / CD27- / CD28-) has been well documented within CLL (Serrano et al. 1997; 
(Göthert et al. 2013; Nunes et al. 2012; Porakishvili et al. 2001). Interestingly, high 
frequencies of CD4+CD57+ T-cells have been associated with advanced disease staging 
(Serrano et al. 1997). Therefore patients that exhibit high frequencies of T-cells expressing 
these markers could exhibit defects in immunosurveillance and ultimately more progressive 
disease. 
Malignant cells can also induce T-cell dysfunction through cultivating a 
microenvironment that favours the development of immunosuppressive T-cell 
populations. Increased frequency and absolute numbers of T-regs, compared to healthy 
controls, has been reported in CLL (D'Arena et al. 2011; Giannopoulos et al. 2008; 
D'Arena et al. 2012). Elevated numbers of T-regs have been associated with a more 
advanced Rai and Binet stage classification (D'Arena et al. 2011; Giannopoulos et al. 2008), 
unfavorable prognostic patient groups, (Weiss et al. 2011) increased tumour burden 
 Chapter 6: Final Discussion 
 
 Page 211 
(D'Arena et al. 2011) and shorter TTFT (Weiss et al. 2011; D'Arena et al. 2012). 
Furthermore, patients that exhibited high frequencies of T-regs (≥10.5% of CD4+ T-cells) 
also exhibited reduced responses against viral and tumour antigens (Giannopoulos et al. 
2008). Therefore it could be hypothesised that the association between T-regs and the 
progression of CLL could be due to defects in immune surveillance. While numerous 
TAAs have been described in CLL (Nunes et al. 2011; Schmidt et al. 2003; Mayr et al. 
2005; Mayr et al. 2006; Rajasagi et al. 2014), immunodominant epitopes have yet to be 
defined. Therefore the identification of a bono fide CLL-specific tumour antigen is essential 
to fully evaluate the effects of immunosuppressive pathways and cell types upon tumour-
specific T-cell populations.  
An alternative, and not mutually exclusive, role for the T-cell populations described 
in this study is that they directly support the growth of CLL cells. In vitro co-culture with 
autologous T-cells has been shown to have an anti-apoptotic effect upon CLL cells, even in 
the absence of cell-to-cell contact (Kiaii et al. 2013). Furthermore, the in vitro activation of 
T-cells from CLL patients has been associated with CLL cell activation and proliferation 
(Borge et al. 2012), which was enhanced by CXCL12. This is a chemokine that has been 
shown to mediate the migration of CLL cells and T-cells within CLL patients to secondary 
lymphoid organs (Burger et al. 1999) (Walsby et al. 2014). Therefore this chemokine may 
play multiple roles in the supportive relationship between T-cell and CLL cells.  
The in vivo significance of T-cells in CLL was shown by Bagnara et al, who reported 
that autologous T-cells, specifically CD4+ T-cells, play an essential role in supporting the 
proliferation and survival of CLL cells in murine model systems (Bagnara et al. 2011); a 
finding subsequently confirmed by others (Oldreive et al 2014). Moreover, proliferating 
CLL cells have been shown to co-localise with CD4+PD-1+ T-cells within the lymph nodes 
of CLL patients (Brusa et al. 2013). This suggests that CLL cell survival and proliferation 
may be preferentially enhanced by interaction with specific T-cell subsets.  
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Further evaluation of the capacity of specific T-cell subsets to influence CLL 
survival and potentially the development of the disease is needed. This could include 
investigating the differential expression and/or production of factors that could support 
CLL cell survival and proliferation, between the different T-cell populations. In addition, it 
would also be interesting to directly investigate the proliferative potential and survival of 
autologous CLL cells in the presence or absence of specific T-cell populations, such as 
those highlighted within this study. 
While this study has provided a greater insight into the T-cell populations of CLL 
patients and highlighted multiple possibilities for further work, one of the main limitations 
of the work, was that only T-cells from the peripheral blood were sampled. Within the 
body, CLL cells have been shown to exist within three main anatomical locations 
(peripheral blood, lymph nodes and bone marrow), which provide different 
microenvironments (Zenz et al. 2010b). Comparative transcriptional analysis of CLL cells 
isolated from each anatomical site indicated that CLL cells from lymph nodes exhibited 
distinct hallmarks of BCR activation, canonical NF-κB signalling and cellular proliferation. 
These observations were confirmed at the protein level. Lymph node-derived CLL 
exhibited increased expression of phospho-SYK (BCR activation), increased 
phosphorylation and subsequent degradation of IκBα (canonical NF-κB signalling) and 
increased expression of the proliferation marker Ki67 (Herishanu et al. 2011). Similar 
observations have been made in xenograft murine models (Herman et al. 2013). Indicating 
the importance of the lymph node microenvironment for CLL cell activation and 
proliferation 
Since activated T-cells play a pivotal role in CLL cell proliferation (Bagnara et al. 
2011; Borge et al. 2012), it could be hypothesised that the lymph node may exhibit an 
enrichment of activated T-cells or habour distinct populations such as CD4+PD-1+ T-cells 
(Brusa et al. 2013), which could preferentially support CLL activation and proliferation. 
Conceivably this could be caused by increased homing of specific “supportive” T-cell 
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populations to the lymph node or microenvironment-mediated differentiation of resident 
T-cells in this niche. Indeed, T-cells from CLL patients have been shown to undergo more 
rapid proliferation within lymph nodes, when compared to the peripheral blood, in 
xenograft murine models (Herman et al. 2013). Therefore it would be valuable to 
investigate the distribution and characteristics of specific T-cell populations, such as those 
highlighted within this study, in different anatomical locations. 
Additionally, many pharmacological therapies used in the treatment of CLL have 
also been shown to mediate effects on T-cell phenotype (Gassner et al. 2014) (Gassner et 
al. 2010) (Simone et al 2013), function (McClanhan et al. 2014) (McClanhan et al. 2013) 
(Gassner et al. 2010), migratory potential (Ramsay et al. 2013) and telomere dynamics 
(Jones et al. 2013), in multiple experimental models. The effects of these agents could have 
implications on T-cell associated tumour control or tumour support, and may impact upon 
the future use and efficacy of T-cell based immunotherapies. Therefore greater evaluation 
of T-cell phenotypes and function in response to treatment would be valuable. 
While chapter 4 has highlighted differences in the relative frequencies of different 
cell populations, it cannot be definitively determined if these observations are due to 
population expansions, contractions or a combination of the two effects. This could be 
resolved by determining the absolute number of cells within the population of interest, 
through the use of reference beads such as Trucount™ (BD). Additionally while 
investigating the frequencies of cell populations expressing markers of interest is a 
common method utilised to interpret flow cytometry data, other approaches such as 
determining the level of expression through the analyses of the MFI could be employed in 
the analysis process. 
Overall the findings from Chapter 4 suggest numerous immunological defects 
within the CD4+ and CD8+ T-cell compartments of CLL patents, which appear to be a 
specific feature of the CLLIR patient group. Individually, increased expression of the 
markers, CD57, CD27 and PD-1 were associated with poorer patient prognosis. Since 
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these markers are enriched in the CLLIR, this could explain the initial observation of a 
relationship between CD4:CD8 ratio and patient clinical outcome (Nunes et al. 2012). In 
addition, multivariate analysis highlighted the role of CD4 (CD4+CD27-PD-1+LAG3+) and 
and CD8 (CD8+CD27-CD57+PD-1+) T-cell subset phenotypes in influencing patient 
progression.  
It is not yet clear whether these specific T-cell populations contribute to “immune 
dysfunction/poor immune surveillance” and/or supporting CLL cell growth. These 
observations could also have implications for selecting the appropriate patients for 
immunotherapy. For example CLLIR patients might exhibit increased hallmarks of T-cell 
dysfunction, which could limit the efficacy of adoptive T-cell therapies. Additionally, this 
could affect the capacity of vaccines to activate T-cell effectors against CLL. Alternatively, 
vaccines might be very effective at expanding the “undesirable” T-cell populations and 
thereby drive CLL growth and disease progression.  
In an attempt to further evaluate the differences between these two patient groups 
(CLLIR and CLLNR) the expression of a subset of genes involved with T-cell activation and 
anergy was investigated in Chapter 5. Previous transcriptional analysis of T-cells from CLL 
patients indicated dysregulation of genes involved in processes associated with T-cells 
survival, proliferative potential, intracellular signalling and effector function (Göthert et al. 
2013; Kiaii et al. 2013; Görgün et al. 2005; Görgün et al. 2009). However, in each of these 
studies CLL patients were compared to healthy controls and differences between specific 
subsets of patients were not evaluated.  
This analysis indicated that CLLNR patients exhibited relatively lower expression of 
genes associated with T-cell activation and effector functions, when compared to CLLIR 
patients in both the CD4+ and CD8+ T-cell compartments. This initial evaluation might 
suggest that T-cells from CLLNR exhibit relative defects in processes involved with 
activation and functionality when compared to CLLIR. However, because of the 
comparative nature of the analysis, it is conceivable that certain differences could be due to 
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increased gene transcription within the CLLIR patient group. Comparison with healthy 
aged-matched controls could assist in resolving this matter.  
Transcriptional analysis of the T-cell memory subsets of healthy individuals have 
shown that the EM and EMRA populations exhibit higher expression of genes associated 
with T-cell cytotoxicity such as Granzyme B, perforin and Fas ligand as well as 
transcription factors such as NFAT, when compared to naïve T-cells (Willinger et al. 2005). 
Therefore the enrichment of EMRA T-cells within the CD8+ compartment of CLLIR 
patients could explain the differential expression of genes related to cytotoxicity. 
Additionally, comparison between PD-1hi and PD-1lo T-cells from healthy individuals 
showed an up-regulation in co-stimulatory ligands such as CD27 and CD28, as well as 
molecules involved in effector functions, cell signalling and proliferation, with PD-1hi T-
cells (Duraiswamy et al. 2011). Therefore it could be inferred that the differential 
expression of genes within the CD4+ T-cell compartment of CLLIR and CLLNR patients 
could, in part, be explained by differences in the distribution of PD-1+ T-cells.  
While both of these studies may suggest some mechanisms behind the 
transcriptional differences between CLLIR and CLLNR patients, they were both performed 
using T-cells from healthy individuals, which were not derived from individuals suffering 
with the high tumour burden and altered microenvironment often observed within CLL. 
This analysis, while being preliminary and in need of validation, has highlighted 
potential differences at the transcriptional level between the CLLIR and CLLNR patients. 
The implication of these differences remains uncertain but indicate the potential for the 
further evaluation of the transcriptional profiles of T-cell populations with different CLL 
subsets.  
In conclusion, three different approaches have been utilised to investigate the 
positive and negative roles of T-cells in CLL. Methodologies developed in Chapter 3 
demonstrated the feasibility of isolating and expanding T-cell clones from CLL patients. 
Flow cytometry investigations in Chapter 4 highlighted numerous phenotypic differences 
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between CLLIR and CLLNR patients and the clinical relevance of specific T-cell populations. 
Furthermore, the preliminary transcriptional analysis in Chapter 5 emphasised further 
differences between CLLIR and CLLNR patients at the level of gene expression. Therefore, it 
is clear that further analysis of T-cell subset composition and function is warranted in this 
disease, specifically between different patient subsets. 
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Appendix 
Appendix 1. Characteristics of the CLL patients 
Factor Subset Number % 
Median age  72  
Range  43 - 94  
Stage A 75 77 
B 6 6 
C 3 3 
Unknown 13 14 
CD38 < 20% 35 36 
> 20% 20 21 
Unknown 42 43 
LDT < 12 months 7 7 
> 12 months 52 54 
Unknown 38 39 
 
Appendix 2. Characteristics of the age-matched controls 
Factor Subset Number % 
Median age  68  
Range  58 - 83  
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Appendix 3. Investigating to the relationship between the CD4:CD8 ratio and CMV serostatus. 
 
 
Serostatus was determined by the Public Health Wales Microbiology Lab, UHW, Cardiff. 
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Appendix 4. The effect of CMV serostatus on the expression of (A)CD27 and (B)CD57 within the 
CD4+ and CD8+ T-cell compartments. 
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Appendix 5. The effect of CMV serostatus on the expression of (A)PD-1, (B)TIM-3 and (C)LAG-3 
within the CD4+ and CD8+ T-cell compartments. 
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Appendix 6. CD4+ T-cell activation array housekeeping gene expression 
 
CD4+ T-cell activation array 
Symbol Patient groups Mean STDEV 
CLLNR CLLNR CLLIR CLLIR CLLIR CLLIR 
ACTB 23.60 27.43 28.05 24.64 23.88 29.69 26.21 2.52 
B2M 22.68 28.09 27.56 24.35 24.91 28.71 26.05 2.41 
GAPDH 29.60 33.57 33.01 30.69 28.62 33.31 31.47 2.12 
HPRT1 29.71 31.88 31.57 30.25 32.34 35.39 31.86 2.00 
RPLP0 23.20 24.63 27.15 24.62 24.53 28.94 25.51 2.11 
 
Appendix 7. CD4+ T-cell anergy array housekeeping gene expression 
 
  CD4+ T-cell anergy array  
Symbol Patient groups Mean STDEV 
CLLNR CLLNR CLLIR CLLIR CLLIR CLLIR 
ACTB 24.18 27.74 27.58 24.77 28.31 31.29 27.31 2.58 
B2M 23.51 25.80 27.92 24.05 27.64 28.80 26.29 2.18 
GAPDH 32.33 31.37 31.27 29.21 30.72 32.81 31.28 1.27 
HPRT1 22.87 31.74 30.20 29.65 31.47 33.75 29.95 3.75 
RPLP0 22.39 25.35 26.50 23.53 25.51 28.27 25.26 2.09 
 
Appendix 8. CD8+ T-cell Activation array housekeeping gene expression 
 
CD8+ T-cell activation array 
Symbol Patient groups Mean STDEV 
CLLNR CLLNR CLLIR CLLIR CLLIR CLLIR CLLIR 
ACTB 23.52 25.83 25.84 20.94 21.95 23.57 24.41 23.72 1.84 
B2M 20.95 25.39 24.02 20.16 20.82 23.14 23.01 22.50 1.92 
GAPDH 26.48 30.18 30.12 25.96 25.87 28.84 30.39 28.26 2.09 
HPRT1 31.69 32.72 30.22 29.71 29.63 29.43 31.79 30.74 1.30 
RPLP0 22.86 24.60 24.17 21.92 22.36 24.33 24.29 23.50 1.09 
 
Appendix 9. CD8+ T-cell anergy array housekeeping gene expression 
 
CD8+ T-cell anergy array 
Symbol Patient groups Mean STDEV 
CLLNR CLLNR CLLIR CLLIR CLLIR CLLIR CLLIR 
ACTB 22.74 26.17 22.73 21.79 21.63 23.94 24.65 23.38 1.64 
B2M 21.18 23.78 23.67 20.81 20.58 22.58 22.24 22.12 1.31 
GAPDH 27.23 29.11 26.29 25.75 24.99 28.19 27.84 27.06 1.45 
HPRT1 29.58 31.23 29.60 29.20 28.01 28.08 28.50 29.17 1.12 
RPLP0 21.77 24.28 23.24 22.12 22.33 23.96 24.57 23.18 1.12 
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Appendix 10. Genes from the T-cell activation array that exhibited a fold change of >2 within the 
CD4+ T-cells of CLLNR patients relative to CLLIR patients. 
 
Up-Down Regulation (CLLNR compared to CLLIR) 
Symbol Fold Regulation 
IL3 -12.03 
CD40 -10.41 
AICDA -8.19 
CXCR3 -7.54 
CCR1 -7.53 
IL15 -7.07 
IL5 -6.90 
FASLG -6.67 
IL12B -6.49 
EGR1 -6.06 
IL6 -6.01 
IL18 -5.98 
CCR2 -5.79 
IL12A -5.36 
IL12RB1 -5.21 
ICOSLG -5.13 
CX3CL1 -5.08 
TLR6 -5.08 
CD40LG -4.68 
CD1D -4.44 
SOCS1 -4.37 
BLNK -4.34 
TLR4 -4.33 
CD86 -4.28 
APC -4.13 
BCL2 -4.00 
CCR3 -3.96 
IL1B -3.93 
MICB -3.70 
CD8A -3.68 
IRF4 -3.59 
IL13 -3.53 
LCK -3.49 
CD4 -3.41 
IL7 -3.38 
TLR1 -3.34 
IL4R -3.31 
CD80 -3.30 
LAG3 -3.30 
VAV1 -3.28 
CD7 -3.25 
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IL2RA -3.21 
FOXP3 -2.98 
CD274 -2.74 
NOS2 -2.73 
DPP4 -2.70 
MS4A1 -2.70 
IL18R1 -2.68 
BLM -2.63 
TLR9 -2.62 
TNFSF14 -2.47 
CD28 -2.37 
IL10 -2.36 
RIPK2 -2.35 
PTPRC -2.31 
CD81 -2.28 
TGFB1 -2.25 
CD27 -2.20 
CCL3 -2.09 
CSF2 -2.06 
IL2 -2.05 
 
Appendix 11. Genes from the T-cell anergy array that exhibited a fold change of >2 within the CD4+ 
T-cells of CLLNR patients relative to CLLIR patients. 
 
Up-Down Regulation (CLLNR compared to CLLIR) 
Symbol Fold Regulation 
CD70 -8.6566 
CD28 -8.5031 
PRKCG -7.9809 
GZMB -7.8891 
SELL -6.6714 
FOXP2 -6.1278 
FOS -5.7917 
TNFRSF18 -5.7536 
IL2RB -5.4541 
LEP -5.233 
TNFSF8 -5.2107 
ING4 -5.1693 
TNFRSF8 -4.9921 
STAT3 -4.9491 
PDCD1 -4.6006 
IL1A -4.5105 
BTLA -4.1722 
IL17A -4.0163 
IL13 -3.924 
CCR4 -3.8869 
FOXP3 -3.7853 
MEF2A -3.3945 
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IL7R -3.3445 
HDAC9 -3.1982 
EGR3 -3.1057 
CD40LG -3.0293 
TNFRSF14 -3.0291 
LGALS3 -3.026 
CSF2 -3.0024 
IRF4 -2.8674 
TNFSF10 -2.845 
DGKZ -2.7963 
IL6 -2.7139 
DGKA -2.6822 
IL10 -2.5786 
IL31 -2.5392 
LTA -2.5258 
JUN -2.5224 
LAT -2.4571 
IL5 -2.4005 
IL2 -2.333 
CD40 -2.2783 
CDK2 -2.0705 
IFNG +2.2466 
FASLG +2.2556 
EOMES +2.3681 
PTGER2 +2.3687 
ICOS +2.412 
ITGA1 +3.1281 
IL15 +4.37 
 
Appendix 12. Genes from the T-cell activation array that exhibited a fold change of >2 within the 
CD8+ T-cells of CLLNR patients relative to CLLIR patients. 
 
Up-Down Regulation (CLLNR compared to CLLIR) 
Symbol Fold Regulation 
TLR4 -349.22 
TLR6 -78.14 
EGR1 -17.88 
IL4 -15.93 
CSF2 -13.59 
IL11 -11.04 
TLR9 -9.81 
IL12B -9.68 
TNFSF14 -8.34 
IL8 -7.96 
FASLG -7.28 
RAG1 -5.93 
IL6 -5.66 
NOS2 -5.35 
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CCR5 -5.05 
IL10 -5.00 
IL18R1 -4.60 
CD27 -4.36 
IL13 -4.23 
SOCS1 -4.13 
MAP3K7 -4.11 
CD2 -4.05 
IL3 -4.01 
PTPRC -3.70 
IL18 -3.68 
LAG3 -3.66 
CD4 -3.63 
TLR1 -3.62 
BLM -3.41 
IRF4 -3.33 
CXCR3 -3.32 
IL2 -3.23 
LCK -3.10 
MICB -3.07 
VAV1 -3.03 
CD40 -3.03 
IL7 -2.86 
CD8A -2.82 
CD81 -2.76 
IL5 -2.68 
CD3E -2.67 
CD274 -2.66 
IL15 -2.53 
TGFB1 -2.39 
CCR3 -2.32 
CCR4 -2.30 
ICOSLG -2.23 
CD5 -2.05 
TLR2 -2.04 
 
Appendix 13. Genes from the T-cell anergy array that exhibited a fold change of >2 within the CD8+ 
T-cells of CLLNR patients relative to CLLIR patients. 
 
Up-Down Regulation (CLLNR compared to CLLIR) 
Symbol Fold Regulation 
IL13 -9.04 
ITGA1 -6.27 
CD27 -5.41 
LEP -4.93 
PRF1 -4.84 
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STAT6 -4.70 
CD40 -4.56 
CD28 -4.52 
IL4 -4.48 
CD70 -4.27 
NFATC2 -4.24 
TBX21 -4.03 
ITCH -3.95 
NFKB1 -3.93 
IL2RB -3.86 
IL7R -3.80 
TNFRSF10A -3.78 
NHLH2 -3.78 
SELL -3.68 
BTLA -3.65 
TNFSF10 -3.65 
EOMES -3.56 
DGKZ -3.51 
IL1A -3.50 
CDK4 -3.49 
TNFRSF8 -3.48 
IL2 -3.46 
IL17A -3.43 
PDCD1 -3.34 
ICAM1 -3.33 
CDK2 -3.28 
JAK3 -3.24 
FASLG -3.23 
TNFRSF4 -3.21 
FOXP2 -3.13 
TNFSF8 -3.12 
NOTCH1 -3.09 
JAK1 -3.04 
TNFRSF18 -3.04 
PTGER2 -3.02 
HDAC9 -3.01 
IL31 -2.93 
TNFRSF9 -2.89 
ING4 -2.88 
IRF4 -2.83 
IL10 -2.75 
IL10RA -2.74 
TNFRSF14 -2.72 
IL15 -2.70 
NFATC1 -2.65 
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IL6 -2.64 
EGR2 -2.62 
CSF2 -2.61 
NFATC3 -2.60 
LAT -2.58 
CD40LG -2.57 
TGFB1 -2.56 
PRKCG -2.40 
IL5 -2.34 
GZMB -2.33 
RNF128 -2.30 
FOXP1 -2.28 
TNFSF14 -2.28 
DGKA -2.25 
LTA -2.24 
EGR3 -2.21 
CSF1 -2.17 
CTLA4 -2.17 
STAT3 -2.02 
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Summary
We set out to clone Bax-specific CD8+ T cells from peripheral blood sam-
ples of patients with primary chronic lymphocytic leukaemia. A number
of clones were generated using a Bax peptide pool and their T-cell epitope
was mapped to two peptides sharing a common 9-amino-acid sequence
(LLSYFGTPT), restricted by HLA-A*0201. However, when these T-cell
clones were tested against highly purified syntheses (> 95%) of the same
peptide sequence, there was no functional response. Subsequent mass
spectrometric analysis and HPLC fractionation suggested that the active
component in the original crude peptide preparations (77% pure) was a
peptide with a tert-butyl (tBu) modification of the tyrosine residue. This
was confirmed by modification of the inactive wild-type sequence to gen-
erate functionally active peptides. Computer modelling of peptide:HLA-
A*0201 structures predicted that the tBu modification would not affect
interactions between peptide residues and the HLA binding site. However,
these models did predict that the tBu modification of tyrosine would
result in an extension of the side chain out of the peptide-binding groove
up towards the T-cell receptor. This modified product formed < 1% of
the original P603 crude peptide preparation and < 0!05% of the origi-
nal 23-peptide mixture used for T-cell stimulation. The data presented
here, illustrate the potential for chemical modifications to change the
immunogenicity of synthetic peptides, and highlight the exquisite capacity
of T-cell receptors to discriminate between structurally similar peptide
sequences. Furthermore, this study highlights potential pitfalls associated
with the use of synthetic peptides for the monitoring and modulating of
human immune responses.
Keywords: CD8+ T cells; mass spectrometry; peptides.
Introduction
Synthetic peptides containing immunogenic T-cell epi-
topes have been widely used in various aspects of immu-
notherapy from adoptive cell transfer1 to peptide
vaccination.2 This approach provides a cost effective and
reliable source of antigens that can be synthesized to suit-
able quantities and purity grades. This process eliminates
the introduction of potential virulence factors, which may
occur with the use of recombinant viral vaccines. Further-
more, the nature of the chemical synthesis process allows
for peptides to be modified to exacting specifications that
can enhance their MHC binding capacity, their in vivo
stability3 and ultimately their immunogenicity.2,4
Historically mixtures of synthetic peptides containing
multiple epitopes originating from specific proteins have
been used to measure human memory T-cell responses
against viruses such as human cytomegalovirus,5 Epstein–
Barr virus6 and human papillomavirus.7 Through the use
of smaller and more refined peptide mixtures it is possi-
ble to map the precise epitope specificity of individual T-
cell clones.8 Such epitopes can then be incorporated into
tetramer reagents to allow direct ex vivo measurement of
memory T cells in response to natural infection or vacci-
nation.9
In a previous study, we used pooled synthetic peptide
mixtures as immunogens to generate human T cells
(from healthy donors) against candidate tumour antigens
ª 2014 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology, 144, 495–505 495
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in vitro. This approach allowed us to test the concept that
Bax, a pro-apoptotic protein that is abnormally degraded
in human cancers, can generate T cells with activity
against primary human cancer cells.8
In the current study, we used the same approach, but
using blood from patients with chronic lymphocytic leu-
kaemia (CLL) in an attempt to generate Bax-specific T-
cell clones. We used a combined immunological (for the
assessment of T-cell function and response) and physico-
chemical (for the identification and characterization of
peptides) approach to map a human CD8+ T-cell clone
specificity to a novel synthetic epitope. This finding high-
lights the immunogenicity of chemically modified pep-
tides and has implications for the use of synthetic
peptides to generate tumour-specific T cells.
Materials and methods
Blood samples
Healthy volunteer blood samples were collected locally
and CLL samples were derived from clinics at the Univer-
sity Hospital of Wales and Llandough Hospital. All sam-
ples were collected with informed consent with ethical
approval [South East Wales Research Ethics Committee
(02/4806)]. Peripheral blood mononuclear cells were iso-
lated by Histopaque-1077 (Sigma-Aldrich, Poole, UK)
centrifugation, as previously described.10
Induction of Bax-specific T cells
CD8+ T cells were immunomagnetically enriched from
peripheral blood mononuclear cells using anti-human
CD8 microbeads according to the manufacturer’s instruc-
tions (Miltenyi Biotec, Woking, UK). After enrichment,
the T cells were cultured at 37°/5% CO2 for 48 hr in AB-
RPMI medium supplemented with interleukin-7 (IL-7;
10 ng/ml; Peprotech, London, UK) to allow for the activa-
tion of autologous CLL cells to be used as a source of anti-
gen-presenting cells. AB-RPMI consisted of RPMI-1640
(Sigma-Aldrich) supplemented with 5% human AB serum,
glutamine (2 mmol/l), streptomycin (100 lg/ml), penicil-
lin (100 U/ml), HEPES (25 mmol/l) (all sourced from Life
Technologies, Paisley, UK). After 48 hr the T cells were
harvested, washed and cultured in the presence of irradi-
ated activated autologous CLL cells at a 4 : 1 ratio in AB-
RPMI supplemented with Bax peptide pool (10 lg/ml; Mi-
motopes, Clayton, Victoria, Australia)8 and IL-2 (40 U/ml;
Proleukin, Novartis, Frimley, UK). After 3 days, 500 ll of
AB-RPMI supplemented with IL-2 (120 U/ml) and IL-7
(30 ng/ml) was added. The cultures were re-stimulated
weekly with the peptide pool and autologous activated
CLL cells. On day 35 the T cells were harvested and Bax
peptide immunogenicity was tested by ELISpot assay.
Isolation and cloning of peptide-specific T cells
Peptide specific interferon-c (IFN-c) production was
induced after culturing the polyclonal T cells with the
Bax peptide pool (10 lg/ml) presented on autologous
activated CLL cells for 5 hr at 37°/5% CO2. Interferon-c
secreting T cells were immunomagnetically enriched using
anti-human IFN-c beads according to the manufacturer’s
protocol (Miltenyi Biotec). The isolated T cells were
‘rested’ overnight in AB-RPMI supplemented in IL-2
(40 U/ml) and IL-7 (10 ng/ml) before cloning by limiting
dilution as previously described.8
Measurement of IFN-c release
For IFN-c ELISA, T cells (1 9 105) were cultured in
200 µl of AB-RPMI at a 1 : 1 ratio with peptide-pulsed
T2 cells for 18 hr in U-bottomed tissue culture plates. T
cells were also cultured with unpulsed T2 cells (negative
control) or mitogen (positive control – phytohaemagglu-
tinin, 10 µg/ml, P1585 – Sigma Aldrich). Cell-free super-
natants were harvested and analysed by ELISA for human
IFN-c (Human IFN-c ELISAPRO kit; Mabtech, Nacka
Strand, Sweden).
Interferon-c ELISpots were performed as previously
described.7 Briefly, T cells were plated in triplicate at
1 9 105 (initial screen) or 1 9 104 to 3 9 104 cells
(clones/lines) per well in MultiScreen HTS IP Filter Plates
(Millipore, Watford, UK). T cells were cultured at 1 : 1
ratio with T2 cells ! Bax peptides (10 lg/ml). T cells
were also incubated in the absence of T2 cells (negative
control) or with mitogen (positive control). The plates
were developed using the AP Conjugate substrate kit
(BioRad, Hemel Hempstead, UK). The numbers of spots/
well were counted with an ELISpot reader (AID, Oxford
Biosystems Cadama, Wheatley, Oxfordshire, UK). Specific
peptide responses were calculated by subtracting the back-
ground response (T cells + T2) from the T
cells + T2 + peptide wells.
For IFN-c ELISA intracellular cytokine staining, T
cells (1 9 105) were cultured in AB-RPMI at 1 : 1 ratio
with T2 cells ! peptide in the presence of GolgiStopTM
and GolgiPlugTM (BD, Oxford, UK). T cells were also
cultured in the presence of mitogen (positive control).
After 5 hr the cells were washed and co-stained with
anti-human CD3-FITC (Biolegend, London, UK – clone
UCHT1) and CD8-peridinin chlorophyll protein (Bioleg-
end – clone HIT8a). The cells were then fixed and per-
meabilized with LeucopermTM (AbD Serotec, Kidlington,
UK) and intracellular IFN-c was identified using anti-
human IFN-c-phycoerythrin (eBioscience, Hatfield,
UK – clone 4S.B3). The cells were analysed using an Ac-
curi C6 (BD) and data analysis was performed using
CFLOW software (BD).
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CD107a surface staining
T cells (1 9 105) were cultured in AB-RPMI at 1 : 1 ratio
with T2 cells ! peptide in the presence of GolgiStopTM
and GolgiPlugTM (BD). T cells were also cultured in the
presence of mitogen (positive control). Changes in the
surface expression of CD107a were determined through
the addition of anti-human CD107a-phycoerthrin (Bio-
legend – clone H4A3) to each culture. After 5 hr the cells
were washed and co-stained with anti-human CD3-FITC
(Biolegend – clone UCHT1) and CD8-peridinin chloro-
phyll protein (Biolegend – clone HIT8a). The cells were
analysed using an Accuri C6 (BD) and data analysis was
performed using CFLOW software (BD).
Peptides
Twenty-three candidate peptides were identified from the
amino acid sequence of Bax using predictive computer
algorithms for HLA binding, as previously described.8
Aliquots from these stock peptides were pooled (Bax pool
601–23) and stored at "80°. Smaller pools of five or six
peptides were made for epitope mapping. Highly purified
(> 95%) Bax P603 peptides were synthesized (ProIm-
mune, Oxford, UK and Peptide Synthetics, Bishops Wal-
tham, UK). Highly purified (> 98%) Bax P603 tBu
peptide was synthesized using t-butyl-modified tyrosine
(PolyPeptide Group, Strasbourg, France).
Peptide analysis
Liquid chromatography mass spectrometry (LCMS) was
performed on an Ultimate 3000 (Dionex, Sunnyvale, CA)
HPLC system interfaced to an amaZon SL ion trap spec-
trometer (Bruker, Billerica, MA). Chromatographic sepa-
ration was performed with a 100 9 2#1 mm Ace Excel 2
column at a flow rate of 0#5 ml/min, eluting with a bin-
ary gradient of acetonitrile/water (0#1% formic acid). The
column was equilibrated for 5 min with 5% acetonitrile,
followed by a linear gradient to 95% acetonitrile over
20 min. MS2 spectra were collected using collision-
induced dissociation with automatic or manual precursor
selection. Specific single amino acid deletion peptides
were identified using multiple reaction monitoring of
each of the corresponding [M + H]+ precursor ions.
Peptide library synthesis
Peptides were synthesized manually on Rink Amide meth-
ylbenzhydryl amine resin (Novabiochem, Watford, UK)
using standard fluorenylmethyloxycarbonyl (Fmoc) proto-
cols, as previously described.11 To prepare the libraries,
the resin was split into three 50 mg portions (1–3) and
single amino acid deletions were introduced into the C-
terminal residues (GTPT, portion 2) and the N-terminal
residues (LSYF, portion 3). After coupling of the
sequence LLSYFGTPT (portion 1), a 20 mg peptide-resin
sample was withdrawn and subjected to a further depro-
tection-coupling cycle with FmocLeu-OH to obtain
LLLSYFGTPT (portion 4).
Fractionation of peptide
Fractionation of LLSYFGTPT-NH2 (portion 1) was per-
formed by HPLC (Waters 2525 pump and 2996 detector;
Waters Corporation, Milford, MA) with a Vydac 218TP
250 9 22 mm column. Peptides were eluted with a bin-
ary gradient of 0 min 95% A/5% B, 1 min 95% A/5% B,
16 min 50% A/50% B where solvent A = H2O, 0#05% tri-
fluoroacetic acid (TFA) and solvent B = acetonitrile,
0#05% TFA at a flow rate of 22#9 ml/min. The principal
peak eluted at 11#5 min, with further peaks collected at
9#1, 9#4, 10#0, 10#4, 13#9, 14#4 and 15#3 min.
Modification of wild-type P603 peptide
An aliquot of P603 (Peptide Synthetics, 95% Pure) in
DMSO was added to diethyl ether and shaken vigorously
to precipitate the peptide. Subsequently the precipitated
peptide was recovered by centrifugation, washed with
diethyl ether and dried in vacuo. The peptide was treated
under different conditions to introduce tBu groups into
the wild-type (wt) peptide sequence.
Briefly, P603 peptide was added to a solution of di-tert-
butyl dicarbonate (12 mg) in CHCl3. The CHCl3 was evap-
orated by a stream of N2, then TFA (1 ml), triisopropylsi-
lane (25 µl) and water (25 µl) were added. After 1 hr, the
solution was concentrated by N2 blowing to approximately
50% of its original volume, then pipetted into diethyl ether
(14 ml). Precipitate was collected by centrifugation,
washed twice with diethyl ether and allowed to dry in air.
P603 was also dissolved in TFA (1 ml) and methylpro-
pene (Sigma-Aldrich) was bubbled through the solution
for 15 min. The solution was blown with a stream of N2
to evaporate volatile material and extracted with water
(14 ml). The aqueous extract was concentrated by rotary
evaporation then lyophilized.
MHC:peptide model preparation
The starting model was based on entry 4I4W12 from the
Protein Data Bank (http://www.rcsb.org). COOT13 was
used to modify the sequence of the peptide to be
LLSYFGTPT. The conformation of the peptide was
restricted to be as close as possible to that in 4I4W. For
the purpose of the present work, this model was referred
to as ‘wild type’, or wt. Y4 of the peptide was modified
by adding a tBu group at the meta position of the aro-
matic ring of the tyrosine side-chain. As this ring can
rotate between two positions around the v2 dihedral, two
ª 2014 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology, 144, 495–505 497
T-cell epitope formed by tBu modification
possible conformations need to be considered (Fig. 6).
The geometry of the Tyr(3-tBu) was regularized by apply-
ing the geometry restraints generated with JLIGAND.14
PYMOL was used to generate the graphical representa-
tions in Fig. 7.
Results
Detection and isolation of Bax peptide-specific T cells
Our original aim was to isolate from patients with CLL
CD8+ T-cell clones specific for peptides derived from the
pro-apoptotic protein, Bax. Subsequently a Bax peptide
pool (P601–623) was used to stimulate CD8+ T cells isolated
from HLA-A*0201+ patients and Bax immunogenicity was
assessed by IFN-c ELISpot. After 5 weeks of peptide stimula-
tion a highly significant (P = 0!0008) Bax-specific response
was observed from patient R6A8R89 (Fig. 1a).
Bax-specific CD8+ T cells were immunomagnetically
enriched on the basis of IFN-c secretion and cloned by
limiting dilution. Six lines (6C2, 6E2, 6C5, 8C9, 7F7 and
9D7) exhibited positive Bax responses (> 20 spots/
3 9 104) and were selected for further characterization
(Fig. 1b). The putative T-cell clones were first tested
against the full peptide pool to reaffirm Bax specificity;
then against four smaller sub pools (Bax P601–606, Bax
P607–612, Bax P613–618 and Bax P619–623) to narrow
down the response, followed by individual peptides for
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Figure 1. T-cell responses against Bax peptides and mapping the specificity of the CD8+ T-cell clone 6C5. (a) Purified CD8+ T cells were cul-
tured with irradiated autologous activated B-CLL cells and Bax peptides 601–23 for 5 weeks before testing by interferon-c (IFN-c) ELISpot. Anti-
gen-presenting cells (APC) were autologous activation B-CLL cells. Numbers shown are spots/105 T cells (mean of triplicates " SD, n = 1)
Statistical analysis (unpaired two-tailed t-test) was carried out using GRAPHPAD PRISM (GraphPad Software, Inc., La Jolla, CA). (b) T-cell cultures
generated by limited dilution were tested for the recognition of Bax peptides 601–23 by IFN-c ELISpot. T cells were plated (~2 9 104 to
3 9 104/well) with APC or with APC + peptides at a 1 : 1 ratio. APC were T2 cells. Background responses (T cells + T2) were subtracted from
the data (n = 1). (c) 6C5 was tested by IFN-c ELISpot against the Bax peptide pool 601–23, split pools, and individual peptides. T cells were pla-
ted (1 9 104/well) in triplicate with T2 or T2 + peptides at a 1 : 1 ratio. Background response (T cells + T2) was subtracted from the data (5
SFC/104 cells) (mean " SD of triplicates, n = 2). (d) 6C5 was assayed against T2 cells pulsed with varying concentrations (20–6!25 lg/ml) of
Bax P603 and Bax P605 at 1 : 1 ratio for 18 hr. Cell-free supernatants were harvested and tested for the presence of IFN-c by ELISA. The EC50
value was calculated using the fitted curve, P603 – 4!92 µM and P605 > 100 µM (mean " SD of duplicates, n = 3).
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epitope identification (Fig. 1c). T-cell clones 6C5 and
8C9 both exhibited positive responses against the full
Bax peptide pool and the sub-pool Bax P601–606. Of the
peptides within the Bax P601–606 pool, only P603 and
P605 induced an ELISpot response (Fig. 1c). Interest-
ingly, these two peptides shared an overlapping nine
amino acid sequence: Bax P603 is a 9mer (Bax161–169;
LLSYFGTPT) and Bax P605 is a 10mer (Bax160–169;
GLLSYFGTPT). T-cell receptor (TCR) Vb chain staining
was performed and indicated the presence of a single Vb
chain (Vb 13.1) in both lines, indicating clonality (data
not shown). Of the two clones identified, 6C5 was
selected for further characterization because of its supe-
rior growth kinetics.
Peptide dose–response experiments confirmed that 6C5
recognized both peptides (P603 and P605) but had a
greater avidity for P603 as determined by comparison of
the EC50 values, P603 = 4!92 lM and P605 > 100 lM
(Fig. 1d).
6C5 recognized crude but not highly purified P603
peptide
The initial results suggested that the T-cell clone 6C5
recognized the nine amino acid sequence (LLSYFGTPT)
common to P603 and P605 (Fig. 1c,d). As neither peptide
preparation was 100% pure it was possible that the
activation of 6C5 was associated with other peptide
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Figure 2. 6C5 recognition of crude P603 but not highly purified P603. Representative sample of flow cytometry analysis (three independent
experiments) of intracellular staining of interferon-c (IFN-c). T cells (1 9 105/tube) were cultured in the presence of T2 or T2 + Bax peptide
P603 (> 95% Pure, 10 lg/ml) or P603 (77% Pure, 10 lg/ml) at a 1 : 1 ratio for 5 hr. Lymphocytes were gated based on their forward and side
scatter profile and then doublet exclusion was performed based on forward scatter height versus forward scatter width. T cells were then gated
on CD3+ CD8+ cells and IFN-c production was assessed through intracellular staining with anti-IFN-c (mean " SD of duplicates, n = 3). Statis-
tical analysis (unpaired two-tailed t-test) was carried out using GRAPHPAD PRISM.
Table 1. Comparison of purified and crude P603 peptide samples by liquid chromatography mass spectrometry
Peptide r.t. (min) Transition Crude P603 Purified P603
LLSYGTPT 5!5 851!5 ? 617!3 (b6#H2O) U U
LSYFGTPT 6!3 885!4 ? 651!3 (b6#H2O) U U
LLSFGTPT 6!8 835!5 ? 601!3 (b6#H2O) U U
LLSYFGTT 7!0 901!5 ? 764!4 (b7#H2O) U U
LLSYFGTPT 7!1 998!5 ? 764!4 (b7#H2O) U U
LLSYFTPT 7!1 941!5 ? 707!4 (b6#H2O) ✗ U
LLSYFGTP 7!2 897!5 ? 764!4 (b7#H2O) U ✗
LLYFGTPT 7!4 911!5 ? 677!4 (b6#H2O) U U
LLLSYFGTPT 8!0 1111!6 ? 877!5 (b8#H2O) U ✗
LLSY(3-tBu)FGTPT 9!3 1054!6 ? 820!5 (b7#H2O) U ✗
Chromatography was performed on an Ace Excel 2 100 9 2!1 mm column (C18), eluting with a linear gradient of 5–95% acetonitrile (0!1% for-
mic acid) at 0!5 ml/min over 20 min. MS/MS spectra were measured on a Bruker amaZon SL ion trap spectrometer. The sequence and retention
times of each of the peptides identified are indicated. The presence (U) or absence (✗) of the peptides in each sample was assessed using
extracted ion chromatograms for the indicated transition.
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species (8mers, 10mers and modified 9mers). Therefore
6C5 was tested against highly purified P603 peptides
(> 95% pure) obtained from two independent commer-
cial sources (Proimmune and Peptide Synthetics). 6C5
failed to respond to the purified forms of P603 (95%
pure), however the original P603 preparation (77% pure)
induced a robust and highly significant (P < 0!0001)
IFN-c response (Fig. 2). These results suggested that the
immunogenicity associated with the original P603 (77%
pure) was not a result of the peptide sequence
(LLSYFGTPT).
Comparison of crude and highly purified P603
Samples of crude and purified P603 peptide were analy-
sed by ion trap LCMS (see Supporting information, Fig.
S1). The samples were investigated for the presence of
8mers, 10mers and modified 9mers (Table 1). Peaks cor-
responding to DF, DL, DY, DP, DT, DS 8mer peptides
were observed in both the crude and purified samples.
Fragmentation spectra of an ion of m/z 1111!6 and the
corresponding doubly charged ion were consistent with a
peptide carrying an additional N-terminal leucine residue,
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Figure 3. 6C5 recognizes a peptide present in fraction 8. (a) CD8+ T-cell clone 6C5 was cultured in the presences of various peptide preparations
representative of potential C-terminal (GTPT) and N-terminal (LSYF) deletions, as well as C-terminal additions. T cells (1 9 105/tube) were cul-
tured in the presence of T2 or T2 + peptides at a 1 : 1 ratio for 5 hr. Interferon-c (IFN-c) production was assessed through intracellular staining
with anti-IFN-c. To facilitate gating, the cultures were also co-stained with anti-CD3 and anti-CD8. Background (T-cells + T2) were subtracted
from the data (mean " SD, n = 3). (b) Fractionation was performed by HPLC (Waters 2525 pump and 2996 detector) with a Vydac 218TP
250 9 22 mm column. Peptides were eluted with a binary gradient of 0 min 95% A, 1 min 95% A, 16 min 50% A where solvent A = H2O,
0!05% trifluoroacetic acid (TFA) and solvent B = acetonitrile, 0!05% TFA at a flow rate of 22!9 ml/min. The chromatogram shows the absor-
bance at 220 nm. (c) CD8+ T-cell clone 6C5 was cultured in the presence of fractions (F1–F8) generated from the fractionation of the P1 peptide
preparation (crude full length 9mer, LLYSFGTPT). T cells (1 9 105/tube) were cultured in the presence of T2 or T2 + peptides at a 1 : 1 ratio
for 5 hr. Lymphocytes were gated based on their forward and side scatter profile and then doublet exclusion was performed based on forward
scatter height versus forward scatter width. T cells were then gated on CD3+ CD8+ cells and IFN-c production was assessed through intracellular
staining with anti-IFN-c. Background (T-cells + T2) was subtracted from the data (mean " SD, n = 3). Statistical analysis (unpaired two-tailed
t-test, in comparison to P603 > 95% Pure) was carried out using GRAPHPAD PRISM. Significance is indicated by ****< 0!0001, ***0!0001–0!001,
**0!001–0!01 and *0!01–0!05.
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LLLSYFGTPT. An ion of m/z 1054!6 was assigned as a
reaction product of the tyrosine side chain with tertiary
butyl cations liberated during the final deprotection and
cleavage of the peptide.
Identification of the immunogenic component of
crude P603
Based on the earlier observations, the activity of 8mer
and 10mer peptides was investigated by deliberate synthe-
sis of a small library of crude peptides. The library con-
sisted of four peptide preparations: (i) full length 9mer
(LLYSFGTPT); (ii) enhanced deletions of the C-terminal
residues (G/T/P/T); (iii) enhanced deletions of the N-ter-
minal residues (L/S/Y/F); (iv) 10mer (LLLSYFGTPT,
additional N-terminal leucine). All four peptide prepara-
tions induced similar levels of IFN-c secretion, suggesting
that neither a deletion peptide nor the 10mer in isolation
were responsible for 6C5 activation (Fig. 3a). These
results suggested a peptide entity common to all four
preparations and the original crude P603 synthesis.
The portion 1 preparation (crude full-length 9mer,
LLYSFGTPT) was fractionated by reverse phase HPLC,
with fraction collection guided by UV absorbance
(Fig. 3b). Individual fractions were collected, lyophilized
and assayed to determine their capacity to induce T-cell
activation. Activity was shown to be associated with a frac-
tion eluting at longer retention time than the principal
component (LLSYFGTPT) of the crude peptide prepara-
tion (Fig. 3c). LCMS analysis of the active fraction
revealed a peptide with m/z 1053!6 that exhibited an essen-
tially identical fragmentation pattern to the species pro-
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were gated based on their forward and side scatter profile and then doublet exclusion was performed based on forward scatter height versus for-
ward scatter width. T cells were then gated on CD3+ CD8+ cells and IFN-c production was assessed through intracellular staining with anti-IFN-
c. Background (T-cells + T2) were subtracted from the data (mean " SD, n = 3). Statistical analysis (unpaired two-tailed t-test, in comparison
to P603 > 95% Pure) was carried out using GRAPHPAD PRISM. Significance was indicated by ****< 0!0001.
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posed to contain Tyr(3-tBu), that was identified in the
crude P603 (see Supporting information, Fig. S1). The dif-
ference in m/z between the two species can be accounted
for by the differences in C-termini of the peptides, amide
versus acid, which arises due to the chemistry of the Rink
resin used for preparation of the peptide library.
Modification of P603
To investigate whether a peptide species containing Tyr
(3-tBu) was responsible for the observed T-cell activation,
the inactive wt P603 (95% pure) preparation was sub-
jected to conditions intended to generate tBu cations. It
was predicted that this treatment would re-introduce the
alkylated side products and confer activity to a previously
inactive wt sequence. Two peptide samples were treated
under different conditions, methylpropene with TFA and
di-tert-butyl dicarbonate with TFA, to mimic the final
step of peptide synthesis (Fig. 4a). Analysis of the reac-
tion products by HPLC and LCMS demonstrated the
introduction of peptides carrying the Tyr(3-tBu). This
was visible in both samples, and displayed the same
retention time and MS2 spectrum as the species observed
in the crude P603 (see Supporting information, Fig. S2).
Both of the Tyr(3-tBu) modified preparations were able
to induce IFN-c secretion; strongly suggesting that a Tyr
(3-tBu) modified peptide was responsible for the activity
(Fig. 4b).
P603 Tyr(3-tBu) stimulates the activation of 6C5
To confirm P603 Tyr(3-tBu) was responsible for the acti-
vation of 6C5, a highly purified (> 98%) peptide prepara-
tion was obtained from a commercial supplier
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Figure 5. Activation of 6C5 is induced by tBu P603. (a) and (b) Representative sample of flow cytometry analysis (three independent experi-
ments) of intracellular staining of interferon-c (IFN-c) and surface staining of CD107a, respectively. T cells (1 9 105/tube) were cultured in the
presence of T2 or T2 + P603 (> 95% Pure, 10 lg/ml), P603 (77% Pure, 10 lg/ml) or P603 tBu (> 98% Pure, 10 lg/ml) at a 1 : 1 ratio for 5 hr.
IFN-c production was assessed through intracellular staining with anti-IFN-c and CD107a expression through surface staining with anti-CD107a.
To facilitate gating, the cultures were also co-stained with anti-CD3 and anti-CD8 (mean ! SD of duplicates, n = 3). Statistical analysis
(unpaired two-tailed t-test) was carried out using GRAPHPAD PRISM. (c) 5 9 105 T2 cells were pulsed with varying concentrations of P603 (77%
Pure, 10 lg/ml to 1 9 10"6 lg/ml) and P603 tBu (> 98% Pure, 10 lg/ml to 1 9 10"6 lg/ml). After 1 hr, unbound peptide was washed off and
the pulsed T2 cells were cultured with 1 9 105 6C5 CD8+ T cells at a 1 : 1 ratio. Cell-free supernatant was harvested and tested for the presence
of IFN-c by ELISA (mean ! SD, n = 3). (d) 1 9 105 6C5 CD8+ T-cells were cultured at 1 : 1 ratio with T2 cells in the presence of varying con-
centrations of P603 (77% Pure, 10 lg/ml to 1 9 10"6 lg/ml) and P603 tBu (> 98% Pure, 10 lg/ml to 1 9 10"6 lg/ml) for 5 hr. Lymphocytes
were gated based on their forward and side scatter profile and then doublet exclusion was performed based on forward scatter height versus for-
ward scatter width. T cells were then gated on CD3+ CD8+ cells and changes in the surface expression of CD107a were determined through cul-
turing the cells in the presences of anti-CD107a (mean ! SD, n = 3). The EC50 value was calculated using the fitted curve using GRAPHPAD
PRISM.
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(PolyPeptide Group). This peptide was able to stimulate
robust and highly significant (P < 0!0001) IFN-c and
CD107a responses in 6C5. However, the unmodified wt
P603 (95% pure) failed to induce T-cell activation in the
same assays (Fig. 5a,b).
Peptide dose–response experiments were performed to
validate the activity of P603 Tyr(3-tBu) and to compare
the activity of this peptide against the original crude (77%
pure) P603 preparation. P603 Tyr(3-tBu) (> 98% pure)
was more potent than P603 (77% pure) as determined by
comparison of the calculated EC50 values (Fig. 5c,d).
Using IFN-c production as a functional read-out, the EC50
values were 0!2 lM for P603 Tyr(3-tBu) (> 98% pure) and
1!4 lM for P603 (77% pure). By contrast using CD107a
expression as a read-out, the EC50 values were 0!52 nM for
P603 Tyr(3-tBu) (> 98% pure) and 610 nM for P603
(77% pure). For both assays the highly purified P603 Tyr
(3-tBu) was recognized with greater activity (1–3 logs)
than the crude P603 (77% pure). These results would be
predicted, as the Tyr(3-tBu) modified form of the peptide
was found by HPLC to comprise < 1% of the crude P603
(77% pure) preparation.
Collectively these findings confirm that the activation
of 6C5 is due to the modified P603 [LLSY(3-tBu)FGTPT]
rather than the wt P603 peptide (LLSYFGTPT). Molecular
modelling of these two peptides indicates that the
presence of the Tyr(3-tBu) results in an extension of the
tyrosine side chain out of the MHC towards the TCR
(Fig. 7a,b). Using the model we have predicted that the
presence of the Tyr(3-tBu) could result in a peptide with
the capacity to adopt two different conformations, due to
the rotation of the aryl ring (Fig. 6b–d). As the presence
of the Tyr(3-tBu) does not appear to affect the peptide
conformation or the position of the MHC anchor residue,
we predict that the discrimination between the modified
and unmodified peptides occurs largely at the level of the
TCR. Peptide binding was assessed by the up-regulation
of HLA-A*0201 expression on T2 cells. Neither the modi-
fied or unmodified peptide were able to significantly up-
regulate HLA-A*0201 in comparison to the positive con-
trol MART1 peptide, suggesting poor or weak binding
under the conditions used (see Supporting information,
Fig. S3). Nevertheless, the results suggest that the modi-
fied peptide does not have better binding to HLA-A*0201
than the unmodified peptide. This supports our hypothe-
sis that the primary effect of the Tyr(3-tBu) modification
is to alter interactions with the TCR.
χ2
(d)(a)
(b)
(c)
OH
CO2H
NH2
Figure 6. Peptide:MHC modelling of unmodified and Tyr(3-tBu)
modified peptides. Computer models illustrating the conformation
of peptides bound to HLA-A*0201 were generated based on entry
4I4W from the PDB. The HLA-A*0201 structure has been removed
for clarity. COOT was used to modify the sequence of the peptide to
be LLSYFGTPT. (a) The resulting modified peptide is capable of
adopting two possible conformations (b) and (c) due to the rotation
of the aromatic ring about its axis (d).
(a)
(b)
Figure 7. Peptide:MHC modelling of unmodified and Tyr(3-tBu)
modified peptide bound to HLA-A*0201. Computer models of Pep-
tide:HLA*0201 complexes were generated using entry 4I4W from the
PDB. COOT was used to modify the sequence of the peptide to be
LLSYFGTPT. (a) and (b) show that for both peptides the anchor
residues at either end of the peptide are well buried in the groove.
However, the presence of the tBu-modified tyrosine results in the
extension of the side chain out of the MHC and towards the T-cell
receptor, which is not observed with the wild-type peptide.
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Discussion
Minor modifications of antigenic peptides have been
shown to have profound positive and negative effects on
peptide recognition. These modifications can vary from
naturally occurring post-translation modifications15 to
specific synthetic alterations of the peptide sequence and/
or individual amino acids.4,16 These changes can alter
MHC binding; the three-dimensional tertiary peptide
structure and the TCR contact residues of the peptides,
and so alter peptide immunogenicity.
We describe the novel discovery of a human CD8+ T-
cell clone that recognizes a tBu-modified peptide LLSY(3-
tBu)FGTPT while showing no recognition of the wt pep-
tide LLSYFGTPT. This modification appears to have no
effect on the potential structure of the MHC:peptide
complex (Fig. 7a,b). But it does have a profound effect
on T-cell recognition. Similarly it has been observed that
a minor change in tyrosine, the conversion of tyrosine to
nitrotyrosine, can abrogate peptide recognition in both
CD4+ T cells17 and CD8+ T cells.18
Peptides containing Tyr(3-tBu) are synthetic entities
and do not occur in nature, so it is unclear how CD8+ T
cells with specificity for Tyr(3-tBu) peptides could arise.
There are two possibilities for the origin of T-cell clone
6C5. First, it could be a memory T-cell generated in vivo
against a naturally occurring epitope that is able to cross-
react on Tyr(3-tBu) peptides. Theoretically, a different,
naturally occurring residue that possesses an extended
side chain could have the correct dimensions to allow for
TCR contact. This could be tested by using large peptide
libraries to establish the amino acid preference of 6C5 for
each position in the peptide.19 Second, the clone could
have been generated from naive T cells primed against
P603 tBu in vitro. It is possible that such naive T cells
could have been activated and expanded to functionally
detectable levels during the 5-week culturing period.20
The identification of P603 Tyr(3-tBu) resulted from the
detection of a minor peptide contaminant (< 0!05%) pres-
ent within a crude pool of synthetic peptides. Historically,
synthetic peptide pools have been successfully used to gen-
erate peptide-specific T-cell responses and clones.8 How-
ever, one of the major drawbacks associated with this
process is the inability to produce completely pure peptide
preparations. Commercially produced peptides are com-
monly subject to stringent purification and quality check-
ing processes, such as reverse-phase HPLC and mass
spectrometry. Despite these efforts, contaminants can still
be present within the final peptide preparations, poten-
tially causing misleading results.21–24 This highlights the
potential risk that the presence of traces of highly immu-
nogenic contaminating peptides could result in misleading
assessment of clinical responses to peptide vaccines. Typi-
cally clinical grade peptides used during in vivo human
vaccine trials range in purity from 95 to ≥ 98%.25–31 As
the contaminant report here constituted < 1% of the ori-
ginal P603 crude peptide preparation and < 0!05% of the
original 23-peptide mixture it is conceivable that minute,
but highly immunogenic peptide species may be present
within clinical grade peptide vaccines. This could lead to
the induction of inappropriate responses in T cells with
the wrong specificity or even cause adverse reactions.
We believe that the tBu-modified peptide identified in
this report was generated during the peptide synthesis
process; most likely due to the alkylation of tyrosine by
tBu cations under peptide de-protection conditions. This
reaction has been reported during model de-protection
conditions32 and for preparative scale synthesis33 of Tyr
(3-tBu), therefore the observation of a peptide containing
Tyr(3-tBu) as a minor constituent of the crude P603
preparation is not surprising.
In conclusion, the data presented here highlight some
issues with interpreting data obtained when using synthetic
peptide mixtures. Additionally we have reported that the
chemical modification of a single amino acid, Tyr?Tyr
(3-tBu), can completely dictate activation of the CD8+ T-
cell clone 6C5. This peptide modification appears to exert
its primary effect via interaction with the TCR rather than
influencing the conformation of the peptide within the
HLA binding site. These findings emphasize the specificity
and sensitivity of TCR and their ability to discriminate
between peptides that have an identical primary amino
sequence but differ by a single chemical modification.
Acknowledgements
This work was supported by a Cardiff University/Medical
Research Council studentship (to RR), Leukaemia Lym-
phoma Research Programme Grant (to CP and CF) and a
Cancer Research Wales Project Grant (to SM). We thank
all the patients and healthy donors who provided blood
samples for this study, and Peptide Synthetics (UK) for
initial analysis of crude peptides.
Authors’ contributions
RAR and JER designed and performed the experiments,
analysed all data and co-wrote the manuscript. PR per-
formed the peptide:MHC computer modelling. CF pro-
vided clinical samples. SM and CP contributed to
experimental design and co-wrote the manuscript.
Disclosures
The authors declare that they have no conflict of interests.
References
1 Kawakami Y, Eliyahu S, Jennings C et al. Recognition of multiple epitopes in the
human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with
in vivo tumor regression. J Immunol 1995; 154:3961–8.
ª 2014 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology, 144, 495–505504
R. A. Reid et al.
2 Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evalu-
ation of a synthetic peptide vaccine for the treatment of patients with metastatic mela-
noma. Nat Med 1998; 4:321–7.
3 Brinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA,
Galavotti HS, Engelhard VH, Slingluff CL Terminal modifications inhibit proteolytic
degradation of an immunogenic mart-127-35 peptide: Implications for peptide vaccines.
Int J Cancer 1999; 83:326–34.
4 Valmori D, Fonteneau JF, Lizana CM et al. Enhanced generation of specific tumor-
reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide ana-
logues. J Immunol 1998; 160:1750–8.
5 Kern F, Faulhaber N, Fr€ommel C et al. Analysis of CD8 T cell reactivity to cytomegalo-
virus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol
2000; 30:1676–82.
6 Gavioli R, Kurilla MG, de Campos-Lima PO, Wallace LE, Dolcetti R, Murray RJ, Rick-
inson AB, Masucci MG. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes
of different immunogenicities in the Epstein–Barr virus-encoded nuclear antigen 4. J
Virol 1993; 67:1572–8.
7 Smith KL, Tristram A, Gallagher KM, Fiander AN, Man S. Epitope specificity and lon-
gevity of a vaccine-induced human T cell response against HPV18. Int Immunol 2005;
17:167–76.
8 Nunes CT, Miners KL, Dolton G, Pepper C, Fegan C, Mason MD, Man S. A novel
tumor antigen derived from enhanced degradation of bax protein in human cancers.
Cancer Res 2011; 71:5435–44.
9 Klenerman P, Cerundolo V, Dunbar PR. Tracking T cells with tetramers: new tales
from new tools. Nat Rev Immunol 2002; 2:263–72.
10 Wong R, Pepper C, Brennan P, Nagorsen D, Man S, Fegan C. Blinatumomab induces
autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica 2013;
98:1930–8.
11 Wellings DA, Atherton E. Standard FMOC protocols. Methods Enzymol 1996; 289:44–
67.
12 Ekeruche-Makinde J, Miles JJ, van den Berg HA et al. Peptide length determines the
outcome of TCR/peptide-MHCI engagement. Blood 2013; 121:1112–23.
13 Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystal-
logr D Biol Crystallogr 2004; 60:2126–32.
14 Lebedev AA, Young P, Isupov MN, Moroz OV, Vagin AA, Murshudov GN. JLigand: a
graphical tool for the CCP4 template-restraint library. Acta Crystallogr D Biol Crystal-
logr 2012; 68:431–40.
15 Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL. Post-translational mod-
ifications of naturally processed MHC-binding epitopes. Curr Opin Immunol 2006;
18:92–7.
16 Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA,
Kawakami Y. Improved induction of melanoma-reactive CTL with peptides from the
melanoma antigen gp100 modified at HLA-A* 0201-binding residues. J Immunol 1996;
157:
2539–48.
17 Birnboim HC, Lemay A-M, Lam DKY, Goldstein R, Webb JR. Cutting edge: MHC class
II-restricted peptides containing the inflammation-associated marker 3-nitrotyrosine
evade central tolerance and elicit a robust cell-mediated immune response. J Immunol
2003; 171:528–32.
18 Hardy LL, Wick DA, Webb JR. Conversion of tyrosine to the inflammation-associated
analog 30-nitrotyrosine at either TCR-or MHC-contact positions can profoundly affect
recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus
glycoprotein 33 by CD8 T cells. J Immunol 2008; 180:5956–62.
19 Wooldridge L, Ekeruche-Makinde J, van den Berg HA et al. A single autoimmune T
cell receptor recognizes more than a million different peptides. J Biol Chem 2012;
287:1168–77.
20 Cerny A, Fowler P, Brothers MA, Houghton M, Schlicht HJ, Chisari FV. Induction in
vitro of a primary human antiviral cytotoxic T cell response. Eur J Immunol 1995;
25:627–30.
21 Brezar V, Culina S, Østerbye T et al. T cells recognizing a peptide contaminant unde-
tectable by mass spectrometry. PLoS ONE 2011; 12:e28866.
22 Mannering SI, Purcell AW, Honeyman MC, McCluskey J, Harrison LC. Human T-cells
recognise N-terminally Fmoc-modified peptide. Vaccine 2003; 21:3638–46.
23 Currier JR, Galley LM, Wenschuh H et al. Peptide impurities in commercial synthetic
peptides and their implications for vaccine trial assessment. Clin Vaccine Immunol
2008; 15:267–76.
24 De Spiegeleer B, Vergote V, Pezeshki A, Peremans K, Burvenich C. Impurity profiling
quality control testing of synthetic peptides using liquid chromatography-photodiode
array-fluorescence and liquid chromatography-electrospray ionization-mass spectrome-
try: the obestatin case. Anal Biochem 2008; 376:229–34.
25 Iinuma H, Fukushima R, Inaba T et al. Phase I clinical study of multiple epitope pep-
tide vaccine combined with chemoradiation therapy in esophageal cancer patients. J
Transl Med 2014; 12:84.
26 Betancourt AA, Delgado CAG, Est"evez ZC et al. Phase I clinical trial in healthy adults
of a nasal vaccine candidate containing recombinant hepatitis B surface and core anti-
gens. Int J Infect Dis 2007; 11:394–401.
27 Hueman MT, Dehqanzada ZA, Novak TE et al. Phase I Clinical trial of a HER-2/neu
peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-
risk prostate cancer patients. Clin Cancer Res 2005; 11:7470–9.
28 Okuno K, Sugiura F, Hida J, Tokoro T, Ishimaru E, Sukegawa Y, Ueda K. Phase I clini-
cal trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorec-
tal cancer. Exp Ther Med 2010; 1:73–9.
29 Aruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, Kazuyoshi T,
Yamamoto M Phase I clinical trial of multiple-peptide vaccination for patients with
advanced biliary tract cancer. J Transl Med 2014; 12:61.
30 Carreno BM, Becker-Hapak M, Huang A et al. IL-12p70-producing patient DC vaccine
elicits Tc1-polarized immunity. J Clin Invest 2013; 123:3383–94.
31 Muderspach L, Wilczynski S, Roman L et al. A phase I trial of a human papillomavirus
(HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial
neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6:3406–16.
32 Lundt BF, Johansen NL, Markussen J. Formation and synthesis of 30-t-butyltyrosine.
Int J Pept Protein Res 1979; 14:344–6.
33 Taka N, Matsuoka H, Sato T et al. Discovery of novel motilin antagonists: conversion
of tetrapeptide leads to orally available peptidomimetics. Bioorg Med Chem Lett 2009;
13:3426–9.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Liquid chromatography mass spectrometry
analysis of purified and crude P603 peptide samples.
Figure S2. MS2 spectra of Tyr(3-tBu) containing pep-
tides.
Figure S3. Peptide binding to HLA-A2.
ª 2014 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology, 144, 495–505 505
T-cell epitope formed by tBu modification
  Bibliography !
! Page 239 
 
Bibliography 
Adams, S., O’Neill, D.W. and Bhardwaj, N. 2005. Recent Advances in Dendritic Cell 
Biology. Journal of Clinical Immunology 25(2), pp. 87–98. 
Aderka, D., Maor, Y., Novick, D., Engelmann, H., Kahn, Y., Levo, Y., Wallach, D., et al. 
1993. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is 
induced by tumor necrosis factor-alpha or -beta. Blood 81(8), pp. 2076–2084. 
Adrain, C., Murphy, B.M. and Martin, S.J. 2005. Molecular ordering of the caspase 
activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) 
protease granzyme B. The Journal of biological chemistry 280(6), pp. 4663–4673. 
Agrawal, S.G., Liu, F.T., Wiseman, C., Shirali, S., Liu, H., Lillington, D., Du, M.Q., et al. 
2008. Increased proteasomal degradation of Bax is a common feature of poor prognosis 
chronic lymphocytic leukemia. Blood 111(5), pp. 2790–2796. 
Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., Wunderlich, J.R., Dudley, M.E., White, 
D.E. and Rosenberg, S.A. 2009. Tumor antigen-specific CD8 T cells infiltrating the tumor 
express high levels of PD-1 and are functionally impaired. Blood 114(8), pp. 1537–1544. 
Akagi, J. and Baba, H. 2008. Prognostic value of CD57+ T lymphocytes in the peripheral 
blood of patients with advanced gastric cancer. International journal of clinical oncology 13(6), 
pp. 528–535. 
Alarcón, B., Mestre, D. and Martínez-Martín, N. 2011. The immunological synapse: a cause 
or consequence of T-cell receptor triggering? Immunology 133(4), pp. 420–425. 
Alderton, G.K. and Bordon, Y. 2012. Tumour immunotherapy — leukocytes take up the 
fight. Nature Reviews Immunology 12(4), pp. 237–237. 
Allam, A., Conze, D.B., Giardino Torchia, M.L., Munitic, I., Yagita, H., Sowell, R.T., 
Marzo, A.L., et al. 2009. The CD8+ memory T-cell state of readiness is actively maintained 
and reversible. Blood 114(10), pp. 2121–2130. 
Alves, N.L., Hooibrink, B., Arosa, F.A. and van Lier, R.A.W. 2003. IL-15 induces antigen-
independent expansion and differentiation of human naive CD8+ T cells in vitro. Blood 
102(7), pp. 2541–2546. 
Andersen, M.H., Fensterle, J., Ugurel, S., Reker, S., Houben, R., Guldberg, P., Berger, T.G., 
et al. 2004. Immunogenicity of constitutively active V599EBRaf. Cancer Research 64(15), pp. 
5456–5460. 
Androlewicz, M.J., Anderson, K.S. and Cresswell, P. 1993. Evidence that transporters 
associated with antigen processing translocate a major histocompatibility complex class I-
binding peptide into the endoplasmic reticulum in an ATP-dependent manner. Proceedings of 
the National Academy of Sciences 90(19), pp. 9130–9134. 
Arch, R.H. and Thompson, C.B. 1998. 4-1BB and Ox40 are members of a tumor necrosis 
factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated 
factors and activate nuclear factor kappaB. Molecular and Cellular Biology 18(1), pp. 558–565. 
  Bibliography !
! Page 240 
Artyomov, M.N., Lis, M., Devadas, S., Davis, M.M. and Chakraborty, A.K. 2010. CD4 and 
CD8 binding to MHC molecules primarily acts to enhance Lck delivery. Proceedings of the 
National Academy of Sciences 107(39), pp. 16916–16921. 
Badoux, X.C., Keating, M.J., Wang, X., O'Brien, S.M., Ferrajoli, A., Faderl, S., Burger, J., et 
al. 2011. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly 
effective treatment for relapsed patients with CLL. Blood 117(11), pp. 3016–3024. 
Bagnara, D., Kaufman, M.S., Calissano, C., Marsilio, S., Patten, P.E.M., Simone, R., Chum, 
P., et al. 2011. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a 
key role for T lymphocytes in the disease. Blood 117(20), pp. 5463–5472. 
Bakker, A.B., Schreurs, M.W., de Boer, A.J., Kawakami, Y., Rosenberg, S.A., Adema, G.J. 
and Figdor, C.G. 1994. Melanocyte lineage-specific antigen gp100 is recognized by 
melanoma-derived tumor-infiltrating lymphocytes. The Journal of Experimental Medicine 
179(3), pp. 1005–1009. 
Banchereau, J. and Steinman, R.M. 1998. Dendritic cells and the control of immunity. 
Nature 392(6673), pp. 245–252. 
Barber, E.K., Dasgupta, J.D., Schlossman, S.F., Trevillyan, J.M. and Rudd, C.E. 1989. The 
CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that 
phosphorylates the CD3 complex. Proceedings of the National Academy of Sciences 86(9), pp. 
3277–3281. 
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., et 
al. 2008. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging 
Antibody. Science 321(5891), pp. 974–977. 
Basler, M., Lauer, C., Moebius, J., Weber, R., Przybylski, M., Kisselev, A.F., Tsu, C., et al. 
2012. Why the structure but not the activity of the immunoproteasome subunit low 
molecular mass polypeptide 2 rescues antigen presentation. The Journal of Immunology 189(4), 
pp. 1868–1877. 
Baumeister, W., Walz, J., Zühl, F. and Seemüller, E. 1998. The Proteasome: Paradigm of a 
Self-Compartmentalizing Protease. Cell 92(3), pp. 367–380. 
Begleiter, A., Mowat, M., Israels, L.G. and Johnston, J.B. 1996. Chlorambucil in chronic 
lymphocytic leukemia: mechanism of action. Leukemia & lymphoma 23(3-4), pp. 187–201. 
Behr, S.I., Korinth, D. and Schriever, F. 1998. Differential adhesion pattern of B cell 
chronic lymphocytic leukemia cells. Leukemia 12(1), pp. 71–77. 
Biagi, E., Rousseau, R., Yvon, E., Schwartz, M., Dotti, G., Foster, A., Havlik-Cooper, D., 
et al. 2005. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine 
in patients with B-cell chronic lymphocytic leukemia. Clinical Cancer Research 11(19 Pt 1), pp. 
6916–6923. 
Binet, J.L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., 
et al. 1981. A new prognostic classification of chronic lymphocytic leukemia derived from a 
multivariate survival analysis. Cancer 48(1), pp. 198–206. 
Birkholz, K., Schwenkert, M., Kellner, C., Gross, S., Fey, G., Schuler-Thurner, B., Schuler, 
G., et al. 2010. Targeting of DEC-205 on human dendritic cells results in efficient MHC 
class II-restricted antigen presentation. Blood 116(13), pp. 2277–2285. 
  Bibliography !
! Page 241 
Birnboim, H.C., Lemay, A.-M., Lam, D.K.Y., Goldstein, R. and Webb, J.R. 2003. Cutting 
edge: MHC class II-restricted peptides containing the inflammation-associated marker 3-
nitrotyrosine evade central tolerance and elicit a robust cell-mediated immune response. 
The Journal of Immunology 171(2), pp. 528–532. 
Blackburn, S.D., Shin, H., Haining, W.N., Zou, T., Workman, C.J., Polley, A., Betts, M.R., 
et al. 2008. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during 
chronic viral infection. Nature immunology 10(1), pp. 29–37. 
Boatright, K.M., Renatus, M., Scott, F.L., Sperandio, S., Shin, H., Pedersen, I.M., Ricci, J.-
E., et al. 2003. A Unified Model for Apical Caspase Activation. Molecular Cell 11(2), pp. 
529–541. 
Boehm, T. 2011. Design principles of adaptive immune systems. Nature Reviews Immunology 
11(5), pp. 307–317. 
Boniface, K., Guignouard, E., Pedretti, N., Garcia, M., Delwail, A., Bernard, F.X., Nau, F., 
et al. 2007. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clinical 
and experimental immunology 150(3), pp. 407–415. 
Bonifaz, L.C., Bonnyay, D.P., Charalambous, A., Darguste, D.I., Fujii, S.-I., Soares, H., 
Brimnes, M.K., et al. 2004. In vivo targeting of antigens to maturing dendritic cells via the 
DEC-205 receptor improves T cell vaccination. The Journal of Experimental Medicine 199(6), 
pp. 815–824. 
Borysiewicz, L.K., Fiander, A., Nimako, M., Man, S., Wilkinson, G.W., Westmoreland, D., 
Evans, A.S., et al. 1996. A recombinant vaccinia virus encoding human papillomavirus 
types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 
347(9014), pp. 1523–1527. 
Bozzacco, L., Trumpfheller, C., Siegal, F.P., Mehandru, S., Markowitz, M., Carrington, M., 
Nussenzweig, M.C., et al. 2007. DEC-205 receptor on dendritic cells mediates presentation 
of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proceedings 
of the National Academy of Sciences 104(4), pp. 1289–1294. 
Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., Hwu, W.-J., Topalian, S.L., Hwu, P., Drake, 
C.G., et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced 
cancer. New England Journal of Medicine 366(26), pp. 2455–2465. 
Brenchley, J.M. 2002. Expression of CD57 defines replicative senescence and antigen-
induced apoptotic death of CD8+ T cells. Blood 101(7), pp. 2711–2720. 
Brentjens, R., Yeh, R., Bernal, Y., Riviere, I. and Sadelain, M. 2009. Treatment of Chronic 
Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an 
Unforeseen Adverse Event in a Phase I Clinical Trial. Molecular Therapy 18(4), pp. 666–668. 
Brezar, V., Culina, S., Østerbye, T., Guillonneau, F., Chiappetta, G., Verdier, Y., Vinh, J., et 
al. 2011. T Cells Recognizing a Peptide Contaminant Undetectable by Mass Spectrometry. 
PLoS ONE 6(12), p. e28866. 
Brossart, P., Stuhler, G., Flad, T., Stevanovic, S., Rammensee, H.-G., Kanz, L. and Brugger, 
W. 1998. Her-2/neu-derived peptides are tumor-associated antigens expressed by human 
renal cell and colon carcinoma lines and are recognized by in vitro induced specific 
cytotoxic T lymphocytes. Cancer Research 58(4), pp. 732–736. 
  Bibliography !
! Page 242 
Brossart, P., Wirths, S., Stuhler, G., Reichardt, V.L., Kanz, L. and Brugger, W. 2000. 
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-
pulsed dendritic cells. Blood 96(9), pp. 3102–3108. 
Brown, J.R., Byrd, J.C., Coutre, S.E., Benson, D.M., Flinn, I.W., Wagner-Johnston, N.D., 
Spurgeon, S.E., et al. 2014. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , 
for relapsed/refractory chronic lymphocytic leukemia. Blood 123(22), pp. 3390–3397. 
Brownlie, R.J. and Zamoyska, R. 2013. T cell receptor signalling networks: branched, 
diversified and bounded. Nature Reviews Immunology 13(4), pp. 257–269. 
Brusa, D., Serra, S., Coscia, M., Rossi, D., D'Arena, G., Laurenti, L., Jaksic, O., et al. 2013. 
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. 
Haematologica 98(6), pp. 953–963. 
Brüstle, A., Heink, S., Huber, M., Rosenplänter, C., Stadelmann, C., Yu, P., Arpaia, E., et al. 
2007. The development of inflammatory TH-17 cells requires interferon-regulatory factor 
4. Nature immunology 8(9), pp. 958–966. 
Buggins, A.G.S., Patten, P.E.M., Richards, J., Thomas, N.S.B., Mufti, G.J. and Devereux, S. 
2007. Tumor-derived IL-6 may contribute to the immunological defect in CLL. Leukemia 
22(5), pp. 1084–1087. 
Bulian, P., Shanafelt, T.D., Fegan, C., Zucchetto, A., Cro, L., Nückel, H., Baldini, L., et al. 
2014. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic 
lymphocytic leukemia. Journal of Clinical Oncology 32(9), pp. 897–904. 
Bund, D., Mayr, C., Kofler, D.M., Hallek, M. and Wendtner, C.-M. 2007. CD23 is 
recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T 
lymphocytes. Experimental Hematology 35(6), pp. 920–930. 
Bund, D., Mayr, C., Kofler, D.M., Hallek, M. and Wendtner, C.-M. 2006. Human Ly9 
(CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-
CLL) recognized by autologous CD8+ T cells. Experimental Hematology 34(7), pp. 860–869. 
Burgdorf, S., Schölz, C., Kautz, A., Tampé, R. and Kurts, C. 2008. Spatial and mechanistic 
separation of cross-presentation and endogenous antigen presentation. Nature immunology 
9(5), pp. 558–566. 
Burger, J.A. and Gribben, J.G. 2014. The microenvironment in chronic lymphocytic 
leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted 
therapies. Seminars in Cancer Biology 24, pp. 71–81. 
Burger, J.A., Burger, M. and Kipps, T.J. 1999. Chronic lymphocytic leukemia B cells 
express functional CXCR4 chemokine receptors that mediate spontaneous migration 
beneath bone marrow stromal cells. Blood 94(11), pp. 3658–3667. 
Burkhardt, U.E., Hainz, U., Stevenson, K., Goldstein, N.R., Pasek, M., Naito, M., Wu, D., 
et al. 2013. Autologous CLL cell vaccination early after transplant induces leukemia-specific 
T cells. The Journal of Clinical Investigation 123(9), pp. 3756–3765. 
Burnet, M. 1957. Cancer—A Biological Approach: I. The Processes Of Control. II. The 
Significance of Somatic Mutation. British Medical Journal 1(5022), p. 779. 
Burstein, H.J. 2005. The distinctive nature of HER2-positive breast cancers. New England 
  Bibliography !
! Page 243 
Journal of Medicine 353(16), pp. 1652–1654. 
Buschle, M., Campana, D., Carding, S.R., Richard, C., Hoffbrand, A.V. and Brenner, M.K. 
1993. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic 
leukemia. The Journal of Experimental Medicine 177(1), pp. 213–218. 
Byrd, J.C., Brown, J.R., O'Brien, S., Barrientos, J.C., Kay, N.E., Reddy, N.M., Coutre, S., et 
al. 2014. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid 
Leukemia. New England Journal of Medicine 371(3), pp. 213–223. 
Bystry, R.S., Aluvihare, V., Welch, K.A., Kallikourdis, M. and Betz, A.G. 2001. B cells and 
professional APCs recruit regulatory T cells via CCL4. Nature immunology 2(12), pp. 1126–
1132. 
Calpe, E., Codony, C., Baptista, M.J., Abrisqueta, P., Carpio, C., Purroy, N., Bosch, F., et al. 
2011. ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing 
CCR7 expression via IgM-ERK1/2 activation. Blood 118(16), pp. 4401–4410. 
Cambier, J.C., Gauld, S.B., Merrell, K.T. and Vilen, B.J. 2007. B-cell anergy: from 
transgenic models to naturally occurring anergic B cells? Nature Reviews Immunology 7(8), pp. 
633–643. 
Cannons, J.L., Lau, P., Ghumman, B., DeBenedette, M.A., Yagita, H., Okumura, K. and 
Watts, T.H. 2001. 4-1BB ligand induces cell division, sustains survival, and enhances 
effector function of CD4 and CD8 T cells with similar efficacy. Journal of Immunology 167(3), 
pp. 1313–1324. 
Cao, E., Zang, X., Ramagopal, U.A., Mukhopadhaya, A., Fedorov, A., Fedorov, E., 
Zencheck, W.D., et al. 2007. T Cell Immunoglobulin Mucin-3 Crystal Structure Reveals a 
Galectin-9-Independent Ligand-Binding Surface. Immunity 26(3), pp. 311–321. 
Carton, J.M., Uhlinger, D.J., Batheja, A.D., Derian, C., Ho, G., Argenteri, D. and 
D'Andrea, M.R. 2003. Enhanced Serine Palmitoyltransferase Expression in Proliferating 
Fibroblasts, Transformed Cell Lines, and Human Tumors. Journal of Histochemistry & 
Cytochemistry 51(6), pp. 715–726. 
Caruso, A., Licenziati, S., Corulli, M., Canaris, A.D., De Francesco, M.A., Fiorentini, S., 
Peroni, L., et al. 1997. Flow cytometric analysis of activation markers on stimulated T cells 
and their correlation with cell proliferation. Cytometry Part A 27(1), pp. 71–76. 
Cebecauer, M., Guillaume, P., Hozák, P., Mark, S., Everett, H., Schneider, P. and Luescher, 
I.F. 2005. Soluble MHC-peptide complexes induce rapid death of CD8+ CTL. The Journal 
of Immunology 174(11), pp. 6809–6819. 
Chames, P., Van Regenmortel, M., Weiss, E. and Baty, D. 2009. Therapeutic antibodies: 
successes, limitations and hopes for the future. British Journal of Pharmacology 157(2), pp. 
220–233. 
Champagne, P., Ogg, G.S., King, A.S., Knabenhans, C., Ellefsen, K., Nobile, M., Appay, 
V., et al. 2001. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 
410(6824), pp. 106–111. 
Chang, C.-S., Chang, J.H., Hsu, N.C., Lin, H.-Y. and Chung, C.-Y. 2007. Expression of 
CD80 and CD86 costimulatory molecules are potential markers for better survival in 
nasopharyngeal carcinoma. BMC cancer 7, p. 88. 
  Bibliography !
! Page 244 
Chang, H.-C., Sehra, S., Goswami, R., Yao, W., Yu, Q., Stritesky, G.L., Jabeen, R., et al. 
2010. The transcription factor PU.1 is required for the development of IL-9-producing T 
cells and allergic inflammation. Nature immunology 11(6), pp. 527–534. 
Chang, H.-C., Zhang, S., Thieu, V.T., Slee, R.B., Bruns, H.A., Laribee, R.N., Klemsz, M.J., 
et al. 2005. PU.1 expression delineates heterogeneity in primary Th2 cells. Immunity 22(6), 
pp. 693–703. 
Chaouchi, N., Wallon, C., Goujard, C., Tertian, G., Rudent, A., Caput, D., Ferrera, P., et al. 
1996. Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic 
lymphocytic leukemia B cells from in vitro apoptosis. Blood 87(3), pp. 1022–1029. 
Chapman, H.A. 2006. Endosomal proteases in antigen presentation. Current opinion in 
immunology 18(1), pp. 78–84. 
Chaturvedi, P., Hengeveld, R., Zechel, M.A., Lee-Chan, E. and Singh, B. 2000. The 
functional role of class II-associated invariant chain peptide (CLIP) in its ability to variably 
modulate immune responses. International immunology 12(6), pp. 757–765. 
Chemnitz, J.M., Parry, R.V., Nichols, K.E., June, C.H. and Riley, J.L. 2004. SHP-1 and 
SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 
upon primary human T cell stimulation, but only receptor ligation prevents T cell 
activation. The Journal of Immunology 173(2), pp. 945–954. 
Chen, L., Apgar, J., Huynh, L., Dicker, F., Giago-McGahan, T., Rassenti, L., Weiss, A., et 
al. 2005. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 
105(5), pp. 2036–2041. 
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., et al. 2003. 
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by 
TGF-beta induction of transcription factor Foxp3. The Journal of Experimental Medicine 
198(12), pp. 1875–1886. 
Cheng, S., Ma, J., Guo, A., Lu, P., Leonard, J.P., Coleman, M., Liu, M., et al. 2014. BTK 
inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling 
activity. Leukemia 28(3), pp. 649–657. 
Chinnaiyan, A.M., O'Rourke, K., Tewari, M. and Dixit, V.M. 1995. FADD, a novel death 
domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. 
Cell 81(4), pp. 505–512. 
Chiorazzi, N. 2012. Implications of new prognostic markers in chronic lymphocytic 
leukemia. Hematology / the Education Program of the American Society of Hematology. American 
Society of Hematology. Education Program 2012, pp. 76–87. 
Chiorazzi, N. and Ferrarini, M. 2011. Cellular origin(s) of chronic lymphocytic leukemia: 
cautionary notes and additional considerations and possibilities. Blood 117(6), pp. 1781–
1791. 
Chong, L.K., Aicheler, R.J., Llewellyn-Lacey, S., Tomasec, P., Brennan, P. and Wang, 
E.C.Y. 2008. Proliferation and interleukin 5 production by CD8hiCD57+ T cells. European 
Journal of Immunology 38(4), pp. 995–1000. 
Chow, A., Toomre, D., Garrett, W. and Mellman, I. 2002. Dendritic cell maturation 
triggers retrograde MHC class II transport from lysosomes to the plasma membrane. 
  Bibliography !
! Page 245 
Nature 418(6901), pp. 988–994. 
Cieri, N., Camisa, B., Cocchiarella, F., Forcato, M., Oliveira, G., Provasi, E., Bondanza, A., 
et al. 2013. IL-7 and IL-15 instruct the generation of human memory stem T cells from 
naive precursors. Blood 121(4), pp. 573–584. 
Ciernik, I.F., Berzofsky, J.A. and Carbone, D.P. 1996. Human lung cancer cells 
endogenously expressing mutant p53 process and present the mutant epitope and are lysed 
by mutant-specific cytotoxic T lymphocytes. Clinical Cancer Research 2(5), pp. 877–882. 
Cocks, B.G., de Waal Malefyt, R., Galizzi, J.P., de Vries, J.E. and Aversa, G. 1993. IL-13 
induces proliferation and differentiation of human B cells activated by the CD40 ligand. 
International immunology 5(6), pp. 657–663. 
Coe, H. and Michalak, M. 2010. ERp57, a multifunctional endoplasmic reticulum resident 
oxidoreductase. International Journal of Biochemistry and Cell Biology 42(6), pp. 796–799. 
Cole, D.K., Edwards, E.S.J., Wynn, K.K., Clement, M., Miles, J.J., Ladell, K., Ekeruche, J., 
et al. 2010. Modification of MHC Anchor Residues Generates Heteroclitic Peptides That 
Alter TCR Binding and T Cell Recognition. The Journal of Immunology 185(4), pp. 2600–2610. 
Couzin-Frankel, J. 2013. Breakthrough of the year 2013. Cancer immunotherapy. Science 
342(6165), pp. 1432–1433. 
Croft, M., So, T., Duan, W. and Soroosh, P. 2009. The significance of OX40 and OX40L 
to T‐cell biology and immune disease. Immunological reviews 229(1), pp. 173–191. 
Damle, R.N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., Buchbinder, A., et al. 
1999. Ig V gene mutation status and CD38 expression as novel prognostic indicators in 
chronic lymphocytic leukemia. Blood 94(6), pp. 1840–1847. 
Day, C.L., Kaufmann, D.E., Kiepiela, P., Brown, J.A., Moodley, E.S., Reddy, S., Mackey, 
E.W., et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell 
exhaustion and disease progression. Nature 443(7109), pp. 350–354. 
de Castro, E., Sigrist, C.J.A., Gattiker, A., Bulliard, V., Langendijk-Genevaux, P.S., 
Gasteiger, E., Bairoch, A., et al. 2006. ScanProsite: detection of PROSITE signature 
matches and ProRule-associated functional and structural residues in proteins. Nucleic Acids 
Research 34(Web Server issue), pp. W362–5. 
de Haan, E.C., Moret, E.E., Wagenaar-Hilbers, J.P.A., Liskamp, R.M.J. and Wauben, 
M.H.M. 2005a. Possibilities and limitations in the rational design of modified peptides for 
T cell mediated immunotherapy. Molecular Immunology 42(3), pp. 365–373. 
de Haan, E.C., Wagenaar-Hilbers, J.P.A., Liskamp, R.M.J., Moret, E.E. and Wauben, 
M.H.M. 2005b. Limited plasticity in T cell recognition of modified T cell receptor contact 
residues in MHC class II bound peptides. Molecular Immunology 42(3), pp. 355–364. 
De Smet, C., Lurquin, C., van der Bruggen, P., De Plaen, E., Brasseur, F. and Boon, T. 
1994. Sequence and expression pattern of the human MAGE2 gene. Immunogenetics 39(2), 
pp. 121–129. 
de Verteuil, D., Muratore-Schroeder, T.L., Granados, D.P., Fortier, M.-H., Hardy, M.-P., 
Bramoullé, A., Caron, É., et al. 2010. Deletion of immunoproteasome subunits imprints on 
the transcriptome and has a broad impact on peptides presented by major 
  Bibliography !
! Page 246 
histocompatibility complex I molecules. Molecular & cellular proteomics : MCP 9(9), pp. 2034–
2047. 
Deaglio, S., Aydin, S., Grand, M.M., Vaisitti, T., Bergui, L., D'Arena, G., Chiorino, G., et al. 
2010. CD38/CD31 interactions activate genetic pathways leading to proliferation and 
migration in chronic lymphocytic leukemia cells. Molecular Medicine 16(3-4), p. 87. 
Dedeoglu, F., Horwitz, B. and Chaudhuri, J. 2004. Induction of activation‐induced cytidine 
deaminase gene expression by IL‐4 and CD40 ligation is dependent on STAT6 and NFκB. 
International Immunology 16(3), pp 395–404. 
Del Poeta, G., Maurillo, L., Venditti, A., Buccisano, F., Epiceno, A.M., Capelli, G., 
Tamburini, A., et al. 2001. Clinical significance of CD38 expression in chronic lymphocytic 
leukemia. Blood 98(9), pp. 2633–2639. 
Del Principe, M.I., Del Poeta, G., Buccisano, F., Maurillo, L., Venditti, A., Zucchetto, A., 
Marini, R., et al. 2006. Clinical significance of ZAP-70 protein expression in B-cell chronic 
lymphocytic leukemia. Blood 108(3), pp. 853–861. 
Denkberg, G., Klechevsky, E. and Reiter, Y. 2002. Modification of a tumor-derived 
peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide 
complex: probing with TCR-like recombinant antibodies. The Journal of Immunology 169(8), 
pp. 4399–4407. 
Denoeud, J. and Moser, M. 2011. Role of CD27/CD70 pathway of activation in immunity 
and tolerance. Journal of leukocyte biology 89(2), pp. 195–203. 
Denzin, L.K. and Cresswell, P. 1995. HLA-DM induces CLIP dissociation from MHC 
class II alpha beta dimers and facilitates peptide loading. Cell 82(1), pp. 155–165. 
Dhein, J., Walczak, H., Bäumler, C., Debatin, K.-M. and Krammer, P.H. 1995. Autocrine 
T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373(6513), pp. 438–441. 
Dhodapkar, M.V., Sznol, M., Zhao, B., Wang, D., Carvajal, R.D., Keohan, M.L., Chuang, 
E., et al. 2014. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 
to the dendritic cell receptor DEC-205. Science Translational Medicine 6(232), p. 232ra51. 
Di Bernardo, M.C., Crowther-Swanepoel, D., Broderick, P., Webb, E., Sellick, G., Wild, R., 
Sullivan, K., et al. 2008. A genome-wide association study identifies six susceptibility loci 
for chronic lymphocytic leukemia. Nature Genetics 40(10), pp. 1204–1210. 
Di Pucchio, T., Chatterjee, B., Smed-Sörensen, A., Clayton, S., Palazzo, A., Montes, M., 
Xue, Y., et al. 2008. Direct proteasome-independent cross-presentation of viral antigen by 
plasmacytoid dendritic cells on major histocompatibility complex class I. Nature immunology 
9(5), pp. 551–557. 
Dighe, A.S., Richards, E., Old, L.J. and Schreiber, R.D. 1994. Enhanced in vivo growth and 
resistance to rejection of tumor cells expressing dominant negative IFNγ receptors. 
Immunity 1(6), pp. 447–456. 
Dighiero, G., Maloum, K., Desablens, B., Cazin, B., Navarro, M., Leblay, R., Leporrier, M., 
et al. 1998. Chlorambucil in Indolent Chronic Lymphocytic Leukemia. New England Journal 
of Medicine 338(21), pp. 1506–1514. 
DiLillo, D.J., Weinberg, J.B., Yoshizaki, A., Horikawa, M., Bryant, J.M., Iwata, Y., 
  Bibliography !
! Page 247 
Matsushita, T., et al. 2012. Chronic lymphocytic leukemia and regulatory B cells share IL-
10 competence and immunosuppressive function. Leukemia 27(1), pp. 170–182. 
Djuranovic, S., Nahvi, A. and Green, R. 2012. miRNA-mediated gene silencing by 
translational repression followed by mRNA deadenylation and decay. Science 336(6078), pp. 
237–240. 
Dolfi, D.V., Boesteanu, A.C., Petrovas, C., Xia, D., Butz, E.A. and Katsikis, P.D. 2008. 
Late Signals from CD27 Prevent Fas-Dependent Apoptosis of Primary CD8+ T Cells. The 
Journal of Immunology 180(5), pp. 2912–2921. 
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, 
K., et al. 2000. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. New 
England Journal of Medicine 343(26), pp. 1910–1916. 
Dreger, P. and Montserrat, E. 2002. Autologous and allogeneic stem cell transplantation 
for chronic lymphocytic leukemia. Leukemia 16(6), pp. 985–992. 
Dreger, P., Dohner, H., Ritgen, M., Bottcher, S., Busch, R., Dietrich, S., Bunjes, D., et al. 
2010. Allogeneic stem cell transplantation provides durable disease control in poor-risk 
chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL 
Study Group CLL3X trial. Blood 116(14), pp. 2438–2447. 
Dunbar, P.R., Chen, J.L., Chao, D., Rust, N., Teisserenc, H., Ogg, G.S., Romero, P., et al. 
1999. Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive 
immunotherapy of melanoma. The Journal of Immunology 162(12), pp. 6959–6962. 
Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J. and Schreiber, R.D. 2002. Cancer 
immunoediting: from immunosurveillance to tumor escape. Nature immunology 3(11), pp. 
991–998. 
Dunn, G.P., Old, L.J. and Schreiber, R.D. 2004. The three Es of cancer immunoediting. 
Annual Review of Immunology 22, pp. 329–360. 
DuPage, M., Mazumdar, C., Schmidt, L.M., Cheung, A.F. and Jacks, T. 2012. Expression 
of tumour-specific antigens underlies cancer immunoediting. Nature 482(7385), pp. 405–
409. 
Dustin, M.L., Chakraborty, A.K. and Shaw, A.S. 2010. Understanding the structure and 
function of the immunological synapse. Cold Spring Harbor Perspectives in Biology 2(10), p. 
a002311. 
Dürig, J., Nückel, H., Cremer, M., Führer, A., Halfmeyer, K., Fandrey, J., Möröy, T., et al. 
2003. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 
17(12), pp. 2426–2434. 
Ekeruche-Makinde, J., Miles, J.J., van den Berg, H.A., Skowera, A., Cole, D.K., Dolton, G., 
Schauenburg, A.J.A., et al. 2013. Peptide length determines the outcome of TCR/peptide-
MHCI engagement. Blood 121(7), pp. 1112–1123. 
Evans, L.S., Witte, P.R., Feldhaus, A.L., Nelson, B.H., Riddell, S.R., Greenberg, P.D., 
Lupton, S.D., et al. 1999. Expression of chimeric granulocyte-macrophage colony-
stimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results 
in granulocyte-macrophage colony-stimulating factor-dependent growth. Human Gene 
Therapy 10(12), pp. 1941–1951. 
  Bibliography !
! Page 248 
Evans, M., Borysiewicz, L.K., Evans, A.S., Rowe, M., Jones, M., Gileadi, U., Cerundolo, V., 
et al. 2001. Antigen processing defects in cervical carcinomas limit the presentation of a 
CTL epitope from human papillomavirus 16 E6. The Journal of Immunology 167(9), pp. 5420–
5428. 
Ewen, C.L., Kane, K.P. and Bleackley, R.C. 2012. A quarter century of granzymes. Cell 
death and differentiation 19(1), pp. 28–35. 
Fayad, L., Keating, M.J., Reuben, J.M., O'Brien, S., Lee, B.N., Lerner, S. and Kurzrock, R. 
2001. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation 
with phenotypic characteristics and outcome. Blood 97(1), pp. 256–263. 
Feau, S., Schoenberger, S.P., Altman, A. and Bécart, S. 2013. SLAT regulates CD8+ T cell 
clonal expansion in a Cdc42- and NFAT1-dependent manner. The Journal of Immunology 
190(1), pp. 174–183. 
Fecteau, J.-F. and Kipps, T.J. 2012. Structure and function of the hematopoietic cancer 
niche: focus on chronic lymphocytic leukemia. Frontiers in bioscience (Scholar edition) 4, pp. 61–
73. 
Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., 
Christian, B., et al. 2005. Long-term results of the R-CHOP study in the treatment of 
elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d‘Etude des 
Lymphomes de l’Adulte. Journal of Clinical Oncology 23(18), pp. 4117–4126. 
Finley, D. 2009. Recognition and processing of ubiquitin-protein conjugates by the 
proteasome. Annual review of biochemistry 78, pp. 477–513. 
Focosi, D., Bestagno, M., Burrone, O. and Petrini, M. 2010. CD57+ T lymphocytes and 
functional immune deficiency. Journal of leukocyte biology 87(1), pp. 107–116. 
Foster, A.E., Okur, F.V., Biagi, E., Lu, A., Dotti, G., Yvon, E., Savoldo, B., et al. 2010. 
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T 
lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia 
24(3), pp. 563–572. 
Fourcade, J., Kudela, P., Sun, Z., Shen, H., Land, S.R., Lenzner, D., Guillaume, P., et al. 
2009. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma 
patients. The Journal of Immunology 182(9), pp. 5240–5249. 
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I.F., Sander, C., Kirkwood, 
J.M., et al. 2010. Upregulation of Tim-3 and PD-1 expression is associated with tumor 
antigen-specific CD8+ T cell dysfunction in melanoma patients. The Journal of Experimental 
Medicine 207(10), pp. 2175–2186. 
Frankel, S.R. and Baeuerle, P.A. 2013. Targeting T cells to tumor cells using bispecific 
antibodies. Current Opinion in Chemical Biology 17(3), pp. 385–392. 
Frassanito, Silvestris, Cafforio and Dammacco 1998. CD8 +/CD57 +cells and apoptosis 
suppress T-cell functions in multiple myeloma. British Journal of Haematology 100(3), pp. 469–
477. 
Freeman, G.J. and Sharpe, A.H. 2012. A new therapeutic strategy for malaria: targeting T 
cell exhaustion. Nature immunology 13(2), pp. 113–115. 
  Bibliography !
! Page 249 
Frishman, J., Long, B., Knospe, W., Gregory, S. and Plate, J. 1993. Genes for interleukin 7 
are transcribed in leukemic cell subsets of individuals with chronic lymphocytic leukemia. 
The Journal of Experimental Medicine 177(4), pp. 955–964. 
Fruman, D.A. and Rommel, C. 2014. PI3K and cancer: lessons, challenges and 
opportunities. Nature Reviews Drug Discovery 13(2), pp. 140–156. 
Fu, D., Calvo, J.A. and Samson, L.D. 2012. Balancing repair and tolerance of DNA damage 
caused by alkylating agents. Nature Reviews Cancer 12(2), pp. 104–120. 
Furman, R.R., Sharman, J.P., Coutre, S.E., Cheson, B.D., Pagel, J.M., Hillmen, P., 
Barrientos, J.C., et al. 2014. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic 
Leukemia. New England Journal of Medicine 370(11), pp. 997–1007. 
Gabrilovich, D.I. and Nagaraj, S. 2009. Myeloid-derived suppressor cells as regulators of 
the immune system. Nature Reviews Immunology 9(3), pp. 162–174. 
Gaffen, S.L. and Liu, K.D. 2004. Overview of interleukin-2 function, production and 
clinical applications. Cytokine 28(3), pp. 109–123. 
Gallagher, K.M.E. and Man, S. 2007. Identification of HLA-DR1- and HLA-DR15-
restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by 
CD4+ T cells from healthy young women. Journal of General Virology 88(5), pp. 1470–1478. 
Garbi, N., Tiwari, N., Momburg, F. and Hämmerling, G.J. 2003. A major role for tapasin 
as a stabilizer of the TAP peptide transporter and consequences for MHC class I 
expression. European Journal of Immunology 33(1), pp. 264–273. 
Gattei, V., Bulian, P., Del Principe, M.I., Zucchetto, A., Maurillo, L., Buccisano, F., 
Bomben, R., et al. 2008. Relevance of CD49d protein expression as overall survival and 
progressive disease prognosticator in chronic lymphocytic leukemia. Blood 111(2), pp. 865–
873. 
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C.M., Quigley, M.F., Almeida, J.R., et al. 
2011. A human memory T cell subset with stem cell–like properties. Nature medicine 17(10), 
pp. 1290–1297. 
Gattinoni, L., Powell, D.J., Rosenberg, S.A. and Restifo, N.P. 2006. Adoptive 
immunotherapy for cancer: building on success. Nature Reviews Immunology 6(5), pp. 383–
393. 
Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J.J., De Plaen, 
E., Lethé, B., et al. 1994. Human gene MAGE-3 codes for an antigen recognized on a 
melanoma by autologous cytolytic T lymphocytes. The Journal of Experimental Medicine 
179(3), pp. 921–930. 
Geginat, J., Lanzavecchia, A. and Sallusto, F. 2003. Proliferation and differentiation 
potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic 
cytokines. Blood 101(11), pp. 4260–4266. 
Gerondakis, S., Fulford, T.S., Messina, N.L. and Grumont, R.J. 2014. NF-κB control of T 
cell development. Nature immunology 15(1), pp. 15–25. 
Giannopoulos, K., Dmoszynska, A., Kowal, M., Rolinski, J., Gostick, E., Price, D.A., 
Greiner, J., et al. 2010. Peptide vaccination elicits leukemia-associated antigen-specific 
  Bibliography !
! Page 250 
cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia. Leukemia 
24(4), pp. 798–805. 
Giannopoulos, K., Li, L., Bojarska-Junak, A., Rolinski, J., Dmoszynska, A., Hus, I., 
Greiner, J., et al. 2006. Expression of RHAMM/CD168 and other tumor-associated 
antigens in patients with B-cell chronic lymphocytic leukemia. International journal of oncology 
29(1), pp. 95–103. 
Gilmore, T. 2015. NF-kB Target Genes [Online]. Available at: http://www.bu.edu/nf-
kb/gene-resources/target-genes/ [Accessed: 25 February 2015]. 
Glickman, M.H. and Ciechanover, A. 2002. The Ubiquitin-Proteasome Proteolytic 
Pathway: Destruction for the Sake of Construction. Physiological Reviews 82, pp. 373–428. 
Goding, S.R., Wilson, K.A., Xie, Y., Harris, K.M., Baxi, A., Akpinarli, A., Fulton, A., et al. 
2013. Restoring immune function of tumor-specific CD4+ T cells during recurrence of 
melanoma. The Journal of Immunology 190(9), pp. 4899–4909. 
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C.M., Chagorova, 
T., et al. 2014. Obinutuzumab plus chlorambucil in patients with CLL and coexisting 
conditions. New England Journal of Medicine 370(12), pp. 1101–1110. 
Golden-Mason, L., Palmer, B., Klarquist, J., Mengshol, J.A., Castelblanco, N. and Rosen, 
H.R. 2007. Upregulation of PD-1 Expression on Circulating and Intrahepatic Hepatitis C 
Virus-Specific CD8+ T Cells Associated with Reversible Immune Dysfunction. Journal of 
Virology 81(17), pp. 9249–9258. 
Goldin, L.R., Bjorkholm, M., Kristinsson, S.Y., Turesson, I. and Landgren, O. 2009. 
Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's 
lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica 
94(5), pp. 647–653. 
Gorgun, G., Ramsay, A.G., Holderried, T.A.W., Zahrieh, D., Le Dieu, R., Liu, F., 
Quackenbush, J., et al. 2009. E -TCL1 mice represent a model for immunotherapeutic 
reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proceedings of the 
National Academy of Sciences 106(15), pp. 6250–6255. 
Gourley, T.S., Wherry, E.J., Masopust, D. and Ahmed, R. 2004. Generation and 
maintenance of immunological memory. Seminars in Immunology 16(5), pp. 323–333. 
Görgün, G., Holderried, T.A.W., Zahrieh, D., Neuberg, D. and Gribben, J.G. 2005. 
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T 
cells. The Journal of Clinical Investigation 115(7), pp. 1797–1805. 
Göthert, J.R., Eisele, L., Klein-Hitpass, L., Weber, S., Zesewitz, M.-L., Sellmann, L., Röth, 
A., et al. 2013. Expanded CD8+ T cells of murine and human CLL are driven into a 
senescent KLRG1+ effector memory phenotype. Cancer Immunology, Immunotherapy 62(11), 
pp. 1697–1709. 
Gribben, J.G. 2010. How I treat CLL up front. Blood 115(2), pp. 187–197. 
Gribben, J.G. 2009. Stem cell transplantation in chronic lymphocytic leukemia. Biology of 
blood and marrow transplantation : journal of the American Society for Blood and Marrow 
Transplantation 15(1 Suppl), pp. 53–58. 
  Bibliography !
! Page 251 
Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, 
D.T., et al. 2013. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid 
Leukemia. New England Journal of Medicine 368(16), pp. 1509–1518. 
Hacken, ten, E. and Burger, J.A. 2014. Molecular pathways: targeting the 
microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. Clinical 
Cancer Research 20(3), pp. 548–556. 
Hainsworth, J.D., Litchy, S., Barton, J.H., Houston, G.A., Hermann, R.C., Bradof, J.E. and 
Greco, F.A. 2003. Single-agent rituximab as first-line and maintenance treatment for 
patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II 
trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology 21(9), pp. 
1746–1751. 
Hallek, M. 2005. Chronic Lymphocytic Leukemia (CLL): First-Line Treatment. Hematology 
/ the Education Program of the American Society of Hematology. American Society of Hematology. 
Education Program 2005(1), pp. 285–291. 
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., 
et al. 2010. Addition of rituximab to fludarabine and cyclophosphamide in patients with 
chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747), 
pp. 1164–1174. 
Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. and Stevenson, F.K. 1999. Unmutated 
Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic 
Leukemia. Blood 94(6), pp. 1848–1854. 
Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.-J., Kefford, R., Wolchok, J.D., et al. 
2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New 
England Journal of Medicine 369(2), pp. 134–144. 
Hanna, B., McClanahan, F., Clear, A., Miller, S., Lichter, P., Seiffert, M and Gribben, J. 
2014. Immune Checkpoint Blockade with Anti-PD-L1 Prevents Immune Dysfuntion and 
CLL Development in the TCL1 Adoptive Transfer Mouse Model. 56th American Society of 
Hematology Annual Meeting & Exposition. San Francisco, 6-9 December. Blood 
 
Hannier, S. and Triebel, F. 1999. The MHC class II ligand lymphocyte activation gene-3 is 
co-distributed with CD8 and CD3–TCR molecules after their engagement by mAb or 
peptide–MHC class I complexes. International immunology 11(11), pp. 1745–1752. 
Hannier, S., Tournier, M., Bismuth, G. and Triebel, F. 1998. CD3/TCR complex-
associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. The Journal 
of Immunology 161(8), pp. 4058–4065. 
Hanson, D.A., Kaspar, A.A., Poulain, F.R. and Krensky, A.M. 1999. Biosynthesis of 
granulysin, a novel cytolytic molecule. Molecular Immunology 36(7), pp. 413–422. 
Hardy, L.L., Wick, D.A. and Webb, J.R. 2008. Conversion of tyrosine to the inflammation-
associated analog 3′-nitrotyrosine at either TCR-or MHC-contact positions can profoundly 
affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis 
virus glycoprotein 33 by CD8 T cells. The Journal of Immunology 180(9), pp. 5956–5962. 
Haribhai, D., Williams, J.B., Jia, S., Nickerson, D., Schmitt, E.G., Edwards, B., Ziegelbauer, 
J., et al. 2011. A Requisite Role for Induced Regulatory T Cells in Tolerance Based on 
Expanding Antigen Receptor Diversity. Immunity 35(1), pp. 109–122. 
  Bibliography !
! Page 252 
Harndahl, M., Justesen, S., Lamberth, K., Røder, G., Nielsen, M. and Buus, S. 2009. 
Peptide binding to HLA class I molecules: homogenous, high-throughput screening, and 
affinity assays. Journal of biomolecular screening 14(2), pp. 173–180. 
Hayashida, K., Shimaoka, Y., Ochi, T. and Lipsky, P.E. 2000. Rheumatoid arthritis synovial 
stromal cells inhibit apoptosis and up-regulate Bcl-xL expression by B cells in a 
CD49/CD29-CD106-dependent mechanism. The Journal of Immunology 164(2), pp. 1110–
1116. 
He, L.-Z., Prostak, N., Thomas, L.J., Vitale, L., Weidlick, J., Crocker, A., Pilsmaker, C.D., 
et al. 2013. Agonist anti-human CD27 monoclonal antibody induces T cell activation and 
tumor immunity in human CD27-transgenic mice. The Journal of Immunology 191(8), pp. 
4174–4183. 
Hegazy, A.N., Peine, M., Helmstetter, C., Panse, I., Fröhlich, A., Bergthaler, A., Flatz, L., et 
al. 2010. Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-
bet(+) cell subset with combined Th2 and Th1 cell functions. Immunity 32(1), pp. 116–128. 
Heibein, J.A., Goping, I.S., Barry, M., Pinkoski, M.J., Shore, G.C., Green, D.R. and 
Bleackley, R.C. 2000. Granzyme B-Mediated Cytochrome C Release Is Regulated by the 
Bcl-2 Family Members Bid and Bax. The Journal of Experimental Medicine 192(10), pp. 1391–
1402. 
Herishanu, Y., Perez-Galan, P., Liu, D., Biancotto, A., Pittaluga, S., Vire, B., Gibellini, F., et 
al. 2011. The lymph node microenvironment promotes B-cell receptor signaling, NF- B 
activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117(2), pp. 563–
574. 
Herman, S.E.M., Sun, X., McAuley, E.M., Hsieh, M.M., Pittaluga, S., Raffeld, M., Liu, D., 
et al. 2013. Modeling tumor–host interactions of chronic lymphocytic leukemia in 
xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia 27(12), 
pp. 2311–2321. 
Hendriks, J., Gravestein, L.A., Tesselaar, K., van Lier, R.A., Schumacher, T.N. and Borst, J. 
2000. CD27 is required for generation and long-term maintenance of T cell immunity. 
Nature immunology 1(5), pp. 433–440. 
Hendriks, R.W., Yuvaraj, S. and Kil, L.P. 2014. Targeting Bruton's tyrosine kinase in B cell 
malignancies. Nature Reviews Cancer 14(4), pp. 219–232. 
Henrickson, S.E., Mempel, T.R., Mazo, I.B., Liu, B., Artyomov, M.N., Zheng, H., Peixoto, 
A., et al. 2008. In Vivo Imaging of T Cell Priming. Science Signaling 1(12), pp. pt2–pt2. 
Herman, S.E.M., Gordon, A.L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., 
Flynn, J., et al. 2011. Bruton tyrosine kinase represents a promising therapeutic target for 
treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 
117(23), pp. 6287–6296. 
Hershko, A., Ciechanover, A., Heller, H., Haas, A.L. and Rose, I.A. 1980. Proposed role of 
ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide 
of ATP-dependent proteolysis. Proceedings of the National Academy of Sciences 77(4), pp. 1783–
1786. 
Heslop, H.E. 2010. Safer CARS. Molecular Therapy 18(4), pp. 661–662. 
  Bibliography !
! Page 253 
Hewitt, E.W. 2003. The MHC class I antigen presentation pathway: strategies for viral 
immune evasion. Immunology 110(2), pp. 163–169. 
Hicklin, D.J., Marincola, F.M. and Ferrone, S. 1999. HLA class I antigen downregulation in 
human cancers: T-cell immunotherapy revives an old story. Molecular Medicine Today 5(4), 
pp. 178–186. 
Hinrichs, C.S., Borman, Z.A., Gattinoni, L., Yu, Z., Burns, W.R., Huang, J., Klebanoff, 
C.A., et al. 2011. Human effector CD8+ T cells derived from naive rather than memory 
subsets possess superior traits for adoptive immunotherapy. Blood 117(3), pp. 808–814. 
Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., 
Gonzalez, R., et al. 2010. Improved Survival with Ipilimumab in Patients with Metastatic 
Melanoma. New England Journal of Medicine 363(8), pp. 711–723. 
Hoellenriegel, J., Meadows, S.A., Sivina, M., Wierda, W.G., Kantarjian, H., Keating, M.J., 
Giese, N., et al. 2011. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-
cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 
118(13), pp. 3603–3612. 
Hong, J.J., Rosenberg, S.A., Dudley, M.E., Yang, J.C., White, D.E., Butman, J.A. and 
Sherry, R.M. 2010. Successful Treatment of Melanoma Brain Metastases with Adoptive 
Cell Therapy. Clinical Cancer Research 16(19), pp. 4892–4898. 
Honma, K., Kimura, D., Tominaga, N., Miyakoda, M., Matsuyama, T. and Yui, K. 2008. 
Interferon regulatory factor 4 differentially regulates the production of Th2 cytokines in 
naive vs. effector/memory CD4+ T cells. Proceedings of the National Academy of Sciences 
105(41), pp. 15890–15895. 
Hori, S., Nomura, T. and Sakaguchi, S. 2003. Control of regulatory T cell development by 
the transcription factor Foxp3. Science 299(5609), pp. 1057–1061. 
Hsu, S.C., Gavrilin, M.A., Lee, H.H., Wu, C.C., Han, S.H. and Lai, M.Z. 1999. NF-kappa 
B-dependent Fas ligand expression. European Journal of Immunology 29(9), pp. 2948–2956. 
Huang, C., Bi, E., Hu, Y., Deng, W., Tian, Z., Dong, C., Hu, Y., et al. 2006. A novel NF-
kappaB binding site controls human granzyme B gene transcription. The Journal of 
Immunology 176(7), pp. 4173–4181. 
Huard, B., Prigent, P., Tournier, M., Bruniquel, D. and Triebel, F. 1995. CD4/major 
histocompatibility complex class II interaction analyzed with CD4‐and lymphocyte 
activation gene‐3 (LAG‐3)‐Ig fusion proteins. European Journal of Immunology 25(9), pp. 
2718–2721. 
Hudecek, M., Lupo-Stanghellini, M.T., Kosasih, P.L., Sommermeyer, D., Jensen, M.C., 
Rader, C. and Riddell, S.R. 2013. Receptor Affinity and Extracellular Domain 
Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T 
Cells. Clinical Cancer Research 19(12), pp. 3153–3164. 
Hudecek, M., Schmitt, T.M., Baskar, S., Lupo-Stanghellini, M.T., Nishida, T., Yamamoto, 
T.N., Bleakley, M., et al. 2010. The B-cell tumor-associated antigen ROR1 can be targeted 
with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116(22), 
pp. 4532–4541. 
Hudis, C.A. 2007. Trastuzumab--mechanism of action and use in clinical practice. New 
  Bibliography !
! Page 254 
England Journal of Medicine 357(1), pp. 39–51. 
Ibegbu, C.C., Xu, Y.-X., Harris, W., Maggio, D., Miller, J.D. and Kourtis, A.P. 2005. 
Expression of killer cell lectin-like receptor G1 on antigen-specific human CD8+ T 
lymphocytes during active, latent, and resolved infection and its relation with CD57. The 
Journal of Immunology 174(10), pp. 6088–6094. 
Ito, D., Visus, C., Hoffmann, T.K., Balz, V., Bier, H., Appella, E., Whiteside, T.L., et al. 
2007. Immunological characterization of missense mutations occurring within cytotoxic T 
cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and 
neck. International Journal of Cancer 120(12), pp. 2618–2624. 
Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, J.J., Cua, D.J., 
et al. 2006. The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of 
Proinflammatory IL-17+ T Helper Cells. Cell 126(6), pp. 1121–1133. 
Janeway, C.A. 2012. Janeway's Immunobiology 8th Ed. Garland Science. 
Janeway, C.A. and Medzhitov, R. 2002. Innate immune recognition. Annual Review of 
Immunology 20, pp. 197–216. 
Jäger, D., Jäger, E. and Knuth, A. 2001. Immune responses to tumour antigens: 
implications for antigen specific immunotherapy of cancer. Journal of clinical pathology 54(9), 
pp. 669–674. 
Jiang, S. and Dong, C. 2013. A complex issue on CD4(+) T-cell subsets. Immunological 
reviews 252(1), pp. 5–11. 
Johnson, A.J. 2006. Characterization of the TCL-1 transgenic mouse as a preclinical drug 
development tool for human chronic lymphocytic leukemia. Blood 108(4), pp. 1334–1338. 
Jones, C., Lin, T., Pratt, G., Fegan, C., Baird, D., and Pepper, C. 2013. Longitudinal 
Analysis Reveals Telomere Length Maintenance In CLL B-Cells But Marked Erosion In 
CLL Patient T-Cells. 55th American Society of Hematology Annual Meeting & Exposition. New 
Orleans, 7-10 December. Blood. 
 
Jonker, D.J., O'Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.-J., Berry, S.R., 
et al. 2007. Cetuximab for the Treatment of Colorectal Cancer. New England Journal of 
Medicine 357(20), pp. 2040–2048. 
Ju, S.-T., Panka, D.J., Cui, H., Ettinger, R., EI-Khatib, M., Sherr, D.H., Stanger, B.Z., et al. 
1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell 
activation. Nature 373(6513), pp. 444–448. 
June, C.H. 2007. Adoptive T cell therapy for cancer in the clinic. The Journal of Clinical 
Investigation 117(6), pp. 1466–1476. 
Kaech, S.M. and Cui, W. 2012. Transcriptional control of effector and memory CD8+ T 
cell differentiation. Nature Reviews Immunology 12(11), pp. 749–761. 
Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A. and June, C.H. 2011. 
T cells with chimeric antigen receptors have potent antitumor effects and can establish 
memory in patients with advanced leukemia. Science Translational Medicine 3(95), p. 95ra73. 
Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, 
  Bibliography !
! Page 255 
C.H., et al. 2010. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. 
New England Journal of Medicine 363(5), pp. 411–422. 
Kaspar, A.A., Okada, S., Kumar, J., Poulain, F.R., Drouvalakis, K.A., Kelekar, A., Hanson, 
D.A., et al. 2001. A Distinct Pathway of Cell-Mediated Apoptosis Initiated by Granulysin. 
The Journal of Immunology 167(1), pp. 350–356. 
Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, 
P.F., et al. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 
by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. The Journal of 
Immunology 154(8), pp. 3961–3968. 
Keating, M.J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., et al. 2002. 
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: 
results of a large international study. Blood 99(10), pp. 3554–3561. 
Keir, M.E., Butte, M.J., Freeman, G.J. and Sharpe, A.H. 2008. PD-1 and its ligands in 
tolerance and immunity. Annual Review of Immunology 26, pp. 677–704. 
Kerkar, S.P. and Restifo, N.P. 2012. Cellular constituents of immune escape within the 
tumor microenvironment. Cancer Research 72(13), pp. 3125–3130. 
Kershaw, M.H., Westwood, J.A., Slaney, C.Y. and Darcy, P.K. 2014. Clinical application of 
genetically modified T cells in cancer therapy. Clinical & translational immunology 3(5), p. e16. 
Khaled, Y.S., Ammori, B.J. and Elkord, E. 2013. Myeloid-derived suppressor cells in 
cancer: recent progress and prospects. Immunology and cell biology 91(8), pp. 493–502. 
Khanna, R. 2004. Predictive algorithms and T cell epitope mapping. The Journal of 
Immunology 173(5), pp. 2895–author reply 2895–6. 
Kiaii, S., Kokhaei, P., Mozaffari, F., Rossmann, E., Pak, F., Moshfegh, A., Palma, M., et al. 
2013. T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and 
have altered gene expression profile. Cancer Immunology, Immunotherapy 62(1), pp. 51–63. 
Kim, R., Emi, M. and Tanabe, K. 2007. Cancer immunoediting from immune surveillance 
to immune escape. Immunology 121(1), pp. 1–14. 
Kim, R., Emi, M., Tanabe, K. and Arihiro, K. 2006. Tumor-driven evolution of 
immunosuppressive networks during malignant progression. Cancer Research 66(11), pp. 
5527–5536. 
King, J., Waxman, J. and Stauss, H. 2008. Advances in tumour immunotherapy. QJM : 
monthly journal of the Association of Physicians 101(9), pp. 675–683. 
Klebanoff, C.A., Acquavella, N., Yu, Z. and Restifo, N.P. 2010. Therapeutic cancer 
vaccines: are we there yet? Immunological reviews 239(1), pp. 27–44. 
Klebanoff, C.A., Gattinoni, L. and Restifo, N.P. 2006. CD8+ T-cell memory in tumor 
immunology and immunotherapy. Immunological reviews 211, pp. 214–224. 
Klebanoff, C.A., Gattinoni, L. and Restifo, N.P. 2012. Sorting Through Subsets. Journal of 
Immunotherapy 35(9), pp. 651–660. 
Knauf, W.U., Lissichkov, T., Aldaoud, A., Liberati, A., Loscertales, J., Herbrecht, R., 
  Bibliography !
! Page 256 
Juliusson, G., et al. 2009. Phase III Randomized Study of Bendamustine Compared With 
Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia. 
Journal of Clinical Oncology 27(26), pp. 4378–4384. 
Kobayashi, K.S. and van den Elsen, P.J. 2012. NLRC5: a key regulator of MHC class I-
dependent immune responses. Nature Reviews Immunology 12(12), pp. 813–820. 
Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., 
Stetler-Stevenson, M., et al. 2012. B-cell depletion and remissions of malignancy along with 
cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-
transduced T cells. Blood 119(12), pp. 2709–2720. 
Koelle, D.M., Chen, H.B., Gavin, M.A., Wald, A., Kwok, W.W. and Corey, L. 2001. CD8 
CTL from genital herpes simplex lesions: recognition of viral tegument and immediate 
early proteins and lysis of infected cutaneous cells. The Journal of Immunology 166(6), pp. 
4049–4058. 
Kono, K., Takahashi, A., Ichihara, F., Amemiya, H., Iizuka, H., Fujii, H., Sekikawa, T., et 
al. 2002. Prognostic significance of adoptive immunotherapy with tumor-associated 
lymphocytes in patients with advanced gastric cancer: a randomized trial. Clinical Cancer 
Research 8(6), pp. 1767–1771. 
Koopman, G., Keehnen, R.M., Lindhout, E., Newman, W., Shimizu, Y., van Seventer, 
G.A., de Groot, C., et al. 1994. Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 
(CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of 
germinal center B cells. The Journal of Immunology 152(8), pp. 3760–3767. 
Kouro, T. and Takatsu, K. 2009. IL-5- and eosinophil-mediated inflammation: from 
discovery to therapy. International immunology 21(12), pp. 1303–1309. 
Kurosaki, T., Kometani, K. and Ise, W. 2015. Memory B cells. Nature Reviews Immunology 
15(3), pp. 149–159. 
Landsverk, O.J.B., Bakke, O. and Gregers, T.F. 2009. MHC II and the Endocytic Pathway: 
Regulation by Invariant Chain. Scandinavian Journal of Immunology 70(3), pp. 184–193. 
Larson, R.A., Sievers, E.L., Stadtmauer, E.A., Löwenberg, B., Estey, E.H., Dombret, H., 
Theobald, M., et al. 2005. Final report of the efficacy and safety of gemtuzumab 
ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first 
recurrence. Cancer 104(7), pp. 1442–1452. 
Lee, H.-W., Park, S.-J., Choi, B.K., Kim, H.H., Nam, K.-O. and Kwon, B.S. 2002. 4-1BB 
promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-
1. The Journal of Immunology 169(9), pp. 4882–4888. 
Lee, J., Su, E.W., Zhu, C., Hainline, S., Phuah, J., Moroco, J.A., Smithgall, T.E., et al. 2011. 
Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways. 
Molecular and Cellular Biology 31(19), pp. 3963–3974. 
Li, F.-J., Zhang, Y., Jin, G.-X., Yao, L. and Wu, D.-Q. 2013. Expression of LAG-3 is 
coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC 
patients. Immunology Letters 150(1-2), pp. 116–122. 
Li, Z. 2004. The generation of antibody diversity through somatic hypermutation and class 
switch recombination. Genes & Development 18(1), pp. 1–11. 
  Bibliography !
! Page 257 
 
Lichtenegger, F.S., Schnorfeil, F.M., Emmerig, K., Neitz, J.S., Beck, B., Draenert, R., 
Hiddemann, W., et al. 2013. Pseudo-Exhaustion Of CD8+ T Cells in AML. 55th American 
Society of Hematology Annual Meeting & Exposition. New Orleans, 7-10 December. Blood. 
Lieberman, J. 2010. Anatomy of a murder: how cytotoxic T cells and NK cells are 
activated, develop, and eliminate their targets. Immunological reviews 235(1), pp. 5–9. 
Lin, K., Doolan, K., Hung, C.-F. and Wu, T.-C. 2010. Perspectives for preventive and 
therapeutic HPV vaccines. Journal of the Formosan Medical Association = Taiwan yi zhi 109(1), 
pp. 4–24. 
Linsley, P.S. and Ledbetter, J.A. 1993. The role of the CD28 receptor during T cell 
responses to antigen. Annual Review of Immunology 11, pp. 191–212. 
Liu, D.-W., Yang, Y.-C., Lin, H.-F., Lin, M.-F., Cheng, Y.-W., Chu, C.-C., Tsao, Y.-P., et al. 
2007. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 
proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients. Journal of 
Virology 81(6), pp. 2869–2879. 
Liu, F.T., Agrawal, S.G., Gribben, J.G., Ye, H., Du, M.Q., Newland, A.C. and Jia, L. 2008. 
Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. 
Blood 111(5), pp. 2797–2805. 
Liu, Z., Fan, H. and Jiang, S. 2013. CD4(+) T-cell subsets in transplantation. Immunological 
reviews 252(1), pp. 183–191. 
Lohoff, M., Mittrücker, H.-W., Brüstle, A., Sommer, F., Casper, B., Huber, M., Ferrick, 
D.A., et al. 2004. Enhanced TCR-induced apoptosis in interferon regulatory factor 4-
deficient CD4(+) Th cells. The Journal of Experimental Medicine 200(2), pp. 247–253. 
Long, B.W., Witte, P.L., Abraham, G.N., Gregory, S.A. and Plate, J.M. 1995. Apoptosis 
and interleukin 7 gene expression in chronic B-lymphocytic leukemia cells. Proceedings of the 
National Academy of Sciences 92(5), pp. 1416–1420. 
Long, E.O., Kim, H.S., Liu, D., Peterson, M.E. and Rajagopalan, S. 2013. Controlling 
Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition. Annual 
Review of Immunology 31, pp. 227–258. 
Lotz, M., Jirik, F., Kabouridis, P., Tsoukas, C., Hirano, T., Kishimoto, T. and Carson, D.A. 
1988. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T 
lymphocytes. The Journal of Experimental Medicine 167(3), pp. 1253–1258. 
Lugli, E., Dominguez, M.H., Gattinoni, L., Chattopadhyay, P.K., Bolton, D.L., Song, K., 
Klatt, N.R., et al. 2013. Superior T memory stem cell persistence supports long-lived T cell 
memory. The Journal of Clinical Investigation 123(2), pp. 594–599. 
Luhder, F., Huang, Y., Dennehy, K.M., Guntermann, C., Muller, I., Winkler, E., Kerkau, 
T., et al. 2003. Topological Requirements and Signaling Properties of T Cell-activating, 
Anti-CD28 Antibody Superagonists. The Journal of Experimental Medicine 197(8), pp. 955–
966. 
Lukenbill, J. and Kalaycio, M. 2013. Fludarabine: A review of the clear benefits and 
potential harms. Leukemia research 37(9), pp. 986–994. 
  Bibliography !
! Page 258 
Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, 
L., et al. 2002. Phase II trial of subcutaneous anti-CD52 monoclonal antibody 
alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic 
lymphocytic leukemia (B-CLL). Blood 100(3), pp. 768–773. 
Lundt, B.F., Johansen, N.L. and Markussen, J. 1979. FORMATION AND SYNTHESIS 
OF 3 ‘‐t‐BUTYLTYROSINE. International journal of peptide and protein research 14(4), pp. 344–
346. 
Mackus, W.J.M. 2003. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-
cell chronic lymphocytic leukemia. Blood 102(3), pp. 1057–1063. 
Maeurer, M.J., Necker, A., Salter, R.D., Castelli, C., Höhn, H., Karbach, J., Freitag, K., et al. 
2002. Improved detection of melanoma antigen‐specific T cells expressing low or high 
levels of CD8 by HLA‐A2 tetramers presenting a Melan‐A/Mart‐1 peptide analogue. 
International Journal of Cancer 97(1), pp. 64–71. 
Mainou-Fowler, T., Craig, V.A., Copplestone, J.A., Hamon, M.D. and Prentice, A.G. 1994. 
Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic 
leukemia cells in vitro independently of bcl-2 expression and is inhibited by IL-4. Blood 
84(7), pp. 2297–2304. 
Majid, A., Lin, T.T., Best, G., Fishlock, K., Hewamana, S., Pratt, G., Yallop, D., et al. 2011. 
CD49d is an independent prognostic marker that is associated with CXCR4 expression in 
CLL. Leukemia research 35(6), pp. 750–756. 
Malavasi, F., Deaglio, S., Damle, R., Cutrona, G., Ferrarini, M. and Chiorazzi, N. 2011. 
CD38 and chronic lymphocytic leukemia: a decade later. Blood 118(13), pp. 3470–3478. 
Maloney, D.G., Grillo-López, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., 
Janakiraman, N., et al. 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody 
therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6), pp. 
2188–2195. 
Mannering, S.I., Purcell, A.W., Honeyman, M.C., McCluskey, J. and Harrison, L.C. 2003. 
Human T-cells recognise N-terminally Fmoc-modified peptide. Vaccine 21(25-26), pp. 
3638–3646. 
Mantovani, A., Cassatella, M.A., Costantini, C. and Jaillon, S. 2011. Neutrophils in the 
activation and regulation of innate and adaptive immunity. Nature Reviews Immunology 11(8), 
pp. 519–531. 
Mariotti, S. and Nisini, R. 2009. Generation of human T cell clones. Methods in molecular 
biology (Clifton, N.J.) 514, pp. 65–93. 
Marks, M.S., Roche, P.A., van Donselaar, E., Woodruff, L., Peters, P.J. and Bonifacino, J.S. 
1995. A lysosomal targeting signal in the cytoplasmic tail of the beta chain directs HLA-
DM to MHC class II compartments. The Journal of Cell Biology 131(2), pp. 351–369. 
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, 
C., et al. 2010. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively 
regulated by LAG-3 and PD-1 in human ovarian cancer. Proceedings of the National Academy of 
Sciences 107(17), pp. 7875–7880. 
Maupin-Furlow, J. 2011. Proteasomes and protein conjugation across domains of life. 
  Bibliography !
! Page 259 
Nature Reviews Microbiology 10(2), pp. 100–111. 
Maus, M.V., Grupp, S.A., Porter, D.L. and June, C.H. 2014. Antibody-modified T cells: 
CARs take the front seat for hematologic malignancies. Blood 123(17), pp. 2625–2635. 
Mayr, C., Bund, D., Schlee, M., Bamberger, M., Kofler, D.M., Hallek, M. and Wendtner, 
C.-M. 2006. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic 
leukemia by CD8+ autologous T lymphocytes. Experimental Hematology 34(1), pp. 44–53. 
Mayr, C., Bund, D., Schlee, M., Moosmann, A., Kofler, D.M., Hallek, M. and Wendtner, 
C.-M. 2005. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic 
lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T 
lymphocytes. Blood 105(4), pp. 1566–1573. 
McClanahan, F., Miller, S., Riches, J., Ghazaly, E., Day, W., Capasso, M., and Gribben, J. 
2013. T-Cell Dysfunction In CLL Is Mediated Not Only By PD-1/PD-L1 But Also By 
PD-1/PD-L2 Interactions - Partial Functionality Is Maintained In PD-1 Defined CD8 
Subsets and This Can Be Further Promoted By Ibrutinib Treatment. 55th American Society of 
Hematology Annual Meeting & Exposition. New Orleans, 7-10 December. Blood. 
 
McClanahan, F., Riches, J., Ghazaly, E., Hanna, B., Day, W., Capasso, M., and Gribben, J. 
2014. PD-1/PD-L1 mediated T-cell dysfunction in CLL is not absolute and can be at least 
partially reversed in vivo by the immune-modulatory drug lenalidomide. NCRI Cancer 
Conference. London, 2 - 5 November.  
 
McMahan, R.H., Golden-Mason, L., Nishimura, M.I., McMahon, B.J., Kemper, M., Allen, 
T.M., Gretch, D.R., et al. 2010. Tim-3 expression on PD-1+ HCV-specific human CTLs is 
associated with viral persistence, and its blockade restores hepatocyte-directed in vitro 
cytotoxicity. The Journal of Clinical Investigation 120(12), p. 4546. 
Medzhitov, R. and Janeway, C.A. 2002. Decoding the patterns of self and nonself by the 
innate immune system. Science 296(5566), pp. 298–300. 
Mempel, T.R., Henrickson, S.E. and Andrian, von, U.H. 2004. T-cell priming by 
dendriticcells in lymph nodes occurs in three distinct phases. Nature 427(6970), pp. 154–
159. 
Menendez, D., Inga, A. and Resnick, M.A. 2009. The expanding universe of p53 targets. 
Nature Reviews Cancer 9(10), pp. 724–737. 
Messmer, B.T., Messmer, D., Allen, S.L., Kolitz, J.E., Kudalkar, P., Cesar, D., Murphy, E.J., 
et al. 2005. In vivo measurements document the dynamic cellular kinetics of chronic 
lymphocytic leukemia B cells. The Journal of Clinical Investigation 115(3), pp. 755–764. 
Meydan, C., Otu, H.H. and Sezerman, O. 2013. Prediction of peptides binding to MHC 
class I and II alleles by temporal motif mining. BMC Bioinformatics 14(Suppl 2), p. S13. 
Mittendorf, E.A., Clifton, G.T., Holmes, J.P., Clive, K.S., Patil, R., Benavides, L.C., Gates, 
J.D., et al. 2011. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast 
cancer recurrence in high-risk patients. Cancer 118(10), pp. 2594–2602. 
Montillo, M., Ricci, F., Miqueleiz, S., Tedeschi, A. and Morra, E. 2008. Alemtuzumab in the 
treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL). Biologics : 
targets & therapy 2(1), pp. 41–52. 
  Bibliography !
! Page 260 
Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M. and Rosenberg, S.A. 
2010. Case Report of a Serious Adverse Event Following the Administration of T Cells 
Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Molecular Therapy 
18(4), pp. 843–851. 
Morrison, V.A. 2010. Infectious complications of chronic lymphocytic leukaemia: 
pathogenesis, spectrum of infection, preventive approaches. Best practice & research. Clinical 
haematology 23(1), pp. 145–153. 
Muniz, V.S., Weller, P.F. and Neves, J.S. 2012. Eosinophil crystalloid granules: structure, 
function, and beyond. Journal of leukocyte biology 92(2), pp. 281–288. 
Murray, P.J. and Wynn, T.A. 2011. Protective and pathogenic functions of macrophage 
subsets. Nature Reviews Immunology 11(11), pp. 723–737. 
Nakayamada, S., Takahashi, H., Kanno, Y. and O'Shea, J.J. 2012. Helper T cell diversity 
and plasticity. Current opinion in immunology 24(3), pp. 297–302. 
Nandi, D., Jiang, H. and Monaco, J.J. 1996. Identification of MECL-1 (LMP-10) as the 
third IFN-gamma-inducible proteasome subunit. The Journal of Immunology 156(7), pp. 2361–
2364. 
Neefjes, J., Jongsma, M.L.M., Paul, P. and Bakke, O. 2011. Towards a systems 
understanding of MHC class I and MHC class II antigen presentation. Nature Reviews 
Immunology 11(12), pp. 823–836. 
Neefjes, J.J., Momburg, F. and Hämmerling, G.J. 1993. Selective and ATP-dependent 
translocation of peptides by the MHC-encoded transporter. Science 261(5122), pp. 769–771. 
Ngiow, S.F., Scheidt, von, B., Akiba, H., Yagita, H., Teng, M.W.L. and Smyth, M.J. 2011. 
Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and 
Suppresses Established Tumors. Cancer Research 71(10), pp. 3540–3551. 
Noelle, R.J., Roy, M., Shepherd, D.M., Stamenkovic, I., Ledbetter, J.A. and Aruffo, A. 
1992. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal 
for cognate activation of B cells. Proceedings of the National Academy of Sciences of the United 
States of America 89(14), pp. 6550–6554. 
Nunes, C., Wong, R., Mason, M., Fegan, C., Man, S. and Pepper, C. 2012. Expansion of a 
CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated 
with Inverted CD4:CD8 Ratios and Disease Progression. Clinical Cancer Research 18(3), pp. 
678–687. 
Nunes, C.T., Miners, K.L., Dolton, G., Pepper, C., Fegan, C., Mason, M.D. and Man, S. 
2011. A novel tumor antigen derived from enhanced degradation of bax protein in human 
cancers. Cancer Research 71(16), pp. 5435–5444. 
Nurieva, R.I., Chung, Y., Martinez, G.J., Yang, X.O., Tanaka, S., Matskevitch, T.D., Wang, 
Y.H., et al. 2009. Bcl6 Mediates the Development of T Follicular Helper Cells. Science 
325(5943), pp. 1001–1005. 
Nückel, H., Switala, M., Collins, C.H., Sellmann, L., Grosse-Wilde, H., Dührsen, U. and 
Rebmann, V. 2009. High CD49d protein and mRNA expression predicts poor outcome in 
chronic lymphocytic leukemia. Clinical Immunology 131(3), pp. 472–480. 
  Bibliography !
! Page 261 
Ochsenbein, A.F. 2004. CD27 Expression Promotes Long-Term Survival of Functional 
Effector-Memory CD8+ Cytotoxic T Lymphocytes in HIV-infected Patients. The Journal of 
Experimental Medicine 200(11), pp. 1407–1417. 
Oh, J.M., Kim, S.H., Cho, E.A., Song, Y.S., Kim, W.H. and Juhnn, Y.S. 2010. Human 
papillomavirus type 16 E5 protein inhibits hydrogen peroxide-induced apoptosis by 
stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer 
cells. Carcinogenesis 31(3), pp. 402–410. 
Okada, R., Kondo, T., Matsuki, F., Takata, H. and Takiguchi, M. 2008. Phenotypic 
classification of human CD4+ T cell subsets and their differentiation. International 
immunology 20(9), pp. 1189–1199. 
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. and Honjo, T. 2001. PD-1 
immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-
domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proceedings of the National 
Academy of Sciences 98(24), pp. 13866–13871. 
Oldreive, C., Skowronska, A., Agathanggelou, A., Parry, H., Krysov, S., Packham, G., 
Zbgniew, R., et al. 2014. Primary CLL Xenograft: A Model System to Study the Role of T-
Cells in CLL Biology and Therapeutic Response. 56th American Society of Hematology Annual 
Meeting & Exposition. San Francisco, 6-9 December. Blood 
 
Olivier, M., Hollstein, M. and Hainaut, P. 2010. TP53 Mutations in Human Cancers: 
Origins, Consequences, and Clinical Use. Cold Spring Harbor Perspectives in Biology 2(1), pp. 
a001008–a001008. 
Olson, J.A. and Jameson, S.C. 2011. Keeping STATs on Memory CD8+ T Cells. Immunity 
35(5), pp. 663–665. 
Olsson, J., Wikby, A., Johansson, B., Löfgren, S., Nilsson, B.O. and Ferguson, F.G. 2000. 
Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus 
infection in the very old: the Swedish longitudinal OCTO immune study. Mechanisms of 
Ageing and Development 121(1-3), pp. 187–201. 
Onishi, Y., Fehervari, Z., Yamaguchi, T. and Sakaguchi, S. 2008. Foxp3+ natural regulatory 
T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their 
maturation. Proceedings of the National Academy of Sciences 105(29), pp. 10113–10118. 
Os, A., Bürgler, S., Ribes, A.P., Funderud, A., Wang, D., Thompson, K.M., Tjønnfjord, 
G.E., et al. 2013. Chronic Lymphocytic Leukemia Cells Are Activated and Proliferate in 
Response to Specific T Helper Cells. Cell Reports 4(3), pp. 566–577. 
 
Osorio, L.M., Aguilar-Santelises, M., De Santiago, A., Hachiya, T., Mellstedt, H. and 
Jondal, M. 2001. Increased serum levels of soluble Fas in progressive B-CLL. European 
Journal of Haematology 66(5), pp. 342–346. 
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C.M., Chow, S.-N., Apter, D., Kitchener, H., 
et al. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine 
against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): 
final analysis of a double-blind, randomised study in young women. Lancet 374(9686), pp. 
301–314. 
Palmer, B.E., Blyveis, N., Fontenot, A.P. and Wilson, C.C. 2005. Functional and 
phenotypic characterization of CD57+CD4+ T cells and their association with HIV-1-
  Bibliography !
! Page 262 
induced T cell dysfunction. The Journal of Immunology 175(12), pp. 8415–8423. 
Palucka, K. and Banchereau, J. 2012. Cancer immunotherapy via dendritic cells. Nature 
Reviews Cancer 12(4), pp. 265–277. 
Palucka, K. and Banchereau, J. 2013. Dendritic-Cell-Based Therapeutic Cancer Vaccines. 
Immunity 39(1), pp. 38–48. 
Parkhurst, M.R., Salgaller, M.L., Southwood, S., Robbins, P.F., Sette, A., Rosenberg, S.A. 
and Kawakami, Y. 1996. Improved induction of melanoma-reactive CTL with peptides 
from the melanoma antigen gp100 modified at HLA-A* 0201-binding residues. The Journal 
of Immunology 157(6), pp. 2539–2548. 
Parry, R.V., Chemnitz, J.M., Frauwirth, K.A., Lanfranco, A.R., Braunstein, I., Kobayashi, 
S.V., Linsley, P.S., et al. 2005. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by 
Distinct Mechanisms. Molecular and Cellular Biology 25(21), pp. 9543–9553. 
Patten, P.E.M., Buggins, A.G.S., Richards, J., Wotherspoon, A., Salisbury, J., Mufti, G.J., 
Hamblin, T.J., et al. 2008. CD38 expression in chronic lymphocytic leukemia is regulated 
by the tumor microenvironment. Blood 111(10), pp. 5173–5181. 
Pede, V., Rombout, A., Vermeire, J., Naessens, E., Vanderstraeten, H., Philippé, J. and 
Verhasselt, B. 2013. Expression of ZAP70 in chronic lymphocytic leukaemia activates NF-
κB signalling. British Journal of Haematology 163(5), pp. 621–630. 
Penel, N., Adenis, A. and Bocci, G. 2012. Cyclophosphamide-based metronomic 
chemotherapy: after 10 years of experience, where do we stand and where are we going? 
Critical reviews in oncology/hematology 82(1), pp. 40–50. 
Pepper, C., Ward, R., Lin, T.T., Brennan, P., Starczynski, J., Musson, M., Rowntree, C., et 
al. 2007. Highly purified CD38+ and CD38- sub-clones derived from the same chronic 
lymphocytic leukemia patient have distinct gene expression signatures despite their 
monoclonal origin. Leukemia 21(4), pp. 687–696. 
Pettitt, A.R. 2003. Mechanism of action of purine analogues in chronic lymphocytic 
leukaemia. British Journal of Haematology 121(5), pp. 692–702. 
Pham, C.D., Woo, M.Y., Kim, Y.S., Park, S. and Kwon, M.H. 2012. An Anti-Nucleic Acid 
Antibody Delivers Antigen to the Cross-Presentation Pathway in Dendritic Cells and 
Potentiates Therapeutic Antitumor Effects. The Journal of Immunology 189(12), pp. 5755–
5763. 
Plunkett, F.J., Franzese, O., Finney, H.M., Fletcher, J.M., Belaramani, L.L., Salmon, M., 
Dokal, I., et al. 2007. The Loss of Telomerase Activity in Highly Differentiated 
CD8+CD28-CD27- T Cells Is Associated with Decreased Akt (Ser473) Phosphorylation. 
The Journal of Immunology 178(12), pp. 7710–7719. 
Ponader, S., Chen, S.-S., Buggy, J.J., Balakrishnan, K., Gandhi, V., Wierda, W.G., Keating, 
M.J., et al. 2012. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic 
lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5), pp. 
1182–1189. 
Porakishvili, N., Roschupkina, T., Kalber, T., Jewell, A.P., Patterson, K., Yong, K. and 
Lydyard, P.M. 2001. Expansion of CD4+ T cells with a cytotoxic phenotype in patients 
with B‐chronic lymphocytic leukaemia (B‐CLL). Clinical and experimental immunology 126(1), 
  Bibliography !
! Page 263 
pp. 29–36. 
Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. and June, C.H. 2011. Chimeric Antigen 
Receptor–Modified T Cells in Chronic Lymphoid Leukemia. New England Journal of Medicine 
365(8), pp. 725–733. 
Pourgheysari, B., Bruton, R., Parry, H., Billingham, L., Fegan, C., Murray, J. and Moss, P. 
2010. The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in 
patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell 
repertoire. Blood 116(16), pp. 2968–2974. 
Prosser, M.E., Brown, C.E., Shami, A.F., Forman, S.J. and Jensen, M.C. 2012. Tumor PD-
L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 
chimeric receptor. Molecular Immunology 51(3-4), pp. 263–272. 
Qiao, M., Thornton, A.M. and Shevach, E.M. 2007. CD4+ CD25+ regulatory T cells 
render naive CD4+ CD25- T cells anergic and suppressive. Immunology 120(4), pp. 447–455. 
Qureshi, O.S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E.M., Baker, 
J., et al. 2011. Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-
Extrinsic Function of CTLA-4. Science 332(6029), pp. 600–603. 
Raa, te, G.D., Pascutti, M.F., García-Vallejo, J.J., Reinen, E., Remmerswaal, E.B., Berge, 
ten, I.J., van Lier, R.A., et al. 2014. CMV-specific CD8+ T-cell function is not impaired in 
chronic lymphocytic leukemia. Blood 123(5), pp. 717–724. 
Raghavan, M., Del Cid, N., Rizvi, S.M. and Peters, L.R. 2008. MHC class I assembly: out 
and about. Trends in Immunology 29(9), pp. 436–443. 
Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N. and Pasternack, B.S. 
1975. Clinical staging of chronic lymphocytic leukemia. Blood 46(2), pp. 219–234. 
Rajasagi, M., Shukla, S.A., Fritsch, E.F., Keskin, D.B., DeLuca, D., Carmona, E., Zhang, 
W., et al. 2014. Systematic identification of personal tumor-specific neoantigens in chronic 
lymphocytic leukemia. Blood 124(3), pp. 453–462. 
Ramsay, A.G., Clear, A.J., Fatah, R. and Gribben, J.G. 2012. Multiple inhibitory ligands 
induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that 
can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in 
human cancer. Blood 120(7), pp. 1412–1421. 
Ramsay, A.G., Johnson, A.J., Lee, A.M., Görgün, G., Le Dieu, R., Blum, W., Byrd, J.C., et 
al. 2008. Chronic lymphocytic leukemia T cells show impaired immunological synapse 
formation that can be reversed with an immunomodulating drug. The Journal of Clinical 
Investigation. 
Rangachari, M., Zhu, C., Sakuishi, K., Xiao, S., Karman, J., Chen, A., Angin, M., et al. 2012. 
Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell 
death and exhaustion. Nature medicine 18(9), pp. 1394–1400. 
Rassenti, L.Z., Jain, S., Keating, M.J., Wierda, W.G., Grever, M.R., Byrd, J.C., Kay, N.E., et 
al. 2008. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in 
predicting aggressive disease in chronic lymphocytic leukemia. Blood 112(5), pp. 1923–1930. 
Redaelli, A., Laskin, B.L., Stepehens, J.M., Bottenman, M.F. and Pashos, C.L. 2004. The 
  Bibliography !
! Page 264 
clinical and epidemiological burden of chronic lymphocytic leukaemia. European journal of 
cancer care 13(3), pp. 279–287. 
Relland, L.M., Mishra, M.K., Haribhai, D., Edwards, B., Ziegelbauer, J. and Williams, C.B. 
2009. Affinity-based selection of regulatory T cells occurs independent of agonist-mediated 
induction of Foxp3 expression. The Journal of Immunology 182(3), pp. 1341–1350. 
Rezk, S.A. and Weiss, L.M. 2007. Epstein-Barr virus–associated lymphoproliferative 
disorders. Human Pathology 38(9), pp. 1293–1304. 
Ricci, F., Tedeschi, A., Morra, E. and Montillo, M. 2009. Fludarabine in the treatment of 
chronic lymphocytic leukemia: a review. Therapeutics and clinical risk management 5(1), pp. 
187–207. 
Richardson, S.J., Matthews, C., Catherwood, M.A., Alexander, H.D., Carey, B.S., Farrugia, 
J., Gardiner, A., et al. 2006. ZAP-70 expression is associated with enhanced ability to 
respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). 
Blood 107(9), pp. 3584–3592. 
Riches, J.C., Davies, J.K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A.G., 
et al. 2013. T cells from CLL patients exhibit features of T-cell exhaustion but retain 
capacity for cytokine production. Blood 121(9), pp. 1612–1621. 
Riedl, S.J. and Salvesen, G.S. 2007. The apoptosome: signalling platform of cell death. 
Nature Reviews Molecular Cell Biology 8(5), pp. 405–413. 
Riese, R.J., Wolf, P.R., Brömme, D., Natkin, L.R., Villadangos, J.A., Ploegh, H.L. and 
Chapman, H.A. 1996. Essential role for cathepsin S in MHC class II-associated invariant 
chain processing and peptide loading. Immunity 4(4), pp. 357–366. 
Rincón, M. and Flavell, R.A. 1994. AP-1 transcriptional activity requires both T-cell 
receptor-mediated and co-stimulatory signals in primary T lymphocytes. The EMBO Journal 
13(18), pp. 4370–4381. 
Rivoltini, L., Carrabba, M., Huber, V., Castelli, C., Novellino, L., Dalerba, P., Mortarini, R., 
et al. 2002. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. 
Immunological reviews 188(1), pp. 97–113. 
Robak, T., Dmoszynska, A., Solal-Celigny, P., Warzocha, K., Loscertales, J., Catalano, J., 
Afanasiev, B.V., et al. 2010. Rituximab Plus Fludarabine and Cyclophosphamide Prolongs 
Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in 
Previously Treated Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 28(10), pp. 
1756–1765. 
Roche, P.A. and Cresswell, P. 1990. Invariant chain association with HLA-DR molecules 
inhibits immunogenic peptide binding. Nature 345(6276), pp. 615–618. 
Roche, P.A., Marks, M.S. and Cresswell, P.J. 1991. Formation of a nine-subunit complex by 
HLA class II glycoproteins and the invariant chain. Nature 354(6352), pp. 392–394. 
Rock, K.L. and Shen, L. 2005. Cross-presentation: underlying mechanisms and role in 
immune surveillance. Immunological reviews 207(1), pp. 166–183. 
Rodig, S.J., Abramson, J.S., Pinkus, G.S., Treon, S.P., Dorfman, D.M., Dong, H.Y., Shipp, 
M.A., et al. 2006. Heterogeneous CD52 Expression among Hematologic Neoplasms: 
  Bibliography !
! Page 265 
Implications for the Use of Alemtuzumab (CAMPATH-1H). Clinical Cancer Research 12(23), 
pp. 7174–7179. 
Rodríguez-Pinto, D. 2005. B cells as antigen presenting cells. Cellular immunology 238(2), pp. 
67–75. 
Romero, P., Zippelius, A., Kurth, I., Pittet, M.J., Touvrey, C., Iancu, E.M., Corthesy, P., et 
al. 2007. Four functionally distinct populations of human effector-memory CD8+ T 
lymphocytes. The Journal of Immunology 178(7), pp. 4112–4119. 
Rose, D.M., Han, J. and Ginsberg, M.H. 2002. alpha4 integrins and the immune response. 
Immunological reviews 186(1), pp. 118–124. 
Rosenberg, H.F., Dyer, K.D. and Foster, P.S. 2012. Eosinophils: changing perspectives in 
health and disease. Nature Reviews Immunology 13(1), pp. 9–22. 
Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A. and Dudley, M.E. 2008. Adoptive 
cell transfer: a clinical path to effective cancer immunotherapy. Nature Reviews Cancer 8(4), 
pp. 299–308. 
Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, 
S.L., Restifo, N.P., et al. 1998. Immunologic and therapeutic evaluation of a synthetic 
peptide vaccine for the treatment of patients with metastatic melanoma. Nature medicine 
4(3), pp. 321–327. 
Rosenberg, S.A., Yang, J.C., Sherry, R.M., Kammula, U.S., Hughes, M.S., Phan, G.Q., 
Citrin, D.E., et al. 2011. Durable complete responses in heavily pretreated patients with 
metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research 17(13), 
pp. 4550–4557. 
Rossi, D., Khiabanian, H., Spina, V., Ciardullo, C., Bruscaggin, A., Famà, R., Rasi, S., et al. 
2014. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. 
Blood 123(14), pp. 2139–2147. 
Rudd, C.E., Taylor, A. and Schneider, H. 2009. CD28 and CTLA-4 coreceptor expression 
and signal transduction. Immunological reviews 229(1), pp. 12–26. 
Ruella, M., Barrett, D., Kenderian, S., Shestova, O., Hofmann, T., Scholler, J., Lacey, S., et 
al. 2014. Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative 
Relapses Occurring after CD19-Targeted Immunotherapies. 56th American Society of 
Hematology Annual Meeting & Exposition. San Francisco, 6-9 December. Blood. 
 
Rufer, N., Migliaccio, M., Antonchuk, J., Humphries, R.K., Roosnek, E. and Lansdorp, 
P.M. 2001. Transfer of the human telomerase reverse transcriptase (TERT) gene into T 
lymphocytes results in extension of replicative potential. Blood 98(3), pp. 597–603. 
Sakaguchi, S., Yamaguchi, T., Nomura, T. and Ono, M. 2008. Regulatory T Cells and 
Immune Tolerance. Cell 133(5), pp. 775–787. 
Sakhdari, A., Mujib, S., Vali, B., Yue, F.Y., MacParland, S., Clayton, K., Jones, R.B., et al. 
2012. Tim-3 Negatively Regulates Cytotoxicity in Exhausted CD8+ T Cells in HIV 
Infection Lichterfeld, M. ed. PLoS ONE 7(7), p. e40146. 
Sakuishi, K., Apetoh, L., Sullivan, J.M., Blazar, B.R., Kuchroo, V.K. and Anderson, A.C. 
2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-
  Bibliography !
! Page 266 
tumor immunity. The Journal of Experimental Medicine 207(10), pp. 2187–2194. 
Sakuishi, K., Jayaraman, P., Behar, S.M., Anderson, A.C. and Kuchroo, V.K. 2011. 
Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends in Immunology 32(8), 
pp. 345–349. 
Saliba, A.-E., Westermann, A.J., Gorski, S.A. and Vogel, J. 2014. Single-cell RNA-seq: 
advances and future challenges. Nucleic Acids Research 42(14), pp. 8845–8860. 
Sallusto, F., Geginat, J. and Lanzavecchia, A. 2004. Central memory and effector memory 
T cell subsets: function, generation, and maintenance. Annual Review of Immunology 22, pp. 
745–763. 
Sallusto, F., Lenig, D., Förster, R., Lipp, M. and Lanzavecchia, A. 1999. Two subsets of 
memory T lymphocytes with distinct homing potentials and effector functions. Nature 
401(6754), pp. 708–712. 
Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R., et 
al. 2006. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung 
Cancer. New England Journal of Medicine 355(24), pp. 2542–2550. 
Saunders, A.E. and Johnson, P. 2010. Modulation of immune cell signalling by the 
leukocyte common tyrosine phosphatase, CD45. Cellular signalling 22(3), pp. 339–348. 
Savina, A. and Amigorena, S. 2007. Phagocytosis and antigen presentation in dendritic 
cells. Immunological reviews 219, pp. 143–156. 
Schall, T.J., Bacon, K., Toy, K.J. and Goeddel, D.V. 1990. Selective attraction of 
monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 
347(6294), pp. 669–671. 
Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J. and Hasmann, M. 2009. 
Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination 
treatment on HER2-positive human xenograft tumor models. Cancer Research 69(24), pp. 
9330–9336. 
Schluns, K.S., Kieper, W.C., Jameson, S.C. and Lefrançois, L. 2000. Interleukin-7 mediates 
the homeostasis of naïve and memory CD8 T cells in vivo. Nature immunology 1(5), pp. 426–
432. 
Schmidt, S.M., Schag, K., Müller, M.R., Weck, M.M., Appel, S., Kanz, L., Grünebach, F., et 
al. 2003. Survivin is a shared tumor-associated antigen expressed in a broad variety of 
malignancies and recognized by specific cytotoxic T cells. Blood 102(2), pp. 571–576. 
Scholler, J., Brady, T.L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K.M., Vogel, 
A.N., et al. 2012. Decade-long safety and function of retroviral-modified chimeric antigen 
receptor T cells. Science Translational Medicine 4(132), p. 132ra53. 
Schultze, J.L., Michalak, S., Seamon, M.J., Dranoff, G., Jung, K., Daley, J., Delgado, J.C., et 
al. 1997. CD40-activated human B cells: an alternative source of highly efficient antigen 
presenting cells to generate autologous antigen-specific T cells for adoptive 
immunotherapy. The Journal of Clinical Investigation 100(11), pp. 2757–2765. 
Schroeder, H.W. and Cavacini, L. 2010. Structure and function of immunoglobulins. The 
Journal of allergy and clinical immunology 125(2 Suppl 2), pp. S41–52. 
  Bibliography !
! Page 267 
 
Schumacher, T.N.M. 2002. T-cell-receptor gene therapy. Nature Reviews Immunology 2(7), pp. 
512–519. 
Schwartzentruber, D.J., Lawson, D.H., Richards, J.M., Conry, R.M., Miller, D.M., 
Treisman, J., Gailani, F., et al. 2011. gp100 Peptide Vaccine and Interleukin-2 in Patients 
with Advanced Melanoma. New England Journal of Medicine 364(22), pp. 2119–2127. 
Schwarz, K., van Den Broek, M., Kostka, S., Kraft, R., Soza, A., Schmidtke, G., Kloetzel, 
P.M., et al. 2000. Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, 
but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic 
choriomeningitis virus T cell epitope. The Journal of Immunology 165(2), pp. 768–778. 
Scott, A.M., Wolchok, J.D. and Old, L.J. 2012. Antibody therapy of cancer. Nature Reviews 
Cancer 12(4), pp. 278–287. 
Scott, F.L., Stec, B., Pop, C., Dobaczewska, M.K., Lee, J.J., Monosov, E., Robinson, H., et 
al. 2009. The Fas-FADD death domain complex structure unravels signalling by receptor 
clustering. Nature 457(7232), pp. 1019–1022. 
Seifert, M., Sellmann, L., Bloehdorn, J., Wein, F., Stilgenbauer, S., Dürig, J. and Küppers, 
R. 2012. Cellular origin and pathophysiology of chronic lymphocytic leukemia. The Journal of 
Experimental Medicine 209(12), pp. 2183–2198. 
Serrano, D., Monteiro, J., Allen, S.L., Kolitz, J., Schulman, P., Lichtman, S.M., Buchbinder, 
A., et al. 1997. Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets 
in chronic lymphocytic leukemia. The Journal of Immunology 158(3), pp. 1482–1489. 
Sharpe, A.H. and Freeman, G.J. 2002. THE B7–CD28 SUPERFAMILY. Nature Reviews 
Immunology 2(2), pp. 116–126. 
Shen, L., Sigal, L.J., Boes, M. and Rock, K.L. 2004. Important role of cathepsin S in 
generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 
21(2), pp. 155–165. 
Shi, L., Sings, H.L., Bryan, J.T., Wang, B., Wang, Y., Mach, H., Kosinski, M., et al. 2007. 
GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to 
bed-side. Clinical pharmacology and therapeutics 81(2), pp. 259–264. 
Sica, A., Dorman, L., Viggiano, V., Cippitelli, M., Ghosh, P., Rice, N. and Young, H.A. 
1997. Interaction of NF-κB and NFAT with the interferon-γ promoter. The Journal of 
biological chemistry 272(48), pp. 30412–30420. 
Simone, R., Marsilio, S., Patten, P., Ferrer, G., Chen, S., Yan, X., Vergani, S., et al. 2013. 
Lenalidomide Promotes The Expansion Of CD8 T Cells With An Effector Memory 
Phenotype In a Murine Xenograft Model Of Chronic Lymphocytic Leukemia. 55th 
American Society of Hematology Annual Meeting & Exposition. New Orleans, 7-10 December. 
Blood. 
 
Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, 
T., et al. 2001. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for 
Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine 
344(11), pp. 783–792. 
  Bibliography !
! Page 268 
Slingluff, C.L., Jr 2011. The Present and Future of Peptide Vaccines for Cancer. The Cancer 
Journal 17(5), pp. 343–350. 
Sloan, V.S., Cameron, P., Porter, G., Gammon, M., Amaya, M., Mellins, E. and Zaller, 
D.M. 1995. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 
375(6534), pp. 802–806. 
Smith, D.M., Benaroudj, N. and Goldberg, A. 2006. Proteasomes and their associated 
ATPases: A destructive combination. Journal of Structural Biology 156(1), pp. 72–83. 
Song, D.G., Ye, Q., Poussin, M., Harms, G.M., Figini, M. and Powell, D.J. 2012. CD27 
costimulation augments the survival and antitumor activity of redirected human T cells in 
vivo. Blood 119(3), pp. 696–706. 
Speedy, H.E., Di Bernardo, M.C., Sava, G.P., Dyer, M.J.S., Holroyd, A., Wang, Y., Sunter, 
N.J., et al. 2013. A genome-wide association study identifies multiple susceptibility loci for 
chronic lymphocytic leukemia. Nature Genetics 46(1), pp. 56–60. 
Srinivasan, L., Sasaki, Y., Calado, D.P., Zhang, B., Paik, J.H., DePinho, R.A., Kutok, J.L., et 
al. 2009. PI3 Kinase Signals BCR-Dependent Mature B Cell Survival. Cell 139(3), pp. 573–
586. 
Stavnezer, J., Guikema, J.E.J. and Schrader, C.E. 2008. Mechanism and regulation of class 
switch recombination. Annual Review of Immunology 26, pp. 261–292. 
Steimle, V., Siegrist, C.-A., Mottet, A., Lisowska-Grospierre, B. and Mach, B. 1994. 
Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivatior 
Gene CIITA. Science 265, pp. 106–109. 
Steinman, R.M. and Idoyaga, J. 2010. Features of the dendritic cell lineage. Immunological 
reviews 234(1), pp. 5–17. 
Stern, L.J., Potolicchio, I. and Santambrogio, L. 2006. MHC class II compartment 
subtypes: structure and function. Current opinion in immunology 18(1), pp. 64–69. 
Strindhall, J., Nilsson, B.-O., Löfgren, S., Ernerudh, J., Pawelec, G., Johansson, B. and 
Wikby, A. 2007. No Immune Risk Profile among individuals who reach 100 years of age: 
Findings from the Swedish NONA immune longitudinal study. Experimental Gerontology 
42(8), pp. 753–761. 
Sullivan, B.M., Juedes, A., Szabo, S.J., Herrath, von, M. and Glimcher, L.H. 2011. Antigen-
driven effector CD8 T cell function regulated by T-bet. Proceedings of the National Academy of 
Sciences 100(26), pp. 15818–15823. 
Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A., Brunner, M.D. 
and Panoskaltsis, N. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal 
antibody TGN1412. New England Journal of Medicine 355(10), pp. 1018–1028. 
Szabo, S.J., Kim, S.T., Costa, G.L., Zhang, X., Fathman, C.G. and Glimcher, L.H. 2000. A 
novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100(6), pp. 655–
669. 
Taka, N., Matsuoka, H., Sato, T., Yoshino, H., Imaoka, I., Sato, H., Kotake, K.-I., et al. 
2009. Discovery of novel motilin antagonists: Conversion of tetrapeptide leads to orally 
available peptidomimetics. Bioorganic & Medicinal Chemistry Letters 19(13), pp. 3426–3429. 
  Bibliography !
! Page 269 
Takata, H. and Takiguchi, M. 2006. Three memory subsets of human CD8+ T cells 
differently expressing three cytolytic effector molecules. The Journal of Immunology 177(7), pp. 
4330–4340. 
Talmadge, J.E. and Gabrilovich, D.I. 2013. History of myeloid-derived suppressor cells. 
Nature Reviews Cancer 13(10), pp. 739–752. 
Tam, C.S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.-A., Thomas, D.A., et 
al. 2008. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen 
as initial therapy of chronic lymphocytic leukemia. Blood 112(4), pp. 975–980. 
Tanner, J.E. and Tosato, G. 1992. Regulation of B-cell growth and immunoglobulin gene 
transcription by interleukin-6. Blood 79(2), pp. 452–459. 
Taylor, G.P. 2006. Molecular aspects of HTLV-I infection and adult T-cell 
leukaemia/lymphoma. Journal of clinical pathology 60(12), pp. 1392–1396. 
Teixeira, L.K., Fonseca, B.P.F., Vieira-de-Abreu, A., Barboza, B.A., Robbs, B.K., Bozza, 
P.T. and Viola, J.P.B. 2005. IFN-gamma production by CD8+ T cells depends on NFAT1 
transcription factor and regulates Th differentiation. The Journal of Immunology 175(9), pp. 
5931–5939. 
Thiery, J., Keefe, D., Boulant, S., Boucrot, E., Walch, M., Martinvalet, D., Goping, I.S., et 
al. 2011. Perforin pores in the endosomal membrane trigger the release of endocytosed 
granzyme B into the cytosol of target cells. Nature immunology 12(8), pp. 770–777. 
Thomas, S., Stauss, H.J. and Morris, E.C. 2010. Molecular immunology lessons from 
therapeutic T-cell receptor gene transfer. Immunology 129(2), pp. 170–177. 
Toda, A. and Piccirillo, C.A. 2006. Development and function of naturally occurring 
CD4+CD25+ regulatory T cells. Journal of leukocyte biology 80(3), pp. 458–470. 
Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., 
Powderly, J.D., et al. 2012. Safety, Activity, and Immune Correlates of Anti–PD-1 
Antibody in Cancer. New England Journal of Medicine 366(26), pp. 2443–2454. 
Topp, M.S., Kufer, P., Gokbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, 
H.A., et al. 2011. Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of 
Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic 
Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival. 
Journal of Clinical Oncology 29(18), pp. 2493–2498. 
Topp, M.S., Riddell, S.R., Akatsuka, Y., Jensen, M.C., Blattman, J.N. and Greenberg, P.D. 
2003. Restoration of CD28 Expression in CD28- CD8+ Memory Effector T Cells 
Reconstitutes Antigen-induced IL-2 Production. The Journal of Experimental Medicine 198(6), 
pp. 947–955. 
Trifari, S., Kaplan, C.D., Tran, E.H., Crellin, N.K. and Spits, H. 2009. Identification of a 
human helper T cell population that has abundant production of interleukin 22 and is 
distinct from T(H)-17, T(H)1 and T(H)2 cells. Nature immunology 10(8), pp. 864–871. 
Turley, S.J., Inaba, K., Garrett, W.S., Ebersold, M., Unternaehrer, J., Steinman, R.M. and 
Mellman, I. 2000. Transport of peptide-MHC class II complexes in developing dendritic 
cells. Science 288(5465), pp. 522–527. 
  Bibliography !
! Page 270 
Vaisitti, T., Audrito, V., Serra, S., Buonincontri, R., Sociali, G., Mannino, E., Pagnani, A., et 
al. 2015. The enzymatic activities of CD38 enhance CLL growth and trafficking: 
implications for therapeutic targeting. Leukemia 29(2), pp. 356–368. 
Vaisitti, T., Aydin, S., Rossi, D., Cottino, F., Bergui, L., D'Arena, G., Bonello, L., et al. 
2010. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic 
leukemia cells. Leukemia 24(5), pp. 958–969. 
Valmori, D., Scheibenbogen, C., Dutoit, V., Nagorsen, D., Asemissen, A., Rubio-Godoy, 
V., Rimoldi, D., et al. 2002. Circulating tumor-reactive CD8(+) T cells in melanoma 
patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific 
cytolytic activity. Cancer Research 62(6), pp. 1743–1750. 
van de Weyer, P.S., Muehlfeit, M., Klose, C., Bonventre, J.V., Walz, G. and Kuehn, E.W. 
2006. A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its 
ligand galectin-9. Biochemical and Biophysical Research Communications 351(2), pp. 571–576. 
van den Broek, M.E., Kägi, D., Ossendorp, F., Toes, R., Vamvakas, S., Lutz, W.K., Melief, 
C.J., et al. 1996. Decreased tumor surveillance in perforin-deficient mice. The Journal of 
Experimental Medicine 184(5), pp. 1781–1790. 
Van den Hove, L.E., Van Gool, S.W., Vandenberghe, P., Bakkus, M., Thielemans, K., 
Boogaerts, M.A. and Ceuppens, J.L. 1997. CD40 triggering of chronic lymphocytic 
leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte 
induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 11(4), 
pp. 572–580. 
Van den Hove, L.E., Van Gool, S.W., Vandenberghe, P., Boogaerts, M.A. and Ceuppens, 
J.L. 1998. CD57+/CD28-T cells in untreated hemato-oncological patients are expanded 
and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced 
tendency to apoptosis. Leukemia 12(10), pp. 1573–1582. 
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, 
B., Knuth, A., et al. 1991. A gene encoding an antigen recognized by cytolytic T 
lymphocytes on a human melanoma. Science 254(5038), pp. 1643–1647. 
van der Burg, S.H., Ressing, M.E., Kwappenberg, K.M., de Jong, A., Straathof, K., de Jong, 
J., Geluk, A., et al. 2001. Natural T-helper immunity against human papillomavirus type 16 
(HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: 
identification of 3 human leukocyte antigen class II-restricted epitopes. International Journal 
of Cancer 91(5), pp. 612–618. 
van Oers, M.H.J., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E., Gascoyne, R.D., Jack, A., 
et al. 2006. Rituximab maintenance improves clinical outcome of relapsed/resistant 
follicular non-Hodgkin lymphoma in patients both with and without rituximab during 
induction: results of a prospective randomized phase 3 intergroup trial. Blood 108(10), pp. 
3295–3301. 
Venturi, G.M., Tu, L., Kadono, T., Khan, A.I., Fujimoto, Y., Oshel, P., Bock, C.B., et al. 
2003. Leukocyte migration is regulated by L-selectin endoproteolytic release. Immunity 
19(5), pp. 713–724. 
Voehringer, D. 2013. Protective and pathological roles of mast cells and basophils. Nature 
Reviews Immunology 13(5), pp. 362–375. 
  Bibliography !
! Page 271 
Voskoboinik, I., Dunstone, M.A., Baran, K., Whisstock, J.C. and Trapani, J.A. 2010. 
Perforin: structure, function, and role in human immunopathology. Immunological reviews 
235(1), pp. 35–54. 
Vu, T. and Claret, F.X. 2012. Trastuzumab: updated mechanisms of action and resistance 
in breast cancer. Frontiers in oncology 2, p. 62. 
Vyas, J.M., Van der Veen, A.G. and Ploegh, H.L. 2008. The known unknowns of antigen 
processing and presentation. Nature Reviews Immunology 8(8), pp. 607–618. 
Waller, E.C.P., McKinney, N., Hicks, R., Carmichael, A.J., Sissons, J.G.P. and Wills, M.R. 
2007. Differential costimulation through CD137 (4 1BB) restores proliferation of human 
virus-specific ‘effector memory’ (CD28 CD45RAHI) CD8+ T cells. Blood 110(13), pp. 
4360–4366. 
Walsby, E., Buggins, A., Devereux, S., Jones, C., Pratt, G., Brennan, P., Fegan, C., et al. 
2014. Development and characterization of a physiologically relevant model of lymphocyte 
migration in chronic lymphocytic leukemia. Blood 123(23), pp. 3607–3617. 
Walsby, E., Brennan, P., Pratt, G., Hartmann, T., Yoshizawa, T., Fegan, C., et al. 2014. 
CXCL12 Enhances CLL Cell and T-Cell Migration in a Dynamic Circulating Model of 
CLL That Can be Abrogated By the CXCR4 Antagonist ONO-7161. 56th American Society 
of Hematology Annual Meeting & Exposition. San Francisco, 6-9 December. Blood, pp. 3293-
3293 
 
Wang, H., Kadlecek, T.A., Au-Yeung, B.B., Goodfellow, H.E.S., Hsu, L.-Y., Freedman, 
T.S. and Weiss, A. 2010. ZAP-70: an essential kinase in T-cell signaling. Cold Spring Harbor 
Perspectives in Biology 2(5), p. a002279. 
Wang, W., Epler, J., Salazar, L.G. and Riddell, S.R. 2006. Recognition of breast cancer cells 
by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Research 66(13), pp. 6826–
6833. 
Warmerdam, P.A., Long, E.O. and Roche, P.A. 1996. Isoforms of the invariant chain 
regulate transport of MHC class II molecules to antigen processing compartments. The 
Journal of Cell Biology 133(2), pp. 281–291. 
Watts, C. 2001. Antigen processing in the endocytic compartment. Current opinion in 
immunology 13, pp. 26–31. 
Wearsch, P.A. and Cresswell, P. 2008. The quality control of MHC class I peptide loading. 
Current Opinion in Cell Biology 20(6), pp. 624–631. 
Wei, F., Zhong, S., Ma, Z., Kong, H., Medvec, A., Ahmed, R., Freeman, G.J., et al. 2013. 
Strength of PD-1 signaling differentially affects T-cell effector functions. Proceedings of the 
National Academy of Sciences 110(27), pp. E2480–9. 
Wen, T., Mellstedt, H. and Jondal, M. 1990. Presence of clonal T cell populations in 
chronic B lymphocytic leukemia and smoldering myeloma. The Journal of Experimental 
Medicine 171(3), pp. 659–666. 
Wherry, E.J. 2011. T cell exhaustion. Nature immunology 12(6), pp. 492–499. 
Wherry, E.J., Teichgräber, V., Becker, T.C., Masopust, D., Kaech, S.M., Antia, R., Andrian, 
von, U.H., et al. 2003. Lineage relationship and protective immunity of memory CD8 T cell 
  Bibliography !
! Page 272 
subsets. Nature immunology 4(3), pp. 225–234. 
Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmann, A., Robak, 
T., et al. 2010. Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-
Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 28(10), pp. 1749–
1755. 
Wierda, W.G., Padmanabhan, S., Chan, G.W., Gupta, I.V., Lisby, S., Osterborg, A.for the 
Hx-CD20-406 Study Investigators 2011. Ofatumumab is active in patients with 
fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 
international study. Blood 118(19), pp. 5126–5129. 
Wikby, A., Johansson, B., Olsson, J., Löfgren, S., Nilsson, B.-O. and Ferguson, F. 2002. 
Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association 
with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. 
Experimental Gerontology 37(2-3), pp. 445–453. 
Willinger, T., Freeman, T., Hasegawa, H., McMichael, A.J. and Callan, M.F.C. 2005. 
Molecular signatures distinguish human central memory from effector memory CD8 T cell 
subsets. The Journal of Immunology 175(9), pp. 5895–5903. 
Wills, M.R., Carmichael, A.J., Weekes, M.P., Mynard, K., Okecha, G., Hicks, R. and 
Sissons, J.G. 1999. Human virus-specific CD8+ CTL clones revert from CD45ROhigh to 
CD45RAhigh in vivo: CD45RAhighCD8+ T cells comprise both naive and memory cells. 
The Journal of Immunology 162(12), pp. 7080–7087. 
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V. and Engert, A. 1999. Cytokine-
release syndrome in patients with B-cell chronic lymphocytic leukemia and high 
lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, 
IDEC-C2B8). Blood 94(7), pp. 2217–2224. 
Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., 
Segal, N.H., et al. 2013. Nivolumab plus Ipilimumab in Advanced Melanoma. New England 
Journal of Medicine 369(2), pp. 122–133. 
Wong, R., Pepper, C., Brennan, P., Nagorsen, D., Man, S. and Fegan, C. 2013. 
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. 
Haematologica 98(12), pp. 1930–1938. 
Woo, S.R., Turnis, M.E., Goldberg, M.V., Bankoti, J., Selby, M., Nirschl, C.J., Bettini, M.L., 
et al. 2012. Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell 
Function to Promote Tumoral Immune Escape. Cancer Research 72(4), pp. 917–927. 
Wooldridge, L., Ekeruche-Makinde, J., van den Berg, H.A., Skowera, A., Miles, J.J., Tan, 
M.P., Dolton, G., et al. 2012. A Single Autoimmune T Cell Receptor Recognizes More 
Than a Million Different Peptides. Journal of Biological Chemistry 287(2), pp. 1168–1177. 
Workman, C.J. and Vignali, D.A.A. 2003. The CD4-related molecule, LAG-3 (CD223), 
regulates the expansion of activated T cells. European Journal of Immunology 33(4), pp. 970–
979. 
Workman, C.J., Dugger, K.J. and Vignali, D.A.A. 2002. Cutting edge: molecular analysis of 
the negative regulatory function of lymphocyte activation gene-3. The Journal of Immunology 
169(10), pp. 5392–5395. 
  Bibliography !
! Page 273 
Wu, W., Shi, Y., Li, S., Zhang, Y., Liu, Y., Wu, Y. and Chen, Z. 2012. Blockade of Tim-3 
signaling restores the virus-specific CD8+T-cell response in patients with chronic hepatitis 
B. European Journal of Immunology 42(5), pp. 1180–1191. 
Xu, T., Shu, C.-T., Purdom, E., Dang, D., Ilsley, D., Guo, Y., Weber, J., et al. 2004. 
Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in 
melanoma patients and healthy donors. Cancer Research 64(10), pp. 3661–3667. 
Yang, X.O., Nurieva, R., Martinez, G.J., Kang, H.S., Chung, Y., Pappu, B.P., Shah, B., et al. 
2008. Molecular Antagonism and Plasticity of Regulatory and Inflammatory T Cell 
Programs. Immunity 29(1), pp. 44–56. 
Yee, C., Thompson, J.A., Byrd, D., Riddell, S.R., Roche, P., Celis, E. and Greenberg, P.D. 
2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment 
of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect 
of transferred T cells. Proceedings of the National Academy of Sciences 99(25), pp. 16168–16173. 
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M. 
and Saito, T. 2012. Programmed cell death 1 forms negative costimulatory microclusters 
that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. The Journal of 
Experimental Medicine 209(6), pp. 1201–1217. 
Younes, A., Gopal, A.K., Smith, S.E., Ansell, S.M., Rosenblatt, J.D., Savage, K.J., 
Ramchandren, R., et al. 2012. Results of a Pivotal Phase II Study of Brentuximab Vedotin 
for Patients With Relapsed or Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology 
30(18), pp. 2183–2189. 
Zamorano, J., Kelly, A.E., Austrian, J., Wang, H.Y. and Keegan, A.D. 2001. Costimulation 
of resting B lymphocytes alters the IL-4-activated IRS2 signaling pathway in a STAT6 
independent manner: implications for cell survival and proliferation. Cell research 11(1), pp. 
44–54. 
Zenz, T. 2013. Exhausting T cells in CLL. Blood 121(9), pp. 1485–1486. 
Zenz, T., Eichhorst, B., Busch, R., Denzel, T., Häbe, S., Winkler, D., Bühler, A., et al. 
2010a. TP53 mutation and survival in chronic lymphocytic leukemia. Journal of Clinical 
Oncology 28(29), pp. 4473–4479. 
Zenz, T., Mertens, D., Küppers, R., Döhner, H. and Stilgenbauer, S. 2010b. From 
pathogenesis to treatment of chronic lymphocytic leukaemia. Nature Reviews Cancer 10(1), 
pp. 37–50. 
Zhao, Y., Wang, Q.J., Yang, S., Kochenderfer, J.N., Zheng, Z., Zhong, X., Sadelain, M., et 
al. 2009. A herceptin-based chimeric antigen receptor with modified signaling domains 
leads to enhanced survival of transduced T lymphocytes and antitumor activity. The Journal 
of Immunology 183(9), pp. 5563–5574. 
Zhou, Q., Munger, M.E., Veenstra, R.G., Weigel, B.J., Hirashima, M., Munn, D.H., 
Murphy, W.J., et al. 2011. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell 
exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 
117(17), pp. 4501–4510. 
Zhu, C., Anderson, A.C., Schubart, A., Xiong, H., Imitola, J., Khoury, S.J., Zheng, X.X., et 
al. 2005. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nature 
immunology 6(12), pp. 1245–1252. 
  Bibliography !
! Page 274 
Zhu, J. and Paul, W.E. 2008. CD4 T cells: fates, functions, and faults. Blood 112(5), pp. 
1557–1569. 
Ziegler, K. and Unanue, E.R. 1981. Identification of a macrophage antigen-processing 
event required for I-region-restricted antigen presentation to T lymphocytes. The Journal of 
Immunology 127(5), pp. 1869–1875. 
Zucchetto, A., Vaisitti, T., Benedetti, D., Tissino, E., Bertagnolo, V., Rossi, D., Bomben, 
R., et al. 2012. The CD49d/CD29 complex is physically and functionally associated with 
CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia 26(6), pp. 1301–1312. 
 
 
